{"414aea261d9ea2b6f95185cbc20a57b254de6578": [["responses to SARS-CoV-2 [4] .", [["SARS", "DISEASE", 13, 17], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "TEST", 13, 17]]], ["Further, serological testing is likely to be valuable in the 82 assessment of vaccine efficacy.", [["serological testing", "TEST", 9, 28], ["vaccine efficacy", "TREATMENT", 78, 94]]], ["However, analyses of seroprevalence, especially in low 83 prevalence settings are hampered by assays with inadequate sensitivity and specificity [5] .", [["seroprevalence", "TEST", 21, 35], ["specificity", "TEST", 133, 144]]], ["84 85 Australia has reported low case numbers of COVID-19 per head of population compared to 86 other developed Westernized countries, especially before the July/August 2020 outbreak in 87", [["head", "ANATOMY", 62, 66], ["head", "ORGANISM_SUBDIVISION", 62, 66], ["COVID", "TEST", 49, 54]]]], "PMC4935779": [["INTRODUCTIONThe Enterovirus genus of the Picornaviridae family comprises many human pathogens, such as poliovirus, coxsackievirus A and B, enterovirus 68, enterovirus 71, and rhinovirus, which can cause a wide spectrum of illnesses (1).", [["coxsackievirus A and B", "DISEASE", 115, 137], ["enterovirus 71", "DISEASE", 155, 169], ["rhinovirus", "DISEASE", 175, 185], ["Enterovirus genus", "ORGANISM", 16, 33], ["human", "ORGANISM", 78, 83], ["poliovirus", "ORGANISM", 103, 113], ["coxsackievirus A", "ORGANISM", 115, 131], ["B, enterovirus 68", "ORGANISM", 136, 153], ["enterovirus 71", "ORGANISM", 155, 169], ["rhinovirus", "ORGANISM", 175, 185], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["coxsackievirus A", "SPECIES", 115, 131], ["enterovirus 68", "SPECIES", 139, 153], ["enterovirus 71", "SPECIES", 155, 169], ["many human pathogens", "PROBLEM", 73, 93], ["poliovirus", "PROBLEM", 103, 113], ["enterovirus", "PROBLEM", 139, 150], ["enterovirus", "PROBLEM", 155, 166], ["rhinovirus", "PROBLEM", 175, 185]]], ["Being obligate intracellular parasites, enteroviruses rely on the machineries of their host cell for propagation.", [["intracellular", "ANATOMY", 15, 28], ["cell", "ANATOMY", 92, 96], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 28], ["host cell", "CELL", 87, 96], ["intracellular parasites", "PROBLEM", 15, 38], ["enteroviruses", "PROBLEM", 40, 53], ["intracellular parasites", "OBSERVATION", 15, 38], ["host cell", "OBSERVATION", 87, 96]]], ["Like all other viruses that carry a positive-sense, single-stranded RNA genome, enteroviruses redecorate the cell\u2019s interior to form new membranous structures that serve as a platform for viral RNA replication (2\u20136).", [["cell", "ANATOMY", 109, 113], ["membranous structures", "ANATOMY", 137, 158], ["enteroviruses", "ORGANISM", 80, 93], ["cell", "CELL", 109, 113], ["single-stranded RNA genome", "DNA", 52, 78], ["all other viruses", "PROBLEM", 5, 22], ["single-stranded RNA genome", "PROBLEM", 52, 78], ["enteroviruses", "PROBLEM", 80, 93], ["viral RNA replication", "TREATMENT", 188, 209], ["viruses", "OBSERVATION", 15, 22], ["RNA genome", "OBSERVATION", 68, 78], ["new", "OBSERVATION_MODIFIER", 133, 136], ["membranous", "OBSERVATION", 137, 147]]], ["These structures may aid in concentrating as well as in conferring the proper topology of all required components for genome replication.", [["genome", "CELLULAR_COMPONENT", 118, 124], ["genome replication", "TREATMENT", 118, 136], ["genome replication", "OBSERVATION", 118, 136]]], ["Furthermore, it has been suggested that they can shield viral RNA products from degradation by cellular RNases or from detection by sensors of the innate immune system (7, 8).INTRODUCTIONThe morphology of the enterovirus-induced membrane structures (often termed replication organelles [ROs]) has been a subject of intense investigation.", [["cellular", "ANATOMY", 95, 103], ["membrane structures", "ANATOMY", 229, 248], ["organelles", "ANATOMY", 275, 285], ["ROs", "ANATOMY", 287, 290], ["cellular", "CELL", 95, 103], ["enterovirus", "ORGANISM", 209, 220], ["membrane", "CELLULAR_COMPONENT", 229, 237], ["organelles", "CELLULAR_COMPONENT", 275, 285], ["viral RNA products", "PROTEIN", 56, 74], ["cellular RNases", "PROTEIN", 95, 110], ["viral RNA products", "TREATMENT", 56, 74], ["induced membrane structures", "PROBLEM", 221, 248], ["intense investigation", "TEST", 315, 336], ["cellular RNases", "OBSERVATION", 95, 110], ["enterovirus", "OBSERVATION", 209, 220]]], ["Two-dimensional electron microscopy (EM) studies have shown both single-membrane and double-membrane structures, depending on the cell type, time point, and experimental procedure (9\u201316).", [["membrane", "ANATOMY", 72, 80], ["double-membrane structures", "ANATOMY", 85, 111], ["cell", "ANATOMY", 130, 134], ["membrane", "CELLULAR_COMPONENT", 72, 80], ["membrane structures", "CELLULAR_COMPONENT", 92, 111], ["cell", "CELL", 130, 134], ["EM) studies", "TEST", 37, 48], ["double-membrane structures", "TREATMENT", 85, 111], ["experimental procedure", "TREATMENT", 157, 179], ["both", "OBSERVATION_MODIFIER", 60, 64], ["single", "OBSERVATION_MODIFIER", 65, 71], ["double-membrane", "OBSERVATION_MODIFIER", 85, 100]]], ["Recently, two studies with poliovirus and coxsackievirus B3 (CVB3) were conducted to reveal the three-dimensional (3D) structure of the ROs in the course of infection using electron tomography (17, 18).", [["ROs", "ANATOMY", 136, 139], ["infection", "DISEASE", 157, 166], ["poliovirus", "ORGANISM", 27, 37], ["coxsackievirus B3", "ORGANISM", 42, 59], ["CVB3", "ORGANISM", 61, 65], ["ROs", "PATHOLOGICAL_FORMATION", 136, 139], ["coxsackievirus B3", "SPECIES", 42, 59], ["coxsackievirus B3", "SPECIES", 42, 59], ["CVB3", "SPECIES", 61, 65], ["two studies", "TEST", 10, 21], ["poliovirus", "PROBLEM", 27, 37], ["coxsackievirus B3 (CVB3", "PROBLEM", 42, 65], ["infection", "PROBLEM", 157, 166], ["electron tomography", "TEST", 173, 192], ["infection", "OBSERVATION", 157, 166]]], ["Both studies showed that the first structures detected upon infection are single-membrane tubular structures.", [["membrane tubular structures", "ANATOMY", 81, 108], ["infection", "DISEASE", 60, 69], ["tubular structures", "MULTI-TISSUE_STRUCTURE", 90, 108], ["Both studies", "TEST", 0, 12], ["infection", "PROBLEM", 60, 69], ["infection", "OBSERVATION", 60, 69], ["membrane", "ANATOMY_MODIFIER", 81, 89], ["tubular", "ANATOMY_MODIFIER", 90, 97]]], ["These tubules appear to be formed at the expense of Golgi membranes, since in most cell sections, the Golgi apparatus is no longer detected when the tubules are present.", [["tubules", "ANATOMY", 6, 13], ["Golgi membranes", "ANATOMY", 52, 67], ["cell sections", "ANATOMY", 83, 96], ["Golgi apparatus", "ANATOMY", 102, 117], ["tubules", "ANATOMY", 149, 156], ["tubules", "TISSUE", 6, 13], ["Golgi membranes", "CELLULAR_COMPONENT", 52, 67], ["cell sections", "MULTI-TISSUE_STRUCTURE", 83, 96], ["Golgi", "CELLULAR_COMPONENT", 102, 107], ["tubules", "TISSUE", 149, 156], ["appear to be", "UNCERTAINTY", 14, 26], ["formed", "OBSERVATION", 27, 33], ["expense", "OBSERVATION_MODIFIER", 41, 48], ["Golgi membranes", "OBSERVATION", 52, 67], ["most cell", "OBSERVATION_MODIFIER", 78, 87], ["sections", "OBSERVATION_MODIFIER", 88, 96], ["Golgi apparatus", "OBSERVATION", 102, 117], ["no longer", "UNCERTAINTY", 121, 130], ["tubules", "OBSERVATION", 149, 156]]], ["The tubules emerge during the exponential phase of viral RNA replication, suggesting that they are the preeminent structures supporting viral genome synthesis.", [["tubules", "ANATOMY", 4, 11], ["tubules", "TISSUE", 4, 11], ["viral RNA replication", "TREATMENT", 51, 72], ["viral genome synthesis", "PROBLEM", 136, 158], ["viral RNA replication", "OBSERVATION", 51, 72], ["viral genome synthesis", "OBSERVATION", 136, 158]]], ["Later in infection, the tubular ROs morph into double-membrane vesicles (DMVs) and multilamellar structures, a phenomenon that is reminiscent of autophagy.", [["tubular", "ANATOMY", 24, 31], ["double-membrane vesicles", "ANATOMY", 47, 71], ["DMVs", "ANATOMY", 73, 77], ["multilamellar structures", "ANATOMY", 83, 107], ["infection", "DISEASE", 9, 18], ["membrane vesicles", "CELLULAR_COMPONENT", 54, 71], ["multilamellar structures", "CELLULAR_COMPONENT", 83, 107], ["infection", "PROBLEM", 9, 18], ["the tubular ROs morph", "TEST", 20, 41], ["double-membrane vesicles (DMVs) and multilamellar structures", "PROBLEM", 47, 107], ["a phenomenon", "PROBLEM", 109, 121], ["autophagy", "PROBLEM", 145, 154], ["infection", "OBSERVATION", 9, 18], ["tubular", "ANATOMY_MODIFIER", 24, 31], ["ROs morph", "OBSERVATION", 32, 41], ["double-", "OBSERVATION_MODIFIER", 47, 54], ["membrane vesicles", "ANATOMY", 54, 71], ["multilamellar structures", "ANATOMY", 83, 107], ["phenomenon", "OBSERVATION", 111, 121]]], ["It was shown for poliovirus that newly synthesized viral RNA localizes not only to the tubular structures but also to the DMVs, implying that the DMVs may also facilitate genome replication (17).", [["tubular structures", "ANATOMY", 87, 105], ["DMVs", "ANATOMY", 122, 126], ["tubular structures", "TISSUE", 87, 105], ["DMVs", "GENE_OR_GENE_PRODUCT", 122, 126], ["DMVs", "GENE_OR_GENE_PRODUCT", 146, 150], ["genome", "CELLULAR_COMPONENT", 171, 177], ["viral RNA", "RNA", 51, 60], ["DMVs", "DNA", 122, 126], ["DMVs", "DNA", 146, 150], ["poliovirus", "SPECIES", 17, 27], ["poliovirus", "PROBLEM", 17, 27], ["newly synthesized viral RNA", "PROBLEM", 33, 60], ["the DMVs", "PROBLEM", 142, 150], ["viral RNA", "OBSERVATION", 51, 60], ["tubular", "ANATOMY_MODIFIER", 87, 94]]], ["In addition, DMVs have been proposed to mediate nonlytic release of progeny virions (19\u201321).INTRODUCTIONWhile EM analyses have provided insight into the structure of the enterovirus ROs, fluorescence microscopy studies have focused on unraveling their origin by investigating the presence of essential host factors or marker proteins on the ROs.", [["virions", "ANATOMY", 76, 83], ["DMVs", "GENE_OR_GENE_PRODUCT", 13, 17], ["enterovirus", "ORGANISM", 170, 181], ["ROs", "SIMPLE_CHEMICAL", 182, 185], ["DMVs", "PROTEIN", 13, 17], ["essential host factors", "PROTEIN", 292, 314], ["marker proteins", "PROTEIN", 318, 333], ["EM analyses", "TEST", 110, 121], ["the enterovirus ROs", "TEST", 166, 185], ["fluorescence microscopy studies", "TEST", 187, 218], ["host factors", "OBSERVATION", 302, 314]]], ["These studies have been performed in cells that had been fixed at various time points postinfection, usually at 1- to 2-h intervals, which gives limited insight into the dynamics of RO formation.", [["cells", "ANATOMY", 37, 42], ["cells", "CELL", 37, 42], ["RO", "SIMPLE_CHEMICAL", 182, 184], ["These studies", "TEST", 0, 13]]], ["ROs are mostly visualized by immunolabeling using antibodies directed against viral proteins that are anchored in the RO membrane, i.e., 2B, 2C, or 3A.", [["RO membrane", "ANATOMY", 118, 129], ["ROs", "SIMPLE_CHEMICAL", 0, 3], ["antibodies directed against viral proteins", "GENE_OR_GENE_PRODUCT", 50, 92], ["RO membrane", "CELLULAR_COMPONENT", 118, 129], ["antibodies", "PROTEIN", 50, 60], ["viral proteins", "PROTEIN", 78, 92], ["2B, 2C, or 3A", "PROTEIN", 137, 150], ["antibodies", "TREATMENT", 50, 60], ["viral proteins", "PROBLEM", 78, 92]]], ["With this approach, ROs were shown to colocalize with several proteins involved in endoplasmic reticulum (ER)-to-Golgi transport (22\u201325) as well as with LC3, a protein involved in the autophagy pathway (11, 13, 19).", [["endoplasmic reticulum", "ANATOMY", 83, 104], ["ER", "ANATOMY", 106, 108], ["Golgi", "ANATOMY", 113, 118], ["ROs", "SIMPLE_CHEMICAL", 20, 23], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 83, 104], ["ER", "GENE_OR_GENE_PRODUCT", 106, 108], ["Golgi", "CELLULAR_COMPONENT", 113, 118], ["LC3", "GENE_OR_GENE_PRODUCT", 153, 156], ["ROs", "PROTEIN", 20, 23], ["LC3", "PROTEIN", 153, 156], ["a protein", "TEST", 158, 167], ["the autophagy pathway", "TEST", 180, 201], ["endoplasmic reticulum", "ANATOMY", 83, 104]]], ["However, ROs are not mere remnants of the early secretory pathway or constituents of the autophagy pathway.", [["ROs", "SIMPLE_CHEMICAL", 9, 12]]], ["Instead, enteroviruses seem highly selective in hijacking components from these pathways to create completely new organelles with a unique protein and lipid composition optimized for genome replication (reviewed in reference 5).INTRODUCTIONAlthough we are learning more and more about the morphology and origin of enterovirus ROs by three-dimensional EM studies and by fluorescence microscopy of fixed cells, it has not been possible thus far to directly visualize ROs in living cells.", [["organelles", "ANATOMY", 114, 124], ["cells", "ANATOMY", 402, 407], ["cells", "ANATOMY", 479, 484], ["enteroviruses", "ORGANISM", 9, 22], ["organelles", "CELLULAR_COMPONENT", 114, 124], ["lipid", "SIMPLE_CHEMICAL", 151, 156], ["enterovirus", "ORGANISM", 314, 325], ["ROs", "SIMPLE_CHEMICAL", 326, 329], ["cells", "CELL", 402, 407], ["ROs", "SIMPLE_CHEMICAL", 465, 468], ["cells", "CELL", 479, 484], ["ROs", "PROTEIN", 465, 468], ["living cells", "CELL_TYPE", 472, 484], ["enteroviruses", "PROBLEM", 9, 22], ["a unique protein and lipid composition", "TREATMENT", 130, 168], ["genome replication", "TREATMENT", 183, 201], ["enterovirus ROs", "PROBLEM", 314, 329], ["fluorescence microscopy", "TEST", 369, 392], ["fixed cells", "PROBLEM", 396, 407], ["selective", "OBSERVATION_MODIFIER", 35, 44], ["fixed cells", "OBSERVATION", 396, 407], ["living cells", "OBSERVATION", 472, 484]]], ["Live-cell imaging can provide unprecedented insights into the dynamics of biological processes, including RO formation and viral effects on other cellular structures or organelles, and may capture rare or rapid events that may be missed in the analysis of fixed cells.", [["Live-cell", "ANATOMY", 0, 9], ["cellular structures", "ANATOMY", 146, 165], ["organelles", "ANATOMY", 169, 179], ["cells", "ANATOMY", 262, 267], ["RO", "SIMPLE_CHEMICAL", 106, 108], ["cellular structures", "CELLULAR_COMPONENT", 146, 165], ["organelles", "CELLULAR_COMPONENT", 169, 179], ["cells", "CELL", 262, 267], ["fixed cells", "CELL_TYPE", 256, 267], ["Live-cell imaging", "TEST", 0, 17], ["RO formation", "TREATMENT", 106, 118], ["viral effects on other cellular structures", "PROBLEM", 123, 165], ["rapid events", "PROBLEM", 205, 217], ["fixed cells", "PROBLEM", 256, 267], ["viral", "OBSERVATION", 123, 128], ["fixed cells", "OBSERVATION", 256, 267]]], ["Moreover, observations by immunolabeling of fixed cells may be compromised by artifacts induced during sample preparation and should be complemented by live-cell imaging (26).", [["cells", "ANATOMY", 50, 55], ["sample", "ANATOMY", 103, 109], ["live-cell", "ANATOMY", 152, 161], ["cells", "CELL", 50, 55], ["cell", "CELL", 157, 161], ["immunolabeling of fixed cells", "PROBLEM", 26, 55], ["artifacts", "PROBLEM", 78, 87], ["fixed cells", "OBSERVATION", 44, 55]]], ["To date, enterovirus ROs have been monitored only indirectly in living cells that expressed a fluorescently labeled cellular protein, the Golgi-resident Arf1-RFP (red fluorescent protein [RFP]-labeled Arf1), as an RO marker (22).", [["cells", "ANATOMY", 71, 76], ["cellular", "ANATOMY", 116, 124], ["enterovirus", "ORGANISM", 9, 20], ["ROs", "GENE_OR_GENE_PRODUCT", 21, 24], ["cells", "CELL", 71, 76], ["cellular", "CELL", 116, 124], ["Arf1", "GENE_OR_GENE_PRODUCT", 153, 157], ["RFP", "GENE_OR_GENE_PRODUCT", 158, 161], ["red fluorescent protein", "GENE_OR_GENE_PRODUCT", 163, 186], ["RFP", "GENE_OR_GENE_PRODUCT", 188, 191], ["Arf1", "GENE_OR_GENE_PRODUCT", 201, 205], ["enterovirus ROs", "PROTEIN", 9, 24], ["fluorescently labeled cellular protein", "PROTEIN", 94, 132], ["Golgi-resident Arf1", "PROTEIN", 138, 157], ["RFP", "PROTEIN", 158, 161], ["red fluorescent protein", "PROTEIN", 163, 186], ["RFP", "PROTEIN", 188, 191], ["Arf1", "PROTEIN", 201, 205], ["enterovirus ROs", "TEST", 9, 24], ["the Golgi-resident Arf1", "TEST", 134, 157], ["red fluorescent protein", "TEST", 163, 186], ["an RO marker", "TEST", 211, 223]]], ["Yet, the use of a cellular protein as a RO marker may complicate investigations examining the transition from the Golgi apparatus to early enterovirus ROs.", [["cellular", "ANATOMY", 18, 26], ["Golgi", "ANATOMY", 114, 119], ["cellular", "CELL", 18, 26], ["Golgi", "CELLULAR_COMPONENT", 114, 119], ["enterovirus", "ORGANISM", 139, 150], ["cellular protein", "PROTEIN", 18, 34], ["a cellular protein", "TREATMENT", 16, 34], ["a RO marker", "TEST", 38, 49], ["the transition", "PROBLEM", 90, 104], ["early enterovirus ROs", "PROBLEM", 133, 154]]], ["A better strategy for direct visualization of ROs in living cells is to label a viral protein involved in their formation.", [["cells", "ANATOMY", 60, 65], ["ROs", "SIMPLE_CHEMICAL", 46, 49], ["cells", "CELL", 60, 65], ["ROs", "PROTEIN", 46, 49], ["viral protein", "PROTEIN", 80, 93], ["direct visualization of ROs", "TEST", 22, 49], ["a viral protein", "PROBLEM", 78, 93], ["viral protein", "OBSERVATION", 80, 93]]], ["The enterovirus genome can accept coding sequences of foreign proteins (green fluorescent protein [GFP] [27, 28], proLC3 [16], Timer [29], and luciferase [27, 30] among others) at the start of the open reading frame before the capsid coding region.", [["enterovirus", "ORGANISM", 4, 15], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 72, 97], ["GFP", "GENE_OR_GENE_PRODUCT", 99, 102], ["proLC3 [16]", "GENE_OR_GENE_PRODUCT", 114, 125], ["Timer [29]", "GENE_OR_GENE_PRODUCT", 127, 137], ["luciferase", "GENE_OR_GENE_PRODUCT", 143, 153], ["enterovirus genome", "DNA", 4, 22], ["foreign proteins", "PROTEIN", 54, 70], ["green fluorescent protein", "PROTEIN", 72, 97], ["GFP", "PROTEIN", 99, 102], ["luciferase", "PROTEIN", 143, 153], ["open reading frame", "DNA", 197, 215], ["capsid coding region", "DNA", 227, 247], ["The enterovirus genome", "PROBLEM", 0, 22], ["foreign proteins", "PROBLEM", 54, 70], ["green fluorescent protein", "TEST", 72, 97], ["GFP", "TEST", 99, 102], ["proLC3", "TEST", 114, 120], ["Timer", "TEST", 127, 132], ["luciferase", "TEST", 143, 153], ["enterovirus genome", "OBSERVATION", 4, 22]]], ["In addition, a poliovirus encoding a viral proteinase (i.e., the 2A protein) tagged with dsRed has been generated (31).", [["viral proteinase", "PROTEIN", 37, 53], ["2A protein", "PROTEIN", 65, 75], ["dsRed", "PROTEIN", 89, 94], ["poliovirus", "SPECIES", 15, 25], ["a poliovirus encoding a viral proteinase", "PROBLEM", 13, 53]]], ["However, 2A is not a bona fide RO marker, as it does not localize exclusively to ROs.", [["RO", "GENE_OR_GENE_PRODUCT", 31, 33], ["ROs", "GENE_OR_GENE_PRODUCT", 81, 84]]], ["Attempts to generate enteroviruses that encode fluorescently labeled, membrane-anchored viral proteins to illuminate ROs have thus far been futile, most likely because fusion of a fluorescent protein to an RO-anchored viral protein impaired its function or liberation from the polyprotein.", [["membrane", "ANATOMY", 70, 78], ["RO", "CHEMICAL", 206, 208], ["enteroviruses", "ORGANISM", 21, 34], ["membrane", "CELLULAR_COMPONENT", 70, 78], ["ROs", "GENE_OR_GENE_PRODUCT", 117, 120], ["membrane-anchored viral proteins", "PROTEIN", 70, 102], ["ROs", "PROTEIN", 117, 120], ["fluorescent protein", "PROTEIN", 180, 199], ["RO-anchored viral protein", "PROTEIN", 206, 231], ["enteroviruses", "PROBLEM", 21, 34], ["membrane-anchored viral proteins", "TREATMENT", 70, 102], ["a fluorescent protein", "PROBLEM", 178, 199], ["an RO", "TEST", 203, 208], ["anchored viral protein", "PROBLEM", 209, 231], ["the polyprotein", "TREATMENT", 273, 288], ["enteroviruses", "OBSERVATION", 21, 34]]], ["The use of small genetically encoded tags may overcome this limitation, as evidenced by the successful generation of recombinant polioviruses that encode small epitope tags (such as hemagglutinin [HA], FLAG, and c-myc) in their 3A protein (32) and a recombinant CVB3 encoding an HA tag in its 2B protein (33).INTRODUCTIONIn this study, we used a split-GFP system (34) to tag the 3A protein of CVB3, a small protein of 89 amino acids with a C-terminal hydrophobic domain that inserts into the RO membranes (35).", [["RO membranes", "ANATOMY", 492, 504], ["amino acids", "CHEMICAL", 421, 432], ["amino acids", "CHEMICAL", 421, 432], ["C", "CHEMICAL", 440, 441], ["hemagglutinin [HA]", "GENE_OR_GENE_PRODUCT", 182, 200], ["FLAG", "GENE_OR_GENE_PRODUCT", 202, 206], ["c-myc", "GENE_OR_GENE_PRODUCT", 212, 217], ["CVB3", "ORGANISM", 262, 266], ["CVB3", "ORGANISM", 393, 397], ["amino acids", "AMINO_ACID", 421, 432], ["RO membranes", "CELLULAR_COMPONENT", 492, 504], ["small epitope tags", "PROTEIN", 154, 172], ["hemagglutinin", "PROTEIN", 182, 195], ["HA", "PROTEIN", 197, 199], ["FLAG", "PROTEIN", 202, 206], ["c-myc", "PROTEIN", 212, 217], ["3A protein", "PROTEIN", 228, 238], ["recombinant CVB3", "PROTEIN", 250, 266], ["HA tag", "PROTEIN", 279, 285], ["2B protein", "PROTEIN", 293, 303], ["3A protein", "PROTEIN", 379, 389], ["CVB3", "PROTEIN", 393, 397], ["C-terminal hydrophobic domain", "PROTEIN", 440, 469], ["CVB3", "SPECIES", 262, 266], ["small genetically encoded tags", "PROBLEM", 11, 41], ["recombinant polioviruses", "PROBLEM", 117, 141], ["small epitope tags", "PROBLEM", 154, 172], ["hemagglutinin [HA", "PROBLEM", 182, 199], ["a recombinant CVB3", "PROBLEM", 248, 266], ["an HA tag", "PROBLEM", 276, 285], ["this study", "TEST", 324, 334], ["CVB3", "TEST", 393, 397], ["a small protein", "TEST", 399, 414], ["amino acids", "TEST", 421, 432], ["a C-terminal hydrophobic domain", "TREATMENT", 438, 469], ["small", "OBSERVATION_MODIFIER", 11, 16], ["small", "OBSERVATION_MODIFIER", 154, 159], ["epitope tags", "OBSERVATION", 160, 172], ["hydrophobic domain", "OBSERVATION", 451, 469], ["RO membranes", "ANATOMY", 492, 504]]], ["This split-GFP system is based on superfolder GFP, a variant of GFP that folds better, matures more rapidly, and fluoresces more brightly than GFP (36).", [["GFP", "GENE_OR_GENE_PRODUCT", 11, 14], ["GFP", "GENE_OR_GENE_PRODUCT", 46, 49], ["GFP", "GENE_OR_GENE_PRODUCT", 64, 67], ["GFP", "GENE_OR_GENE_PRODUCT", 143, 146], ["superfolder GFP", "PROTEIN", 34, 49], ["GFP", "PROTEIN", 64, 67], ["GFP (36)", "PROTEIN", 143, 151], ["superfolder GFP", "PROBLEM", 34, 49], ["GFP", "TEST", 143, 146]]], ["Like GFP, superfolder GFP has a beta barrel structure consisting of eleven \u03b2-strands, which in this system are split into a large fragment [strands 1 to 10; GFP(S1-10)] and a small fragment [strand 11; GFP(S11)] of only 16 amino acids.", [["amino acids", "CHEMICAL", 223, 234], ["amino acids", "CHEMICAL", 223, 234], ["GFP", "GENE_OR_GENE_PRODUCT", 5, 8], ["superfolder GFP", "GENE_OR_GENE_PRODUCT", 10, 25], ["GFP", "GENE_OR_GENE_PRODUCT", 157, 160], ["S1-10", "GENE_OR_GENE_PRODUCT", 161, 166], ["GFP", "GENE_OR_GENE_PRODUCT", 202, 205], ["amino acids", "AMINO_ACID", 223, 234], ["GFP", "PROTEIN", 5, 8], ["superfolder GFP", "PROTEIN", 10, 25], ["beta barrel structure", "PROTEIN", 32, 53], ["\u03b2-strands", "PROTEIN", 75, 84], ["GFP", "PROTEIN", 157, 160], ["S1", "PROTEIN", 161, 163], ["GFP", "PROTEIN", 202, 205], ["S11", "PROTEIN", 206, 209], ["superfolder GFP", "TEST", 10, 25], ["a beta barrel structure", "PROBLEM", 30, 53], ["eleven \u03b2-strands", "PROBLEM", 68, 84], ["a large fragment", "PROBLEM", 122, 138], ["GFP", "TEST", 157, 160], ["S1", "TEST", 161, 163], ["a small fragment [strand", "PROBLEM", 173, 197], ["GFP", "TEST", 202, 205], ["16 amino acids", "TREATMENT", 220, 234], ["beta barrel", "OBSERVATION_MODIFIER", 32, 43], ["eleven", "OBSERVATION_MODIFIER", 68, 74], ["\u03b2-strands", "OBSERVATION", 75, 84], ["split", "OBSERVATION", 111, 116], ["large", "OBSERVATION_MODIFIER", 124, 129], ["fragment", "OBSERVATION", 130, 138], ["strands", "OBSERVATION_MODIFIER", 140, 147], ["small", "OBSERVATION_MODIFIER", 175, 180], ["fragment", "OBSERVATION", 181, 189]]], ["Separately, these two fragments are nonfluorescent.", [["fragments", "ANATOMY", 22, 31], ["two", "OBSERVATION_MODIFIER", 18, 21], ["fragments", "OBSERVATION", 22, 31], ["nonfluorescent", "OBSERVATION_MODIFIER", 36, 50]]], ["Green fluorescence is emitted only when they assemble into superfolder GFP (34).", [["GFP", "GENE_OR_GENE_PRODUCT", 71, 74], ["fluorescence", "OBSERVATION", 6, 18]]], ["We show that tagging 3A with GFP(S11) does not affect its known functions when 3A is expressed alone.", [["GFP", "GENE_OR_GENE_PRODUCT", 29, 32], ["S11", "GENE_OR_GENE_PRODUCT", 33, 36], ["GFP", "PROTEIN", 29, 32], ["S11", "PROTEIN", 33, 36]]], ["When introduced into the viral genome of CVB3, GFP(S11)-tagged 3A assembled with GFP(S1-10) to illuminate enterovirus ROs as shown by correlative light electron microscopy (CLEM).", [["enterovirus ROs", "DISEASE", 106, 121], ["CVB3", "ORGANISM", 41, 45], ["GFP(S11)-tagged 3A", "GENE_OR_GENE_PRODUCT", 47, 65], ["GFP", "GENE_OR_GENE_PRODUCT", 81, 84], ["S1-10", "GENE_OR_GENE_PRODUCT", 85, 90], ["enterovirus", "ORGANISM", 106, 117], ["ROs", "CANCER", 118, 121], ["viral genome", "DNA", 25, 37], ["GFP(S11)-tagged 3A", "PROTEIN", 47, 65], ["GFP", "PROTEIN", 81, 84], ["S1", "PROTEIN", 85, 87], ["enterovirus ROs", "PROTEIN", 106, 121], ["CVB3", "SPECIES", 41, 45], ["GFP", "TEST", 47, 50], ["GFP", "TEST", 81, 84], ["S1", "TEST", 85, 87], ["illuminate enterovirus ROs", "PROBLEM", 95, 121], ["correlative light electron microscopy", "TEST", 134, 171], ["viral genome", "OBSERVATION", 25, 37]]], ["We illustrate the suitability of CVB3 encoding this split-GFP-tagged 3A for live-cell imaging by monitoring the development of ROs and the disintegration of the Golgi apparatus, as visualized using GM130-mCherry, in infected cells in real time.", [["cell", "ANATOMY", 81, 85], ["Golgi apparatus", "ANATOMY", 161, 176], ["cells", "ANATOMY", 225, 230], ["GM130-mCherry", "CHEMICAL", 198, 211], ["CVB3", "ORGANISM", 33, 37], ["GFP", "GENE_OR_GENE_PRODUCT", 58, 61], ["live-cell", "CELL", 76, 85], ["ROs", "GENE_OR_GENE_PRODUCT", 127, 130], ["Golgi", "CELLULAR_COMPONENT", 161, 166], ["cells", "CELL", 225, 230], ["split-GFP-tagged 3A", "PROTEIN", 52, 71], ["infected cells", "CELL_TYPE", 216, 230], ["CVB3", "SPECIES", 33, 37], ["live-cell imaging", "TEST", 76, 93], ["infected cells", "OBSERVATION", 216, 230]]], ["This new tool simplifies the visualization of enterovirus ROs, avoiding immunolabeling of viral proteins in fixed cells, and will have multiple applications in future studies on the origin, location, and function of enterovirus ROs.3A tagged with GFP(S11) assembles with GFP(S1-10) to yield GFP fluorescence. ::: RESULTSIn order to visualize the enterovirus ROs in living cells, one of the nonstructural proteins that is anchored in the membranes of the ROs should be labeled with a fluorescent tag.", [["cells", "ANATOMY", 114, 119], ["cells", "ANATOMY", 372, 377], ["membranes", "ANATOMY", 437, 446], ["ROs", "ANATOMY", 454, 457], ["enterovirus", "ORGANISM", 46, 57], ["ROs", "GENE_OR_GENE_PRODUCT", 58, 61], ["cells", "CELL", 114, 119], ["enterovirus", "ORGANISM", 216, 227], ["ROs", "GENE_OR_GENE_PRODUCT", 228, 231], ["GFP", "GENE_OR_GENE_PRODUCT", 247, 250], ["S11", "GENE_OR_GENE_PRODUCT", 251, 254], ["GFP", "GENE_OR_GENE_PRODUCT", 271, 274], ["S1-10", "GENE_OR_GENE_PRODUCT", 275, 280], ["GFP", "GENE_OR_GENE_PRODUCT", 291, 294], ["enterovirus", "ORGANISM", 346, 357], ["ROs", "SIMPLE_CHEMICAL", 358, 361], ["cells", "CELL", 372, 377], ["membranes", "CELLULAR_COMPONENT", 437, 446], ["ROs", "GENE_OR_GENE_PRODUCT", 454, 457], ["viral proteins", "PROTEIN", 90, 104], ["fixed cells", "CELL_TYPE", 108, 119], ["GFP", "PROTEIN", 247, 250], ["S11", "PROTEIN", 251, 254], ["GFP", "PROTEIN", 271, 274], ["S1", "PROTEIN", 275, 277], ["enterovirus ROs", "PROTEIN", 346, 361], ["nonstructural proteins", "PROTEIN", 390, 412], ["ROs", "PROTEIN", 454, 457], ["enterovirus ROs", "PROBLEM", 46, 61], ["viral proteins in fixed cells", "PROBLEM", 90, 119], ["multiple applications", "TREATMENT", 135, 156], ["future studies", "TEST", 160, 174], ["enterovirus ROs", "PROBLEM", 216, 231], ["GFP", "TEST", 247, 250], ["GFP", "TEST", 271, 274], ["the enterovirus ROs", "PROBLEM", 342, 361], ["the nonstructural proteins", "PROBLEM", 386, 412], ["a fluorescent tag", "PROBLEM", 481, 498], ["viral proteins", "OBSERVATION", 90, 104], ["fixed cells", "OBSERVATION", 108, 119], ["enterovirus", "OBSERVATION", 346, 357]]], ["A transposon-based insertion mutagenesis study revealed that the N-terminal region of poliovirus 3A tolerates small insertions (32, 37).", [["N-", "CHEMICAL", 65, 67], ["poliovirus 3A", "ORGANISM", 86, 99], ["N-terminal region", "PROTEIN", 65, 82], ["poliovirus 3A", "PROTEIN", 86, 99], ["poliovirus 3A", "SPECIES", 86, 99], ["A transposon-based insertion mutagenesis study", "TEST", 0, 46], ["the N-terminal region of poliovirus 3A", "PROBLEM", 61, 99], ["poliovirus 3A", "OBSERVATION", 86, 99], ["small", "OBSERVATION_MODIFIER", 110, 115], ["insertions", "OBSERVATION_MODIFIER", 116, 126]]], ["Since the 3A proteins of coxsackievirus B3 (CVB3) and poliovirus are highly homologous, these positions were good candidates for introduction of a small tag in CVB3 3A.", [["coxsackievirus B3", "ORGANISM", 25, 42], ["CVB3", "ORGANISM", 44, 48], ["poliovirus", "ORGANISM", 54, 64], ["CVB3 3A", "ORGANISM", 160, 167], ["3A proteins", "PROTEIN", 10, 21], ["coxsackievirus B3", "SPECIES", 25, 42], ["coxsackievirus B3", "SPECIES", 25, 42], ["CVB3", "SPECIES", 44, 48], ["poliovirus", "SPECIES", 54, 64], ["CVB3 3A", "SPECIES", 160, 167], ["coxsackievirus B3 (CVB3", "PROBLEM", 25, 48], ["poliovirus", "PROBLEM", 54, 64], ["a small tag in CVB3 3A", "TREATMENT", 145, 167], ["coxsackievirus B3", "OBSERVATION", 25, 42], ["small", "OBSERVATION_MODIFIER", 147, 152]]], ["We chose to insert GFP(S11) after amino acid 2 in CVB3 3A without using any linker residues, yielding 3A(S11aa2) (Fig. 1A).3A tagged with GFP(S11) assembles with GFP(S1-10) to yield GFP fluorescence. ::: RESULTSBefore introducing GFP(S11) into the viral genome, we first tested whether inserting the tag into 3A at this position would generate GFP fluorescence upon coexpression with GFP(S1-10).", [["amino acid", "CHEMICAL", 34, 44], ["amino acid", "CHEMICAL", 34, 44], ["GFP", "GENE_OR_GENE_PRODUCT", 19, 22], ["S11", "GENE_OR_GENE_PRODUCT", 23, 26], ["amino acid", "AMINO_ACID", 34, 44], ["CVB3", "ORGANISM", 50, 54], ["GFP", "GENE_OR_GENE_PRODUCT", 138, 141], ["S11", "GENE_OR_GENE_PRODUCT", 142, 145], ["GFP", "GENE_OR_GENE_PRODUCT", 162, 165], ["S1-10", "GENE_OR_GENE_PRODUCT", 166, 171], ["GFP", "GENE_OR_GENE_PRODUCT", 182, 185], ["GFP", "GENE_OR_GENE_PRODUCT", 230, 233], ["S11", "GENE_OR_GENE_PRODUCT", 234, 237], ["A", "GENE_OR_GENE_PRODUCT", 310, 311], ["GFP", "GENE_OR_GENE_PRODUCT", 344, 347], ["GFP", "GENE_OR_GENE_PRODUCT", 384, 387], ["S1-10", "GENE_OR_GENE_PRODUCT", 388, 393], ["GFP", "PROTEIN", 19, 22], ["S11", "PROTEIN", 23, 26], ["S11aa2", "PROTEIN", 105, 111], ["GFP", "PROTEIN", 138, 141], ["S11", "PROTEIN", 142, 145], ["GFP", "PROTEIN", 162, 165], ["S1", "PROTEIN", 166, 168], ["GFP", "PROTEIN", 182, 185], ["GFP", "PROTEIN", 230, 233], ["S11", "PROTEIN", 234, 237], ["viral genome", "DNA", 248, 260], ["GFP", "PROTEIN", 384, 387], ["S1", "PROTEIN", 388, 390], ["CVB3", "SPECIES", 50, 54], ["GFP", "TEST", 19, 22], ["amino acid", "TEST", 34, 44], ["any linker residues", "TREATMENT", 72, 91], ["GFP", "TEST", 162, 165], ["GFP fluorescence", "TEST", 182, 198], ["GFP", "TEST", 384, 387], ["viral genome", "OBSERVATION", 248, 260]]], ["Staining with an anti-3A antibody demonstrated that the expression pattern of 3A(S11aa2) resembled that of untagged 3A [i.e., lacking GFP(S11)] in HeLa cells (see Fig. S1A in the supplemental material) and in BGM (buffalo green monkey) cells (data not shown), indicating that the GFP(S11) tag does not alter the localization of 3A.", [["HeLa cells", "ANATOMY", 147, 157], ["green monkey) cells", "ANATOMY", 222, 241], ["anti-3A", "GENE_OR_GENE_PRODUCT", 17, 24], ["3A", "GENE_OR_GENE_PRODUCT", 78, 80], ["S11aa2", "GENE_OR_GENE_PRODUCT", 81, 87], ["3A", "GENE_OR_GENE_PRODUCT", 116, 118], ["GFP", "GENE_OR_GENE_PRODUCT", 134, 137], ["S11", "GENE_OR_GENE_PRODUCT", 138, 141], ["HeLa cells", "CELL", 147, 157], ["S1A", "GENE_OR_GENE_PRODUCT", 168, 171], ["BGM (buffalo green monkey) cells", "CELL", 209, 241], ["GFP", "GENE_OR_GENE_PRODUCT", 280, 283], ["anti-3A antibody", "PROTEIN", 17, 33], ["3A", "PROTEIN", 78, 80], ["S11aa2", "PROTEIN", 81, 87], ["untagged 3A", "PROTEIN", 107, 118], ["GFP", "PROTEIN", 134, 137], ["S11", "PROTEIN", 138, 141], ["HeLa cells", "CELL_LINE", 147, 157], ["S1A", "PROTEIN", 168, 171], ["BGM (buffalo green monkey) cells", "CELL_LINE", 209, 241], ["GFP(S11) tag", "PROTEIN", 280, 292], ["buffalo green monkey", "SPECIES", 214, 234], ["Staining", "TEST", 0, 8], ["an anti-3A antibody", "TEST", 14, 33], ["HeLa cells", "PROBLEM", 147, 157], ["BGM", "TEST", 209, 212], ["HeLa cells", "OBSERVATION", 147, 157]]], ["Coexpression of GFP(S1-10) with 3A(S11aa2), but not with untagged 3A, resulted in a GFP signal that greatly overlapped with the 3A pattern generated with the anti-3A antibody (see Fig. S1B, HeLa cells not shown).", [["HeLa cells", "ANATOMY", 190, 200], ["GFP", "GENE_OR_GENE_PRODUCT", 16, 19], ["S1-10", "GENE_OR_GENE_PRODUCT", 20, 25], ["3A", "GENE_OR_GENE_PRODUCT", 32, 34], ["S11aa2", "GENE_OR_GENE_PRODUCT", 35, 41], ["GFP", "GENE_OR_GENE_PRODUCT", 84, 87], ["anti-3A antibody", "GENE_OR_GENE_PRODUCT", 158, 174], ["S1B", "GENE_OR_GENE_PRODUCT", 185, 188], ["HeLa cells", "CELL", 190, 200], ["GFP(S1-10", "PROTEIN", 16, 25], ["3A", "PROTEIN", 32, 34], ["S11aa2", "PROTEIN", 35, 41], ["untagged 3A", "PROTEIN", 57, 68], ["anti-3A antibody", "PROTEIN", 158, 174], ["HeLa cells", "CELL_LINE", 190, 200], ["GFP", "TEST", 16, 19], ["S1", "TEST", 20, 22], ["a GFP signal", "PROBLEM", 82, 94], ["HeLa cells", "TEST", 190, 200], ["HeLa cells", "OBSERVATION", 190, 200]]], ["Furthermore, 3A(S11aa2) was not GFP fluorescent in the absence of GFP(S1-10) (see Fig. S1A).", [["S11aa2", "GENE_OR_GENE_PRODUCT", 16, 22], ["GFP", "GENE_OR_GENE_PRODUCT", 32, 35], ["GFP", "GENE_OR_GENE_PRODUCT", 66, 69], ["S1A", "GENE_OR_GENE_PRODUCT", 87, 90], ["S11aa2", "PROTEIN", 16, 22], ["GFP", "PROTEIN", 32, 35], ["GFP", "PROTEIN", 66, 69], ["S1", "PROTEIN", 70, 72], ["S1A", "PROTEIN", 87, 90], ["GFP fluorescent", "PROBLEM", 32, 47], ["GFP", "TEST", 66, 69]]], ["Thus, GFP(S1-10) can assemble with 3A(S11aa2) to yield GFP fluorescence at the sites where 3A is localized in the cell.Introduction of GFP(S11) into 3A does not impair its known functions. ::: RESULTSNext, we investigated whether 3A(S11aa2) is able to perform the same functions as untagged 3A.", [["cell", "ANATOMY", 114, 118], ["GFP", "GENE_OR_GENE_PRODUCT", 6, 9], ["S1-10", "GENE_OR_GENE_PRODUCT", 10, 15], ["S11aa2", "GENE_OR_GENE_PRODUCT", 38, 44], ["GFP", "GENE_OR_GENE_PRODUCT", 55, 58], ["cell", "CELL", 114, 118], ["GFP", "GENE_OR_GENE_PRODUCT", 135, 138], ["S11", "GENE_OR_GENE_PRODUCT", 139, 142], ["S11aa2", "GENE_OR_GENE_PRODUCT", 233, 239], ["GFP(S1-10", "PROTEIN", 6, 15], ["S11aa2", "PROTEIN", 38, 44], ["GFP", "PROTEIN", 55, 58], ["GFP(S11)", "PROTEIN", 135, 143], ["S11aa2", "PROTEIN", 233, 239], ["untagged 3A", "PROTEIN", 282, 293], ["GFP", "TEST", 6, 9], ["GFP fluorescence", "TEST", 55, 71], ["Introduction of GFP(S11)", "TREATMENT", 119, 143], ["cell", "ANATOMY", 114, 118]]], ["Enteroviruses hijack the Golgi-resident PI4KB (phosphatidylinositol 4-kinase III\u03b2) via their 3A protein to ROs to enrich these membranes in PI4P (phosphatidylinositol 4-phosphate), an essential lipid for viral RNA replication (22).", [["membranes", "ANATOMY", 127, 136], ["phosphatidylinositol 4-phosphate", "CHEMICAL", 146, 178], ["phosphatidylinositol", "CHEMICAL", 47, 67], ["phosphatidylinositol 4-phosphate", "CHEMICAL", 146, 178], ["PI4KB", "GENE_OR_GENE_PRODUCT", 40, 45], ["phosphatidylinositol 4-kinase III\u03b2", "GENE_OR_GENE_PRODUCT", 47, 81], ["ROs", "SIMPLE_CHEMICAL", 107, 110], ["membranes", "CELLULAR_COMPONENT", 127, 136], ["PI4P (phosphatidylinositol 4-phosphate", "GENE_OR_GENE_PRODUCT", 140, 178], ["Golgi-resident PI4KB", "PROTEIN", 25, 45], ["phosphatidylinositol 4-kinase III\u03b2", "PROTEIN", 47, 81], ["3A protein", "PROTEIN", 93, 103], ["ROs", "PROTEIN", 107, 110], ["phosphatidylinositol", "TEST", 47, 67], ["PI4P (phosphatidylinositol", "TREATMENT", 140, 166], ["phosphate", "TREATMENT", 169, 178], ["an essential lipid", "TREATMENT", 181, 199], ["viral RNA replication", "TREATMENT", 204, 225]]], ["In line with previous observations (22, 38, 39), PI4KB was present in a faint Golgi-like pattern in untransfected HeLa cells, whereas in 3A-transfected cells, an intense PI4KB signal was detected at membranes containing untagged 3A (Fig. 1B).", [["Golgi", "ANATOMY", 78, 83], ["HeLa cells", "ANATOMY", 114, 124], ["cells", "ANATOMY", 152, 157], ["membranes", "ANATOMY", 199, 208], ["PI4KB", "GENE_OR_GENE_PRODUCT", 49, 54], ["Golgi", "CELLULAR_COMPONENT", 78, 83], ["HeLa cells", "CELL", 114, 124], ["cells", "CELL", 152, 157], ["PI4KB", "GENE_OR_GENE_PRODUCT", 170, 175], ["membranes", "CELLULAR_COMPONENT", 199, 208], ["Fig. 1B", "GENE_OR_GENE_PRODUCT", 233, 240], ["PI4KB", "PROTEIN", 49, 54], ["untransfected HeLa cells", "CELL_LINE", 100, 124], ["3A-transfected cells", "CELL_LINE", 137, 157], ["PI4KB", "PROTEIN", 170, 175], ["untagged 3A", "PROTEIN", 220, 231], ["Fig. 1B", "PROTEIN", 233, 240], ["previous observations", "TEST", 13, 34], ["a faint Golgi-like pattern in untransfected HeLa cells", "PROBLEM", 70, 124], ["an intense PI4KB signal", "PROBLEM", 159, 182], ["untransfected HeLa cells", "OBSERVATION", 100, 124], ["transfected cells", "OBSERVATION", 140, 157], ["intense", "OBSERVATION_MODIFIER", 162, 169]]], ["Likewise, in cells coexpressing 3A(S11aa2) and GFP(S1-10), PI4KB recruitment was observed to the membranes containing fluorescent 3A (Fig. 1B).Introduction of GFP(S11) into 3A does not impair its known functions. ::: RESULTSThe enterovirus 3A protein interacts directly with GBF1, an essential host factor for enterovirus replication (27, 30).", [["cells", "ANATOMY", 13, 18], ["membranes", "ANATOMY", 97, 106], ["cells", "CELL", 13, 18], ["3A", "GENE_OR_GENE_PRODUCT", 32, 34], ["S11aa2", "GENE_OR_GENE_PRODUCT", 35, 41], ["GFP", "GENE_OR_GENE_PRODUCT", 47, 50], ["S1-10", "GENE_OR_GENE_PRODUCT", 51, 56], ["PI4KB", "GENE_OR_GENE_PRODUCT", 59, 64], ["membranes", "CELLULAR_COMPONENT", 97, 106], ["Fig. 1B", "GENE_OR_GENE_PRODUCT", 134, 141], ["GFP", "GENE_OR_GENE_PRODUCT", 159, 162], ["S11", "GENE_OR_GENE_PRODUCT", 163, 166], ["enterovirus 3A", "GENE_OR_GENE_PRODUCT", 228, 242], ["GBF1", "GENE_OR_GENE_PRODUCT", 275, 279], ["enterovirus", "ORGANISM", 310, 321], ["3A", "PROTEIN", 32, 34], ["S11aa2", "PROTEIN", 35, 41], ["GFP", "PROTEIN", 47, 50], ["S1", "PROTEIN", 51, 53], ["PI4KB", "PROTEIN", 59, 64], ["fluorescent 3A", "PROTEIN", 118, 132], ["GFP(S11)", "PROTEIN", 159, 167], ["enterovirus 3A protein", "PROTEIN", 228, 250], ["GBF1", "PROTEIN", 275, 279], ["essential host factor", "PROTEIN", 284, 305], ["GFP", "TEST", 47, 50], ["PI4KB recruitment", "TREATMENT", 59, 76], ["Introduction of GFP(S11)", "TREATMENT", 143, 167], ["enterovirus replication", "TREATMENT", 310, 333]]], ["Under normal conditions, GBF1 is an activator of the small GTPase Arf1, which in turn recruits the COP-I complex to Golgi membranes upon activation (40).", [["Golgi membranes", "ANATOMY", 116, 131], ["GBF1", "GENE_OR_GENE_PRODUCT", 25, 29], ["Arf1", "GENE_OR_GENE_PRODUCT", 66, 70], ["COP-I", "GENE_OR_GENE_PRODUCT", 99, 104], ["Golgi membranes", "CELLULAR_COMPONENT", 116, 131], ["GBF1", "PROTEIN", 25, 29], ["small GTPase", "PROTEIN", 53, 65], ["Arf1", "PROTEIN", 66, 70], ["COP-I complex", "PROTEIN", 99, 112], ["the small GTPase Arf1", "PROBLEM", 49, 70], ["normal conditions", "OBSERVATION", 6, 23], ["small", "OBSERVATION_MODIFIER", 53, 58], ["GTPase Arf1", "OBSERVATION", 59, 70], ["Golgi membranes", "OBSERVATION", 116, 131]]], ["The COP-I coat initiates budding of transport vesicles that ferry cargo at the ER-Golgi interface and in the Golgi apparatus (41).", [["transport vesicles", "ANATOMY", 36, 54], ["ER-Golgi", "ANATOMY", 79, 87], ["Golgi apparatus", "ANATOMY", 109, 124], ["COP-I", "GENE_OR_GENE_PRODUCT", 4, 9], ["transport vesicles", "CELLULAR_COMPONENT", 36, 54], ["ferry cargo", "CELLULAR_COMPONENT", 60, 71], ["ER", "GENE_OR_GENE_PRODUCT", 79, 81], ["Golgi", "CELLULAR_COMPONENT", 82, 87], ["Golgi apparatus", "CELLULAR_COMPONENT", 109, 124], ["COP-I coat", "PROTEIN", 4, 14], ["ER", "PROTEIN", 79, 81], ["Golgi interface", "OBSERVATION", 82, 97]]], ["Expression of 3A in isolation leads to the perturbation of ER-to-Golgi transport (30, 42\u201344), as demonstrated by the dissociation of COP-I from Golgi membranes in BGM cells (44), presumably as a result of the interaction of 3A with GBF1 (30, 44).", [["Golgi", "ANATOMY", 65, 70], ["Golgi membranes", "ANATOMY", 144, 159], ["BGM cells", "ANATOMY", 163, 172], ["ER", "GENE_OR_GENE_PRODUCT", 59, 61], ["Golgi", "CELLULAR_COMPONENT", 65, 70], ["COP-I", "GENE_OR_GENE_PRODUCT", 133, 138], ["Golgi membranes", "CELLULAR_COMPONENT", 144, 159], ["BGM cells", "CELL", 163, 172], ["GBF1", "GENE_OR_GENE_PRODUCT", 232, 236], ["ER", "PROTEIN", 59, 61], ["COP-I", "PROTEIN", 133, 138], ["BGM cells", "CELL_LINE", 163, 172], ["GBF1", "PROTEIN", 232, 236], ["Golgi membranes in BGM cells", "PROBLEM", 144, 172], ["dissociation", "OBSERVATION", 117, 129], ["COP", "OBSERVATION", 133, 136], ["Golgi membranes", "OBSERVATION", 144, 159]]], ["Similar to untagged 3A, 3A(S11aa2) visualized by coexpression of GFP(S1-10) clearly caused COP-I dissociation (Fig. 1C).Introduction of GFP(S11) into 3A does not impair its known functions. ::: RESULTSIn addition to the interaction with GBF1, enterovirus 3A also directly binds to the host factor ACBD3 (acyl coenzyme A [acyl-CoA]-binding protein domain 3), although the role of this protein in enterovirus replication is still enigmatic (38, 39, 45\u201347).", [["acyl coenzyme A [acyl-CoA", "CHEMICAL", 304, 329], ["acyl", "CHEMICAL", 304, 308], ["acyl-CoA", "CHEMICAL", 321, 329], ["untagged 3A, 3A", "GENE_OR_GENE_PRODUCT", 11, 26], ["S11", "GENE_OR_GENE_PRODUCT", 27, 30], ["aa2", "GENE_OR_GENE_PRODUCT", 30, 33], ["GFP", "GENE_OR_GENE_PRODUCT", 65, 68], ["S1-10", "GENE_OR_GENE_PRODUCT", 69, 74], ["COP-I", "GENE_OR_GENE_PRODUCT", 91, 96], ["GFP", "GENE_OR_GENE_PRODUCT", 136, 139], ["S11", "GENE_OR_GENE_PRODUCT", 140, 143], ["GBF1", "GENE_OR_GENE_PRODUCT", 237, 241], ["enterovirus 3A", "ORGANISM", 243, 257], ["ACBD3", "GENE_OR_GENE_PRODUCT", 297, 302], ["acyl coenzyme A [acyl-CoA]-binding protein domain 3", "GENE_OR_GENE_PRODUCT", 304, 355], ["enterovirus", "ORGANISM", 395, 406], ["untagged 3A, 3A", "PROTEIN", 11, 26], ["S11aa2", "PROTEIN", 27, 33], ["GFP", "PROTEIN", 65, 68], ["S1", "PROTEIN", 69, 71], ["GFP(S11)", "PROTEIN", 136, 144], ["GBF1", "PROTEIN", 237, 241], ["enterovirus 3A", "PROTEIN", 243, 257], ["host factor", "PROTEIN", 285, 296], ["ACBD3", "PROTEIN", 297, 302], ["acyl coenzyme A [acyl-CoA]-binding protein domain 3", "PROTEIN", 304, 355], ["GFP", "TEST", 65, 68], ["COP-I dissociation", "PROBLEM", 91, 109], ["Introduction of GFP(S11)", "TREATMENT", 120, 144], ["enterovirus 3A", "PROBLEM", 243, 257], ["acyl coenzyme", "TEST", 304, 317], ["A [acyl-CoA]-binding protein domain", "TREATMENT", 318, 353], ["this protein in enterovirus replication", "PROBLEM", 379, 418]]], ["We tested whether 3A(S11aa2) could still interact with GBF1 and ACBD3 in a mammalian two-hybrid system (38, 39).", [["S11", "GENE_OR_GENE_PRODUCT", 21, 24], ["aa2", "GENE_OR_GENE_PRODUCT", 24, 27], ["GBF1", "GENE_OR_GENE_PRODUCT", 55, 59], ["ACBD3", "GENE_OR_GENE_PRODUCT", 64, 69], ["S11aa2", "PROTEIN", 21, 27], ["GBF1", "PROTEIN", 55, 59], ["ACBD3", "PROTEIN", 64, 69], ["ACBD3", "TREATMENT", 64, 69], ["hybrid system", "OBSERVATION", 89, 102]]], ["Similar to untagged 3A, 3A(S11aa2) interacted with GBF1 and ACBD3, even in the presence of overexpressed GFP(S1-10) (see Fig. S2 in the supplemental material).Introduction of GFP(S11) into 3A does not impair its known functions. ::: RESULTSCollectively, our results demonstrate that introduction of GFP(S11) in CVB3 3A after the second residue does not affect the ability of 3A to interact with previously identified host factors or to perform its known functions, which prompted us to introduce GFP(S11) into the viral genome of CVB3.Tagging 3A with GFP(S11) results in a replication-competent CVB3 that generates fluorescent replication organelles. ::: RESULTSIntroduction of the GFP(S11) tag into the infectious clone of CVB3 yielded viable virus, i.e., CVB3-3A(S11aa2).", [["organelles", "ANATOMY", 639, 649], ["clone", "ANATOMY", 715, 720], ["untagged 3A, 3A", "GENE_OR_GENE_PRODUCT", 11, 26], ["S11", "GENE_OR_GENE_PRODUCT", 27, 30], ["aa2", "GENE_OR_GENE_PRODUCT", 30, 33], ["GBF1", "GENE_OR_GENE_PRODUCT", 51, 55], ["ACBD3", "GENE_OR_GENE_PRODUCT", 60, 65], ["GFP", "GENE_OR_GENE_PRODUCT", 105, 108], ["S1-10", "GENE_OR_GENE_PRODUCT", 109, 114], ["GFP", "GENE_OR_GENE_PRODUCT", 175, 178], ["S11", "GENE_OR_GENE_PRODUCT", 179, 182], ["GFP", "GENE_OR_GENE_PRODUCT", 299, 302], ["S11", "GENE_OR_GENE_PRODUCT", 303, 306], ["CVB3 3A", "ORGANISM", 311, 318], ["GFP", "GENE_OR_GENE_PRODUCT", 496, 499], ["S11", "GENE_OR_GENE_PRODUCT", 500, 503], ["CVB3", "ORGANISM", 530, 534], ["Tagging 3A", "GENE_OR_GENE_PRODUCT", 535, 545], ["GFP", "GENE_OR_GENE_PRODUCT", 551, 554], ["S11", "GENE_OR_GENE_PRODUCT", 555, 558], ["CVB3", "ORGANISM", 595, 599], ["organelles", "CELLULAR_COMPONENT", 639, 649], ["GFP", "GENE_OR_GENE_PRODUCT", 682, 685], ["S11", "GENE_OR_GENE_PRODUCT", 686, 689], ["CVB3", "ORGANISM", 724, 728], ["CVB3-3A", "ORGANISM", 757, 764], ["S11aa2", "GENE_OR_GENE_PRODUCT", 765, 771], ["untagged 3A, 3A", "PROTEIN", 11, 26], ["S11aa2", "PROTEIN", 27, 33], ["GBF1", "PROTEIN", 51, 55], ["ACBD3", "PROTEIN", 60, 65], ["GFP", "PROTEIN", 105, 108], ["S1", "PROTEIN", 109, 111], ["S2", "PROTEIN", 126, 128], ["GFP(S11)", "PROTEIN", 175, 183], ["GFP", "PROTEIN", 299, 302], ["S11", "PROTEIN", 303, 306], ["CVB3 3A", "PROTEIN", 311, 318], ["host factors", "PROTEIN", 417, 429], ["GFP", "PROTEIN", 496, 499], ["S11", "PROTEIN", 500, 503], ["viral genome", "DNA", 514, 526], ["Tagging 3A", "PROTEIN", 535, 545], ["GFP", "PROTEIN", 551, 554], ["S11", "PROTEIN", 555, 558], ["GFP(S11) tag", "DNA", 682, 694], ["CVB3", "SPECIES", 311, 315], ["CVB3", "SPECIES", 530, 534], ["CVB3", "SPECIES", 595, 599], ["CVB3", "SPECIES", 724, 728], ["CVB3-3A", "SPECIES", 757, 764], ["GBF1", "TEST", 51, 55], ["ACBD3", "TREATMENT", 60, 65], ["overexpressed GFP", "PROBLEM", 91, 108], ["Introduction of GFP(S11)", "TREATMENT", 159, 183], ["GFP", "TEST", 299, 302], ["the second residue", "PROBLEM", 325, 343], ["a replication", "TREATMENT", 571, 584], ["the GFP", "TEST", 678, 685], ["CVB3", "PROBLEM", 724, 728], ["viable virus", "PROBLEM", 737, 749], ["CVB3", "TEST", 757, 761], ["supplemental material", "OBSERVATION", 136, 157], ["viral genome", "OBSERVATION", 514, 526], ["infectious", "OBSERVATION_MODIFIER", 704, 714], ["viable virus", "OBSERVATION", 737, 749]]], ["Sequence analysis of the viral genome confirmed that the tag was retained in the 3A protein without mutations.", [["tag", "GENE_OR_GENE_PRODUCT", 57, 60], ["viral genome", "DNA", 25, 37], ["3A protein", "PROTEIN", 81, 91], ["Sequence analysis", "TEST", 0, 17], ["the viral genome", "TEST", 21, 37], ["the tag", "TEST", 53, 60], ["mutations", "PROBLEM", 100, 109], ["viral genome", "OBSERVATION", 25, 37]]], ["In addition, we generated a replication-competent CVB3 with the short affinity tag StrepII of 10 residues in 3A [i.e., CVB3-3A(StrepIIaa2)].", [["CVB3", "ORGANISM", 50, 54], ["CVB3-3A", "GENE_OR_GENE_PRODUCT", 119, 126], ["StrepIIaa2", "GENE_OR_GENE_PRODUCT", 127, 137], ["StrepII", "PROTEIN", 83, 90], ["StrepIIaa2", "PROTEIN", 127, 137], ["CVB3", "SPECIES", 50, 54], ["a replication", "TREATMENT", 26, 39], ["the short affinity tag StrepII", "TREATMENT", 60, 90]]], ["Insertion of the StrepII tag also did not affect the known functions of 3A (data not shown), and the tag was retained in 3A for five passages (data not shown), further demonstrating that residue 2 is an amenable site for introduction of a small tag.Tagging 3A with GFP(S11) results in a replication-competent CVB3 that generates fluorescent replication organelles. ::: RESULTSSubsequently, we tested whether the GFP(S11) tag in 3A affects the replication kinetics of the virus.", [["organelles", "ANATOMY", 353, 363], ["Tagging 3A", "GENE_OR_GENE_PRODUCT", 249, 259], ["GFP", "GENE_OR_GENE_PRODUCT", 265, 268], ["S11", "GENE_OR_GENE_PRODUCT", 269, 272], ["CVB3", "ORGANISM", 309, 313], ["organelles", "CELLULAR_COMPONENT", 353, 363], ["GFP(S11) tag in 3A", "GENE_OR_GENE_PRODUCT", 412, 430], ["StrepII tag", "DNA", 17, 28], ["3A", "PROTEIN", 72, 74], ["Tagging 3A", "PROTEIN", 249, 259], ["GFP", "PROTEIN", 265, 268], ["S11", "PROTEIN", 269, 272], ["GFP(S11) tag", "PROTEIN", 412, 424], ["CVB3", "SPECIES", 309, 313], ["the StrepII tag", "TREATMENT", 13, 28], ["residue 2", "PROBLEM", 187, 196], ["a small tag", "PROBLEM", 237, 248], ["a replication", "TREATMENT", 285, 298], ["the GFP", "TEST", 408, 415], ["the virus", "PROBLEM", 467, 476], ["small tag", "OBSERVATION", 239, 248], ["replication kinetics", "OBSERVATION", 443, 463]]], ["Since cells that have been transfected with plasmid DNA are less susceptible to picornavirus infection (48), we generated single-cell clones of HeLa and BGM cells that stably express GFP(S1-10).", [["cells", "ANATOMY", 6, 11], ["single-cell clones", "ANATOMY", 122, 140], ["HeLa", "ANATOMY", 144, 148], ["BGM cells", "ANATOMY", 153, 162], ["picornavirus infection", "DISEASE", 80, 102], ["cells", "CELL", 6, 11], ["DNA", "CELLULAR_COMPONENT", 52, 55], ["single-cell clones", "CELL", 122, 140], ["HeLa", "CELL", 144, 148], ["BGM cells", "CELL", 153, 162], ["GFP", "GENE_OR_GENE_PRODUCT", 183, 186], ["S1-10", "GENE_OR_GENE_PRODUCT", 187, 192], ["plasmid DNA", "DNA", 44, 55], ["single-cell clones", "CELL_LINE", 122, 140], ["HeLa", "CELL_LINE", 144, 148], ["BGM cells", "CELL_LINE", 153, 162], ["GFP", "PROTEIN", 183, 186], ["S1", "PROTEIN", 187, 189], ["plasmid DNA", "PROBLEM", 44, 55], ["picornavirus infection", "PROBLEM", 80, 102], ["BGM cells", "TEST", 153, 162], ["GFP", "TEST", 183, 186], ["plasmid DNA", "OBSERVATION_MODIFIER", 44, 55], ["less susceptible", "OBSERVATION_MODIFIER", 60, 76], ["picornavirus", "OBSERVATION_MODIFIER", 80, 92], ["infection", "OBSERVATION", 93, 102]]], ["Next, we compared the growth kinetics of CVB3-3A(S11aa2) to wild-type (wt) CVB3 in the presence and absence of GFP(S1-10).", [["CVB3-3A", "ORGANISM", 41, 48], ["S11aa2", "GENE_OR_GENE_PRODUCT", 49, 55], ["wild-type (wt) CVB3", "ORGANISM", 60, 79], ["GFP", "GENE_OR_GENE_PRODUCT", 111, 114], ["S11aa2", "PROTEIN", 49, 55], ["GFP", "PROTEIN", 111, 114], ["S1", "PROTEIN", 115, 117], ["CVB3-3A", "SPECIES", 41, 48], ["CVB3", "SPECIES", 75, 79], ["CVB3", "TEST", 41, 45], ["CVB3", "PROBLEM", 75, 79], ["GFP", "TEST", 111, 114]]], ["Samples were subjected to endpoint titration to determine the production of infectious virus or quantitative PCR to measure viral RNA levels.", [["Samples", "ANATOMY", 0, 7], ["viral RNA", "RNA", 124, 133], ["infectious virus", "SPECIES", 76, 92], ["Samples", "TEST", 0, 7], ["endpoint titration", "TREATMENT", 26, 44], ["infectious virus", "PROBLEM", 76, 92], ["quantitative PCR", "TEST", 96, 112], ["viral RNA levels", "TEST", 124, 140]]], ["Replication of wt CVB3 in BGM cells and BGM(GFPS1-10) cells was nearly identical, showing that the presence of GFP(S1-10) did not alter CVB3 replication kinetics (Fig. 2A and B).", [["BGM cells", "ANATOMY", 26, 35], ["BGM(GFPS1-10) cells", "ANATOMY", 40, 59], ["CVB3", "ORGANISM", 18, 22], ["BGM cells", "CELL", 26, 35], ["BGM(GFPS1-10) cells", "CELL", 40, 59], ["GFP", "GENE_OR_GENE_PRODUCT", 111, 114], ["S1-10", "GENE_OR_GENE_PRODUCT", 115, 120], ["CVB3", "ORGANISM", 136, 140], ["BGM cells", "CELL_LINE", 26, 35], ["BGM(GFPS1-10) cells", "CELL_LINE", 40, 59], ["GFP", "PROTEIN", 111, 114], ["S1", "PROTEIN", 115, 117], ["CVB3", "SPECIES", 18, 22], ["CVB3", "SPECIES", 136, 140], ["BGM cells", "TEST", 26, 35], ["BGM", "TEST", 40, 43], ["GFPS1", "TEST", 44, 49], ["cells", "TEST", 54, 59], ["GFP", "TEST", 111, 114]]], ["The replication kinetics of tagged CVB3 in BGM(GFPS1-10) cells also resembled that of BGM cells, indicating that binding of GFP(S1-10) to 3A(S11aa2) does not impede replication (Fig. 2A and B).", [["BGM(GFPS1-10) cells", "ANATOMY", 43, 62], ["BGM cells", "ANATOMY", 86, 95], ["CVB3", "ORGANISM", 35, 39], ["BGM", "CELL", 43, 46], ["GFPS1-10) cells", "CELL", 47, 62], ["BGM cells", "CELL", 86, 95], ["GFP", "GENE_OR_GENE_PRODUCT", 124, 127], ["S1-10", "GENE_OR_GENE_PRODUCT", 128, 133], ["3A", "GENE_OR_GENE_PRODUCT", 138, 140], ["S11aa2", "GENE_OR_GENE_PRODUCT", 141, 147], ["B", "GENE_OR_GENE_PRODUCT", 190, 191], ["BGM(GFPS1-10) cells", "CELL_LINE", 43, 62], ["BGM cells", "CELL_LINE", 86, 95], ["GFP(S1-10) to 3A", "PROTEIN", 124, 140], ["S11aa2", "PROTEIN", 141, 147], ["B", "PROTEIN", 190, 191], ["CVB3", "SPECIES", 35, 39], ["tagged CVB3", "TEST", 28, 39], ["BGM", "TEST", 43, 46], ["GFPS1", "TEST", 47, 52], ["BGM cells", "TEST", 86, 95], ["GFP", "TEST", 124, 127], ["replication", "OBSERVATION", 165, 176]]], ["Both infectious virus production and viral RNA levels of the tagged CVB3 were delayed compared to those of wt CVB3 (Fig. 2B).", [["infectious virus", "ORGANISM", 5, 21], ["CVB3", "ORGANISM", 68, 72], ["CVB3", "ORGANISM", 110, 114], ["Fig. 2B", "ORGANISM", 116, 123], ["viral RNA", "RNA", 37, 46], ["CVB3", "SPECIES", 68, 72], ["CVB3", "SPECIES", 110, 114], ["Both infectious virus production", "PROBLEM", 0, 32], ["viral RNA levels", "TEST", 37, 53], ["the tagged CVB3", "TEST", 57, 72], ["infectious", "OBSERVATION_MODIFIER", 5, 15], ["virus", "OBSERVATION", 16, 21], ["viral RNA", "OBSERVATION", 37, 46]]], ["This delay in replication has also been observed for recombinant polioviruses that encode 3A proteins with small epitope tags (32).", [["3A proteins", "PROTEIN", 90, 101], ["This delay", "PROBLEM", 0, 10], ["recombinant polioviruses", "PROBLEM", 53, 77], ["small epitope tags", "PROBLEM", 107, 125], ["small", "OBSERVATION_MODIFIER", 107, 112], ["epitope tags", "OBSERVATION", 113, 125]]], ["Together, these findings showed that replication of CVB3-3A(S11aa2) is similar to other enteroviruses that encode small tags in a viral protein.Tagging 3A with GFP(S11) results in a replication-competent CVB3 that generates fluorescent replication organelles. ::: RESULTSHaving produced replication-competent CVB3-3A(S11aa2), we then tested whether this virus induced GFP fluorescence in cells expressing GFP(S1-10).", [["organelles", "ANATOMY", 248, 258], ["cells", "ANATOMY", 388, 393], ["CVB3-3A", "ORGANISM", 52, 59], ["S11aa2", "GENE_OR_GENE_PRODUCT", 60, 66], ["enteroviruses", "ORGANISM", 88, 101], ["Tagging 3A", "GENE_OR_GENE_PRODUCT", 144, 154], ["GFP", "GENE_OR_GENE_PRODUCT", 160, 163], ["S11", "GENE_OR_GENE_PRODUCT", 164, 167], ["CVB3", "ORGANISM", 204, 208], ["organelles", "CELLULAR_COMPONENT", 248, 258], ["CVB3-3A", "ORGANISM", 309, 316], ["S11aa2", "GENE_OR_GENE_PRODUCT", 317, 323], ["GFP", "GENE_OR_GENE_PRODUCT", 368, 371], ["cells", "CELL", 388, 393], ["GFP", "GENE_OR_GENE_PRODUCT", 405, 408], ["S1-10", "GENE_OR_GENE_PRODUCT", 409, 414], ["S11aa2", "DNA", 60, 66], ["viral protein", "PROTEIN", 130, 143], ["Tagging 3A", "PROTEIN", 144, 154], ["GFP", "PROTEIN", 160, 163], ["S11", "PROTEIN", 164, 167], ["CVB3-3A", "DNA", 309, 316], ["S11aa2", "DNA", 317, 323], ["GFP", "PROTEIN", 405, 408], ["S1", "PROTEIN", 409, 411], ["CVB3-3A", "SPECIES", 52, 59], ["CVB3", "SPECIES", 204, 208], ["CVB3", "TEST", 52, 56], ["other enteroviruses", "PROBLEM", 82, 101], ["small tags", "PROBLEM", 114, 124], ["a viral protein", "TEST", 128, 143], ["a replication", "TREATMENT", 180, 193], ["this virus", "PROBLEM", 349, 359], ["GFP fluorescence", "TEST", 368, 384], ["GFP", "TEST", 405, 408], ["S1", "TEST", 409, 411], ["enteroviruses", "OBSERVATION", 88, 101], ["small", "OBSERVATION_MODIFIER", 114, 119], ["tags", "OBSERVATION", 120, 124], ["viral protein", "OBSERVATION", 130, 143], ["replication", "OBSERVATION", 287, 298]]], ["Figure 3 shows that these cells do emit GFP fluorescence upon infection with CVB3-3A(S11aa2).", [["cells", "ANATOMY", 26, 31], ["infection", "DISEASE", 62, 71], ["cells", "CELL", 26, 31], ["GFP", "GENE_OR_GENE_PRODUCT", 40, 43], ["CVB3-3A", "ORGANISM", 77, 84], ["S11aa2", "GENE_OR_GENE_PRODUCT", 85, 91], ["these cells", "PROBLEM", 20, 31], ["infection", "PROBLEM", 62, 71], ["CVB3", "TEST", 77, 81], ["infection", "OBSERVATION", 62, 71]]], ["To investigate whether the GFP fluorescence was restricted to the sites where the 3A(S11aa2) proteins are localized in the cell, we first stained cells with an anti-GFP antibody.", [["sites", "ANATOMY", 66, 71], ["cell", "ANATOMY", 123, 127], ["cells", "ANATOMY", 146, 151], ["GFP", "GENE_OR_GENE_PRODUCT", 27, 30], ["S11", "GENE_OR_GENE_PRODUCT", 85, 88], ["aa2", "GENE_OR_GENE_PRODUCT", 88, 91], ["cell", "CELL", 123, 127], ["cells", "CELL", 146, 151], ["anti-GFP", "GENE_OR_GENE_PRODUCT", 160, 168], ["GFP", "PROTEIN", 27, 30], ["3A(S11aa2) proteins", "PROTEIN", 82, 101], ["anti-GFP antibody", "PROTEIN", 160, 177], ["the GFP fluorescence", "TEST", 23, 43], ["an anti-GFP antibody", "TEST", 157, 177]]], ["Figure 3A shows that the anti-GFP antibody recognized GFP(S1-10) as demonstrated by the cytoplasmic staining in uninfected cells, whereas BGM cells lacking GFP(S1-10) were negative (data not shown).", [["cytoplasmic", "ANATOMY", 88, 99], ["cells", "ANATOMY", 123, 128], ["BGM cells", "ANATOMY", 138, 147], ["anti-GFP", "GENE_OR_GENE_PRODUCT", 25, 33], ["GFP", "GENE_OR_GENE_PRODUCT", 54, 57], ["S1-10", "GENE_OR_GENE_PRODUCT", 58, 63], ["cytoplasmic", "ORGANISM_SUBSTANCE", 88, 99], ["cells", "CELL", 123, 128], ["BGM cells", "CELL", 138, 147], ["GFP", "GENE_OR_GENE_PRODUCT", 156, 159], ["S1-10", "GENE_OR_GENE_PRODUCT", 160, 165], ["anti-GFP antibody", "PROTEIN", 25, 42], ["GFP", "PROTEIN", 54, 57], ["S1", "PROTEIN", 58, 60], ["uninfected cells", "CELL_TYPE", 112, 128], ["BGM cells", "CELL_LINE", 138, 147], ["GFP", "PROTEIN", 156, 159], ["S1", "PROTEIN", 160, 162], ["the anti-GFP antibody", "TEST", 21, 42], ["the cytoplasmic staining in uninfected cells", "PROBLEM", 84, 128], ["BGM cells", "TEST", 138, 147], ["GFP", "TEST", 156, 159], ["S1", "TEST", 160, 162], ["cytoplasmic staining", "OBSERVATION", 88, 108], ["uninfected cells", "OBSERVATION", 112, 128]]], ["In infected cells, GFP fluorescence was not observed throughout the cytoplasm but in a pattern that is reminiscent of a 3A staining pattern.", [["cells", "ANATOMY", 12, 17], ["cytoplasm", "ANATOMY", 68, 77], ["cells", "CELL", 12, 17], ["GFP", "GENE_OR_GENE_PRODUCT", 19, 22], ["cytoplasm", "ORGANISM_SUBSTANCE", 68, 77], ["GFP", "PROTEIN", 19, 22], ["infected cells", "PROBLEM", 3, 17], ["GFP fluorescence", "TEST", 19, 35], ["a 3A staining pattern", "PROBLEM", 118, 139], ["infected cells", "OBSERVATION", 3, 17], ["GFP fluorescence", "OBSERVATION", 19, 35]]], ["This suggests that assembled, fluorescent GFP is found only at sites that contain 3A(S11aa2).", [["GFP", "GENE_OR_GENE_PRODUCT", 42, 45], ["aa2", "GENE_OR_GENE_PRODUCT", 88, 91], ["GFP", "PROTEIN", 42, 45], ["S11aa2", "PROTEIN", 85, 91], ["fluorescent GFP", "TEST", 30, 45], ["fluorescent GFP", "OBSERVATION", 30, 45]]], ["Interestingly, while anti-GFP antibody staining in infected cells was detected throughout the cytoplasm, the signal was more intense at regions corresponding to GFP fluorescence.", [["cells", "ANATOMY", 60, 65], ["cytoplasm", "ANATOMY", 94, 103], ["anti-GFP", "GENE_OR_GENE_PRODUCT", 21, 29], ["cells", "CELL", 60, 65], ["cytoplasm", "ORGANISM_SUBSTANCE", 94, 103], ["GFP", "GENE_OR_GENE_PRODUCT", 161, 164], ["anti-GFP antibody", "PROTEIN", 21, 38], ["anti-GFP antibody staining", "TEST", 21, 47], ["infected cells", "PROBLEM", 51, 65], ["GFP fluorescence", "TEST", 161, 177], ["infected cells", "OBSERVATION", 51, 65], ["cytoplasm", "OBSERVATION_MODIFIER", 94, 103], ["more intense", "OBSERVATION_MODIFIER", 120, 132], ["GFP fluorescence", "OBSERVATION", 161, 177]]], ["This is likely the result of recruitment of GFP(S1-10) to sites where 3A is localized.", [["GFP", "GENE_OR_GENE_PRODUCT", 44, 47], ["S1-10", "GENE_OR_GENE_PRODUCT", 48, 53], ["GFP", "PROTEIN", 44, 47], ["S1", "PROTEIN", 48, 50], ["recruitment of GFP", "PROBLEM", 29, 47], ["likely the result of", "UNCERTAINTY", 8, 28], ["recruitment", "OBSERVATION_MODIFIER", 29, 40]]], ["Another possibility is that the anti-GFP antibody has a higher affinity for full-length, assembled GFP.Tagging 3A with GFP(S11) results in a replication-competent CVB3 that generates fluorescent replication organelles. ::: RESULTSTo ensure that GFP fluorescence is emitted exclusively from 3A(S11aa2)-containing sites, cells from the same infection were stained with an anti-3A antibody.", [["organelles", "ANATOMY", 207, 217], ["sites", "ANATOMY", 312, 317], ["cells", "ANATOMY", 319, 324], ["infection", "DISEASE", 339, 348], ["anti-GFP", "GENE_OR_GENE_PRODUCT", 32, 40], ["GFP", "GENE_OR_GENE_PRODUCT", 99, 102], ["Tagging 3A", "GENE_OR_GENE_PRODUCT", 103, 113], ["GFP", "GENE_OR_GENE_PRODUCT", 119, 122], ["S11", "GENE_OR_GENE_PRODUCT", 123, 126], ["CVB3", "ORGANISM", 163, 167], ["organelles", "CELLULAR_COMPONENT", 207, 217], ["GFP", "GENE_OR_GENE_PRODUCT", 245, 248], ["aa2", "GENE_OR_GENE_PRODUCT", 296, 299], ["cells", "CELL", 319, 324], ["anti-3A antibody", "GENE_OR_GENE_PRODUCT", 370, 386], ["anti-GFP antibody", "PROTEIN", 32, 49], ["GFP", "PROTEIN", 99, 102], ["Tagging 3A", "PROTEIN", 103, 113], ["GFP", "PROTEIN", 119, 122], ["S11", "PROTEIN", 123, 126], ["3A(S11aa2)-containing sites", "DNA", 290, 317], ["anti-3A antibody", "PROTEIN", 370, 386], ["CVB3", "SPECIES", 163, 167], ["the anti-GFP antibody", "TEST", 28, 49], ["a replication", "TREATMENT", 139, 152], ["GFP fluorescence", "TEST", 245, 261], ["the same infection", "PROBLEM", 330, 348], ["an anti-3A antibody", "TEST", 367, 386], ["infection", "OBSERVATION", 339, 348]]], ["Figure 3B shows that GFP fluorescence was detected in a pattern that greatly overlapped with 3A visualized by immunofluorescence.", [["GFP", "GENE_OR_GENE_PRODUCT", 21, 24], ["Figure 3B", "TEST", 0, 9], ["GFP fluorescence", "TEST", 21, 37], ["immunofluorescence", "TEST", 110, 128], ["GFP fluorescence", "OBSERVATION", 21, 37]]], ["However, the immunofluorescence with the 3A antibody generated a slightly more extensive 3A pattern, most likely as a consequence of not all 3A(S11aa2) proteins being bound by GFP(S1-10).", [["S11aa2", "GENE_OR_GENE_PRODUCT", 144, 150], ["GFP", "GENE_OR_GENE_PRODUCT", 176, 179], ["S1-10", "GENE_OR_GENE_PRODUCT", 180, 185], ["3A antibody", "PROTEIN", 41, 52], ["3A(S11aa2) proteins", "PROTEIN", 141, 160], ["GFP", "PROTEIN", 176, 179], ["S1", "PROTEIN", 180, 182], ["the immunofluorescence", "TEST", 9, 31], ["the 3A antibody", "TEST", 37, 52], ["a slightly more extensive 3A pattern", "PROBLEM", 63, 99], ["GFP", "TEST", 176, 179], ["slightly more", "OBSERVATION_MODIFIER", 65, 78], ["extensive 3A", "OBSERVATION_MODIFIER", 79, 91], ["most likely", "UNCERTAINTY", 101, 112]]], ["This could be due to partial inaccessibility of 3A(S11aa2) proteins to their GFP(S1-10) counterparts, as 3A proteins localize to densely packed ROs.Tagging 3A with GFP(S11) results in a replication-competent CVB3 that generates fluorescent replication organelles. ::: RESULTSNext, we set out to confirm that the emerging GFP fluorescence is emitted from ROs that contain 3A(S11aa2).", [["organelles", "ANATOMY", 252, 262], ["S11aa2", "GENE_OR_GENE_PRODUCT", 51, 57], ["GFP", "GENE_OR_GENE_PRODUCT", 77, 80], ["S1-10", "GENE_OR_GENE_PRODUCT", 81, 86], ["ROs", "PATHOLOGICAL_FORMATION", 144, 147], ["Tagging 3A", "GENE_OR_GENE_PRODUCT", 148, 158], ["GFP", "GENE_OR_GENE_PRODUCT", 164, 167], ["S11", "GENE_OR_GENE_PRODUCT", 168, 171], ["CVB3", "ORGANISM", 208, 212], ["organelles", "CELLULAR_COMPONENT", 252, 262], ["GFP", "GENE_OR_GENE_PRODUCT", 321, 324], ["ROs", "GENE_OR_GENE_PRODUCT", 354, 357], ["aa2", "GENE_OR_GENE_PRODUCT", 377, 380], ["3A(S11aa2) proteins", "PROTEIN", 48, 67], ["GFP(S1-10) counterparts", "PROTEIN", 77, 100], ["3A proteins", "PROTEIN", 105, 116], ["Tagging 3A", "PROTEIN", 148, 158], ["GFP", "PROTEIN", 164, 167], ["S11", "PROTEIN", 168, 171], ["ROs", "PROTEIN", 354, 357], ["S11aa2", "PROTEIN", 374, 380], ["CVB3", "SPECIES", 208, 212], ["a replication", "TREATMENT", 184, 197], ["the emerging GFP fluorescence", "TEST", 308, 337], ["could be due to", "UNCERTAINTY", 5, 20], ["partial", "OBSERVATION_MODIFIER", 21, 28], ["inaccessibility", "OBSERVATION", 29, 44], ["densely packed", "OBSERVATION_MODIFIER", 129, 143]]], ["To this end, we applied correlative light electron microscopy (CLEM) (49, 50), which provides a direct link between fluorescent signals and the virus-induced structures that underlie them at high resolution.", [["correlative light electron microscopy", "TEST", 24, 61], ["a direct link between fluorescent signals", "PROBLEM", 94, 135], ["the virus-induced structures", "PROBLEM", 140, 168]]], ["The emerging fluorescent signal in BGM(GFPS1-10) cells infected with CVB3-3A(S11aa2) and stained with MitoTracker deep red FM was monitored by live-cell imaging.", [["BGM(GFPS1-10) cells", "ANATOMY", 35, 54], ["cell", "ANATOMY", 148, 152], ["BGM", "CELL", 35, 38], ["GFPS1-10) cells", "CELL", 39, 54], ["CVB3-3A", "ORGANISM", 69, 76], ["S11aa2", "CELL", 77, 83], ["MitoTracker", "SIMPLE_CHEMICAL", 102, 113], ["FM", "MULTI-TISSUE_STRUCTURE", 123, 125], ["cell", "CELL", 148, 152], ["BGM(GFPS1-10) cells", "CELL_LINE", 35, 54], ["CVB3-3A", "SPECIES", 69, 76], ["BGM", "TEST", 35, 38], ["GFPS1", "TEST", 39, 44], ["cells", "TEST", 49, 54], ["CVB3", "TEST", 69, 73], ["MitoTracker deep red FM", "PROBLEM", 102, 125], ["cell imaging", "TEST", 148, 160]]], ["Cells were imaged and fixed at an intermediate time point in infection.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 61, 70], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["infection", "PROBLEM", 61, 70], ["infection", "OBSERVATION", 61, 70]]], ["Following sample processing and EM imaging, the MitoTracker signal and corresponding mitochondria were used to orient fluorescence and EM images with an independent marker.", [["sample", "ANATOMY", 10, 16], ["mitochondria", "ANATOMY", 85, 97], ["MitoTracker", "SIMPLE_CHEMICAL", 48, 59], ["mitochondria", "CELLULAR_COMPONENT", 85, 97], ["sample processing", "TEST", 10, 27], ["EM imaging", "TEST", 32, 42], ["the MitoTracker signal", "TEST", 44, 66], ["EM images", "TEST", 135, 144]]], ["Using this method, 3A(S11aa2) was found to localize to ROs, evident as both tubules and clusters of DMVs and multilamellar structures (Fig. 4).", [["tubules", "ANATOMY", 76, 83], ["DMVs", "ANATOMY", 100, 104], ["multilamellar structures", "ANATOMY", 109, 133], ["S11aa2", "GENE_OR_GENE_PRODUCT", 22, 28], ["ROs", "GENE_OR_GENE_PRODUCT", 55, 58], ["tubules", "TISSUE", 76, 83], ["DMVs", "GENE_OR_GENE_PRODUCT", 100, 104], ["multilamellar structures", "CELLULAR_COMPONENT", 109, 133], ["S11aa2", "PROTEIN", 22, 28], ["ROs", "PROTEIN", 55, 58], ["clusters", "OBSERVATION_MODIFIER", 88, 96], ["multilamellar", "ANATOMY_MODIFIER", 109, 122]]], ["Furthermore, the CLEM results not only show that GFP fluorescence was emitted from bona fide ROs, they also demonstrate that the GFP(S11) insertion in 3A does not affect the development of the different RO morphologies typically observed during enterovirus infections.Live-cell imaging reveals the dynamics of Golgi disassembly in live infected cells. ::: RESULTSEnterovirus infections trigger the disassembly of the Golgi apparatus, which coincides with the formation of early ROs (18, 22).", [["Live-cell", "ANATOMY", 268, 277], ["Golgi", "ANATOMY", 310, 315], ["cells", "ANATOMY", 345, 350], ["Golgi apparatus", "ANATOMY", 417, 432], ["enterovirus infections", "DISEASE", 245, 267], ["infections", "DISEASE", 375, 385], ["GFP", "GENE_OR_GENE_PRODUCT", 49, 52], ["ROs", "GENE_OR_GENE_PRODUCT", 93, 96], ["GFP", "GENE_OR_GENE_PRODUCT", 129, 132], ["S11", "GENE_OR_GENE_PRODUCT", 133, 136], ["enterovirus", "ORGANISM", 245, 256], ["Golgi", "CELLULAR_COMPONENT", 310, 315], ["cells", "CELL", 345, 350], ["Golgi apparatus", "CELLULAR_COMPONENT", 417, 432], ["ROs", "GENE_OR_GENE_PRODUCT", 478, 481], ["GFP(S11) insertion", "DNA", 129, 147], ["live infected cells", "CELL_TYPE", 331, 350], ["GFP fluorescence", "TEST", 49, 65], ["the GFP(S11) insertion", "TREATMENT", 125, 147], ["the different RO morphologies", "PROBLEM", 189, 218], ["enterovirus infections", "PROBLEM", 245, 267], ["Live-cell imaging", "TEST", 268, 285], ["RESULTSEnterovirus infections", "PROBLEM", 356, 385], ["the Golgi apparatus", "TEST", 413, 432], ["early ROs", "PROBLEM", 472, 481], ["enterovirus infections", "OBSERVATION", 245, 267], ["infections", "OBSERVATION", 375, 385], ["Golgi apparatus", "OBSERVATION", 417, 432], ["early", "OBSERVATION_MODIFIER", 472, 477], ["ROs", "OBSERVATION_MODIFIER", 478, 481]]], ["Here, we used live-cell imaging to visualize this process in living cells.", [["live-cell", "ANATOMY", 14, 23], ["cells", "ANATOMY", 68, 73], ["cell", "CELL", 19, 23], ["cells", "CELL", 68, 73], ["living cells", "CELL_TYPE", 61, 73], ["live-cell imaging", "TEST", 14, 31]]], ["To this end, BGM cells stably expressing GFP(S1-10) were transduced with murine leukemia virus (MLV) particles encoding mCherry-GM130 as a traceable marker for the Golgi apparatus.", [["BGM cells", "ANATOMY", 13, 22], ["Golgi apparatus", "ANATOMY", 164, 179], ["BGM cells", "CELL", 13, 22], ["GFP", "GENE_OR_GENE_PRODUCT", 41, 44], ["S1-10", "ORGANISM", 45, 50], ["murine leukemia virus", "ORGANISM", 73, 94], ["MLV", "ORGANISM", 96, 99], ["mCherry-GM130", "GENE_OR_GENE_PRODUCT", 120, 133], ["Golgi apparatus", "CELLULAR_COMPONENT", 164, 179], ["BGM cells", "CELL_LINE", 13, 22], ["GFP", "PROTEIN", 41, 44], ["S1", "PROTEIN", 45, 47], ["mCherry", "PROTEIN", 120, 127], ["GM130", "PROTEIN", 128, 133], ["murine", "SPECIES", 73, 79], ["murine leukemia virus", "SPECIES", 73, 94], ["MLV", "SPECIES", 96, 99], ["BGM cells", "TEST", 13, 22], ["GFP", "TEST", 41, 44], ["S1", "TEST", 45, 47], ["murine leukemia virus", "PROBLEM", 73, 94], ["leukemia virus", "OBSERVATION", 80, 94]]], ["Live-cell confocal imaging was first carried out with a narrow pinhole (95.56 \u00b5m) to detect the first local changes in Golgi structure during infection.", [["Live-cell", "ANATOMY", 0, 9], ["Golgi", "ANATOMY", 119, 124], ["infection", "DISEASE", 142, 151], ["cell", "CELL", 5, 9], ["Golgi", "CELLULAR_COMPONENT", 119, 124], ["confocal imaging", "TEST", 10, 26], ["a narrow pinhole", "TREATMENT", 54, 70], ["the first local changes in Golgi structure during infection", "PROBLEM", 92, 151], ["Golgi structure", "OBSERVATION", 119, 134], ["infection", "OBSERVATION", 142, 151]]], ["As expected, GM130 was observed as a condensed perinuclear signal in uninfected cells (Fig. 5A) or early in infection with CVB3-3A(S11aa2) when fluorescent 3A (which will be further referred to as 3A-GFP) could not yet be detected (Fig. 5B; see Movies S1 and S2 in the supplemental material).", [["perinuclear", "ANATOMY", 47, 58], ["cells", "ANATOMY", 80, 85], ["infection", "DISEASE", 108, 117], ["GM130", "GENE_OR_GENE_PRODUCT", 13, 18], ["perinuclear", "CELLULAR_COMPONENT", 47, 58], ["cells", "CELL", 80, 85], ["Fig. 5A", "CELL", 87, 94], ["CVB3-3A", "ORGANISM", 123, 130], ["S11aa2", "GENE_OR_GENE_PRODUCT", 131, 137], ["fluorescent 3A", "GENE_OR_GENE_PRODUCT", 144, 158], ["3A-GFP", "GENE_OR_GENE_PRODUCT", 197, 203], ["GM130", "PROTEIN", 13, 18], ["uninfected cells", "CELL_TYPE", 69, 85], ["S11aa2", "PROTEIN", 131, 137], ["fluorescent 3A", "PROTEIN", 144, 158], ["3A", "PROTEIN", 197, 199], ["GFP", "PROTEIN", 200, 203], ["S2", "PROTEIN", 259, 261], ["CVB3-3A", "SPECIES", 123, 130], ["a condensed perinuclear signal in uninfected cells", "PROBLEM", 35, 85], ["early in infection", "PROBLEM", 99, 117], ["CVB3", "TEST", 123, 127], ["perinuclear signal", "OBSERVATION", 47, 65], ["uninfected cells", "OBSERVATION", 69, 85], ["infection", "OBSERVATION", 108, 117], ["S2", "ANATOMY", 259, 261]]], ["Strikingly, the first 3A-GFP signal detected in infected cells was rarely associated with GM130, but could instead be observed as distinct cytoplasmic punctae.", [["cells", "ANATOMY", 57, 62], ["GM130", "ANATOMY", 90, 95], ["cytoplasmic punctae", "ANATOMY", 139, 158], ["GFP", "GENE_OR_GENE_PRODUCT", 25, 28], ["cells", "CELL", 57, 62], ["GM130", "GENE_OR_GENE_PRODUCT", 90, 95], ["cytoplasmic", "ORGANISM_SUBSTANCE", 139, 150], ["punctae", "ORGANISM_SUBSTANCE", 151, 158], ["GFP", "PROTEIN", 25, 28], ["infected cells", "CELL_TYPE", 48, 62], ["GM130", "PROTEIN", 90, 95], ["infected cells", "PROBLEM", 48, 62], ["distinct cytoplasmic punctae", "PROBLEM", 130, 158], ["infected cells", "OBSERVATION", 48, 62], ["distinct", "OBSERVATION_MODIFIER", 130, 138], ["cytoplasmic punctae", "OBSERVATION", 139, 158]]], ["Localization of 3A-GFP signal to the Golgi region typically occurred within 25 min (n = 17; range, 0 to 45 min) of initial detection.", [["Golgi region", "ANATOMY", 37, 49], ["GFP", "GENE_OR_GENE_PRODUCT", 19, 22], ["Golgi", "CELLULAR_COMPONENT", 37, 42], ["Golgi region", "DNA", 37, 49], ["initial detection", "TEST", 115, 132], ["Golgi", "ANATOMY_MODIFIER", 37, 42], ["region", "ANATOMY_MODIFIER", 43, 49]]], ["This was followed by a sharp increase in the intensity and number of Golgi-adjacent 3A-GFP punctae and a local perturbation of Golgi morphology, characterized by the onset of GM130 signal fragmentation (Fig. 5B, white asterisk in the GM130 channel).", [["punctae", "ANATOMY", 91, 98], ["Golgi", "ANATOMY", 127, 132], ["GM130", "ANATOMY", 175, 180], ["GM130", "ANATOMY", 234, 239], ["GFP", "GENE_OR_GENE_PRODUCT", 87, 90], ["Golgi", "CELLULAR_COMPONENT", 127, 132], ["GM130", "GENE_OR_GENE_PRODUCT", 175, 180], ["GM130", "GENE_OR_GENE_PRODUCT", 234, 239], ["Golgi-adjacent 3A", "PROTEIN", 69, 86], ["GFP punctae", "PROTEIN", 87, 98], ["GM130", "PROTEIN", 175, 180], ["GM130 channel", "PROTEIN", 234, 247], ["a sharp increase in the intensity", "PROBLEM", 21, 54], ["GM130 signal fragmentation", "PROBLEM", 175, 201], ["white asterisk", "TEST", 212, 226], ["sharp", "OBSERVATION_MODIFIER", 23, 28], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["intensity", "OBSERVATION_MODIFIER", 45, 54], ["number", "OBSERVATION_MODIFIER", 59, 65], ["GFP punctae", "OBSERVATION", 87, 98], ["local perturbation", "OBSERVATION", 105, 123], ["Golgi morphology", "OBSERVATION", 127, 143], ["signal fragmentation", "OBSERVATION", 181, 201]]], ["Interestingly, while this rapidly increasing 3A-GFP signal was clearly detected in the Golgi region, it rarely colocalized directly with the GM130 marker (Fig. 5B, inset), which is in agreement with previous observations in fixed cells (22).", [["Golgi region", "ANATOMY", 87, 99], ["GM130", "ANATOMY", 141, 146], ["cells", "ANATOMY", 230, 235], ["GFP", "GENE_OR_GENE_PRODUCT", 48, 51], ["Golgi region", "CELLULAR_COMPONENT", 87, 99], ["GM130", "GENE_OR_GENE_PRODUCT", 141, 146], ["cells", "CELL", 230, 235], ["GFP", "PROTEIN", 48, 51], ["Golgi region", "PROTEIN", 87, 99], ["GM130", "PROTEIN", 141, 146], ["rapidly", "OBSERVATION_MODIFIER", 26, 33], ["increasing", "OBSERVATION_MODIFIER", 34, 44], ["GFP signal", "OBSERVATION", 48, 58], ["Golgi", "ANATOMY_MODIFIER", 87, 92], ["region", "ANATOMY_MODIFIER", 93, 99]]], ["This suggests that RO membranes originate from a Golgi compartment that is not labeled by the cis-Golgi marker GM130 or that 3A resides there only transiently before accumulating in the ROs.Live-cell imaging reveals the dynamics of Golgi disassembly in live infected cells. ::: RESULTSThe first signs of disruption of Golgi morphology largely began during or even preceding the accumulation of visible 3A signal (Fig. 5B, white asterisk in the 3A-GFP channel; also see Movie S1 in the supplemental material), suggesting that local changes to morphology occur rapidly and may be triggered by 3A accumulation in regions of the Golgi apparatus outside the imaging plane.", [["RO membranes", "ANATOMY", 19, 31], ["Golgi compartment", "ANATOMY", 49, 66], ["cis-Golgi", "ANATOMY", 94, 103], ["Live-cell", "ANATOMY", 190, 199], ["Golgi", "ANATOMY", 232, 237], ["cells", "ANATOMY", 267, 272], ["Golgi", "ANATOMY", 318, 323], ["Golgi apparatus", "ANATOMY", 625, 640], ["RO membranes", "CELLULAR_COMPONENT", 19, 31], ["Golgi compartment", "CELLULAR_COMPONENT", 49, 66], ["cis-Golgi", "CELLULAR_COMPONENT", 94, 103], ["GM130", "GENE_OR_GENE_PRODUCT", 111, 116], ["ROs", "PATHOLOGICAL_FORMATION", 186, 189], ["Golgi", "CELLULAR_COMPONENT", 232, 237], ["cells", "CELL", 267, 272], ["Golgi", "CELLULAR_COMPONENT", 318, 323], ["GFP", "GENE_OR_GENE_PRODUCT", 447, 450], ["Golgi", "CELLULAR_COMPONENT", 625, 630], ["cis-Golgi marker", "PROTEIN", 94, 110], ["GM130", "PROTEIN", 111, 116], ["3A", "PROTEIN", 125, 127], ["live infected cells", "CELL_TYPE", 253, 272], ["GFP channel", "PROTEIN", 447, 458], ["Movie S1", "PROTEIN", 469, 477], ["RO membranes", "PROBLEM", 19, 31], ["Live-cell imaging", "TEST", 190, 207], ["disruption of Golgi morphology", "PROBLEM", 304, 334], ["visible 3A signal (Fig. 5B", "PROBLEM", 394, 420], ["white asterisk", "TEST", 422, 436], ["3A accumulation", "PROBLEM", 591, 606], ["RO membranes", "OBSERVATION", 19, 31], ["Golgi compartment", "OBSERVATION", 49, 66], ["disruption", "OBSERVATION", 304, 314], ["Golgi morphology", "OBSERVATION", 318, 334], ["local", "OBSERVATION", 525, 530], ["may be", "UNCERTAINTY", 571, 577], ["3A accumulation", "OBSERVATION", 591, 606], ["regions", "ANATOMY_MODIFIER", 610, 617], ["Golgi apparatus", "OBSERVATION", 625, 640]]], ["To facilitate the detection of the whole Golgi complex and to monitor large-scale changes in Golgi morphology, imaging was carried out using a wider confocal pinhole (600 \u00b5m).", [["Golgi complex", "ANATOMY", 41, 54], ["Golgi", "ANATOMY", 93, 98], ["Golgi", "CELLULAR_COMPONENT", 41, 46], ["Golgi", "CELLULAR_COMPONENT", 93, 98], ["Golgi complex", "PROTEIN", 41, 54], ["the detection", "TEST", 14, 27], ["imaging", "TEST", 111, 118], ["a wider confocal pinhole", "TREATMENT", 141, 165]]], ["Global Golgi fragmentation typically began 10 to 30 min after 3A started to accumulate in large amounts (Fig. 6) (n = 8; range, 0 to 45 min), which presumably reflects the time taken for the cumulative local changes to become apparent within the entire structure, and was completed 75 to 105 min after the initial detection of 3A-GFP signal (n = 8).", [["Golgi", "ANATOMY", 7, 12], ["Golgi", "CELLULAR_COMPONENT", 7, 12], ["GFP", "GENE_OR_GENE_PRODUCT", 330, 333], ["GFP", "PROTEIN", 330, 333], ["Global Golgi fragmentation", "PROBLEM", 0, 26], ["the cumulative local changes", "PROBLEM", 187, 215], ["the initial detection", "TEST", 302, 323], ["Golgi fragmentation", "OBSERVATION", 7, 26], ["large", "OBSERVATION_MODIFIER", 90, 95], ["amounts", "OBSERVATION_MODIFIER", 96, 103]]], ["Together, these data show that 3A accumulation coincides with the local disruption of Golgi morphology, leading to global fragmentation and eventual disassembly of the Golgi apparatus.", [["Golgi", "ANATOMY", 86, 91], ["Golgi apparatus", "ANATOMY", 168, 183], ["Golgi", "CELLULAR_COMPONENT", 86, 91], ["Golgi apparatus", "CELLULAR_COMPONENT", 168, 183], ["these data", "TEST", 10, 20], ["3A accumulation", "PROBLEM", 31, 46], ["global fragmentation", "PROBLEM", 115, 135], ["local", "OBSERVATION_MODIFIER", 66, 71], ["disruption", "OBSERVATION", 72, 82], ["Golgi morphology", "OBSERVATION", 86, 102], ["global", "OBSERVATION_MODIFIER", 115, 121], ["fragmentation", "OBSERVATION", 122, 135], ["Golgi apparatus", "OBSERVATION", 168, 183]]], ["After complete Golgi fragmentation, the 3A-GFP signal expands throughout the cell and eventually occupies the entire cytoplasm before the cell goes into demise, demonstrating that 3A-GFP signals can be imaged to the point of cell lysis (Movies S1 and S2).Construction of CVB3 encoding both GFP(S1-10) and 3A(S11aa2). ::: RESULTSStudying ROs induced by CVB3 encoding split-GFP-tagged 3A in distinct cell types requires the cellular expression of GFP(S1-10).", [["Golgi", "ANATOMY", 15, 20], ["cell", "ANATOMY", 77, 81], ["cytoplasm", "ANATOMY", 117, 126], ["cell", "ANATOMY", 138, 142], ["cell", "ANATOMY", 225, 229], ["cell", "ANATOMY", 398, 402], ["cellular", "ANATOMY", 422, 430], ["Golgi", "CELLULAR_COMPONENT", 15, 20], ["GFP", "GENE_OR_GENE_PRODUCT", 43, 46], ["cell", "CELL", 77, 81], ["cytoplasm", "ORGANISM_SUBSTANCE", 117, 126], ["cell", "CELL", 138, 142], ["GFP", "GENE_OR_GENE_PRODUCT", 183, 186], ["cell", "CELL", 225, 229], ["CVB3", "ORGANISM", 271, 275], ["GFP", "GENE_OR_GENE_PRODUCT", 290, 293], ["S1-10", "GENE_OR_GENE_PRODUCT", 294, 299], ["3A", "GENE_OR_GENE_PRODUCT", 305, 307], ["S11aa2", "GENE_OR_GENE_PRODUCT", 308, 314], ["ROs", "SIMPLE_CHEMICAL", 337, 340], ["CVB3", "ORGANISM", 352, 356], ["split-GFP-tagged 3A", "GENE_OR_GENE_PRODUCT", 366, 385], ["cell", "CELL", 398, 402], ["cellular", "CELL", 422, 430], ["GFP", "GENE_OR_GENE_PRODUCT", 445, 448], ["S1-10", "GENE_OR_GENE_PRODUCT", 449, 454], ["GFP", "PROTEIN", 43, 46], ["GFP", "PROTEIN", 183, 186], ["S2", "PROTEIN", 251, 253], ["GFP(S1-10) and 3A", "PROTEIN", 290, 307], ["S11aa2", "PROTEIN", 308, 314], ["ROs", "PROTEIN", 337, 340], ["CVB3 encoding split-GFP-tagged 3A", "PROTEIN", 352, 385], ["GFP", "PROTEIN", 445, 448], ["S1", "PROTEIN", 449, 451], ["CVB3", "SPECIES", 271, 275], ["CVB3", "SPECIES", 352, 356], ["complete Golgi fragmentation", "PROBLEM", 6, 34], ["cell lysis", "TEST", 225, 235], ["GFP", "TEST", 445, 448], ["Golgi fragmentation", "OBSERVATION", 15, 34], ["cell", "OBSERVATION", 77, 81], ["entire", "OBSERVATION_MODIFIER", 110, 116], ["cytoplasm", "OBSERVATION_MODIFIER", 117, 126], ["cell lysis", "OBSERVATION", 225, 235], ["S2", "ANATOMY", 251, 253], ["distinct cell types", "OBSERVATION", 389, 408]]], ["To bypass the need for delivering the GFP(S1-10) gene via retroviral transduction or by generating stable cell lines, we constructed a CVB3 that encodes not only 3A(S11aa2) but also GFP(S1-10) (Fig. 7A).", [["cell lines", "ANATOMY", 106, 116], ["GFP", "GENE_OR_GENE_PRODUCT", 38, 41], ["S1-10", "GENE_OR_GENE_PRODUCT", 42, 47], ["retroviral", "ORGANISM", 58, 68], ["cell lines", "CELL", 106, 116], ["CVB3", "ORGANISM", 135, 139], ["S11aa2", "GENE_OR_GENE_PRODUCT", 165, 171], ["GFP", "GENE_OR_GENE_PRODUCT", 182, 185], ["S1-10", "GENE_OR_GENE_PRODUCT", 186, 191], ["Fig. 7A", "GENE_OR_GENE_PRODUCT", 194, 201], ["GFP(S1-10) gene", "DNA", 38, 53], ["cell lines", "CELL_LINE", 106, 116], ["3A", "PROTEIN", 162, 164], ["S11aa2", "PROTEIN", 165, 171], ["GFP", "PROTEIN", 182, 185], ["S1", "PROTEIN", 186, 188], ["CVB3", "SPECIES", 135, 139], ["bypass", "TREATMENT", 3, 9], ["the GFP(S1", "TREATMENT", 34, 44], ["retroviral transduction", "TREATMENT", 58, 81], ["GFP", "TEST", 182, 185], ["bypass", "OBSERVATION", 3, 9], ["stable cell lines", "OBSERVATION", 99, 116]]], ["To do this, the gene encoding GFP(S1-10) was inserted upstream of the capsid coding region (P1) in the infectious clone containing 3A(S11aa2).", [["GFP", "GENE_OR_GENE_PRODUCT", 30, 33], ["S1-10", "GENE_OR_GENE_PRODUCT", 34, 39], ["S11aa2", "GENE_OR_GENE_PRODUCT", 134, 140], ["GFP(S1-10", "PROTEIN", 30, 39], ["capsid coding region", "DNA", 70, 90], ["P1", "DNA", 92, 94], ["S11aa2", "DNA", 134, 140], ["infectious", "OBSERVATION", 103, 113]]], ["GFP(S1-10) was followed by an artificial 3CD cleavage site to release the protein from the P1 region upon translation.", [["GFP", "GENE_OR_GENE_PRODUCT", 0, 3], ["S1-10", "GENE_OR_GENE_PRODUCT", 4, 9], ["GFP", "PROTEIN", 0, 3], ["S1", "PROTEIN", 4, 6], ["3CD cleavage site", "DNA", 41, 58], ["P1 region", "DNA", 91, 100], ["GFP", "TEST", 0, 3], ["an artificial 3CD cleavage site", "TREATMENT", 27, 58]]], ["Viable virus [i.e., CVB3-GFP(S1-10)-3A(S11aa2)] was obtained upon transfection of BGM cells with RNA transcripts of the infectious clone.", [["BGM cells", "ANATOMY", 82, 91], ["clone", "ANATOMY", 131, 136], ["CVB3", "ORGANISM", 20, 24], ["GFP", "GENE_OR_GENE_PRODUCT", 25, 28], ["S1-10)-3A", "GENE_OR_GENE_PRODUCT", 29, 38], ["S11aa2", "GENE_OR_GENE_PRODUCT", 39, 45], ["BGM cells", "CELL", 82, 91], ["clone", "CELL", 131, 136], ["BGM cells", "CELL_LINE", 82, 91], ["RNA transcripts", "RNA", 97, 112], ["Viable virus", "PROBLEM", 0, 12], ["CVB3", "TEST", 20, 24], ["BGM cells", "TEST", 82, 91], ["RNA transcripts", "PROBLEM", 97, 112], ["the infectious clone", "PROBLEM", 116, 136], ["virus", "OBSERVATION", 7, 12], ["infectious clone", "OBSERVATION", 120, 136]]], ["After harvesting CVB3-GFP(S1-10)-3A(S11aa2), we compared its replication kinetics in BGM cells to CVB3-3A(S11aa2) in BGM(GFPS1-10) cells, so that in both cases the 3A(S11aa2) protein would bind to GFP(S1-10).", [["BGM cells", "ANATOMY", 85, 94], ["BGM(GFPS1-10) cells", "ANATOMY", 117, 136], ["CVB3", "ORGANISM", 17, 21], ["GFP", "GENE_OR_GENE_PRODUCT", 22, 25], ["S1-10)-3A", "GENE_OR_GENE_PRODUCT", 26, 35], ["S11aa2", "GENE_OR_GENE_PRODUCT", 36, 42], ["BGM cells", "CELL", 85, 94], ["CVB3-3A", "ORGANISM", 98, 105], ["S11aa2", "CELL", 106, 112], ["BGM", "CELL", 117, 120], ["GFPS1-10) cells", "CELL", 121, 136], ["S11aa2", "GENE_OR_GENE_PRODUCT", 167, 173], ["GFP", "GENE_OR_GENE_PRODUCT", 197, 200], ["S1-10", "GENE_OR_GENE_PRODUCT", 201, 206], ["CVB3-GFP(S1-10)-3A", "DNA", 17, 35], ["S11aa2", "PROTEIN", 36, 42], ["BGM cells", "CELL_LINE", 85, 94], ["BGM(GFPS1-10) cells", "CELL_LINE", 117, 136], ["3A(S11aa2) protein", "PROTEIN", 164, 182], ["GFP", "PROTEIN", 197, 200], ["S1", "PROTEIN", 201, 203], ["CVB3", "SPECIES", 17, 21], ["CVB3", "TEST", 17, 21], ["S1", "TEST", 26, 28], ["BGM cells", "TEST", 85, 94], ["CVB3", "TEST", 98, 102], ["BGM", "TEST", 117, 120], ["GFPS1", "TEST", 121, 126], ["cells", "TEST", 131, 136], ["GFP", "TEST", 197, 200], ["S1", "TEST", 201, 203]]], ["The levels of viral RNA replication were nearly identical for both viruses (Fig. 7B), suggesting that the generation of ROs during the course of infection occurs similarly.", [["infection", "DISEASE", 145, 154], ["ROs", "GENE_OR_GENE_PRODUCT", 120, 123], ["viral RNA replication", "TREATMENT", 14, 35], ["infection", "PROBLEM", 145, 154], ["viral RNA replication", "OBSERVATION", 14, 35], ["infection", "OBSERVATION", 145, 154]]], ["However, the virus encoding both GFP fragments [i.e., CVB3-GFP(S1-10)-3A(S11aa2)] exhibited delayed production of infectious progeny compared to CVB3-3A(S11aa2) (Fig. 7B).", [["GFP", "GENE_OR_GENE_PRODUCT", 33, 36], ["CVB3-GFP", "GENE_OR_GENE_PRODUCT", 54, 62], ["S1-10)-3A", "GENE_OR_GENE_PRODUCT", 63, 72], ["S11aa2", "GENE_OR_GENE_PRODUCT", 73, 79], ["CVB3-3A", "ORGANISM", 145, 152], ["S11aa2", "CELL", 153, 159], ["GFP fragments", "DNA", 33, 46], ["S11aa2", "PROTEIN", 73, 79], ["CVB3-3A", "SPECIES", 145, 152], ["the virus encoding both GFP fragments", "PROBLEM", 9, 46], ["CVB3", "TEST", 54, 58], ["S1", "TEST", 63, 65], ["delayed production of infectious progeny", "PROBLEM", 92, 132], ["CVB3", "TEST", 145, 149], ["virus", "OBSERVATION", 13, 18], ["both", "OBSERVATION_MODIFIER", 28, 32], ["GFP fragments", "OBSERVATION", 33, 46], ["infectious", "OBSERVATION", 114, 124]]], ["In line with a previous study (51), we found that the processing of the artificial 3CD cleavage site between a foreign protein and P1 is suboptimal (see Fig. S3 in the supplemental material), which may explain the delay in progeny virion production.Construction of CVB3 encoding both GFP(S1-10) and 3A(S11aa2). ::: RESULTSNext, we tested whether BGM cells became GFP fluorescent upon infection with CVB3-GFP(S1-10)-3A(S11aa2).", [["virion", "ANATOMY", 231, 237], ["BGM cells", "ANATOMY", 346, 355], ["infection", "DISEASE", 384, 393], ["3CD", "GENE_OR_GENE_PRODUCT", 83, 86], ["S3", "GENE_OR_GENE_PRODUCT", 158, 160], ["CVB3", "ORGANISM", 265, 269], ["GFP", "GENE_OR_GENE_PRODUCT", 284, 287], ["S1-10", "GENE_OR_GENE_PRODUCT", 288, 293], ["3A", "GENE_OR_GENE_PRODUCT", 299, 301], ["S11aa2", "GENE_OR_GENE_PRODUCT", 302, 308], ["BGM cells", "CELL", 346, 355], ["GFP", "GENE_OR_GENE_PRODUCT", 363, 366], ["CVB3", "ORGANISM", 399, 403], ["GFP", "GENE_OR_GENE_PRODUCT", 404, 407], ["S1-10)-3A", "GENE_OR_GENE_PRODUCT", 408, 417], ["S11aa2", "GENE_OR_GENE_PRODUCT", 418, 424], ["3CD cleavage site", "DNA", 83, 100], ["foreign protein", "PROTEIN", 111, 126], ["P1", "PROTEIN", 131, 133], ["S3", "PROTEIN", 158, 160], ["GFP(S1-10) and 3A", "PROTEIN", 284, 301], ["S11aa2", "PROTEIN", 302, 308], ["BGM cells", "CELL_LINE", 346, 355], ["GFP", "PROTEIN", 363, 366], ["CVB3-GFP(S1-10)-3A", "DNA", 399, 417], ["S11aa2", "PROTEIN", 418, 424], ["CVB3", "SPECIES", 265, 269], ["a previous study", "TEST", 13, 29], ["the artificial 3CD cleavage site", "TREATMENT", 68, 100], ["a foreign protein and P1", "TREATMENT", 109, 133], ["the delay in progeny virion production", "PROBLEM", 210, 248], ["BGM cells", "TEST", 346, 355], ["GFP fluorescent upon infection", "PROBLEM", 363, 393], ["CVB3", "TEST", 399, 403], ["S1", "TEST", 408, 410], ["foreign protein", "OBSERVATION", 111, 126], ["supplemental material", "OBSERVATION", 168, 189], ["may explain", "UNCERTAINTY", 198, 209], ["delay", "OBSERVATION_MODIFIER", 214, 219], ["progeny virion production", "OBSERVATION", 223, 248]]], ["Figure 7C shows that GFP fluorescence colocalized with 3A, visualized by using an anti-3A antibody, both early and later in infection.", [["infection", "DISEASE", 124, 133], ["GFP", "GENE_OR_GENE_PRODUCT", 21, 24], ["anti-3A antibody", "GENE_OR_GENE_PRODUCT", 82, 98], ["anti-3A antibody", "PROTEIN", 82, 98], ["Figure 7C", "TEST", 0, 9], ["GFP fluorescence", "TEST", 21, 37], ["an anti-3A antibody", "TREATMENT", 79, 98], ["infection", "PROBLEM", 124, 133], ["infection", "OBSERVATION", 124, 133]]], ["Yet, the GFP fluorescence was substantially dimmer compared to BGM(GFPS1-10) cells infected with CVB3-3A(S11aa2).", [["BGM(GFPS1-10) cells", "ANATOMY", 63, 82], ["GFP", "GENE_OR_GENE_PRODUCT", 9, 12], ["GFPS1-10) cells", "CELL", 67, 82], ["CVB3-3A", "ORGANISM", 97, 104], ["S11aa2", "GENE_OR_GENE_PRODUCT", 105, 111], ["BGM(GFPS1-10) cells", "CELL_LINE", 63, 82], ["CVB3-3A", "SPECIES", 97, 104], ["the GFP fluorescence", "TEST", 5, 25], ["BGM", "TEST", 63, 66], ["GFPS1", "TEST", 67, 72], ["cells", "TEST", 77, 82], ["CVB3", "TEST", 97, 101]]], ["It is plausible that the dimmer signal is a result of the equimolar ratios of 3A(S11aa2) and GFP(S1-10) generated by this virus, while BGM(GFPS1-10) cells produce an excess of GFP(S1-10).", [["BGM(GFPS1-10) cells", "ANATOMY", 135, 154], ["S11aa2", "GENE_OR_GENE_PRODUCT", 81, 87], ["GFP", "GENE_OR_GENE_PRODUCT", 93, 96], ["S1-10", "GENE_OR_GENE_PRODUCT", 97, 102], ["GFPS1-10) cells", "CELL", 139, 154], ["GFP", "GENE_OR_GENE_PRODUCT", 176, 179], ["S1-10", "GENE_OR_GENE_PRODUCT", 180, 185], ["S11aa2", "PROTEIN", 81, 87], ["GFP", "PROTEIN", 93, 96], ["S1", "PROTEIN", 97, 99], ["BGM(GFPS1-10) cells", "CELL_LINE", 135, 154], ["GFP", "PROTEIN", 176, 179], ["S1", "PROTEIN", 180, 182], ["the dimmer signal", "TEST", 21, 38], ["the equimolar ratios", "TEST", 54, 74], ["GFP", "TEST", 93, 96], ["S1", "TEST", 97, 99], ["this virus", "PROBLEM", 117, 127], ["BGM", "TEST", 135, 138], ["GFPS1", "TEST", 139, 144], ["an excess of GFP", "PROBLEM", 163, 179]]], ["Another explanation for the dim GFP fluorescence is the suboptimal cleavage of the artificial cleavage site.", [["GFP", "GENE_OR_GENE_PRODUCT", 32, 35], ["artificial cleavage site", "DNA", 83, 107], ["the dim GFP fluorescence", "PROBLEM", 24, 48], ["the artificial cleavage site", "TREATMENT", 79, 107], ["artificial cleavage", "OBSERVATION", 83, 102]]], ["When GFP(S1-10) is still fused to P1, it might be unable to assemble with 3A(S11aa2) and/or become fluorescent.", [["GFP", "GENE_OR_GENE_PRODUCT", 5, 8], ["S1-10", "GENE_OR_GENE_PRODUCT", 9, 14], ["S11aa2", "GENE_OR_GENE_PRODUCT", 77, 83], ["GFP", "PROTEIN", 5, 8], ["S1", "PROTEIN", 9, 11], ["P1", "DNA", 34, 36], ["3A", "PROTEIN", 74, 76], ["S11aa2", "PROTEIN", 77, 83], ["GFP", "TEST", 5, 8], ["fluorescent", "OBSERVATION", 99, 110]]], ["Nevertheless, these findings suggest that the virus containing both GFP fragments is suitable for live-cell imaging.DISCUSSIONLive-cell imaging is a powerful technology to gain insight into the dynamics of biological processes.", [["cell", "ANATOMY", 103, 107], ["cell", "ANATOMY", 131, 135], ["GFP", "GENE_OR_GENE_PRODUCT", 68, 71], ["cell", "CELL", 103, 107], ["DISCUSSIONLive-cell", "CELL", 116, 135], ["GFP fragments", "DNA", 68, 81], ["the virus containing both GFP fragments", "PROBLEM", 42, 81], ["live-cell imaging", "TEST", 98, 115], ["cell imaging", "TEST", 131, 143], ["virus", "OBSERVATION", 46, 51], ["GFP fragments", "OBSERVATION", 68, 81]]], ["In the field of virology, this method has mostly been applied to visualize the entry and egress pathways of viruses by following the fate of fluorescently labeled, individual virus particles in living cells and monitoring their interactions with cellular structures (52).", [["cells", "ANATOMY", 201, 206], ["cellular structures", "ANATOMY", 246, 265], ["cells", "CELL", 201, 206], ["cellular structures", "MULTI-TISSUE_STRUCTURE", 246, 265], ["living cells", "CELL_TYPE", 194, 206], ["this method", "TREATMENT", 26, 37], ["viruses", "PROBLEM", 108, 115], ["individual virus particles in living cells", "PROBLEM", 164, 206], ["viruses", "OBSERVATION", 108, 115]]], ["To date, imaging replication structures during infection has been reported for only a few viruses, including hepatitis C virus (53, 54), vaccinia virus (55), turnip mosaic virus (56), mouse hepatitis virus (57, 58), and equine arteritis virus (59).", [["infection", "DISEASE", 47, 56], ["hepatitis C virus", "DISEASE", 109, 126], ["vaccinia virus", "DISEASE", 137, 151], ["turnip mosaic virus", "DISEASE", 158, 177], ["mouse hepatitis virus", "DISEASE", 184, 205], ["equine arteritis", "DISEASE", 220, 236], ["hepatitis C virus", "ORGANISM", 109, 126], ["vaccinia virus", "ORGANISM", 137, 151], ["turnip mosaic virus", "ORGANISM", 158, 177], ["mouse hepatitis virus", "ORGANISM", 184, 205], ["equine arteritis virus", "ORGANISM", 220, 242], ["hepatitis C virus", "SPECIES", 109, 126], ["vaccinia virus", "SPECIES", 137, 151], ["turnip mosaic virus", "SPECIES", 158, 177], ["mouse", "SPECIES", 184, 189], ["hepatitis virus", "SPECIES", 190, 205], ["equine arteritis virus", "SPECIES", 220, 242], ["hepatitis C virus", "SPECIES", 109, 126], ["vaccinia virus", "SPECIES", 137, 151], ["turnip mosaic virus", "SPECIES", 158, 177], ["mouse hepatitis virus", "SPECIES", 184, 205], ["equine arteritis virus", "SPECIES", 220, 242], ["imaging replication structures during infection", "PROBLEM", 9, 56], ["a few viruses", "PROBLEM", 84, 97], ["hepatitis C virus", "PROBLEM", 109, 126], ["vaccinia virus", "PROBLEM", 137, 151], ["turnip mosaic virus", "TEST", 158, 177], ["mouse hepatitis virus", "PROBLEM", 184, 205], ["equine arteritis virus", "PROBLEM", 220, 242], ["infection", "OBSERVATION", 47, 56], ["few", "OBSERVATION_MODIFIER", 86, 89], ["viruses", "OBSERVATION", 90, 97], ["hepatitis virus", "OBSERVATION", 190, 205], ["equine arteritis virus", "OBSERVATION", 220, 242]]], ["In most of these studies, replication structures are illuminated by a viral protein that is fused to GFP.", [["GFP", "GENE_OR_GENE_PRODUCT", 101, 104], ["viral protein", "PROTEIN", 70, 83], ["GFP", "PROTEIN", 101, 104], ["these studies", "TEST", 11, 24], ["a viral protein", "TEST", 68, 83]]], ["Recombinant enteroviruses that encode an RO-anchored viral protein fused to GFP (or another fluorescent reporter) have not been reported thus far.", [["enteroviruses", "ORGANISM", 12, 25], ["GFP", "GENE_OR_GENE_PRODUCT", 76, 79], ["RO-anchored viral protein", "PROTEIN", 41, 66], ["GFP", "PROTEIN", 76, 79], ["Recombinant enteroviruses", "PROBLEM", 0, 25], ["anchored viral protein fused", "PROBLEM", 44, 72], ["enteroviruses", "OBSERVATION", 12, 25]]], ["On the other hand, small epitope tags have been successfully introduced into the 3A protein of poliovirus (32), which prompted us to test whether small tags suitable for fluorescent labeling are accepted in the 3A protein of CVB3.", [["poliovirus", "ORGANISM", 95, 105], ["CVB3", "ORGANISM", 225, 229], ["3A protein", "PROTEIN", 81, 91], ["3A protein", "PROTEIN", 211, 221], ["CVB3", "SPECIES", 225, 229], ["small epitope tags", "PROBLEM", 19, 37], ["poliovirus", "PROBLEM", 95, 105], ["small tags", "PROBLEM", 146, 156], ["fluorescent labeling", "TEST", 170, 190], ["small", "OBSERVATION_MODIFIER", 19, 24], ["epitope tags", "OBSERVATION", 25, 37]]], ["The smallest tag for fluorescent labeling of a protein is the tetracysteine tag of 6 to 20 residues (depending on the version), but it requires visualization with biarsenical dyes FlAsH and ReAsH in extra labeling steps and results in fluorescence with a relatively poor quantum yield (60, 61).", [["ReAsH", "CHEMICAL", 190, 195], ["tetracysteine", "CHEMICAL", 62, 75], ["FlAsH", "CHEMICAL", 180, 185], ["ReAsH", "CHEMICAL", 190, 195], ["FlAsH", "SIMPLE_CHEMICAL", 180, 185], ["ReAsH", "SIMPLE_CHEMICAL", 190, 195], ["tetracysteine tag", "PROTEIN", 62, 79], ["ReAsH", "PROTEIN", 190, 195], ["the tetracysteine tag", "TREATMENT", 58, 79], ["visualization", "TEST", 144, 157], ["biarsenical dyes FlAsH", "PROBLEM", 163, 185], ["smallest", "OBSERVATION_MODIFIER", 4, 12], ["tag", "OBSERVATION", 13, 16]]], ["The split-GFP system uses a tag of 16 residues, GFP(S11), which has the advantage that it does not require staining but becomes directly fluorescent upon assembly with the large GFP(S1-10) fragment in living cells (34).", [["cells", "ANATOMY", 208, 213], ["GFP", "GENE_OR_GENE_PRODUCT", 10, 13], ["GFP", "GENE_OR_GENE_PRODUCT", 48, 51], ["S11", "GENE_OR_GENE_PRODUCT", 52, 55], ["GFP", "GENE_OR_GENE_PRODUCT", 178, 181], ["S1-10", "GENE_OR_GENE_PRODUCT", 182, 187], ["cells", "CELL", 208, 213], ["16 residues", "PROTEIN", 35, 46], ["GFP", "PROTEIN", 48, 51], ["S11", "PROTEIN", 52, 55], ["GFP(S1-10) fragment", "PROTEIN", 178, 197], ["staining", "PROBLEM", 107, 115], ["fragment in living cells", "PROBLEM", 189, 213], ["large", "OBSERVATION_MODIFIER", 172, 177]]], ["This system has been successfully applied before in the context of a virus to study the intracellular trafficking of ribonucleoproteins of influenza A virus, where the PB2 polymerase subunit was tagged with GFP(S11) (62).", [["intracellular", "ANATOMY", 88, 101], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 88, 101], ["influenza A virus", "ORGANISM", 139, 156], ["GFP", "GENE_OR_GENE_PRODUCT", 207, 210], ["ribonucleoproteins", "PROTEIN", 117, 135], ["PB2 polymerase subunit", "PROTEIN", 168, 190], ["GFP", "PROTEIN", 207, 210], ["S11", "PROTEIN", 211, 214], ["influenza A virus", "SPECIES", 139, 156], ["influenza A virus", "SPECIES", 139, 156], ["a virus", "PROBLEM", 67, 74], ["influenza A virus", "PROBLEM", 139, 156], ["the PB2 polymerase subunit", "TEST", 164, 190], ["GFP", "TEST", 207, 210]]], ["In our study, we incorporated GFP(S11) into the RO-anchored 3A protein of CVB3.", [["GFP", "GENE_OR_GENE_PRODUCT", 30, 33], ["S11", "GENE_OR_GENE_PRODUCT", 34, 37], ["RO-anchored 3A", "GENE_OR_GENE_PRODUCT", 48, 62], ["CVB3", "ORGANISM", 74, 78], ["GFP", "PROTEIN", 30, 33], ["S11", "PROTEIN", 34, 37], ["RO-anchored 3A protein", "PROTEIN", 48, 70], ["CVB3", "SPECIES", 74, 78], ["our study", "TEST", 3, 12], ["CVB3", "PROBLEM", 74, 78]]], ["We show that the introduction of GFP(S11) after the second residue does not affect the localization or function of 3A when it is expressed in isolation.", [["GFP", "GENE_OR_GENE_PRODUCT", 33, 36], ["S11", "GENE_OR_GENE_PRODUCT", 37, 40], ["3A", "GENE_OR_GENE_PRODUCT", 115, 117], ["GFP", "PROTEIN", 33, 36], ["S11", "PROTEIN", 37, 40], ["3A", "PROTEIN", 115, 117], ["GFP(S11", "TREATMENT", 33, 40], ["the second residue", "PROBLEM", 48, 66]]], ["Whether binding of GFP(S1-10) affects the function of 3A(S11aa2) proteins remains unknown, as it is possible that not all 3A(S11aa2) proteins are bound by the GFP(S1-10) counterparts.", [["GFP", "GENE_OR_GENE_PRODUCT", 19, 22], ["S1-10", "GENE_OR_GENE_PRODUCT", 23, 28], ["3A", "GENE_OR_GENE_PRODUCT", 54, 56], ["S11aa2", "GENE_OR_GENE_PRODUCT", 57, 63], ["S11aa2", "GENE_OR_GENE_PRODUCT", 125, 131], ["GFP", "GENE_OR_GENE_PRODUCT", 159, 162], ["S1-10", "GENE_OR_GENE_PRODUCT", 163, 168], ["GFP(S1-10", "PROTEIN", 19, 28], ["3A(S11aa2) proteins", "PROTEIN", 54, 73], ["3A(S11aa2) proteins", "PROTEIN", 122, 141], ["GFP(S1-10) counterparts", "PROTEIN", 159, 182], ["GFP", "TEST", 19, 22]]], ["Therefore, the subset of unbound 3A(S11aa2) proteins could be solely responsible for exerting the 3A functions.DISCUSSIONHaving found that the 3A protein was not functionally hampered by the introduction of the GFP(S11) tag, we generated a recombinant CVB3 that encodes 3A(S11aa2).", [["unbound 3A", "GENE_OR_GENE_PRODUCT", 25, 35], ["S11", "GENE_OR_GENE_PRODUCT", 36, 39], ["aa2", "GENE_OR_GENE_PRODUCT", 39, 42], ["GFP", "GENE_OR_GENE_PRODUCT", 211, 214], ["S11", "GENE_OR_GENE_PRODUCT", 215, 218], ["CVB3", "ORGANISM", 252, 256], ["S11aa2", "GENE_OR_GENE_PRODUCT", 273, 279], ["unbound 3A(S11aa2) proteins", "PROTEIN", 25, 52], ["3A protein", "PROTEIN", 143, 153], ["GFP(S11) tag", "PROTEIN", 211, 223], ["recombinant CVB3 that encodes 3A", "PROTEIN", 240, 272], ["S11aa2", "PROTEIN", 273, 279], ["CVB3", "SPECIES", 252, 256], ["the 3A protein", "TEST", 139, 153]]], ["Infections of this virus in BGM cells stably expressing GFP(S1-10) yielded discrete fluorescent signals.", [["BGM cells", "ANATOMY", 28, 37], ["BGM cells", "CELL", 28, 37], ["GFP", "GENE_OR_GENE_PRODUCT", 56, 59], ["BGM cells", "CELL_LINE", 28, 37], ["GFP", "PROTEIN", 56, 59], ["S1", "PROTEIN", 60, 62], ["this virus", "PROBLEM", 14, 24], ["BGM cells", "TEST", 28, 37], ["discrete fluorescent signals", "PROBLEM", 75, 103], ["fluorescent signals", "OBSERVATION", 84, 103]]], ["However, confirming that the fluorescent foci localize to virus-induced structures demands the higher-resolution images of subcellular structures, in the context of their surroundings, that EM can provide.", [["foci", "ANATOMY", 41, 45], ["subcellular structures", "ANATOMY", 123, 145], ["the fluorescent foci", "PROBLEM", 25, 45], ["virus", "PROBLEM", 58, 63], ["foci", "OBSERVATION", 41, 45], ["virus", "OBSERVATION", 58, 63], ["subcellular structures", "ANATOMY", 123, 145]]], ["Establishing this link with ultrastructure is particularly interesting in the case of enteroviruses, since their ROs can adopt various morphologies during infection (i.e., tubules, DMVs, and multilamellar structures) which, as observed by EM, often coexist.", [["tubules", "ANATOMY", 172, 179], ["DMVs", "ANATOMY", 181, 185], ["multilamellar structures", "ANATOMY", 191, 215], ["enteroviruses", "DISEASE", 86, 99], ["infection", "DISEASE", 155, 164], ["enteroviruses", "ORGANISM", 86, 99], ["ROs", "SIMPLE_CHEMICAL", 113, 116], ["tubules", "TISSUE", 172, 179], ["DMVs", "GENE_OR_GENE_PRODUCT", 181, 185], ["multilamellar structures", "CELLULAR_COMPONENT", 191, 215], ["enteroviruses", "PROBLEM", 86, 99], ["infection", "PROBLEM", 155, 164], ["tubules, DMVs, and multilamellar structures", "PROBLEM", 172, 215], ["enteroviruses", "OBSERVATION", 86, 99], ["infection", "OBSERVATION", 155, 164]]], ["In this study, CLEM was employed to confirm that the GFP fluorescent foci localize to ROs and to establish which subset of enterovirus RO morphologies this fluorescence corresponded to.", [["foci", "ANATOMY", 69, 73], ["GFP", "GENE_OR_GENE_PRODUCT", 53, 56], ["ROs", "GENE_OR_GENE_PRODUCT", 86, 89], ["enterovirus", "ORGANISM", 123, 134], ["ROs", "PROTEIN", 86, 89], ["this study", "TEST", 3, 13], ["the GFP fluorescent foci", "PROBLEM", 49, 73], ["enterovirus RO morphologies", "PROBLEM", 123, 150]]], ["CLEM revealed that the GFP fluorescence was present at bona fide ROs, which took the form of both tubular structures and DMVs resembling those observed previously with wt CVB3 in Vero cells (18).", [["tubular structures", "ANATOMY", 98, 116], ["DMVs", "ANATOMY", 121, 125], ["Vero cells", "ANATOMY", 179, 189], ["GFP", "GENE_OR_GENE_PRODUCT", 23, 26], ["ROs", "GENE_OR_GENE_PRODUCT", 65, 68], ["tubular structures", "TISSUE", 98, 116], ["DMVs", "GENE_OR_GENE_PRODUCT", 121, 125], ["CVB3", "ORGANISM", 171, 175], ["Vero cells", "CELL", 179, 189], ["CLEM", "PROTEIN", 0, 4], ["Vero cells", "CELL_LINE", 179, 189], ["the GFP fluorescence", "TEST", 19, 39], ["DMVs", "PROBLEM", 121, 125], ["fide ROs", "OBSERVATION", 60, 68], ["both", "ANATOMY_MODIFIER", 93, 97], ["tubular", "ANATOMY_MODIFIER", 98, 105]]], ["Split-GFP CLEM thus allows the unambiguous identification of RO morphologies underlying the 3A signal and opens up new possibilities for a better understanding of the requirements for their development.", [["GFP", "GENE_OR_GENE_PRODUCT", 6, 9], ["Split-GFP CLEM", "PROTEIN", 0, 14]]], ["For instance, while immunogold labeling of proteins is a popular technique that couples an electron-dense gold particle to the protein of interest, allowing it to be visualized by EM, its success depends largely upon the antibody used and the resilience of epitopes during EM sample preparation.", [["sample", "ANATOMY", 276, 282], ["electron", "SIMPLE_CHEMICAL", 91, 99], ["epitopes", "PROTEIN", 257, 265], ["an electron-dense gold particle", "PROBLEM", 88, 119], ["the antibody", "TREATMENT", 217, 229], ["EM sample preparation", "TREATMENT", 273, 294], ["dense", "OBSERVATION_MODIFIER", 100, 105], ["gold particle", "OBSERVATION", 106, 119]]], ["In our experience, sample preparation procedures for immunolabeling of CVB3 3A that retain RO membranes unfortunately do so at the expense of viral epitope integrity, resulting in insufficient labeling of 3A (unpublished data).DISCUSSIONEnterovirus ROs were imaged in living BGM(GFPS1-10) cells upon infection with CVB3-3A(S11aa2).", [["sample", "ANATOMY", 19, 25], ["RO membranes", "ANATOMY", 91, 103], ["BGM(GFPS1-10) cells", "ANATOMY", 275, 294], ["infection", "DISEASE", 300, 309], ["CVB3 3A", "ORGANISM", 71, 78], ["BGM(GFPS1-10) cells", "CELL", 275, 294], ["CVB3-3A", "ORGANISM", 315, 322], ["S11aa2", "GENE_OR_GENE_PRODUCT", 323, 329], ["CVB3 3A", "PROTEIN", 71, 78], ["BGM(GFPS1-10) cells", "CELL_LINE", 275, 294], ["CVB3", "SPECIES", 71, 75], ["DISCUSSIONEnterovirus", "SPECIES", 227, 248], ["CVB3-3A", "SPECIES", 315, 322], ["sample preparation procedures", "TEST", 19, 48], ["immunolabeling of CVB3 3A", "TREATMENT", 53, 78], ["RO membranes", "PROBLEM", 91, 103], ["viral epitope integrity", "PROBLEM", 142, 165], ["living BGM", "TEST", 268, 278], ["GFPS1", "TEST", 279, 284], ["infection", "PROBLEM", 300, 309], ["CVB3", "TEST", 315, 319], ["viral epitope integrity", "OBSERVATION", 142, 165], ["infection", "OBSERVATION", 300, 309]]], ["As a proof of concept, we also expressed GM130-mCherry in these cells to visualize Golgi disassembly in real time.", [["cells", "ANATOMY", 64, 69], ["Golgi", "ANATOMY", 83, 88], ["GM", "CHEMICAL", 41, 43], ["mCherry", "GENE_OR_GENE_PRODUCT", 47, 54], ["cells", "CELL", 64, 69], ["Golgi", "CELLULAR_COMPONENT", 83, 88], ["GM130", "PROTEIN", 41, 46], ["mCherry", "PROTEIN", 47, 54]]], ["The onset of Golgi fragmentation was found to correspond to a period of rapid 3A accumulation in the Golgi region.", [["Golgi", "ANATOMY", 13, 18], ["Golgi region", "ANATOMY", 101, 113], ["Golgi", "CELLULAR_COMPONENT", 13, 18], ["Golgi region", "CELLULAR_COMPONENT", 101, 113], ["Golgi fragmentation", "PROBLEM", 13, 32], ["rapid 3A accumulation in the Golgi region", "PROBLEM", 72, 113], ["Golgi fragmentation", "OBSERVATION", 13, 32], ["rapid", "OBSERVATION_MODIFIER", 72, 77], ["3A accumulation", "OBSERVATION", 78, 93], ["Golgi", "ANATOMY_MODIFIER", 101, 106], ["region", "ANATOMY_MODIFIER", 107, 113]]], ["Under the experimental conditions used, Golgi disruption was completed within 75 to 105 min after the first detection of 3A-GFP.", [["Golgi", "ANATOMY", 40, 45], ["Golgi", "CELLULAR_COMPONENT", 40, 45], ["GFP", "GENE_OR_GENE_PRODUCT", 124, 127], ["GFP", "PROTEIN", 124, 127], ["Golgi disruption", "PROBLEM", 40, 56]]], ["Interestingly, while 3A accumulation occurred adjacent to the GM130 signal, 3A rarely colocalized with GM130-mCherry before and during Golgi disassembly.", [["GM130", "ANATOMY", 62, 67], ["Golgi", "ANATOMY", 135, 140], ["GM130-mCherry", "CHEMICAL", 103, 116], ["GM130", "GENE_OR_GENE_PRODUCT", 62, 67], ["GM130", "GENE_OR_GENE_PRODUCT", 103, 108], ["mCherry", "GENE_OR_GENE_PRODUCT", 109, 116], ["Golgi", "CELLULAR_COMPONENT", 135, 140], ["GM130", "PROTEIN", 62, 67], ["GM130", "PROTEIN", 103, 108], ["mCherry", "PROTEIN", 109, 116]]], ["While this does not preclude the transient localization of 3A to the cis-Golgi, our findings suggest that ROs may be generated from another Golgi compartment not labeled by GM130, which is in line with previous observations that suggest that RO formation is initiated at the trans-Golgi network (22).DISCUSSIONEnteroviruses can infect both polarized and nonpolarized cells.", [["cis-Golgi", "ANATOMY", 69, 78], ["Golgi compartment", "ANATOMY", 140, 157], ["GM130", "ANATOMY", 173, 178], ["trans-Golgi network", "ANATOMY", 275, 294], ["cells", "ANATOMY", 367, 372], ["RO", "CHEMICAL", 242, 244], ["3A", "GENE_OR_GENE_PRODUCT", 59, 61], ["cis-Golgi", "CELLULAR_COMPONENT", 69, 78], ["ROs", "GENE_OR_GENE_PRODUCT", 106, 109], ["Golgi compartment", "CELLULAR_COMPONENT", 140, 157], ["GM130", "GENE_OR_GENE_PRODUCT", 173, 178], ["RO", "SIMPLE_CHEMICAL", 242, 244], ["cells", "CELL", 367, 372], ["cis-Golgi", "PROTEIN", 69, 78], ["ROs", "PROTEIN", 106, 109], ["GM130", "PROTEIN", 173, 178], ["polarized and nonpolarized cells", "CELL_TYPE", 340, 372], ["RO formation", "PROBLEM", 242, 254], ["polarized", "OBSERVATION_MODIFIER", 340, 349], ["nonpolarized cells", "OBSERVATION", 354, 372]]], ["The use of CVB3 encoding split-GFP-tagged 3A in distinct cell types relies on the cellular expression of GFP(S1-10).", [["cell", "ANATOMY", 57, 61], ["cellular", "ANATOMY", 82, 90], ["CVB3", "ORGANISM", 11, 15], ["split-GFP-tagged 3A", "GENE_OR_GENE_PRODUCT", 25, 44], ["cell", "CELL", 57, 61], ["cellular", "CELL", 82, 90], ["GFP", "GENE_OR_GENE_PRODUCT", 105, 108], ["S1-10", "GENE_OR_GENE_PRODUCT", 109, 114], ["CVB3 encoding split-GFP-tagged 3A", "PROTEIN", 11, 44], ["GFP", "PROTEIN", 105, 108], ["S1", "PROTEIN", 109, 111], ["CVB3", "SPECIES", 11, 15], ["GFP", "TEST", 105, 108], ["distinct cell types", "OBSERVATION", 48, 67]]], ["As an alternative to delivering the GFP(S1-10) gene via transduction, we introduced the coding sequence of GFP(S1-10) into the viral genome together with 3A(S11aa2).", [["GFP", "GENE_OR_GENE_PRODUCT", 36, 39], ["S1-10", "GENE_OR_GENE_PRODUCT", 40, 45], ["GFP", "GENE_OR_GENE_PRODUCT", 107, 110], ["S1-10", "GENE_OR_GENE_PRODUCT", 111, 116], ["S11aa2", "GENE_OR_GENE_PRODUCT", 157, 163], ["GFP(S1-10) gene", "DNA", 36, 51], ["coding sequence", "DNA", 88, 103], ["GFP(S1-10", "DNA", 107, 116], ["viral genome", "DNA", 127, 139], ["S11aa2", "DNA", 157, 163], ["the GFP", "TEST", 32, 39], ["viral genome", "OBSERVATION", 127, 139]]], ["This new recombinant CVB3 encoding both GFP fragments also induced GFP fluorescent foci that colocalized with 3A.", [["foci", "ANATOMY", 83, 87], ["CVB3", "ORGANISM", 21, 25], ["GFP", "GENE_OR_GENE_PRODUCT", 40, 43], ["GFP", "GENE_OR_GENE_PRODUCT", 67, 70], ["GFP fragments", "DNA", 40, 53], ["CVB3", "SPECIES", 21, 25], ["This new recombinant CVB3", "PROBLEM", 0, 25], ["both GFP fragments", "PROBLEM", 35, 53], ["GFP fluorescent foci", "PROBLEM", 67, 87], ["GFP fragments", "OBSERVATION", 40, 53], ["GFP", "OBSERVATION", 67, 70], ["fluorescent foci", "OBSERVATION", 71, 87]]], ["While progeny virion production by this virus was delayed, the viral RNA levels were very similar to the levels in CVB3-3A(S11aa2) infection of BGM(GFPS1-10) cells, implying that the \u201ctwo-fragment virus\u201d retained its ability to form ROs.", [["BGM(GFPS1-10) cells", "ANATOMY", 144, 163], ["infection", "DISEASE", 131, 140], ["CVB3-3A", "ORGANISM", 115, 122], ["S11aa2", "GENE_OR_GENE_PRODUCT", 123, 129], ["BGM", "CELL", 144, 147], ["GFPS1-10) cells", "CELL", 148, 163], ["ROs", "PATHOLOGICAL_FORMATION", 233, 236], ["BGM(GFPS1-10) cells", "CELL_LINE", 144, 163], ["ROs", "PROTEIN", 233, 236], ["CVB3-3A", "SPECIES", 115, 122], ["this virus", "PROBLEM", 35, 45], ["the viral RNA levels", "TEST", 59, 79], ["the levels", "TEST", 101, 111], ["CVB3", "TEST", 115, 119], ["infection", "PROBLEM", 131, 140], ["BGM", "TEST", 144, 147], ["GFPS1", "TEST", 148, 153], ["the \u201ctwo-fragment virus", "PROBLEM", 179, 202], ["virion production", "OBSERVATION", 14, 31], ["fragment virus", "OBSERVATION", 188, 202]]], ["Hence, this virus would be suitable for studying enterovirus ROs in physiologically more relevant cell types, including pancreatic cells (14) and 3D-cultured CaCo-2 cells (63), without the need for ectopic expression of GFP(S1-10).DISCUSSIONIn conclusion, we have presented split-GFP-tagged CVB3 as a new tool for the direct visualization of enterovirus ROs in living cells, which will allow the study of their dynamics.", [["cell", "ANATOMY", 98, 102], ["pancreatic cells", "ANATOMY", 120, 136], ["CaCo-2 cells", "ANATOMY", 158, 170], ["cells", "ANATOMY", 368, 373], ["enterovirus", "ORGANISM", 49, 60], ["ROs", "SIMPLE_CHEMICAL", 61, 64], ["cell", "CELL", 98, 102], ["pancreatic cells", "CELL", 120, 136], ["CaCo-2 cells", "CELL", 158, 170], ["GFP", "GENE_OR_GENE_PRODUCT", 220, 223], ["S1-10", "GENE_OR_GENE_PRODUCT", 224, 229], ["GFP", "GENE_OR_GENE_PRODUCT", 280, 283], ["CVB3", "ORGANISM", 291, 295], ["enterovirus", "ORGANISM", 342, 353], ["ROs", "SIMPLE_CHEMICAL", 354, 357], ["cells", "CELL", 368, 373], ["pancreatic cells", "CELL_TYPE", 120, 136], ["3D-cultured CaCo-2 cells", "CELL_LINE", 146, 170], ["GFP", "PROTEIN", 220, 223], ["S1", "PROTEIN", 224, 226], ["GFP", "PROTEIN", 280, 283], ["enterovirus ROs", "PROTEIN", 342, 357], ["living cells", "CELL_TYPE", 361, 373], ["enterovirus", "SPECIES", 49, 60], ["CVB3", "SPECIES", 291, 295], ["this virus", "PROBLEM", 7, 17], ["studying enterovirus ROs", "TEST", 40, 64], ["pancreatic cells", "TEST", 120, 136], ["3D-cultured CaCo", "TEST", 146, 162], ["ectopic expression of GFP", "PROBLEM", 198, 223], ["the direct visualization", "TEST", 314, 338], ["enterovirus ROs", "PROBLEM", 342, 357], ["the study", "TEST", 392, 401], ["pancreatic", "ANATOMY", 120, 130]]], ["Furthermore, the combination of live-cell imaging with CLEM will enable us to establish a direct link between events observed by fluorescence microscopy and morphologically distinct ROs, which could shed light onto the possible differentiated roles of these different virus-induced structures in enterovirus infection.", [["cell", "ANATOMY", 37, 41], ["enterovirus infection", "DISEASE", 296, 317], ["cell", "CELL", 37, 41], ["ROs", "GENE_OR_GENE_PRODUCT", 182, 185], ["enterovirus", "ORGANISM", 296, 307], ["live-cell imaging", "TEST", 32, 49], ["fluorescence microscopy", "TEST", 129, 152], ["these different virus", "PROBLEM", 252, 273], ["enterovirus infection", "PROBLEM", 296, 317], ["different virus", "OBSERVATION", 258, 273], ["enterovirus infection", "OBSERVATION", 296, 317]]], ["This system will therefore serve as a valuable tool for future studies on the origin and function of enterovirus ROs.Cells. ::: MATERIALS AND METHODSHeLa R19, BGM (buffalo green monkey), and COS-1 cells were grown in Dulbecco\u2019s minimal essential medium (DMEM; Lonza) supplemented with 10% fetal bovine serum and penicillin and streptomycin at 37\u00b0C and 5% CO2.Plasmids and infectious clones. ::: MATERIALS AND METHODSThe expression construct encoding wild-type (wt) 3A, i.e., p3A-myc, was described elsewhere (64).", [["Cells", "ANATOMY", 117, 122], ["COS-1 cells", "ANATOMY", 191, 202], ["fetal bovine serum", "ANATOMY", 289, 307], ["clones", "ANATOMY", 383, 389], ["penicillin", "CHEMICAL", 312, 322], ["streptomycin", "CHEMICAL", 327, 339], ["CO2", "CHEMICAL", 355, 358], ["penicillin", "CHEMICAL", 312, 322], ["streptomycin", "CHEMICAL", 327, 339], ["CO2", "CHEMICAL", 355, 358], ["enterovirus", "ORGANISM", 101, 112], ["ROs", "GENE_OR_GENE_PRODUCT", 113, 116], ["Cells", "CELL", 117, 122], ["buffalo green monkey", "ORGANISM", 164, 184], ["COS-1 cells", "CELL", 191, 202], ["bovine", "ORGANISM", 295, 301], ["serum", "ORGANISM_SUBSTANCE", 302, 307], ["penicillin", "SIMPLE_CHEMICAL", 312, 322], ["streptomycin", "SIMPLE_CHEMICAL", 327, 339], ["CO2", "SIMPLE_CHEMICAL", 355, 358], ["infectious clones", "CELL", 372, 389], ["wild-type (wt) 3A", "ORGANISM", 450, 467], ["p3A-myc", "GENE_OR_GENE_PRODUCT", 475, 482], ["COS-1 cells", "CELL_LINE", 191, 202], ["wild-type (wt) 3A", "PROTEIN", 450, 467], ["p3A", "PROTEIN", 475, 478], ["myc", "PROTEIN", 479, 482], ["buffalo", "SPECIES", 164, 171], ["monkey", "SPECIES", 178, 184], ["bovine", "SPECIES", 295, 301], ["buffalo green monkey", "SPECIES", 164, 184], ["COS-1", "SPECIES", 191, 196], ["bovine", "SPECIES", 295, 301], ["future studies", "TEST", 56, 70], ["enterovirus ROs", "PROBLEM", 101, 116], ["METHODSHeLa", "TEST", 142, 153], ["BGM", "TEST", 159, 162], ["Dulbecco", "TEST", 217, 225], ["10% fetal bovine serum", "TREATMENT", 285, 307], ["penicillin", "TREATMENT", 312, 322], ["streptomycin", "TREATMENT", 327, 339], ["Plasmids", "TREATMENT", 359, 367], ["infectious clones", "PROBLEM", 372, 389], ["enterovirus", "OBSERVATION", 101, 112], ["infectious clones", "OBSERVATION", 372, 389]]], ["GFP(S11), i.e., the residues RDHMVLHEYVNAAGIT, were inserted after amino acid 2 in CVB3 3A to yield p3A(S11aa2)-myc.", [["amino acid", "CHEMICAL", 67, 77], ["amino acid", "CHEMICAL", 67, 77], ["GFP", "GENE_OR_GENE_PRODUCT", 0, 3], ["S11", "GENE_OR_GENE_PRODUCT", 4, 7], ["CVB3", "ORGANISM", 83, 87], ["p3A(S11aa2)-myc", "GENE_OR_GENE_PRODUCT", 100, 115], ["GFP", "PROTEIN", 0, 3], ["S11", "PROTEIN", 4, 7], ["residues RDHMVLHEYVNAAGIT", "PROTEIN", 20, 45], ["p3A", "PROTEIN", 100, 103], ["S11aa2", "PROTEIN", 104, 110], ["myc", "PROTEIN", 112, 115], ["GFP", "TEST", 0, 3], ["the residues RDHMVLHEYVNAAGIT", "PROBLEM", 16, 45], ["amino acid", "TEST", 67, 77], ["p3A", "TEST", 100, 103], ["myc", "PROBLEM", 112, 115]]], ["For this, a forward primer containing the GFP(S11) tag was used in a PCR with p3A-myc as the template to generate 3A(S11aa2) as a PCR product.", [["GFP", "GENE_OR_GENE_PRODUCT", 42, 45], ["p3A-myc", "GENE_OR_GENE_PRODUCT", 78, 85], ["aa2", "GENE_OR_GENE_PRODUCT", 120, 123], ["forward primer", "DNA", 12, 26], ["GFP(S11) tag", "DNA", 42, 54], ["p3A", "PROTEIN", 78, 81], ["myc", "DNA", 82, 85], ["S11aa2", "PROTEIN", 117, 123], ["a forward primer", "TREATMENT", 10, 26], ["the GFP(S11) tag", "TREATMENT", 38, 54], ["a PCR", "TEST", 67, 72], ["p3A", "TEST", 78, 81], ["a PCR product", "TREATMENT", 128, 141]]], ["Wild-type 3A in p3A-myc was replaced with this PCR product using standard DNA cloning techniques.", [["p3A-myc", "GENE_OR_GENE_PRODUCT", 16, 23], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["p3A", "PROTEIN", 16, 19], ["myc", "PROTEIN", 20, 23], ["this PCR product", "TREATMENT", 42, 58], ["standard DNA cloning techniques", "TREATMENT", 65, 96]]], ["The same strategy was used to introduce GFP(S11) or the StrepII tag (i.e., residues SAWSHPQFEK) in the infectious clone of CVB3 (p53CB3/T7) described elsewhere (64), yielding p53CB3-3A(S11aa2)/T7 or p53CB3-3A(StrepIIaa2)/T7.", [["GFP", "GENE_OR_GENE_PRODUCT", 40, 43], ["S11", "GENE_OR_GENE_PRODUCT", 44, 47], ["StrepII tag", "GENE_OR_GENE_PRODUCT", 56, 67], ["CVB3", "ORGANISM", 123, 127], ["p53CB3/T7", "ORGANISM", 129, 138], ["p53CB3-3A", "GENE_OR_GENE_PRODUCT", 175, 184], ["S11aa2", "GENE_OR_GENE_PRODUCT", 185, 191], ["p53CB3-3A", "GENE_OR_GENE_PRODUCT", 199, 208], ["GFP", "PROTEIN", 40, 43], ["S11", "PROTEIN", 44, 47], ["StrepII tag", "PROTEIN", 56, 67], ["residues SAWSHPQFEK", "PROTEIN", 75, 94], ["p53CB3", "PROTEIN", 175, 181], ["S11aa2", "PROTEIN", 185, 191], ["T7 or p53CB3-3A(StrepIIaa2)/T7", "DNA", 193, 223], ["CVB3", "SPECIES", 123, 127], ["GFP(S11", "TREATMENT", 40, 47], ["the StrepII tag", "TREATMENT", 52, 67], ["CVB3", "TEST", 123, 127], ["p53CB3", "TEST", 175, 181], ["p53CB3", "TEST", 199, 205], ["infectious clone", "OBSERVATION", 103, 119], ["T7", "ANATOMY", 136, 138], ["T7", "ANATOMY", 193, 195], ["T7", "ANATOMY", 221, 223]]], ["The GFP(S1-10) expression construct pCMV-mGFP(S1-10) (CMV stands for cytomegalovirus, and mGFP stands for modified GFP) was purchased from Sandia Biotech.", [["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["S1-10", "GENE_OR_GENE_PRODUCT", 8, 13], ["pCMV-mGFP", "GENE_OR_GENE_PRODUCT", 36, 45], ["S1-10", "GENE_OR_GENE_PRODUCT", 46, 51], ["CMV", "ORGANISM", 54, 57], ["cytomegalovirus", "ORGANISM", 69, 84], ["GFP", "GENE_OR_GENE_PRODUCT", 115, 118], ["GFP(S1-10) expression construct", "DNA", 4, 35], ["pCMV", "PROTEIN", 36, 40], ["mGFP", "PROTEIN", 41, 45], ["S1", "PROTEIN", 46, 48], ["mGFP", "PROTEIN", 90, 94], ["GFP", "PROTEIN", 115, 118], ["The GFP", "TEST", 0, 7], ["S1", "TEST", 8, 10], ["pCMV", "TEST", 36, 40], ["mGFP", "TEST", 41, 45], ["S1", "TEST", 46, 48], ["CMV stands", "TEST", 54, 64], ["cytomegalovirus", "PROBLEM", 69, 84]]], ["For the production of CVB3 encoding both GFP(S1-10) and 3A(S11aa2), the GFP(S1-10) gene followed by a 3CD cleavage site was placed directly upstream of the capsid coding region P1 in p53CB3-3A(S11aa2)/T7, similar to modifications previously described for CVB3 encoding luciferase (27).", [["CVB3", "ORGANISM", 22, 26], ["GFP", "GENE_OR_GENE_PRODUCT", 41, 44], ["S1-10", "GENE_OR_GENE_PRODUCT", 45, 50], ["3A", "GENE_OR_GENE_PRODUCT", 56, 58], ["S11aa2", "GENE_OR_GENE_PRODUCT", 59, 65], ["GFP", "GENE_OR_GENE_PRODUCT", 72, 75], ["S1-10", "GENE_OR_GENE_PRODUCT", 76, 81], ["p53CB3-3A", "GENE_OR_GENE_PRODUCT", 183, 192], ["CVB3", "ORGANISM", 255, 259], ["luciferase", "GENE_OR_GENE_PRODUCT", 269, 279], ["CVB3", "DNA", 22, 26], ["GFP", "PROTEIN", 41, 44], ["S1", "PROTEIN", 45, 47], ["3A", "PROTEIN", 56, 58], ["S11aa2", "PROTEIN", 59, 65], ["GFP(S1-10) gene", "DNA", 72, 87], ["3CD cleavage site", "DNA", 102, 119], ["capsid coding region", "DNA", 156, 176], ["P1", "DNA", 177, 179], ["p53CB3", "DNA", 183, 189], ["S11aa2", "DNA", 193, 199], ["T7", "DNA", 201, 203], ["luciferase", "PROTEIN", 269, 279], ["CVB3", "SPECIES", 22, 26], ["CVB3", "SPECIES", 255, 259], ["CVB3", "PROBLEM", 22, 26], ["S1", "TEST", 45, 47], ["the GFP", "TEST", 68, 75], ["a 3CD cleavage site", "TREATMENT", 100, 119], ["CVB3 encoding luciferase", "TEST", 255, 279], ["T7", "ANATOMY", 201, 203]]], ["For the production of murine leukemia virus (MLV) particles, our genes of interest were cloned into the retroviral vectors pQCXIP [for GFP(S1-10) or mCherry-P4M-SidM] or pRetroQ-mCherry (for GM130), both purchased from Clontech, with standard DNA cloning techniques.", [["GM130", "ANATOMY", 191, 196], ["murine leukemia virus", "DISEASE", 22, 43], ["murine leukemia virus", "ORGANISM", 22, 43], ["MLV", "ORGANISM", 45, 48], ["retroviral", "ORGANISM", 104, 114], ["pQCXIP", "GENE_OR_GENE_PRODUCT", 123, 129], ["GFP", "GENE_OR_GENE_PRODUCT", 135, 138], ["S1-10", "GENE_OR_GENE_PRODUCT", 139, 144], ["mCherry-P4M-SidM", "GENE_OR_GENE_PRODUCT", 149, 165], ["pRetroQ-mCherry", "GENE_OR_GENE_PRODUCT", 170, 185], ["GM130", "GENE_OR_GENE_PRODUCT", 191, 196], ["Clontech", "GENE_OR_GENE_PRODUCT", 219, 227], ["DNA", "CELLULAR_COMPONENT", 243, 246], ["pQCXIP", "DNA", 123, 129], ["GFP", "PROTEIN", 135, 138], ["S1", "PROTEIN", 139, 141], ["mCherry", "DNA", 149, 156], ["P4M", "DNA", 157, 160], ["SidM", "DNA", 161, 165], ["pRetroQ", "DNA", 170, 177], ["mCherry", "DNA", 178, 185], ["GM130", "PROTEIN", 191, 196], ["murine", "SPECIES", 22, 28], ["murine leukemia virus", "SPECIES", 22, 43], ["MLV", "SPECIES", 45, 48], ["murine leukemia virus", "PROBLEM", 22, 43], ["GFP", "TEST", 135, 138], ["mCherry", "TEST", 149, 156], ["standard DNA cloning techniques", "TREATMENT", 234, 265], ["murine leukemia virus", "OBSERVATION", 22, 43]]], ["In the resulting plasmids, the gene of interest is followed by an internal ribosomal entry site (IRES) and a puromycin resistance gene for the production of stable cell lines.Retroviral particles and the production of stable cell lines. ::: MATERIALS AND METHODSFor the delivery of genes [i.e., GFP(S1-10), mCherry-GM130, or mCherry-SidM-P4M] into cells, we used an MLV-based retroviral vector system (Clontech).", [["plasmids", "ANATOMY", 17, 25], ["ribosomal", "ANATOMY", 75, 84], ["cell lines", "ANATOMY", 164, 174], ["cell lines", "ANATOMY", 225, 235], ["cells", "ANATOMY", 348, 353], ["puromycin", "CHEMICAL", 109, 118], ["puromycin", "CHEMICAL", 109, 118], ["ribosomal", "CELLULAR_COMPONENT", 75, 84], ["puromycin", "SIMPLE_CHEMICAL", 109, 118], ["cell lines", "CELL", 164, 174], ["Retroviral", "ORGANISM", 175, 185], ["cell lines", "CELL", 225, 235], ["GFP", "GENE_OR_GENE_PRODUCT", 295, 298], ["S1-10", "GENE_OR_GENE_PRODUCT", 299, 304], ["mCherry", "GENE_OR_GENE_PRODUCT", 307, 314], ["GM130", "GENE_OR_GENE_PRODUCT", 315, 320], ["mCherry-SidM-P4M", "GENE_OR_GENE_PRODUCT", 325, 341], ["cells", "CELL", 348, 353], ["retroviral", "ORGANISM", 376, 386], ["plasmids", "DNA", 17, 25], ["internal ribosomal entry site", "DNA", 66, 95], ["IRES", "DNA", 97, 101], ["puromycin resistance gene", "DNA", 109, 134], ["stable cell lines", "CELL_LINE", 157, 174], ["stable cell lines", "CELL_LINE", 218, 235], ["GFP(S1-10", "DNA", 295, 304], ["mCherry", "DNA", 307, 314], ["GM130", "DNA", 315, 320], ["mCherry", "DNA", 325, 332], ["SidM", "DNA", 333, 337], ["P4M", "DNA", 338, 341], ["Retroviral", "SPECIES", 175, 185], ["an internal ribosomal entry site", "TREATMENT", 63, 95], ["a puromycin resistance gene", "TREATMENT", 107, 134], ["stable cell lines", "TREATMENT", 157, 174], ["Retroviral particles", "PROBLEM", 175, 195], ["stable cell lines", "TREATMENT", 218, 235], ["GFP", "TEST", 295, 298], ["mCherry", "TEST", 307, 314], ["mCherry", "TEST", 325, 332], ["an MLV-based retroviral vector system", "TREATMENT", 363, 400], ["plasmids", "OBSERVATION", 17, 25], ["stable cell lines", "OBSERVATION", 157, 174], ["particles", "OBSERVATION", 186, 195], ["stable", "OBSERVATION_MODIFIER", 218, 224], ["cell lines", "OBSERVATION", 225, 235], ["retroviral vector", "OBSERVATION", 376, 393]]], ["MLV stocks were produced by cotransfecting HEK293T cells with the pCAGGS-VSV-G plasmid encoding vesicular stomatitis virus protein G (VSV-G), the pMLV-Gag/Pol plasmid encoding the capsid proteins, reverse transcriptase, and integrase proteins, and the plasmid pQCXIP or pRetroQ-mCherry containing the gene of interest.", [["HEK293T cells", "ANATOMY", 43, 56], ["plasmid", "ANATOMY", 252, 259], ["MLV", "ORGANISM", 0, 3], ["HEK293T cells", "CELL", 43, 56], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 66, 72], ["VSV", "ORGANISM", 73, 76], ["vesicular stomatitis virus", "ORGANISM", 96, 122], ["G", "GENE_OR_GENE_PRODUCT", 131, 132], ["VSV-G", "ORGANISM", 134, 139], ["pMLV", "GENE_OR_GENE_PRODUCT", 146, 150], ["Gag", "GENE_OR_GENE_PRODUCT", 151, 154], ["Pol", "GENE_OR_GENE_PRODUCT", 155, 158], ["pQCXIP", "GENE_OR_GENE_PRODUCT", 260, 266], ["pRetroQ-mCherry", "GENE_OR_GENE_PRODUCT", 270, 285], ["HEK293T cells", "CELL_LINE", 43, 56], ["pCAGGS-VSV-G plasmid", "DNA", 66, 86], ["vesicular stomatitis virus protein G", "PROTEIN", 96, 132], ["VSV", "PROTEIN", 134, 137], ["pMLV", "PROTEIN", 146, 150], ["Gag", "PROTEIN", 151, 154], ["Pol plasmid", "DNA", 155, 166], ["capsid proteins", "PROTEIN", 180, 195], ["reverse transcriptase", "PROTEIN", 197, 218], ["integrase proteins", "PROTEIN", 224, 242], ["pQCXIP", "DNA", 260, 266], ["pRetroQ", "PROTEIN", 270, 277], ["mCherry", "DNA", 278, 285], ["stomatitis virus", "SPECIES", 106, 122], ["MLV", "SPECIES", 0, 3], ["stomatitis virus", "SPECIES", 106, 122], ["MLV stocks", "TREATMENT", 0, 10], ["the pCAGGS", "TEST", 62, 72], ["VSV", "TEST", 73, 76], ["G plasmid encoding vesicular stomatitis", "PROBLEM", 77, 116], ["VSV", "TEST", 134, 137], ["the pMLV", "TEST", 142, 150], ["Gag/Pol plasmid", "TREATMENT", 151, 166], ["the capsid proteins", "TREATMENT", 176, 195], ["reverse transcriptase", "TREATMENT", 197, 218], ["integrase proteins", "TREATMENT", 224, 242], ["the plasmid pQCXIP", "TREATMENT", 248, 266], ["pRetroQ-mCherry", "TREATMENT", 270, 285], ["vesicular stomatitis", "ANATOMY", 96, 116]]], ["Four to 5 days posttransfection (p.t.), supernatants were harvested and cleared of cell debris by centrifugation and filtration through a 0.45-\u00b5m-pore-size filter.", [["supernatants", "ANATOMY", 40, 52], ["cell", "ANATOMY", 83, 87], ["cell", "CELL", 83, 87], ["supernatants", "TREATMENT", 40, 52], ["cell debris", "PROBLEM", 83, 94], ["filtration", "TREATMENT", 117, 127], ["a 0.45-\u00b5m-pore-size filter", "TREATMENT", 136, 162], ["cell debris", "OBSERVATION", 83, 94], ["size", "OBSERVATION_MODIFIER", 151, 155], ["filter", "OBSERVATION", 156, 162]]], ["Stocks were buffered with 10 mM HEPES, aliquoted, and frozen at \u221280\u00b0C for later use.", [["HEPES", "CHEMICAL", 32, 37], ["10 mM HEPES", "TREATMENT", 26, 37]]], ["Prior to transduction, the MLV particles were 5 to 10 times concentrated using a 100-kDa concentrator (Millipore).", [["MLV", "ORGANISM", 27, 30], ["transduction", "TREATMENT", 9, 21], ["the MLV particles", "TREATMENT", 23, 40], ["a 100-kDa concentrator (Millipore", "TREATMENT", 79, 112]]], ["For the generation of single-cell clones stably expressing GFP(S1-10), BGM and HeLa cells were transduced and grown in the presence of puromycin (2 \u00b5g/ml for HeLa cells; 30 \u00b5g/ml for BGM cells) to generate pools of GFP(S1-10)-expressing cells, which were subsequently used to prepare single-cell clones by limiting dilution.", [["single-cell clones", "ANATOMY", 22, 40], ["BGM", "ANATOMY", 71, 74], ["HeLa cells", "ANATOMY", 79, 89], ["HeLa cells", "ANATOMY", 158, 168], ["BGM cells", "ANATOMY", 183, 192], ["cells", "ANATOMY", 237, 242], ["single-cell clones", "ANATOMY", 284, 302], ["puromycin", "CHEMICAL", 135, 144], ["puromycin", "CHEMICAL", 135, 144], ["single-cell clones", "CELL", 22, 40], ["GFP", "GENE_OR_GENE_PRODUCT", 59, 62], ["S1-10", "ORGANISM", 63, 68], ["BGM", "CELL", 71, 74], ["HeLa cells", "CELL", 79, 89], ["puromycin", "SIMPLE_CHEMICAL", 135, 144], ["HeLa cells", "CELL", 158, 168], ["BGM cells", "CELL", 183, 192], ["GFP", "GENE_OR_GENE_PRODUCT", 215, 218], ["S1-10", "GENE_OR_GENE_PRODUCT", 219, 224], ["cells", "CELL", 237, 242], ["single-cell clones", "CELL", 284, 302], ["single-cell clones", "CELL_LINE", 22, 40], ["GFP", "PROTEIN", 59, 62], ["S1", "PROTEIN", 63, 65], ["BGM", "CELL_LINE", 71, 74], ["HeLa cells", "CELL_LINE", 79, 89], ["HeLa cells", "CELL_LINE", 158, 168], ["BGM cells", "CELL_LINE", 183, 192], ["GFP(S1-10)-expressing cells", "CELL_LINE", 215, 242], ["single-cell clones", "CELL_LINE", 284, 302], ["single-cell clones", "TEST", 22, 40], ["GFP", "TEST", 59, 62], ["BGM", "TEST", 71, 74], ["HeLa cells", "TEST", 79, 89], ["puromycin", "TREATMENT", 135, 144], ["HeLa cells", "TEST", 158, 168], ["BGM cells", "TEST", 183, 192], ["GFP", "TEST", 215, 218], ["S1", "TEST", 219, 221], ["expressing cells", "PROBLEM", 226, 242], ["single-cell clones", "TREATMENT", 284, 302], ["HeLa cells", "OBSERVATION", 79, 89]]], ["Expression of GFP(S1-10) was monitored during passaging by immunofluorescence microscopy using the GFP antibody.Mammalian two-hybrid assay. ::: MATERIALS AND METHODSpACT, pBIND, and pG5Luc (Luc stands for luciferase) vectors were from Promega. pBIND-GBF1 encoding the N terminus of GBF1, pACT-3A, and pBIND-3A were described previously (38, 39). pACT-ACBD3 was a kind gift from J. Sasaki (Fujita Health University School of Medicine, Aichi, Japan) (45). pACT-3A(S11aa2) and pBIND-3A(S11aa2) were cloned with a forward primer containing the GFP(S11) tag using standard DNA cloning techniques.", [["GFP", "GENE_OR_GENE_PRODUCT", 14, 17], ["S1-10", "GENE_OR_GENE_PRODUCT", 18, 23], ["GFP", "GENE_OR_GENE_PRODUCT", 99, 102], ["pBIND", "GENE_OR_GENE_PRODUCT", 171, 176], ["pG5Luc", "GENE_OR_GENE_PRODUCT", 182, 188], ["Luc", "GENE_OR_GENE_PRODUCT", 190, 193], ["luciferase", "GENE_OR_GENE_PRODUCT", 205, 215], ["pBIND-GBF1", "GENE_OR_GENE_PRODUCT", 244, 254], ["GBF1", "GENE_OR_GENE_PRODUCT", 282, 286], ["pACT-3A", "GENE_OR_GENE_PRODUCT", 288, 295], ["pBIND-3A", "GENE_OR_GENE_PRODUCT", 301, 309], ["pACT-3A", "GENE_OR_GENE_PRODUCT", 454, 461], ["S11aa2", "GENE_OR_GENE_PRODUCT", 462, 468], ["pBIND-3A", "GENE_OR_GENE_PRODUCT", 474, 482], ["S11aa2", "GENE_OR_GENE_PRODUCT", 483, 489], ["GFP", "GENE_OR_GENE_PRODUCT", 540, 543], ["DNA", "CELLULAR_COMPONENT", 568, 571], ["GFP", "PROTEIN", 14, 17], ["S1", "PROTEIN", 18, 20], ["GFP antibody", "PROTEIN", 99, 111], ["METHODSpACT, pBIND, and pG5Luc (Luc stands for luciferase) vectors", "DNA", 158, 224], ["pBIND", "PROTEIN", 244, 249], ["GBF1", "PROTEIN", 250, 254], ["N terminus", "PROTEIN", 268, 278], ["GBF1", "PROTEIN", 282, 286], ["pACT", "PROTEIN", 288, 292], ["3A", "PROTEIN", 293, 295], ["pBIND", "PROTEIN", 301, 306], ["pACT-3A", "DNA", 454, 461], ["S11aa2", "PROTEIN", 462, 468], ["pBIND-3A", "DNA", 474, 482], ["S11aa2", "DNA", 483, 489], ["forward primer", "DNA", 510, 524], ["GFP(S11) tag", "DNA", 540, 552], ["GFP", "TEST", 14, 17], ["immunofluorescence microscopy", "TEST", 59, 88], ["the GFP antibody", "TEST", 95, 111], ["pBIND", "TREATMENT", 171, 176], ["pG5Luc (Luc stands", "TREATMENT", 182, 200], ["luciferase) vectors", "TREATMENT", 205, 224], ["pBIND", "TEST", 244, 249], ["pACT", "TEST", 288, 292], ["pBIND", "TEST", 301, 306], ["pACT", "TEST", 454, 458], ["pBIND", "TEST", 474, 479], ["a forward primer", "TREATMENT", 508, 524], ["standard DNA cloning techniques", "TREATMENT", 559, 590], ["GBF1", "ANATOMY", 282, 286], ["3A", "ANATOMY_MODIFIER", 307, 309]]], ["Subconfluent layers of COS-1 cells seeded in 24-well plates were transfected with 350 ng of pACT, pBIND, and pG5Luc plasmids using Fugene6 (Promega) according to the manufacturer\u2019s protocol.", [["Subconfluent layers", "ANATOMY", 0, 19], ["COS-1 cells", "ANATOMY", 23, 34], ["plasmids", "ANATOMY", 116, 124], ["COS-1 cells", "CELL", 23, 34], ["pACT", "GENE_OR_GENE_PRODUCT", 92, 96], ["pBIND", "GENE_OR_GENE_PRODUCT", 98, 103], ["COS-1 cells", "CELL_LINE", 23, 34], ["pACT, pBIND, and pG5Luc plasmids", "DNA", 92, 124], ["Subconfluent layers of COS", "TEST", 0, 26], ["pACT", "TREATMENT", 92, 96], ["pBIND", "TREATMENT", 98, 103], ["pG5Luc plasmids", "TREATMENT", 109, 124], ["Fugene6 (Promega)", "TREATMENT", 131, 148], ["the manufacturer\u2019s protocol", "TREATMENT", 162, 189], ["layers", "OBSERVATION_MODIFIER", 13, 19]]], ["At 48 h p.t., cells were lysed, and Renilla and firefly luciferase levels were measured using the Dual-Luciferase assay kit (Promega) following the manufacturer\u2019s protocol.", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["Renilla", "GENE_OR_GENE_PRODUCT", 36, 43], ["luciferase", "GENE_OR_GENE_PRODUCT", 56, 66], ["luciferase", "PROTEIN", 56, 66], ["cells", "TEST", 14, 19], ["Renilla and firefly luciferase levels", "TEST", 36, 73], ["the Dual-Luciferase assay kit", "TREATMENT", 94, 123], ["the manufacturer\u2019s protocol", "TREATMENT", 144, 171], ["Renilla", "ANATOMY", 36, 43]]], ["Values were converted to firefly/Renilla signal ratios to correct for transfection efficiencies.Virus infection. ::: MATERIALS AND METHODSThe production of CVB3 from infectious clones was described previously (39).", [["clones", "ANATOMY", 177, 183], ["Virus infection", "DISEASE", 96, 111], ["Virus", "ORGANISM", 96, 101], ["CVB3", "ORGANISM", 156, 160], ["infectious clones", "CELL", 166, 183], ["CVB3", "SPECIES", 156, 160], ["Values", "TEST", 0, 6], ["Renilla signal ratios", "TEST", 33, 54], ["transfection efficiencies", "PROBLEM", 70, 95], ["Virus infection", "PROBLEM", 96, 111], ["CVB3", "PROBLEM", 156, 160], ["infectious clones", "PROBLEM", 166, 183], ["transfection efficiencies", "OBSERVATION", 70, 95], ["infection", "OBSERVATION", 102, 111], ["CVB3", "OBSERVATION", 156, 160], ["infectious", "OBSERVATION_MODIFIER", 166, 176]]], ["Virus titers were determined by endpoint titration according to the method of Reed and Muench and expressed as 50% cell culture infective doses (CCID50).", [["cell", "ANATOMY", 115, 119], ["Virus", "ORGANISM", 0, 5], ["cell", "CELL", 115, 119], ["Virus titers", "TEST", 0, 12]]], ["BGM or HeLa cells were infected with virus for 30 min to 1 h.", [["BGM", "ANATOMY", 0, 3], ["HeLa cells", "ANATOMY", 7, 17], ["BGM", "CELL", 0, 3], ["HeLa cells", "CELL", 7, 17], ["BGM", "CELL_LINE", 0, 3], ["HeLa cells", "CELL_LINE", 7, 17], ["BGM", "TEST", 0, 3], ["HeLa cells", "PROBLEM", 7, 17], ["virus", "TREATMENT", 37, 42], ["HeLa cells", "OBSERVATION", 7, 17]]], ["Following removal of the inoculum, fresh medium was added to the cells.", [["cells", "ANATOMY", 65, 70], ["cells", "CELL", 65, 70], ["removal of the inoculum", "TREATMENT", 10, 33], ["fresh medium", "TREATMENT", 35, 47], ["cells", "ANATOMY", 65, 70]]], ["At the time points indicated in the figures, cells were either fixed for immunolabeling, lysed to measure the amount of viral RNA by quantitative PCR, or frozen to determine the amount of infectious virus particles by titration analysis.Quantitative PCR. ::: MATERIALS AND METHODSRNA was isolated from infected cells using a NucleoSpin RNA kit (Macherey-Nagel). cDNA was synthesized using random hexamers as primers with a TaqMan reverse transcription reagent kit (Roche).", [["cells", "ANATOMY", 45, 50], ["cells", "ANATOMY", 311, 316], ["cells", "CELL", 45, 50], ["cells", "CELL", 311, 316], ["viral RNA", "RNA", 120, 129], ["infected cells", "CELL_TYPE", 302, 316], ["cDNA", "DNA", 362, 366], ["immunolabeling", "PROBLEM", 73, 87], ["viral RNA", "PROBLEM", 120, 129], ["quantitative PCR", "TEST", 133, 149], ["infectious virus particles", "PROBLEM", 188, 214], ["titration analysis", "TEST", 218, 236], ["Quantitative PCR", "TEST", 237, 253], ["infected cells", "PROBLEM", 302, 316], ["a NucleoSpin RNA kit", "TREATMENT", 323, 343], ["random hexamers as primers", "TREATMENT", 389, 415], ["a TaqMan", "TEST", 421, 429], ["infectious", "OBSERVATION", 188, 198], ["infected cells", "OBSERVATION", 302, 316]]], ["The cDNA was used for quantitative PCR with the forward primer 5\u2032-CGTGGGGCTACAATCAAGTT-3\u2032, the reverse primer 5\u2032-TAACAGGAGCTTTGGGCATC-3\u2032, and the LightCycler 480 SYBR green I master kit (Roche) for 45 cycles (5 s at 95\u00b0C, 10 s at 60\u00b0C, and 20 s at 72\u00b0C) on a LightCycler 480 system (Roche).Western blot analysis. ::: MATERIALS AND METHODSProteins were separated with 10% gradient PAGE using the Gradi-Gel gradient analysis kit (Elpis Biotech).", [["cDNA", "DNA", 4, 8], ["forward primer 5\u2032-CGTGGGGCTACAATCAAGTT-3\u2032", "DNA", 48, 89], ["reverse primer 5", "DNA", 95, 111], ["The cDNA", "TEST", 0, 8], ["quantitative PCR", "TEST", 22, 38], ["the forward primer", "TEST", 44, 62], ["CGTGGGGCTACAATCAAGTT", "TEST", 66, 86], ["TAACAGGAGCTTTGGGCATC", "TEST", 113, 133], ["the LightCycler", "TEST", 142, 157], ["Western blot analysis", "TEST", 290, 311], ["METHODSProteins", "TREATMENT", 331, 346], ["the Gradi", "TEST", 391, 400]]], ["Samples were transferred to nitrocellulose membranes (Bio-Rad).", [["Samples", "ANATOMY", 0, 7], ["membranes", "ANATOMY", 43, 52], ["nitrocellulose", "CHEMICAL", 28, 42], ["membranes", "CELLULAR_COMPONENT", 43, 52], ["Samples", "TEST", 0, 7], ["nitrocellulose membranes", "TREATMENT", 28, 52]]], ["After the membrane was cut at the 15-kDa band of the marker, one membrane (proteins larger than 15 kDa) was incubated with primary antibodies against mouse monoclonal anti-\u03b2-actin (Sigma) and rabbit polyclonal anti-GFP described previously (44), which also recognizes GFP(S1-10).", [["membrane", "ANATOMY", 10, 18], ["membrane", "ANATOMY", 65, 73], ["membrane", "CELLULAR_COMPONENT", 10, 18], ["membrane", "CELLULAR_COMPONENT", 65, 73], ["mouse", "ORGANISM", 150, 155], ["anti-\u03b2-actin", "GENE_OR_GENE_PRODUCT", 167, 179], ["Sigma", "GENE_OR_GENE_PRODUCT", 181, 186], ["rabbit", "ORGANISM", 192, 198], ["anti-GFP", "GENE_OR_GENE_PRODUCT", 210, 218], ["GFP", "GENE_OR_GENE_PRODUCT", 268, 271], ["15 kDa", "PROTEIN", 96, 102], ["primary antibodies", "PROTEIN", 123, 141], ["mouse monoclonal anti-\u03b2-actin", "PROTEIN", 150, 179], ["Sigma", "PROTEIN", 181, 186], ["rabbit polyclonal anti-GFP", "PROTEIN", 192, 218], ["GFP", "PROTEIN", 268, 271], ["S1", "PROTEIN", 272, 274], ["mouse", "SPECIES", 150, 155], ["rabbit", "SPECIES", 192, 198], ["mouse", "SPECIES", 150, 155], ["rabbit", "SPECIES", 192, 198], ["the marker", "TEST", 49, 59], ["primary antibodies", "TEST", 123, 141], ["rabbit polyclonal anti-GFP", "TEST", 192, 218], ["GFP", "TEST", 268, 271]]], ["The membrane with proteins smaller than 15 kDa was incubated with rabbit polyclonal anti-3A described previously (44).", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["rabbit", "ORGANISM", 66, 72], ["anti-3A", "GENE_OR_GENE_PRODUCT", 84, 91], ["rabbit polyclonal anti-3A", "PROTEIN", 66, 91], ["rabbit", "SPECIES", 66, 72], ["rabbit", "SPECIES", 66, 72], ["rabbit polyclonal anti", "TEST", 66, 88], ["smaller", "OBSERVATION_MODIFIER", 27, 34]]], ["Secondary antibodies included IRDye 680-conjugated goat anti-mouse or IRDye 800-conjugated goat anti-rabbit (LI-COR).", [["IRDye 680", "CHEMICAL", 30, 39], ["IRDye 800", "CHEMICAL", 70, 79], ["IRDye", "CHEMICAL", 30, 35], ["IRDye 680", "SIMPLE_CHEMICAL", 30, 39], ["IRDye 800", "SIMPLE_CHEMICAL", 70, 79], ["LI-COR", "GENE_OR_GENE_PRODUCT", 109, 115], ["IRDye 680", "PROTEIN", 30, 39], ["conjugated goat anti-mouse", "PROTEIN", 40, 66], ["IRDye 800", "PROTEIN", 70, 79], ["conjugated goat anti-rabbit", "PROTEIN", 80, 107], ["LI", "PROTEIN", 109, 111], ["COR", "PROTEIN", 112, 115], ["goat", "SPECIES", 51, 55], ["anti-mouse", "SPECIES", 56, 66], ["goat", "SPECIES", 91, 95], ["anti-rabbit", "SPECIES", 96, 107], ["goat", "SPECIES", 51, 55], ["goat", "SPECIES", 91, 95], ["Secondary antibodies", "TEST", 0, 20], ["IRDye", "TEST", 30, 35], ["conjugated goat anti-mouse", "TREATMENT", 40, 66], ["IRDye", "TEST", 70, 75]]], ["Images of blots were acquired with Odyssey imaging system (LI-COR).Immunofluorescence microscopy. ::: MATERIALS AND METHODSBGM or HeLa cells were grown to subconfluency on coverslips in 24-well plates.", [["HeLa cells", "ANATOMY", 130, 140], ["HeLa cells", "CELL", 130, 140], ["HeLa cells", "CELL_LINE", 130, 140], ["Images of blots", "TEST", 0, 15], ["Odyssey imaging system", "TEST", 35, 57], ["Immunofluorescence microscopy", "TEST", 67, 96], ["HeLa cells", "PROBLEM", 130, 140], ["coverslips", "TEST", 172, 182], ["HeLa cells", "OBSERVATION", 130, 140]]], ["Where indicated, cells were transfected with 200 ng of plasmid DNA using Fugene6 according to the manufacturer\u2019s protocol or infected with CVB3-3A(S11aa2) at a multiplicity of infection (MOI) of 1 to 10.", [["cells", "ANATOMY", 17, 22], ["plasmid", "ANATOMY", 55, 62], ["infection", "DISEASE", 176, 185], ["cells", "CELL", 17, 22], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["CVB3-3A", "ORGANISM", 139, 146], ["S11aa2", "ORGANISM", 147, 153], ["plasmid DNA", "DNA", 55, 66], ["CVB3-3A", "SPECIES", 139, 146], ["plasmid DNA", "TREATMENT", 55, 66], ["Fugene6", "TREATMENT", 73, 80], ["the manufacturer\u2019s protocol", "TREATMENT", 94, 121], ["CVB3", "TEST", 139, 143], ["infection", "PROBLEM", 176, 185], ["infection", "OBSERVATION", 176, 185]]], ["At 24 h p.t. or 5 to 6 h postinfection (p.i.), cells were fixed with 4% paraformaldehyde for 20 min at room temperature, followed by permeabilization with phosphate-buffered saline (PBS) containing 0.1% Triton X-100 for 10 min.", [["cells", "ANATOMY", 47, 52], ["phosphate", "CHEMICAL", 155, 164], ["Triton X-100", "CHEMICAL", 203, 215], ["paraformaldehyde", "CHEMICAL", 72, 88], ["phosphate", "CHEMICAL", 155, 164], ["cells", "CELL", 47, 52], ["paraformaldehyde", "SIMPLE_CHEMICAL", 72, 88], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 155, 180], ["Triton X-100", "SIMPLE_CHEMICAL", 203, 215], ["4% paraformaldehyde", "TREATMENT", 69, 88], ["phosphate-buffered saline (PBS)", "TREATMENT", 155, 186]]], ["Cells were then incubated sequentially with primary and secondary antibodies diluted in PBS containing 2% normal goat serum.", [["Cells", "ANATOMY", 0, 5], ["serum", "ANATOMY", 118, 123], ["Cells", "CELL", 0, 5], ["goat", "ORGANISM", 113, 117], ["serum", "ORGANISM_SUBSTANCE", 118, 123], ["secondary antibodies", "PROTEIN", 56, 76], ["goat", "SPECIES", 113, 117], ["goat", "SPECIES", 113, 117], ["primary and secondary antibodies", "TREATMENT", 44, 76]]], ["Cellular proteins were detected with primary antibodies against PI4KIII\u03b2 (Millipore), GBF1 (BD Biosciences), and COP-I (provided by F. Wieland, Biochemie-Zentrum, Heidelberg, Germany).", [["Cellular", "ANATOMY", 0, 8], ["PI4KIII\u03b2", "GENE_OR_GENE_PRODUCT", 64, 72], ["GBF1", "GENE_OR_GENE_PRODUCT", 86, 90], ["COP-I", "GENE_OR_GENE_PRODUCT", 113, 118], ["Cellular proteins", "PROTEIN", 0, 17], ["primary antibodies", "PROTEIN", 37, 55], ["PI4KIII\u03b2", "PROTEIN", 64, 72], ["Millipore", "PROTEIN", 74, 83], ["GBF1", "PROTEIN", 86, 90], ["BD Biosciences", "PROTEIN", 92, 106], ["COP", "PROTEIN", 113, 116], ["Cellular proteins", "TEST", 0, 17], ["primary antibodies", "TEST", 37, 55], ["PI4KIII", "TEST", 64, 71]]], ["GFP(S1-10) was detected with a GFP antibody, and CVB3 3A proteins were detected with a 3A antibody, both described previously (44).", [["GFP", "GENE_OR_GENE_PRODUCT", 0, 3], ["S1-10", "GENE_OR_GENE_PRODUCT", 4, 9], ["GFP", "GENE_OR_GENE_PRODUCT", 31, 34], ["CVB3 3A", "GENE_OR_GENE_PRODUCT", 49, 56], ["GFP", "PROTEIN", 0, 3], ["S1", "PROTEIN", 4, 6], ["GFP antibody", "PROTEIN", 31, 43], ["CVB3 3A proteins", "PROTEIN", 49, 65], ["3A antibody", "PROTEIN", 87, 98], ["CVB3", "SPECIES", 49, 53], ["GFP(S1", "TEST", 0, 6], ["a GFP antibody", "TEST", 29, 43], ["CVB3 3A proteins", "TEST", 49, 65], ["a 3A antibody", "TEST", 85, 98]]], ["Alexa Fluor 488- or Alexa Fluor 594-conjugated goat anti-rabbit and goat anti-mouse (Molecular Probes) were used as secondary antibodies.", [["Alexa Fluor 488", "CHEMICAL", 0, 15], ["Alexa Fluor 594", "CHEMICAL", 20, 35], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 0, 15], ["Alexa Fluor 594", "SIMPLE_CHEMICAL", 20, 35], ["goat", "ORGANISM", 47, 51], ["anti-rabbit", "SIMPLE_CHEMICAL", 52, 63], ["goat", "ORGANISM", 68, 72], ["Alexa Fluor 488", "PROTEIN", 0, 15], ["Alexa Fluor 594-conjugated goat anti-rabbit", "PROTEIN", 20, 63], ["goat anti-mouse", "PROTEIN", 68, 83], ["Molecular Probes", "PROTEIN", 85, 101], ["secondary antibodies", "PROTEIN", 116, 136], ["goat", "SPECIES", 47, 51], ["anti-rabbit", "SPECIES", 52, 63], ["goat", "SPECIES", 68, 72], ["anti-mouse", "SPECIES", 73, 83], ["Alexa Fluor 594", "SPECIES", 20, 35], ["goat", "SPECIES", 47, 51], ["anti-rabbit", "SPECIES", 52, 63], ["goat", "SPECIES", 68, 72], ["Alexa Fluor", "TEST", 0, 11], ["Alexa Fluor", "TEST", 20, 31], ["conjugated goat anti-rabbit", "TREATMENT", 36, 63], ["goat anti-mouse (Molecular Probes", "TREATMENT", 68, 101], ["secondary antibodies", "PROBLEM", 116, 136]]], ["Nuclei were stained using 4\u2032,6\u2032-diamidino-2-phenylindole (DAPI).", [["Nuclei", "ANATOMY", 0, 6], ["4\u2032,6\u2032-diamidino-2-phenylindole", "CHEMICAL", 26, 56], ["4\u2032,6\u2032-diamidino-2-phenylindole", "CHEMICAL", 26, 56], ["DAPI", "CHEMICAL", 58, 62], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["4\u2032,6\u2032-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 26, 56], ["DAPI", "SIMPLE_CHEMICAL", 58, 62], ["diamidino", "TREATMENT", 32, 41]]], ["Coverslips were mounted with FluorSave (Calbiochem).", [["FluorSave (Calbiochem", "TREATMENT", 29, 50]]], ["Images were acquired with an Olympus BX60 fluorescence microscope with a 40\u00d7 (0.75-numerical-aperture [NA]) dry objective or a Leica SPE-II DMI-4000 confocal laser scanning microscope equipped with a 100\u00d7 (1.4-NA) oil immersion objective, and the confocal pinhole was adjusted to 1 airy unit (AU).Live-cell imaging. ::: MATERIALS AND METHODSBGM(GFPS1-10) cells were seeded in glass-bottom four-chamber 35-mm dishes (CELLview) and grown to ~35% confluency before transduction with MLV mCherry-GM130 particles.", [["Live-cell", "ANATOMY", 297, 306], ["GFPS1-10) cells", "ANATOMY", 345, 360], ["Live-cell", "CELL", 297, 306], ["GFPS1-10) cells", "CELL", 345, 360], ["MLV", "ORGANISM", 480, 483], ["GM130", "GENE_OR_GENE_PRODUCT", 492, 497], ["METHODSBGM(GFPS1-10) cells", "CELL_LINE", 334, 360], ["GM130", "PROTEIN", 492, 497], ["Images", "TEST", 0, 6], ["an Olympus", "TEST", 26, 36], ["a Leica SPE", "TEST", 125, 136], ["confocal laser scanning microscope", "TEST", 149, 183], ["the confocal pinhole", "TREATMENT", 243, 263], ["Live-cell imaging", "TEST", 297, 314], ["METHODSBGM(GFPS1-10) cells", "TREATMENT", 334, 360], ["MLV mCherry", "TREATMENT", 480, 491]]], ["Infection with CVB3-3A(S11aa2) was carried out 18 to 24 h later.", [["CVB3-3A", "ORGANISM", 15, 22], ["S11aa2", "ORGANISM", 23, 29], ["CVB3-3A", "SPECIES", 15, 22], ["Infection", "PROBLEM", 0, 9], ["CVB3", "PROBLEM", 15, 19], ["CVB3", "OBSERVATION", 15, 19]]], ["Cells were washed with Fluorobrite medium (Thermo Fisher Scientific) supplemented with 8% fetal calf serum (FCS) and 25 mM HEPES just prior to imaging.", [["Cells", "ANATOMY", 0, 5], ["fetal calf serum", "ANATOMY", 90, 106], ["HEPES", "CHEMICAL", 123, 128], ["Cells", "CELL", 0, 5], ["Fluorobrite", "SIMPLE_CHEMICAL", 23, 34], ["fetal calf", "ORGANISM_SUBSTANCE", 90, 100], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["FCS", "ORGANISM_SUBSTANCE", 108, 111], ["calf", "SPECIES", 96, 100], ["Fluorobrite medium", "TREATMENT", 23, 41], ["8% fetal calf serum (FCS", "TREATMENT", 87, 111], ["25 mM HEPES", "TREATMENT", 117, 128], ["imaging", "TEST", 143, 150], ["calf", "ANATOMY", 96, 100]]], ["Imaging was performed with a Leica SP5 confocal microscope equipped with a HyD detector and a 63\u00d7 (1.4-NA) oil immersion objective, and the confocal pinhole was adjusted to 95.56 \u00b5m as the standard or 600 \u00b5m to approximate wide-field imaging.", [["Imaging", "TEST", 0, 7], ["a HyD detector", "TEST", 73, 87], ["the confocal pinhole", "TREATMENT", 136, 156], ["wide-field imaging", "TEST", 223, 241]]], ["Cells were maintained in a live-cell imaging chamber at 37\u00b0C and 5% CO2.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 32, 36], ["CO2", "CHEMICAL", 68, 71], ["CO2", "CHEMICAL", 68, 71], ["Cells", "CELL", 0, 5], ["cell", "CELL", 32, 36], ["CO2", "SIMPLE_CHEMICAL", 68, 71]]], ["GFP and mCherry were excited using a 488-nm or 561-nm laser, respectively, and the appropriate emission filter, and the positions (xyz) were marked and imaged sequentially at 5-min intervals.", [["GFP", "GENE_OR_GENE_PRODUCT", 0, 3], ["mCherry", "GENE_OR_GENE_PRODUCT", 8, 15], ["GFP", "PROTEIN", 0, 3], ["mCherry", "PROTEIN", 8, 15], ["GFP", "TEST", 0, 3], ["the appropriate emission filter", "TREATMENT", 79, 110], ["emission filter", "OBSERVATION", 95, 110]]], ["For the generation of movies, live-cell imaging data were processed in ImageJ and aligned using the StackReg plugin.Correlative light electron microscopy. ::: MATERIALS AND METHODSAsymmetrical guide marks were scratched into glass-bottom eight-well chamber \u03bc-slides (Ibidi); BGM(GFPS1-10) cells were grown to subconfluency and infected with CVB3-3A(S11aa2) on these slides.", [["cell", "ANATOMY", 35, 39], ["BGM(GFPS1-10) cells", "ANATOMY", 275, 294], ["cell", "CELL", 35, 39], ["GFPS1-10) cells", "CELL", 279, 294], ["CVB3-3A", "ORGANISM", 341, 348], ["S11aa2", "CELL", 349, 355], ["Ibidi", "CELL_LINE", 267, 272], ["BGM(GFPS1-10) cells", "CELL_LINE", 275, 294], ["CVB3-3A", "SPECIES", 341, 348], ["live-cell imaging data", "TEST", 30, 52], ["Correlative light electron microscopy", "TEST", 116, 153], ["Ibidi", "TEST", 267, 272], ["BGM", "TEST", 275, 278], ["GFPS1", "TEST", 279, 284], ["CVB3", "TEST", 341, 345], ["these slides", "TEST", 360, 372], ["infected", "OBSERVATION_MODIFIER", 327, 335]]], ["Just prior to imaging and to later aid in the correlation of fluorescent and EM images, cells were incubated with 100 nM MitoTracker deep red FM (Thermo Fisher) for 30 min, then washed several times in Fluorobrite medium supplemented with 8% fetal calf serum (FCS) and 25 mM HEPES.", [["cells", "ANATOMY", 88, 93], ["fetal calf serum", "ANATOMY", 242, 258], ["HEPES", "CHEMICAL", 275, 280], ["cells", "CELL", 88, 93], ["MitoTracker", "SIMPLE_CHEMICAL", 121, 132], ["fetal calf", "ORGANISM_SUBSTANCE", 242, 252], ["serum", "ORGANISM_SUBSTANCE", 253, 258], ["FCS", "ORGANISM_SUBSTANCE", 260, 263], ["calf", "SPECIES", 248, 252], ["imaging", "TEST", 14, 21], ["fluorescent and EM images", "TEST", 61, 86], ["8% fetal calf serum (FCS", "TREATMENT", 239, 263], ["25 mM HEPES", "TREATMENT", 269, 280], ["calf", "ANATOMY", 248, 252]]], ["Imaging was carried out from ~2 h p.i. in a live-cell chamber at 37\u00b0C and 5% CO2 with a Leica SP8 confocal microscope equipped with a HyD detector and with a 63\u00d7 (1.4-NA) oil immersion objective.", [["cell", "ANATOMY", 49, 53], ["CO2", "CHEMICAL", 77, 80], ["CO2", "CHEMICAL", 77, 80], ["CO2", "SIMPLE_CHEMICAL", 77, 80], ["Imaging", "TEST", 0, 7], ["a HyD detector", "TEST", 132, 146]]], ["For each position of interest, a low-resolution tile scan was taken of the surrounding area, including guide marks, to aid in later reidentification.", [["a low-resolution tile scan", "TEST", 31, 57]]], ["Z-stacks were acquired using a 1-AU pinhole and Nyquist frequency sampling.", [["Z-stacks", "TEST", 0, 8], ["a 1-AU pinhole and Nyquist frequency sampling", "TREATMENT", 29, 74]]], ["The cells were then fixed with 4% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M S\u00f8renson\u2019s phosphate buffer (PB) and processed for electron microscopy.", [["cells", "ANATOMY", 4, 9], ["glutaraldehyde", "CHEMICAL", 60, 74], ["S\u00f8renson\u2019s phosphate", "CHEMICAL", 84, 104], ["paraformaldehyde", "CHEMICAL", 34, 50], ["glutaraldehyde", "CHEMICAL", 60, 74], ["phosphate", "CHEMICAL", 95, 104], ["cells", "CELL", 4, 9], ["paraformaldehyde", "SIMPLE_CHEMICAL", 34, 50], ["glutaraldehyde", "SIMPLE_CHEMICAL", 60, 74], ["S\u00f8renson\u2019s phosphate buffer", "SIMPLE_CHEMICAL", 84, 111], ["4% paraformaldehyde", "TREATMENT", 31, 50], ["2.5% glutaraldehyde", "TREATMENT", 55, 74], ["S\u00f8renson\u2019s phosphate buffer (PB)", "TREATMENT", 84, 116], ["electron microscopy", "TEST", 135, 154]]], ["The cells were postfixed first with 1% osmium tetroxide for 1 h in PB and then with 1% tannic acid in PB for 30 min.", [["cells", "ANATOMY", 4, 9], ["osmium tetroxide", "CHEMICAL", 39, 55], ["tannic acid", "CHEMICAL", 87, 98], ["PB", "CHEMICAL", 102, 104], ["osmium tetroxide", "CHEMICAL", 39, 55], ["tannic acid", "CHEMICAL", 87, 98], ["cells", "CELL", 4, 9], ["osmium tetroxide", "SIMPLE_CHEMICAL", 39, 55], ["tannic acid", "SIMPLE_CHEMICAL", 87, 98], ["PB", "SIMPLE_CHEMICAL", 102, 104], ["1% osmium tetroxide", "TREATMENT", 36, 55], ["1% tannic acid in PB", "TREATMENT", 84, 104]]], ["The cells were then serially dehydrated in ethanol and infiltrated and embedded in LX 112 resin (Ladd Research Industries) before polymerization at 60\u00b0C. Positions of interest imaged earlier were identified on the resin block surface through comparison with (horizontally flipped) tile scan images, the appropriate block faces were trimmed, and serial thin sections were cut and collected on copper slot grids covered with a carbon-coated formvar layer.", [["cells", "ANATOMY", 4, 9], ["sections", "ANATOMY", 357, 365], ["ethanol", "CHEMICAL", 43, 50], ["LX 112 resin", "CHEMICAL", 83, 95], ["copper", "CHEMICAL", 392, 398], ["ethanol", "CHEMICAL", 43, 50], ["copper", "CHEMICAL", 392, 398], ["carbon", "CHEMICAL", 425, 431], ["cells", "CELL", 4, 9], ["ethanol", "SIMPLE_CHEMICAL", 43, 50], ["Ladd Research Industries", "TREATMENT", 97, 121], ["polymerization", "TREATMENT", 130, 144], ["horizontally flipped) tile scan images", "TEST", 259, 297], ["the appropriate block faces", "TREATMENT", 299, 326], ["serial thin sections", "TEST", 345, 365], ["copper slot grids", "TREATMENT", 392, 409], ["a carbon-coated formvar layer", "TREATMENT", 423, 452]]], ["After poststaining grids with lead citrate and uranyl acetate, image meshes spanning large areas of the grid were collected on an FEI Tecnai 20 FEG electron microscope operated at 120 kV with a charge-coupled-device (CCD) camera (US4000; Gatan) (4,000 [4K] by 4K pixel) with binning 2 and a final image pixel size of 1.94 nm.", [["lead citrate", "CHEMICAL", 30, 42], ["uranyl acetate", "CHEMICAL", 47, 61], ["citrate", "CHEMICAL", 35, 42], ["uranyl acetate", "CHEMICAL", 47, 61], ["citrate", "SIMPLE_CHEMICAL", 35, 42], ["uranyl acetate", "SIMPLE_CHEMICAL", 47, 61], ["lead citrate", "TREATMENT", 30, 42], ["uranyl acetate", "TREATMENT", 47, 61], ["image meshes", "TREATMENT", 63, 75], ["a charge-coupled-device (CCD)", "TREATMENT", 192, 221], ["K pixel", "TEST", 261, 268], ["binning", "TEST", 275, 282], ["a final image pixel size", "TEST", 289, 313], ["large", "OBSERVATION_MODIFIER", 85, 90], ["areas", "OBSERVATION_MODIFIER", 91, 96], ["1.94 nm", "OBSERVATION_MODIFIER", 317, 324]]], ["These individual images were later combined into composite stitches (65).", [["These individual images", "TEST", 0, 23], ["composite stitches", "TREATMENT", 49, 67]]], ["Cells of interest were digitally extracted from their raw image files using ImageJ and Aperio Imagescope software packages for light microscope and electron microscope images, respectively.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["ImageJ", "TEST", 76, 82], ["light microscope", "TEST", 127, 143], ["electron microscope images", "TEST", 148, 174]]], ["These images were then overlaid using Adobe Photoshop CS6.", [["These images", "TEST", 0, 12]]], ["The mitochondrial pattern in the EM images was compared with the MitoTracker deep red FM signal to find the right transformations to correlate both types of data.", [["mitochondrial", "ANATOMY", 4, 17], ["mitochondrial", "CELLULAR_COMPONENT", 4, 17], ["MitoTracker", "SIMPLE_CHEMICAL", 65, 76], ["the EM images", "TEST", 29, 42], ["the MitoTracker deep red FM signal", "TEST", 61, 95], ["mitochondrial pattern", "OBSERVATION", 4, 25], ["right", "ANATOMY_MODIFIER", 108, 113]]], ["While the discrepancy in the axial resolution of the light and electron microscopes limited the precision of the overlay, the use of this secondary marker was critical to determine the z-plane in the confocal data, the best fit of the EM cell section under analysis, and the xy orientation of both images, thus providing an independent marker for an unbiased localization of the 3A signal.", [["cell", "ANATOMY", 238, 242], ["electron microscopes", "TEST", 63, 83], ["the EM cell section under analysis", "TEST", 231, 265], ["the xy orientation of both images", "TEST", 271, 304]]]], "5d2ac2ff6f411fe4321845f33954828e6c96fc6d": [], "PMC7135049": [["Pharyngitis ::: INFECTIONS IN THE ORAL CAVITYAcute pharyngitis is a common illness that sends nearly 1% of all children and adults to seek care from physicians and emergency rooms each year.", [["Pharyngitis", "DISEASE", 0, 11], ["pharyngitis", "DISEASE", 51, 62], ["children", "ORGANISM", 111, 119], ["children", "SPECIES", 111, 119], ["Pharyngitis", "PROBLEM", 0, 11], ["INFECTIONS", "PROBLEM", 16, 26], ["THE ORAL CAVITYAcute pharyngitis", "PROBLEM", 30, 62], ["ORAL CAVITYAcute", "ANATOMY", 34, 50], ["pharyngitis", "OBSERVATION", 51, 62]]], ["Searching for a specific organism, Streptococcus pyogenes, as the causative pathogen is the most common infectious disease diagnostic effort performed on the oral cavity.", [["oral cavity", "ANATOMY", 158, 169], ["Streptococcus pyogenes", "DISEASE", 35, 57], ["Streptococcus pyogenes", "ORGANISM", 35, 57], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 158, 169], ["Streptococcus pyogenes", "SPECIES", 35, 57], ["Streptococcus pyogenes", "SPECIES", 35, 57], ["a specific organism", "PROBLEM", 14, 33], ["Streptococcus pyogenes", "PROBLEM", 35, 57], ["the causative pathogen", "PROBLEM", 62, 84], ["Streptococcus pyogenes", "OBSERVATION", 35, 57], ["most common", "OBSERVATION_MODIFIER", 92, 103], ["infectious", "OBSERVATION_MODIFIER", 104, 114]]], ["The primary cause of most microbial pharyngitis is a virus in most adults; however, S. pyogenes, also known as the group A \u03b2-hemolytic streptococcus (GABHS), is the most important organism to recognize.", [["pharyngitis", "DISEASE", 36, 47], ["GABHS", "DISEASE", 150, 155], ["S. pyogenes", "ORGANISM", 84, 95], ["A \u03b2-hemolytic streptococcus", "ORGANISM", 121, 148], ["S. pyogenes", "SPECIES", 84, 95], ["S. pyogenes", "SPECIES", 84, 95], ["most microbial pharyngitis", "PROBLEM", 21, 47], ["a virus", "PROBLEM", 51, 58], ["S. pyogenes", "PROBLEM", 84, 95], ["the group A \u03b2-hemolytic streptococcus (GABHS", "PROBLEM", 111, 155], ["most microbial", "OBSERVATION_MODIFIER", 21, 35], ["pharyngitis", "OBSERVATION", 36, 47], ["virus", "OBSERVATION", 53, 58], ["pyogenes", "OBSERVATION", 87, 95]]], ["The inflammatory syndrome of the pharynx resulting from S. pyogenes infection is marked by a wide variety of signs and symptoms, and nearly always is accompanied by fever and sore throat.6, 35, 64 It is important for physicians to accurately diagnose which organism is causing the disease because infection with GABHS should be treated with antibiotics such as penicillin and erythromycin, whereas viruses do not respond to such therapy.", [["pharynx", "ANATOMY", 33, 40], ["inflammatory syndrome of the pharynx", "DISEASE", 4, 40], ["S. pyogenes infection", "DISEASE", 56, 77], ["fever", "DISEASE", 165, 170], ["sore throat", "DISEASE", 175, 186], ["infection", "DISEASE", 297, 306], ["GABHS", "DISEASE", 312, 317], ["penicillin", "CHEMICAL", 361, 371], ["erythromycin", "CHEMICAL", 376, 388], ["penicillin", "CHEMICAL", 361, 371], ["erythromycin", "CHEMICAL", 376, 388], ["pharynx", "ORGAN", 33, 40], ["S. pyogenes", "ORGANISM", 56, 67], ["throat", "ORGANISM_SUBDIVISION", 180, 186], ["penicillin", "SIMPLE_CHEMICAL", 361, 371], ["erythromycin", "SIMPLE_CHEMICAL", 376, 388], ["S. pyogenes", "SPECIES", 56, 67], ["S. pyogenes", "SPECIES", 56, 67], ["The inflammatory syndrome of the pharynx", "PROBLEM", 0, 40], ["S. pyogenes infection", "PROBLEM", 56, 77], ["signs and symptoms", "PROBLEM", 109, 127], ["fever", "PROBLEM", 165, 170], ["sore throat", "PROBLEM", 175, 186], ["the disease", "PROBLEM", 277, 288], ["infection", "PROBLEM", 297, 306], ["GABHS", "PROBLEM", 312, 317], ["antibiotics", "TREATMENT", 341, 352], ["penicillin", "TREATMENT", 361, 371], ["erythromycin", "TREATMENT", 376, 388], ["such therapy", "TREATMENT", 424, 436], ["inflammatory syndrome", "OBSERVATION", 4, 25], ["pharynx", "ANATOMY", 33, 40], ["pyogenes", "OBSERVATION_MODIFIER", 59, 67], ["infection", "OBSERVATION", 68, 77], ["marked", "OBSERVATION_MODIFIER", 81, 87], ["wide", "OBSERVATION_MODIFIER", 93, 97], ["variety", "OBSERVATION_MODIFIER", 98, 105], ["fever", "OBSERVATION", 165, 170], ["sore throat", "ANATOMY", 175, 186]]], ["S. pyogenes also causes suppurative infections of the tonsils, sinuses, and middle ear, or cellulitis as secondary sequelae after an episode of pharyngitis.", [["tonsils", "ANATOMY", 54, 61], ["sinuses", "ANATOMY", 63, 70], ["middle ear", "ANATOMY", 76, 86], ["suppurative infections of the tonsils", "DISEASE", 24, 61], ["cellulitis", "DISEASE", 91, 101], ["pharyngitis", "DISEASE", 144, 155], ["S. pyogenes", "ORGANISM", 0, 11], ["tonsils", "ORGAN", 54, 61], ["sinuses", "MULTI-TISSUE_STRUCTURE", 63, 70], ["ear", "ORGAN", 83, 86], ["S. pyogenes", "SPECIES", 0, 11], ["S. pyogenes", "SPECIES", 0, 11], ["S. pyogenes", "PROBLEM", 0, 11], ["suppurative infections of the tonsils", "PROBLEM", 24, 61], ["sinuses, and middle ear", "PROBLEM", 63, 86], ["cellulitis", "PROBLEM", 91, 101], ["secondary sequelae", "PROBLEM", 105, 123], ["pharyngitis", "PROBLEM", 144, 155], ["pyogenes", "OBSERVATION", 3, 11], ["suppurative", "OBSERVATION_MODIFIER", 24, 35], ["infections", "OBSERVATION", 36, 46], ["tonsils", "ANATOMY", 54, 61], ["sinuses", "ANATOMY", 63, 70], ["middle ear", "ANATOMY", 76, 86], ["cellulitis", "OBSERVATION", 91, 101], ["pharyngitis", "OBSERVATION", 144, 155]]], ["Treatment of GABHS pharyngitis is crucial because this can shorten the duration of symptoms and prevent the spread of the organism to other patients.", [["GABHS", "DISEASE", 13, 18], ["pharyngitis", "DISEASE", 19, 30], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["GABHS pharyngitis", "PROBLEM", 13, 30], ["symptoms", "PROBLEM", 83, 91], ["GABHS pharyngitis", "OBSERVATION", 13, 30]]], ["It will also prevent the potential damage that S. pyogenes may cause to the heart and kidneys from rheumatic fever and glomerulonephritis, respectively.Pharyngitis ::: INFECTIONS IN THE ORAL CAVITYThe gold standard diagnostic test for GABHS infection is the throat culture.6 Unfortunately, the culture takes 24 to 48 hours to complete.", [["heart", "ANATOMY", 76, 81], ["kidneys", "ANATOMY", 86, 93], ["throat culture", "ANATOMY", 258, 272], ["S. pyogenes", "DISEASE", 47, 58], ["rheumatic fever", "DISEASE", 99, 114], ["glomerulonephritis", "DISEASE", 119, 137], ["Pharyngitis", "DISEASE", 152, 163], ["GABHS infection", "DISEASE", 235, 250], ["S. pyogenes", "ORGANISM", 47, 58], ["heart", "ORGAN", 76, 81], ["kidneys", "ORGAN", 86, 93], ["S. pyogenes", "SPECIES", 47, 58], ["S. pyogenes", "SPECIES", 47, 58], ["S. pyogenes", "PROBLEM", 47, 58], ["rheumatic fever", "PROBLEM", 99, 114], ["glomerulonephritis", "PROBLEM", 119, 137], ["Pharyngitis", "PROBLEM", 152, 163], ["INFECTIONS IN THE ORAL CAVITY", "PROBLEM", 168, 197], ["The gold standard diagnostic test", "TEST", 197, 230], ["GABHS infection", "PROBLEM", 235, 250], ["the throat culture", "TEST", 254, 272], ["the culture", "TEST", 290, 301], ["pyogenes", "OBSERVATION", 50, 58], ["heart", "ANATOMY", 76, 81], ["kidneys", "ANATOMY", 86, 93], ["rheumatic", "OBSERVATION_MODIFIER", 99, 108], ["fever", "OBSERVATION", 109, 114], ["glomerulonephritis", "OBSERVATION", 119, 137], ["ORAL CAVITY", "ANATOMY", 186, 197]]], ["If the patient leaves their physician or healthcare facility with a prescription for antibiotics, the treatment would then begin before the microbial entity is known.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["antibiotics", "TREATMENT", 85, 96], ["the treatment", "TREATMENT", 98, 111]]], ["In the age of emerging drug resistance, unnecessary antimicrobial agent use must be avoided.", [["emerging drug resistance", "TREATMENT", 14, 38], ["unnecessary antimicrobial agent", "TREATMENT", 40, 71], ["drug resistance", "OBSERVATION", 23, 38]]], ["Because untreated GABHS infection may have serious consequences for the patient, rapid detection methods for S. pyogenes were developed to give nearly immediate results in order to make the diagnosis of streptococcal pharyngitis possible while the patient is still in the office or clinic.", [["GABHS infection", "DISEASE", 18, 33], ["streptococcal pharyngitis", "DISEASE", 203, 228], ["patient", "ORGANISM", 72, 79], ["S. pyogenes", "ORGANISM", 109, 120], ["patient", "ORGANISM", 248, 255], ["patient", "SPECIES", 72, 79], ["S. pyogenes", "SPECIES", 109, 120], ["patient", "SPECIES", 248, 255], ["S. pyogenes", "SPECIES", 109, 120], ["untreated GABHS infection", "PROBLEM", 8, 33], ["rapid detection methods", "TEST", 81, 104], ["S. pyogenes", "PROBLEM", 109, 120], ["streptococcal pharyngitis", "PROBLEM", 203, 228], ["GABHS", "OBSERVATION", 18, 23], ["streptococcal", "OBSERVATION_MODIFIER", 203, 216], ["pharyngitis", "OBSERVATION", 217, 228]]], ["There are several manufacturers of rapid identification test kits for GABHS in the marketplace today.34, 47, 52 The Centers for Disease Control and Prevention (CDC) reviewed 25 published studies that examined the sensitivity of these rapid identification test kits.18 They found the sensitivity of these tests ranged from 62% to 100%.", [["GABHS", "DISEASE", 70, 75], ["rapid identification test kits", "TEST", 35, 65], ["GABHS", "PROBLEM", 70, 75], ["Disease Control", "TREATMENT", 128, 143], ["published studies", "TEST", 177, 194], ["these rapid identification test kits", "TEST", 228, 264], ["these tests", "TEST", 298, 309], ["rapid", "OBSERVATION_MODIFIER", 35, 40]]], ["Within any one institution, the sensitivity of a single kit varied by as much as 20%.", [["a single kit", "TEST", 47, 59]]], ["Assuming that a good diagnostic screening test should have a sensitivity of at least 95% (so almost all infected patients will be detected), this study showed that a negative rapid identification test for GABHS cannot accurately rule out infection, and that a corresponding culture also is needed.18", [["GABHS", "DISEASE", 205, 210], ["infection", "DISEASE", 238, 247], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["a good diagnostic screening test", "TEST", 14, 46], ["this study", "TEST", 141, 151], ["a negative rapid identification test", "PROBLEM", 164, 200], ["GABHS", "PROBLEM", 205, 210], ["infection", "PROBLEM", 238, 247], ["a corresponding culture", "TEST", 258, 281], ["infection", "OBSERVATION", 238, 247]]]], "PMC7172423": [["IntroductionRespiratory virus infections account for significant morbidity and mortality.", [["IntroductionRespiratory virus infections", "DISEASE", 0, 40], ["IntroductionRespiratory virus", "ORGANISM", 0, 29], ["IntroductionRespiratory virus infections", "PROBLEM", 0, 40], ["significant morbidity", "PROBLEM", 53, 74], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["morbidity", "OBSERVATION", 65, 74]]], ["Viruses most frequently associated with respiratory tract infections include rhinoviruses, coronaviruses, influenza viruses, parainfluenza viruses, respiratory syncytial viruses and adenoviruses.", [["respiratory tract", "ANATOMY", 40, 57], ["respiratory tract infections", "DISEASE", 40, 68], ["rhinoviruses, coronaviruses", "DISEASE", 77, 104], ["influenza viruses", "DISEASE", 106, 123], ["parainfluenza viruses", "DISEASE", 125, 146], ["respiratory syncytial viruses", "DISEASE", 148, 177], ["respiratory tract", "ORGANISM_SUBDIVISION", 40, 57], ["rhinoviruses", "ORGANISM", 77, 89], ["influenza viruses", "ORGANISM", 106, 123], ["parainfluenza viruses", "ORGANISM", 125, 146], ["respiratory syncytial viruses", "ORGANISM", 148, 177], ["adenoviruses", "ORGANISM", 182, 194], ["influenza viruses", "SPECIES", 106, 123], ["parainfluenza", "SPECIES", 125, 138], ["respiratory syncytial viruses", "SPECIES", 148, 177], ["Viruses", "PROBLEM", 0, 7], ["respiratory tract infections", "PROBLEM", 40, 68], ["rhinoviruses", "PROBLEM", 77, 89], ["coronaviruses", "PROBLEM", 91, 104], ["influenza viruses", "PROBLEM", 106, 123], ["parainfluenza viruses", "PROBLEM", 125, 146], ["respiratory syncytial viruses", "PROBLEM", 148, 177], ["adenoviruses", "PROBLEM", 182, 194], ["respiratory tract", "ANATOMY", 40, 57], ["rhinoviruses", "OBSERVATION", 77, 89], ["influenza viruses", "OBSERVATION", 106, 123], ["parainfluenza viruses", "OBSERVATION", 125, 146], ["respiratory syncytial viruses", "OBSERVATION", 148, 177]]], ["However, the causative agents for a significant portion of respiratory infections are still unknown.", [["respiratory", "ANATOMY", 59, 70], ["respiratory infections", "DISEASE", 59, 81], ["respiratory infections", "PROBLEM", 59, 81], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["respiratory", "ANATOMY", 59, 70], ["infections", "OBSERVATION", 71, 81]]], ["Recently, van den Hoogen et al. reported the isolation of a new paramyxovirus in the Netherlands that was tentatively assigned to the Metapneumovirus genus of the Pneumovirinae subfamily (van den Hoogen et al., 2001).", [["paramyxovirus", "ORGANISM", 64, 77], ["Pneumovirinae subfamily", "PROTEIN", 163, 186], ["a new paramyxovirus", "PROBLEM", 58, 77], ["new", "OBSERVATION_MODIFIER", 60, 63], ["paramyxovirus", "OBSERVATION", 64, 77], ["Metapneumovirus", "OBSERVATION", 134, 149]]], ["This hMPV has been associated with respiratory illnesses ranging from upper respiratory tract disease to severe bronchiolitis and pneumonia similar to those caused by human respiratory syncytial virus (HRSV) infection. hMPV is currently being isolated from patients with respiratory disease in several countries suggesting that hMPV may be present throughout the world (Pelletier et al., 2002, Peret et al., 2002, Stockon et al., 2002).", [["respiratory", "ANATOMY", 35, 46], ["upper respiratory tract", "ANATOMY", 70, 93], ["respiratory", "ANATOMY", 271, 282], ["hMPV", "DISEASE", 5, 9], ["respiratory illnesses", "DISEASE", 35, 56], ["respiratory tract disease", "DISEASE", 76, 101], ["bronchiolitis", "DISEASE", 112, 125], ["pneumonia", "DISEASE", 130, 139], ["respiratory syncytial virus (HRSV) infection", "DISEASE", 173, 217], ["hMPV", "DISEASE", 219, 223], ["respiratory disease", "DISEASE", 271, 290], ["hMPV", "DISEASE", 328, 332], ["hMPV", "ORGANISM", 5, 9], ["upper", "ORGANISM_SUBDIVISION", 70, 75], ["respiratory tract", "ORGANISM_SUBDIVISION", 76, 93], ["human respiratory syncytial virus", "ORGANISM", 167, 200], ["HRSV", "ORGANISM", 202, 206], ["hMPV", "ORGANISM", 219, 223], ["patients", "ORGANISM", 257, 265], ["hMPV", "ORGANISM", 328, 332], ["human", "SPECIES", 167, 172], ["respiratory syncytial virus", "SPECIES", 173, 200], ["HRSV", "SPECIES", 202, 206], ["patients", "SPECIES", 257, 265], ["hMPV", "SPECIES", 5, 9], ["human respiratory syncytial virus", "SPECIES", 167, 200], ["HRSV", "SPECIES", 202, 206], ["hMPV", "SPECIES", 219, 223], ["hMPV", "SPECIES", 328, 332], ["This hMPV", "PROBLEM", 0, 9], ["respiratory illnesses", "PROBLEM", 35, 56], ["upper respiratory tract disease", "PROBLEM", 70, 101], ["severe bronchiolitis", "PROBLEM", 105, 125], ["pneumonia", "PROBLEM", 130, 139], ["human respiratory syncytial virus (HRSV) infection", "PROBLEM", 167, 217], ["hMPV", "PROBLEM", 219, 223], ["respiratory disease", "PROBLEM", 271, 290], ["hMPV", "PROBLEM", 328, 332], ["associated with", "UNCERTAINTY", 19, 34], ["respiratory illnesses", "OBSERVATION", 35, 56], ["upper", "ANATOMY_MODIFIER", 70, 75], ["respiratory tract", "ANATOMY", 76, 93], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["bronchiolitis", "OBSERVATION", 112, 125], ["pneumonia", "OBSERVATION", 130, 139], ["respiratory syncytial virus", "OBSERVATION", 173, 200], ["infection", "OBSERVATION", 208, 217], ["respiratory disease", "OBSERVATION", 271, 290], ["hMPV", "OBSERVATION", 328, 332]]], ["Partial sequence analysis demonstrated sequence similarity between the Dutch and Canadian isolates and the presence of two potential genetic clusters.", [["Partial sequence analysis", "TEST", 0, 25]]], ["Phylogenetic analysis of hMPV and the other members of the Pneumovirinae revealed that hMPV is more closely related to avian pneumovirus (van den Hoogen et al., 2001).", [["hMPV", "ORGANISM", 25, 29], ["Pneumovirinae", "GENE_OR_GENE_PRODUCT", 59, 72], ["hMPV", "ORGANISM", 87, 91], ["avian pneumovirus", "ORGANISM", 119, 136], ["avian pneumovirus", "SPECIES", 119, 136], ["hMPV", "SPECIES", 25, 29], ["hMPV", "SPECIES", 87, 91], ["Phylogenetic analysis", "TEST", 0, 21], ["hMPV", "PROBLEM", 25, 29], ["the Pneumovirinae", "TEST", 55, 72], ["hMPV", "PROBLEM", 87, 91], ["hMPV", "OBSERVATION", 25, 29], ["hMPV", "OBSERVATION", 87, 91]]], ["To gain a better understanding of the molecular biology of hMPV, we report the complete sequence of N, P, M and F genes and intervening regions of multiple recent isolates of this virus from Canada.Specimens and patients ::: Materials and methodsFifteen specimens were collected from patients with acute respiratory illnesses from 1997 to 2000 in Quebec City, Quebec, Canada.", [["Specimens", "ANATOMY", 198, 207], ["specimens", "ANATOMY", 254, 263], ["respiratory", "ANATOMY", 304, 315], ["acute respiratory illnesses", "DISEASE", 298, 325], ["hMPV", "ORGANISM", 59, 63], ["patients", "ORGANISM", 212, 220], ["patients", "ORGANISM", 284, 292], ["N, P, M and F genes", "DNA", 100, 119], ["patients", "SPECIES", 212, 220], ["patients", "SPECIES", 284, 292], ["hMPV", "SPECIES", 59, 63], ["hMPV", "PROBLEM", 59, 63], ["this virus", "PROBLEM", 175, 185], ["methodsFifteen specimens", "TEST", 239, 263], ["acute respiratory illnesses", "PROBLEM", 298, 325], ["multiple", "OBSERVATION_MODIFIER", 147, 155], ["acute", "OBSERVATION_MODIFIER", 298, 303], ["respiratory", "ANATOMY", 304, 315]]], ["The specimens were inoculated onto LLC-MK2 cells and serially blind passaged (Peret et al., 2002).", [["specimens", "ANATOMY", 4, 13], ["LLC-MK2 cells", "ANATOMY", 35, 48], ["specimens", "CELL", 4, 13], ["LLC-MK2 cells", "CELL", 35, 48], ["LLC-MK2 cells", "CELL_LINE", 35, 48], ["The specimens", "TEST", 0, 13], ["MK2 cells", "OBSERVATION", 39, 48]]], ["Following viral isolation, the virus was cultured at 37 \u00b0C in Eagle's MEM supplemented with penicillin (100 U/ml), streptomycin (100 \u03bcg/ml), 30 \u03bcg/ml l-glutamine (Life Technologies) and 0.02% TPKC trypsin (Sigma).", [["MEM", "CHEMICAL", 70, 73], ["penicillin", "CHEMICAL", 92, 102], ["streptomycin", "CHEMICAL", 115, 127], ["l-glutamine", "CHEMICAL", 150, 161], ["penicillin", "CHEMICAL", 92, 102], ["streptomycin", "CHEMICAL", 115, 127], ["l-glutamine", "CHEMICAL", 150, 161], ["penicillin", "SIMPLE_CHEMICAL", 92, 102], ["streptomycin", "SIMPLE_CHEMICAL", 115, 127], ["l-glutamine", "SIMPLE_CHEMICAL", 150, 161], ["TPKC trypsin", "GENE_OR_GENE_PRODUCT", 192, 204], ["trypsin", "PROTEIN", 197, 204], ["viral isolation", "TREATMENT", 10, 25], ["the virus", "PROBLEM", 27, 36], ["penicillin", "TREATMENT", 92, 102], ["streptomycin", "TREATMENT", 115, 127], ["glutamine (Life Technologies", "TREATMENT", 152, 180], ["viral isolation", "OBSERVATION", 10, 25]]], ["The virus isolates were cultured for a maximum of 21 days with weekly media change.", [["The virus isolates", "PROBLEM", 0, 18], ["weekly media change", "TREATMENT", 63, 82], ["virus isolates", "OBSERVATION", 4, 18]]], ["The cells usually displayed cytopathic effects at 8\u201314 post inoculation, characterized by focal rounding and cell destruction without apparent syncytia formation.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 109, 113], ["syncytia", "ANATOMY", 143, 151], ["cells", "CELL", 4, 9], ["cell", "CELL", 109, 113], ["syncytia", "CELL", 143, 151], ["cytopathic effects", "PROBLEM", 28, 46], ["inoculation", "PROBLEM", 60, 71], ["focal rounding", "PROBLEM", 90, 104], ["cell destruction", "PROBLEM", 109, 125], ["apparent syncytia formation", "PROBLEM", 134, 161], ["cytopathic", "OBSERVATION_MODIFIER", 28, 38], ["post inoculation", "OBSERVATION_MODIFIER", 55, 71], ["focal", "OBSERVATION_MODIFIER", 90, 95], ["rounding", "OBSERVATION_MODIFIER", 96, 104], ["cell destruction", "OBSERVATION", 109, 125], ["without apparent", "UNCERTAINTY", 126, 142], ["syncytia formation", "OBSERVATION", 143, 161]]], ["The specimens were negative when tested by indirect immunofluorescent assays for influenza virus A and B, parainfluenza viruses 1, 2 and 3, adenovirus and respiratory syncytial virus (Bartels; Chemicon).", [["specimens", "ANATOMY", 4, 13], ["parainfluenza viruses", "DISEASE", 106, 127], ["respiratory syncytial virus", "DISEASE", 155, 182], ["specimens", "CANCER", 4, 13], ["influenza virus A", "ORGANISM", 81, 98], ["B", "GENE_OR_GENE_PRODUCT", 103, 104], ["parainfluenza viruses 1", "ORGANISM", 106, 129], ["3", "GENE_OR_GENE_PRODUCT", 137, 138], ["adenovirus", "ORGANISM", 140, 150], ["respiratory syncytial virus", "ORGANISM", 155, 182], ["influenza virus", "SPECIES", 81, 96], ["parainfluenza viruses 1", "SPECIES", 106, 129], ["respiratory syncytial virus", "SPECIES", 155, 182], ["influenza virus A", "SPECIES", 81, 98], ["respiratory syncytial virus", "SPECIES", 155, 182], ["The specimens", "TEST", 0, 13], ["indirect immunofluorescent assays", "TEST", 43, 76], ["influenza virus A", "PROBLEM", 81, 98], ["parainfluenza viruses", "PROBLEM", 106, 127], ["adenovirus", "PROBLEM", 140, 150], ["respiratory syncytial virus", "PROBLEM", 155, 182], ["respiratory syncytial", "ANATOMY", 155, 176]]], ["These isolates were also negative for influenza A and B, parainfluenza 1, 2, 3, 4 and HRSV by an in-house RT-PCR.Primer sequences ::: Materials and methodsPrimers used for amplification and sequencing were based on the published N (AF371365), P (AF371366), M and F (AF371367) hMPV sequences (van den Hoogen et al., 2001, van den Hoogen et al., 2002).", [["influenza A", "ORGANISM", 38, 49], ["B", "GENE_OR_GENE_PRODUCT", 54, 55], ["parainfluenza 1", "ORGANISM", 57, 72], ["3", "GENE_OR_GENE_PRODUCT", 77, 78], ["4", "GENE_OR_GENE_PRODUCT", 80, 81], ["HRSV", "ORGANISM", 86, 90], ["Primer sequences", "DNA", 113, 129], ["parainfluenza", "SPECIES", 57, 70], ["influenza A", "SPECIES", 38, 49], ["HRSV", "SPECIES", 86, 90], ["These isolates", "TEST", 0, 14], ["influenza", "PROBLEM", 38, 47], ["parainfluenza", "TEST", 57, 70], ["HRSV", "PROBLEM", 86, 90], ["methodsPrimers", "TREATMENT", 148, 162], ["amplification and sequencing", "TEST", 172, 200], ["P", "TEST", 243, 244], ["hMPV sequences", "TEST", 276, 290]]], ["The primer pairs used to amplify each gene and gene junction are described in Table 1.RT-PCR and sequence analysis ::: Materials and methodsViral RNA was extracted from 100 \u03bcl of tissue culture fluid using the RNeasy Mini Kit (QIAGEN).", [["tissue culture fluid", "ANATOMY", 179, 199], ["Viral", "ORGANISM", 140, 145], ["tissue", "TISSUE", 179, 185], ["primer pairs", "DNA", 4, 16], ["Viral RNA", "RNA", 140, 149], ["The primer pairs", "TREATMENT", 0, 16], ["RT-PCR and sequence analysis", "TEST", 86, 114], ["methodsViral RNA", "PROBLEM", 133, 149], ["tissue culture fluid", "TEST", 179, 199], ["the RNeasy Mini Kit (QIAGEN)", "TREATMENT", 206, 234], ["gene junction", "ANATOMY", 47, 60]]], ["Viral RNA was amplified in a one step RT-PCR reaction (QIAGEN) following the manufacturer's recommendations.", [["Viral", "ORGANISM", 0, 5], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["RNA", "OBSERVATION", 6, 9]]], ["Briefly, 2\u201310 \u03bcl of RNA was added to the RT-PCR mixture containing 2 \u03bcl QIAGEN OneStep RT-PCR enzyme mix, 10 \u03bcl of 5X QIAGEN OneStep RT-PCR buffer, 400 \u03bcM dNTP, 0.6 \u03bcM of each primer and 10 \u03bcl of Q-solution in a final volume of 50 \u03bcl.", [["NTP", "CHEMICAL", 156, 159], ["NTP", "SIMPLE_CHEMICAL", 156, 159], ["RNA", "TREATMENT", 20, 23], ["the RT-PCR mixture", "TREATMENT", 37, 55], ["PCR enzyme mix", "TEST", 90, 104], ["\u03bcM dNTP", "TREATMENT", 152, 159], ["a final volume", "TEST", 210, 224]]], ["The thermocycler conditions used were: 50 \u00b0C for 30 min for reverse transcription, 95 \u00b0C for 15 min for the activation of the HotStart DNA polymerase; then 35 cycles of 94 \u00b0C for 1 min, 50 \u00b0C for 1 min, 72 \u00b0C for 2 min, followed by an extension of 7 min at 72 \u00b0C. The PCR products were purified using QIAquick PCR purification kit (QIAGEN) and cloned in vector pCR2.1 (Invitrogen) according to the manufacturer's instructions.", [["DNA", "CELLULAR_COMPONENT", 135, 138], ["HotStart DNA polymerase", "PROTEIN", 126, 149], ["vector pCR2.1", "DNA", 354, 367], ["reverse transcription", "TREATMENT", 60, 81], ["the HotStart DNA polymerase", "TREATMENT", 122, 149], ["The PCR products", "TREATMENT", 264, 280], ["QIAquick PCR purification kit (QIAGEN)", "TREATMENT", 301, 339]]], ["Two independent purified PCR amplicons for each gene were either sequenced directly, or sequenced using M13-specific primers after cloning in pCR2.1, on an ABI 377 Sequencer, using a fluorescent dye-terminator kit (Applied Biosystems).", [["PCR amplicons", "DNA", 25, 38], ["M13", "DNA", 104, 107], ["pCR2.1", "DNA", 142, 148], ["Two independent purified PCR amplicons", "TREATMENT", 0, 38], ["an ABI", "TEST", 153, 159], ["a fluorescent dye-terminator kit", "TREATMENT", 181, 213]]], ["The DNA sequences were assembled and analyzed with SEQMAN, EDITSEQ and MEGALIGN programs in Lasergene (DNASTAR, Madison, WI).", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNA sequences", "DNA", 4, 17], ["The DNA sequences", "TEST", 0, 17]]], ["Phylogenetic trees were generated by Neighbor-Joining method using the MEGA program (Kumar et al., 2001).Nucleotide sequence database accession numbers ::: Materials and methodsThe nucleotide sequence database accession numbers of the pneumovirus strains used in this paper are: HRSV-A (all ORFs:M11486); HRSV-B (all ORFs:AF013254); BRSV (all ORFs:AF092942); APV-A (N:U39295, P:U22110, M:X58639, F:Y14294); APV-B (N:U39296, P:AF325443, M:U37586, F:Y14293); APV-C (N:AF176590, P:AF176591, M: AF072682; F:AF187152); PVM (N:D10331, P:U092942, M:U66893; F:D11128); hMPV Netherlands isolate 00-1 (NLD00-1) (N: AF371365, P: AF371366, M and F:AF371367).", [["nucleotide", "CHEMICAL", 181, 191], ["APV", "CHEMICAL", 359, 362], ["APV", "CHEMICAL", 407, 410], ["APV", "CHEMICAL", 457, 460], ["nucleotide", "CHEMICAL", 181, 191], ["APV-A", "CHEMICAL", 359, 364], ["APV-B", "CHEMICAL", 407, 412], ["APV-C", "CHEMICAL", 457, 462], ["HRSV-A", "ORGANISM", 279, 285], ["HRSV-B", "GENE_OR_GENE_PRODUCT", 305, 311], ["BRSV", "ORGANISM", 333, 337], ["ORFs", "DNA", 291, 295], ["ORFs", "DNA", 317, 321], ["ORFs", "DNA", 343, 347], ["BRSV", "SPECIES", 333, 337], ["HRSV-A", "SPECIES", 279, 285], ["HRSV-B", "SPECIES", 305, 311], ["BRSV", "SPECIES", 333, 337], ["Phylogenetic trees", "PROBLEM", 0, 18], ["The nucleotide sequence", "TEST", 177, 200], ["the pneumovirus strains", "TREATMENT", 231, 254], ["HRSV", "TEST", 279, 283], ["HRSV", "TEST", 305, 309], ["BRSV", "TEST", 333, 337], ["APV", "TEST", 359, 362], ["P", "TEST", 376, 377], ["U", "TEST", 378, 379], ["APV", "TEST", 407, 410], ["P", "TEST", 424, 425], ["U", "TEST", 438, 439], ["APV", "TEST", 457, 460], ["C", "TEST", 461, 462], ["AF", "TEST", 466, 468], ["P", "TEST", 476, 477], ["AF", "TEST", 478, 480], ["PVM", "TEST", 514, 517], ["D10331", "TEST", 521, 527], ["P", "TEST", 529, 530], ["U", "TEST", 542, 543], ["D", "TEST", 552, 553], ["hMPV Netherlands isolate", "TEST", 561, 585], ["NLD00", "TEST", 592, 597], ["AF", "TEST", 605, 607], ["P", "TEST", 615, 616], ["AF", "TEST", 618, 620], ["AF", "TEST", 636, 638]]], ["The hMPV sequences described in this paper have been deposited in GeneBank under accession numbers AY145242\u2013AY145301.hMPV isolates ::: ResultsFifteen isolates obtained from patients suffering from respiratory illnesses were used for the current study.", [["respiratory", "ANATOMY", 197, 208], ["AY145242", "CHEMICAL", 99, 107], ["respiratory illnesses", "DISEASE", 197, 218], ["hMPV", "ORGANISM", 4, 8], ["patients", "ORGANISM", 173, 181], ["hMPV sequences", "DNA", 4, 18], ["patients", "SPECIES", 173, 181], ["hMPV", "SPECIES", 4, 8], ["AY145242\u2013AY145301.hMPV", "SPECIES", 99, 121], ["The hMPV sequences", "TEST", 0, 18], ["respiratory illnesses", "PROBLEM", 197, 218], ["the current study", "TEST", 233, 250], ["respiratory illnesses", "OBSERVATION", 197, 218]]], ["Initial testing of the samples by RT-PCR analysis using primer sets specific for HRSV, parainfluenza virus 1, 2, 3, and 4 as well as Influenza A and B were all negative.", [["samples", "ANATOMY", 23, 30], ["HRSV", "ORGANISM", 81, 85], ["parainfluenza virus 1", "ORGANISM", 87, 108], ["2", "GENE_OR_GENE_PRODUCT", 110, 111], ["3", "GENE_OR_GENE_PRODUCT", 113, 114], ["Influenza A", "ORGANISM", 133, 144], ["B", "CANCER", 149, 150], ["parainfluenza virus 1", "SPECIES", 87, 108], ["HRSV", "SPECIES", 81, 85], ["parainfluenza virus 1", "SPECIES", 87, 108], ["Influenza A", "SPECIES", 133, 144], ["Initial testing", "TEST", 0, 15], ["the samples", "TEST", 19, 30], ["RT-PCR analysis", "TEST", 34, 49], ["primer sets", "TEST", 56, 67], ["HRSV", "PROBLEM", 81, 85], ["parainfluenza virus", "PROBLEM", 87, 106], ["Influenza A", "TEST", 133, 144]]], ["Subsequently, the 15 isolates were identified as hMPV using a RT-PCR test based on the fusion (F) protein gene (Peret et al., 2002).Phylogenetic analyses ::: ResultsPhylogenetic trees were constructed based on the N, P, M and F ORF sequences of 15 hMPV Canadian isolates, the published full-length hMPV sequence and the A, B and C APV sequences.", [["hMPV", "ORGANISM", 49, 53], ["hMPV", "ORGANISM", 248, 252], ["hMPV", "ORGANISM", 298, 302], ["fusion (F) protein gene", "DNA", 87, 110], ["N, P, M and F ORF sequences", "DNA", 214, 241], ["full-length hMPV sequence", "DNA", 286, 311], ["A, B and C APV sequences", "DNA", 320, 344], ["hMPV", "SPECIES", 49, 53], ["hMPV", "PROBLEM", 49, 53], ["a RT-PCR test", "TEST", 60, 73], ["Phylogenetic analyses", "TEST", 132, 153], ["ORF sequences", "TEST", 228, 241], ["the A, B and C APV sequences", "TEST", 316, 344]]], ["As shown in Fig. 1, for each of the four ORFs analyzed, all fifteen isolates fell into two distinct genetic clusters or groups that were tentatively named 1 and 2 (Fig. 1).", [["ORFs", "DNA", 41, 45], ["the four ORFs", "TEST", 32, 45]]], ["Additional variability was also observed within the individual groups.", [["variability", "OBSERVATION_MODIFIER", 11, 22]]], ["These results confirm data previously reported for the partial sequences of the N, M, F and L genes of hMPV isolates from the Netherlands and Canada (Peret et al., 2002, van den Hoogen et al., 2001).", [["hMPV", "ORGANISM", 103, 107], ["N, M, F and L genes", "DNA", 80, 99], ["hMPV isolates", "PROBLEM", 103, 116]]], ["Partial sequences of the N and F genes of hMPV isolated in Australia have also been reported (Nissen et al., 2002).", [["N and F", "GENE_OR_GENE_PRODUCT", 25, 32], ["hMPV", "ORGANISM", 42, 46], ["N and F genes", "DNA", 25, 38], ["hMPV", "SPECIES", 42, 46], ["hMPV", "SPECIES", 42, 46], ["hMPV", "PROBLEM", 42, 46], ["hMPV", "OBSERVATION", 42, 46]]], ["Phylogenetic analysis of the N and F genes of Australian, Canadian and Dutch isolates also shows the same two distinct genetic clusters (data not shown).", [["N and F genes", "DNA", 29, 42], ["Phylogenetic analysis", "TEST", 0, 21], ["Dutch isolates", "TEST", 71, 85]]], ["Representatives of both clusters 1 and 2 were present in hMPV isolates from the Netherlands and Canada, whereas the Australian isolates all belonged to cluster 1.", [["2", "GENE_OR_GENE_PRODUCT", 39, 40], ["hMPV", "ORGANISM", 57, 61], ["hMPV", "SPECIES", 57, 61], ["hMPV isolates", "PROBLEM", 57, 70], ["the Australian isolates", "TREATMENT", 112, 135]]], ["The hMPV Dutch isolates (NDL00-1) characterized by van den Hoogen et al. clustered with group 1 isolates (van den Hoogen et al., 2002).hMPV noncoding sequences ::: ResultsFollowing the phylogenetic analysis, isolates CAN99-81 (cluster 1) and CAN98-76 (cluster 2) were selected as representatives of each hMPV cluster.", [["hMPV", "ORGANISM", 4, 8], ["hMPV", "ORGANISM", 135, 139], ["CAN98-76", "GENE_OR_GENE_PRODUCT", 242, 250], ["hMPV", "ORGANISM", 304, 308], ["hMPV noncoding sequences", "DNA", 135, 159], ["CAN99-81", "DNA", 217, 225], ["CAN98-76", "DNA", 242, 250], ["hMPV cluster", "DNA", 304, 316], ["hMPV", "SPECIES", 135, 139], ["CAN98-76", "SPECIES", 242, 250], ["The hMPV Dutch isolates", "TEST", 0, 23], ["the phylogenetic analysis", "TEST", 181, 206], ["isolates CAN99", "TEST", 208, 222], ["CAN98", "TEST", 242, 247], ["hMPV cluster", "OBSERVATION", 304, 316]]], ["Their genomes were sequenced from the gene start codon of the N gene to the one of the M2 gene.", [["M2", "GENE_OR_GENE_PRODUCT", 87, 89], ["gene start codon", "DNA", 38, 54], ["N gene", "DNA", 62, 68], ["M2 gene", "DNA", 87, 94], ["M2", "ANATOMY", 87, 89]]], ["The putative gene start signals for the N, P, M and F genes were identified by comparison with those of the hMPV Dutch isolate (NDL00-1) and other pneumoviruses: human and bovine respiratory virus (HRSV, BRSV), avian pneumovirus (APV) and pneumonia virus of the mice (PVM).", [["avian pneumovirus", "DISEASE", 211, 228], ["APV", "CHEMICAL", 230, 233], ["pneumonia", "DISEASE", 239, 248], ["F", "GENE_OR_GENE_PRODUCT", 52, 53], ["hMPV", "ORGANISM", 108, 112], ["NDL00-1", "ORGANISM", 128, 135], ["human", "ORGANISM", 162, 167], ["bovine respiratory virus", "ORGANISM", 172, 196], ["HRSV", "ORGANISM", 198, 202], ["BRSV", "ORGANISM", 204, 208], ["avian pneumovirus (APV)", "ORGANISM", 211, 234], ["pneumonia virus", "ORGANISM", 239, 254], ["mice", "ORGANISM", 262, 266], ["N, P, M and F genes", "DNA", 40, 59], ["human", "SPECIES", 162, 167], ["bovine", "SPECIES", 172, 178], ["respiratory virus", "SPECIES", 179, 196], ["HRSV", "SPECIES", 198, 202], ["BRSV", "SPECIES", 204, 208], ["avian pneumovirus", "SPECIES", 211, 228], ["mice", "SPECIES", 262, 266], ["hMPV Dutch isolate (NDL00-1", "SPECIES", 108, 135], ["human", "SPECIES", 162, 167], ["bovine respiratory virus", "SPECIES", 172, 196], ["HRSV", "SPECIES", 198, 202], ["BRSV", "SPECIES", 204, 208], ["APV", "SPECIES", 230, 233], ["mice", "SPECIES", 262, 266], ["the hMPV Dutch isolate", "TEST", 104, 126], ["human and bovine respiratory virus", "PROBLEM", 162, 196], ["HRSV", "PROBLEM", 198, 202], ["BRSV", "PROBLEM", 204, 208], ["avian pneumovirus (APV)", "PROBLEM", 211, 234], ["pneumonia virus", "PROBLEM", 239, 254], ["respiratory virus", "OBSERVATION", 179, 196], ["pneumonia", "OBSERVATION", 239, 248]]], ["Nucleotide sequence analysis revealed the presence of a well conserved region located at the beginning of each hMPV gene that potentially serves as gene-start signal (Table 2).", [["hMPV", "ORGANISM", 111, 115], ["hMPV gene", "DNA", 111, 120], ["Nucleotide sequence analysis", "TEST", 0, 28], ["a well conserved region", "PROBLEM", 54, 77], ["hMPV", "OBSERVATION", 111, 115]]], ["However, since these signals were identified from the viral RNA, they remain tentative and should be confirmed by sequencing of the viral mRNA.", [["viral RNA", "RNA", 54, 63], ["viral mRNA", "RNA", 132, 142], ["the viral RNA", "PROBLEM", 50, 63], ["the viral mRNA", "PROBLEM", 128, 142], ["viral RNA", "OBSERVATION", 54, 63], ["viral mRNA", "OBSERVATION", 132, 142]]], ["The same is true for the gene end sequences described below.", [["gene end sequences", "DNA", 25, 43], ["the gene end sequences", "TEST", 21, 43]]], ["No sequence variation was observed between the two genetic clusters or the NDL00-1 isolate for N and P putative gene start signals (van den Hoogen et al., 2002).", [["NDL00-1", "GENE_OR_GENE_PRODUCT", 75, 82], ["NDL00-1 isolate", "DNA", 75, 90], ["N and P putative gene", "DNA", 95, 116], ["sequence variation", "TEST", 3, 21]]], ["The putative gene start signal of the M gene had one A/C nucleotide change and the F gene one A/G substitution between the two clusters.", [["nucleotide", "CHEMICAL", 57, 67], ["M gene", "DNA", 38, 44], ["F gene", "DNA", 83, 89], ["A/C nucleotide change", "TREATMENT", 53, 74], ["A/G substitution", "TREATMENT", 94, 110]]], ["The CAN99-81 (cluster 1) putative gene start sequence was identical to the one of NDL00-1 (cluster 1).", [["CAN99-81", "GENE_OR_GENE_PRODUCT", 4, 12], ["cluster 1", "GENE_OR_GENE_PRODUCT", 14, 23], ["NDL00-1", "GENE_OR_GENE_PRODUCT", 82, 89], ["CAN99-81 (cluster 1) putative gene start sequence", "DNA", 4, 53], ["NDL00-1", "DNA", 82, 89], ["The CAN99", "TEST", 0, 9], ["putative gene start sequence", "TEST", 25, 53]]], ["All gene start sequences contained a (GGGACAAG/AU) motif that is identical to the gene start signal characterized for the matching genes of APV subgroups A, B and C (Dar et al., 2001, Li et al., 1996, Ling et al., 1995, Naylor et al., 1998, Randhawa et al., 1996, Seal, 1998, Seal et al., 2000, Yu et al., 1992).", [["gene start sequences", "DNA", 4, 24], ["a (GGGACAAG/AU) motif", "TREATMENT", 35, 56]]], ["In contrast, no consensus sequences could be identified as a common gene termination signal.", [["consensus sequences", "DNA", 16, 35], ["consensus sequences", "TEST", 16, 35], ["a common gene termination signal", "PROBLEM", 59, 91]]], ["Comparison with NDL00-1 sequences revealed the presence of a putative gene end signal for each of the genes analyzed (bolded in Table 2).", [["NDL00-1", "GENE_OR_GENE_PRODUCT", 16, 23], ["NDL00-1 sequences", "DNA", 16, 33], ["Comparison with NDL00-1 sequences", "TEST", 0, 33], ["a putative gene end signal", "PROBLEM", 59, 85]]], ["Each putative gene end signal was conserved between the two hMPV genetic clusters and NDL00-1.", [["hMPV", "ORGANISM", 60, 64], ["NDL00-1", "GENE_OR_GENE_PRODUCT", 86, 93], ["NDL00-1", "DNA", 86, 93]]], ["Further comparison with APV sequences showed that the putative gene end signal for the hMPV N gene (AGUAAUUA6) was identical to the one characterized for APV-C (Dar et al., 2001, van den Hoogen et al., 2002).", [["APV", "CHEMICAL", 24, 27], ["APV", "CHEMICAL", 154, 157], ["APV", "CHEMICAL", 24, 27], ["APV-C", "CHEMICAL", 154, 159], ["hMPV N", "GENE_OR_GENE_PRODUCT", 87, 93], ["APV-C", "SIMPLE_CHEMICAL", 154, 159], ["APV sequences", "DNA", 24, 37], ["hMPV N gene", "DNA", 87, 98], ["AGUAAUUA6", "DNA", 100, 109], ["Further comparison with APV sequences", "TEST", 0, 37]]], ["Similar analysis revealed that the putative gene end sequence for the P gene (UAGUUUAAUA5) contained the same (AGUU) element of transcription as those of APV P genes (Dar et al., 2001, Ling et al., 1995).", [["putative gene end sequence", "DNA", 35, 61], ["P gene", "DNA", 70, 76], ["UAGUUUAAUA5", "DNA", 78, 89], ["AGUU", "DNA", 111, 115], ["APV P genes", "DNA", 154, 165], ["Similar analysis", "TEST", 0, 16]]], ["The putative gene end signals identified for the M (AGUUAUAUA5) and F (UAGUUAGUUAAUUA5) genes of hMPV possess a similar (AGUUA) element of transcription stop signal found for the F genes of APV-A and C, but varies from those found for APV M gene (AGUCA/APV-A, AGUUU/APV-B, UAUUA/APV-C) (Naylor et al., 1998, Randhawa et al., 1996, Seal, 1998, Seal et al., 2000, Yu et al., 1992).hMPV noncoding sequences ::: ResultsSimilarly to other pneumoviruses, the putative gene end and intergenic sequences of the hMPV gene varied in length (Table 2).", [["APV", "CHEMICAL", 190, 193], ["APV-C", "CHEMICAL", 279, 284], ["M (AGUUAUAUA5)", "GENE_OR_GENE_PRODUCT", 49, 63], ["F (UAGUUAGUUAAUUA5)", "GENE_OR_GENE_PRODUCT", 68, 87], ["hMPV", "ORGANISM", 97, 101], ["APV-A", "GENE_OR_GENE_PRODUCT", 190, 195], ["C", "GENE_OR_GENE_PRODUCT", 200, 201], ["APV M", "GENE_OR_GENE_PRODUCT", 235, 240], ["hMPV", "ORGANISM", 379, 383], ["pneumoviruses", "CANCER", 434, 447], ["hMPV", "ORGANISM", 503, 507], ["M (AGUUAUAUA5) and F (UAGUUAGUUAAUUA5) genes", "DNA", 49, 93], ["F genes", "DNA", 179, 186], ["APV M gene", "DNA", 235, 245], ["hMPV noncoding sequences", "DNA", 379, 403], ["pneumoviruses", "DNA", 434, 447], ["putative gene end", "DNA", 453, 470], ["intergenic sequences", "DNA", 475, 495], ["hMPV gene", "DNA", 503, 512], ["hMPV", "SPECIES", 379, 383], ["hMPV", "PROBLEM", 97, 101], ["AGUCA", "TEST", 247, 252], ["APV", "TEST", 253, 256], ["AGUUU", "TEST", 260, 265], ["APV", "TEST", 266, 269], ["UAUUA", "TEST", 273, 278], ["APV", "TEST", 279, 282], ["Seal", "TEST", 331, 335], ["intergenic sequences", "TEST", 475, 495], ["hMPV", "OBSERVATION", 503, 507]]], ["That region of the P gene was strictly conserved between the two clusters and NDL00-1, whereas those of the N, M and F genes varied.", [["NDL00-1", "GENE_OR_GENE_PRODUCT", 78, 85], ["F", "GENE_OR_GENE_PRODUCT", 117, 118], ["P gene", "DNA", 19, 25], ["NDL00", "DNA", 78, 83], ["N, M and F genes", "DNA", 108, 124]]], ["In particular, that region of the M gene showed only 37% identity between the cluster 1 and 2, and cluster 1 sequence had three additional nucleotides.", [["nucleotides", "CHEMICAL", 139, 150], ["M gene", "DNA", 34, 40], ["cluster 1 and 2, and cluster 1 sequence", "DNA", 78, 117]]], ["It was suggested that this region contained part of a potential secondary ORF of 33 aa residues that starts at nt 2281 (van den Hoogen et al., 2002).", [["ORF", "DNA", 74, 77], ["a potential secondary ORF of 33 aa residues", "PROBLEM", 52, 95]]], ["The corresponding region of the F gene varied greatly in length (20\u201380 nucleotides long) between clusters.", [["F", "GENE_OR_GENE_PRODUCT", 32, 33], ["F gene", "DNA", 32, 38], ["varied", "OBSERVATION_MODIFIER", 39, 45], ["greatly", "OBSERVATION_MODIFIER", 46, 53], ["length", "OBSERVATION_MODIFIER", 57, 63]]], ["The NDL00-1 putative gene end and intergenic sequences were more closely related with CAN99-81, but were not identical.", [["NDL00-1", "GENE_OR_GENE_PRODUCT", 4, 11], ["CAN99-81", "GENE_OR_GENE_PRODUCT", 86, 94], ["NDL00-1 putative gene end", "DNA", 4, 29], ["intergenic sequences", "DNA", 34, 54], ["CAN99-81", "DNA", 86, 94], ["The NDL00", "TEST", 0, 9], ["intergenic sequences", "TEST", 34, 54], ["CAN99", "TEST", 86, 91]]], ["Four nucleotide changes were found in those M noncoding sequences (nt: 2947-G/A, 2976-U/C, 2990-U/C, 3053-U/C) of NDL00-1.", [["nucleotide", "CHEMICAL", 5, 15], ["nucleotide", "CHEMICAL", 5, 15], ["NDL00-1", "GENE_OR_GENE_PRODUCT", 114, 121], ["M noncoding sequences", "DNA", 44, 65], ["NDL00-1", "DNA", 114, 121], ["Four nucleotide changes", "PROBLEM", 0, 23], ["C", "TEST", 88, 89], ["U", "TEST", 96, 97], ["C", "TEST", 98, 99], ["U/C", "TEST", 106, 109], ["NDL00", "TEST", 114, 119]]], ["The F putative gene end and intergenic sequences of NDL00-1 contained two nucleotides substitution (4712-A/T, 4717-T/A) and had a 21 nucleotides deletion (4724-4744) in comparison to CAN99-81 sequences.Sequence of the N gene ::: ResultsSequence alignment with other members of the pneumovirus genus revealed that the N gene coding region was 1185 bases in length.", [["nucleotides", "CHEMICAL", 74, 85], ["NDL00-1", "GENE_OR_GENE_PRODUCT", 52, 59], ["F putative gene end", "DNA", 4, 23], ["intergenic sequences", "DNA", 28, 48], ["NDL00-1", "DNA", 52, 59], ["21 nucleotides deletion", "DNA", 130, 153], ["4724-4744", "DNA", 155, 164], ["CAN99-81 sequences", "DNA", 183, 201], ["N gene", "DNA", 218, 224], ["N gene coding region", "DNA", 317, 337], ["intergenic sequences", "TEST", 28, 48], ["NDL00", "TEST", 52, 57], ["two nucleotides substitution", "TEST", 70, 98], ["a 21 nucleotides deletion", "PROBLEM", 128, 153], ["CAN99", "TEST", 183, 188], ["the pneumovirus genus", "TEST", 277, 298], ["bases", "ANATOMY_MODIFIER", 347, 352]]], ["The deduced N protein was 394 aa in length with an estimated molecular mass of 43.5 kDa (Fig. 2).", [["N protein", "PROTEIN", 12, 21], ["The deduced N protein", "TEST", 0, 21], ["an estimated molecular mass", "PROBLEM", 48, 75], ["molecular", "OBSERVATION_MODIFIER", 61, 70], ["mass", "OBSERVATION", 71, 75], ["43.5 kDa", "OBSERVATION_MODIFIER", 79, 87]]], ["The N protein of hMPV is similar in size to the ones of other pneumoviruses (391\u2013394 residues), which is relatively smaller than those reported for the other members of the Paramyxoviridae family (489\u2013583 residues) (Barr et al., 1991, Collins et al., 1985, Curran and Kolakofsky, 1999, Dar et al., 2001, Spriggs and Collins, 1986).", [["hMPV", "ORGANISM", 17, 21], ["pneumoviruses", "GENE_OR_GENE_PRODUCT", 62, 75], ["Paramyxoviridae", "GENE_OR_GENE_PRODUCT", 173, 188], ["N protein", "PROTEIN", 4, 13], ["Paramyxoviridae family", "PROTEIN", 173, 195], ["The N protein", "TEST", 0, 13], ["hMPV", "PROBLEM", 17, 21], ["hMPV", "OBSERVATION", 17, 21], ["similar", "OBSERVATION_MODIFIER", 25, 32], ["size", "OBSERVATION_MODIFIER", 36, 40], ["relatively", "OBSERVATION_MODIFIER", 105, 115], ["smaller", "OBSERVATION_MODIFIER", 116, 123]]], ["The N gene of isolates within the same cluster were highly conserved with nucleotide sequence identity of 93.8\u2013100%, whereas sequence identity between the two different groups was 85.3\u201386.1% (Table 3).", [["nucleotide", "CHEMICAL", 74, 84], ["nucleotide", "CHEMICAL", 74, 84], ["N gene", "DNA", 4, 10], ["The N gene of isolates", "TREATMENT", 0, 22], ["nucleotide sequence identity", "TEST", 74, 102]]], ["The aa identity was higher both within and between groups, 98.3\u2013100% and 94.2\u201395.9%, respectively.", [["The aa identity", "TEST", 0, 15], ["higher", "OBSERVATION_MODIFIER", 20, 26]]], ["The N protein of NDL00-1 was identical to the one of CAN99-81 and therefore showed similar level of aa identity with the respective hMPV cluster.", [["NDL00-1", "GENE_OR_GENE_PRODUCT", 17, 24], ["CAN99-81", "CELL", 53, 61], ["hMPV", "ORGANISM", 132, 136], ["N protein", "PROTEIN", 4, 13], ["NDL00", "PROTEIN", 17, 22], ["CAN99-81", "DNA", 53, 61], ["The N protein", "TEST", 0, 13], ["NDL00", "TEST", 17, 22], ["CAN99", "TEST", 53, 58], ["the respective hMPV cluster", "PROBLEM", 117, 144], ["hMPV cluster", "OBSERVATION", 132, 144]]], ["The levels of aa identity observed between the two hMPV clusters are comparable to the ones observed between the two subgroups of HRSV (96%) (Johnson and Collins, 1989).", [["hMPV", "ORGANISM", 51, 55], ["HRSV", "ORGANISM", 130, 134], ["HRSV", "SPECIES", 130, 134], ["aa identity", "TEST", 14, 25], ["HRSV", "TEST", 130, 134], ["hMPV clusters", "OBSERVATION", 51, 64]]], ["The N proteins of APVs are not highly conserved, with 69\u201389% aa identity between the different subgroups (Dar et al., 2001, Li et al., 1996).", [["APVs", "GENE_OR_GENE_PRODUCT", 18, 22], ["N proteins", "PROTEIN", 4, 14], ["APVs", "PROTEIN", 18, 22], ["The N proteins of APVs", "TEST", 0, 22]]], ["When compared to the other pneumovirus members, the hMPV N gene showed 69\u201389% aa identity with APV members, 42\u201344% with RSV members and 45% with PVM (Barr et al., 1991, Buchholz et al., 1999, Dar et al., 2001, Karron et al., 1997, Li et al., 1996, Venkatesan et al., 1983) (Table 4).", [["APV", "CHEMICAL", 95, 98], ["hMPV", "ORGANISM", 52, 56], ["RSV", "ORGANISM", 120, 123], ["hMPV N gene", "DNA", 52, 63], ["RSV", "SPECIES", 120, 123], ["the hMPV N gene", "TEST", 48, 63], ["APV members", "TEST", 95, 106], ["PVM", "PROBLEM", 145, 148]]], ["The N genes of all non-segmented, negative-stranded RNA viruses have three relatively conserved domains with homology in sequence and predicted secondary structure (Barr et al., 1991, Li et al., 1996, Dar et al., 2001).", [["N genes", "DNA", 4, 11], ["stranded RNA viruses", "PROBLEM", 43, 63]]], ["Sequence comparison with APV N genes allowed us to identify the position of these domains at residues 161\u2013173, 251\u2013263 and 279\u2013326 (Li et al., 1996) (Fig. 2).", [["APV", "CHEMICAL", 25, 28], ["APV N genes", "DNA", 25, 36]]], ["These three domains were highly conserved between the two hMPV clusters and only one conservative aa substitution (aa 164) was found with their closest pneumovirus relative (APV-C).", [["hMPV", "ORGANISM", 58, 62], ["conservative", "OBSERVATION_MODIFIER", 85, 97], ["aa substitution", "OBSERVATION", 98, 113]]], ["Most of the aa changes (66.6%) in the N genes of the two hMPV clusters were located within the first 136 aa of the protein.", [["hMPV", "ORGANISM", 57, 61], ["N genes", "DNA", 38, 45], ["the aa changes", "TEST", 8, 22], ["the two hMPV clusters", "PROBLEM", 49, 70]]], ["However the majority of these (62.5%) were conservative substitutions.", [["conservative substitutions", "TREATMENT", 43, 69]]], ["Two of the remaining changes were found in the central part of the protein, and the last two in the last 38 aa.Sequence of the P gene ::: ResultsThe coding region of the P gene was 885 bases in length, encoding a predicted protein of 294 aa residues with a molecular mass of 32.5 kDa.", [["P gene", "DNA", 127, 133], ["P gene", "DNA", 170, 176], ["a predicted protein", "TEST", 211, 230], ["a molecular mass", "PROBLEM", 255, 271], ["central", "ANATOMY_MODIFIER", 47, 54], ["mass", "OBSERVATION", 267, 271], ["32.5 kDa", "OBSERVATION_MODIFIER", 275, 283]]], ["The size of the hMPV P protein was comparable to those of APVs and PVM (279\u2013295 aa), but was larger than the non-avian pneumovirus (241 aa) (Barr et al., 1994, Buchholz et al., 1999, Dar et al., 2001, Karron et al., 1997, Ling et al., 1995, Satake et al., 1984) (Fig. 3).", [["hMPV", "ORGANISM", 16, 20], ["APVs", "GENE_OR_GENE_PRODUCT", 58, 62], ["hMPV P protein", "PROTEIN", 16, 30], ["APVs", "PROTEIN", 58, 62], ["the hMPV P protein", "TEST", 12, 30], ["APVs", "TEST", 58, 62], ["PVM", "TEST", 67, 70], ["aa", "TEST", 80, 82], ["size", "OBSERVATION_MODIFIER", 4, 8], ["hMPV", "OBSERVATION", 16, 20], ["larger", "OBSERVATION_MODIFIER", 93, 99]]], ["Within each cluster the nucleotide sequence identity was 91\u2013100% and the identity for the predicted aa sequence was 94.6\u2013100% (Table 3).", [["nucleotide", "CHEMICAL", 24, 34], ["nucleotide", "CHEMICAL", 24, 34], ["the nucleotide sequence identity", "TEST", 20, 52], ["the predicted aa sequence", "TEST", 86, 111]]], ["The P gene was less conserved between clusters with 78.0\u201379.4% and 81.6\u201385.7% identity levels for the nucleotide and aa sequences, respectively.", [["nucleotide", "CHEMICAL", 102, 112], ["nucleotide", "CHEMICAL", 102, 112], ["P gene", "DNA", 4, 10], ["nucleotide and aa sequences", "DNA", 102, 129], ["The P gene", "TEST", 0, 10], ["the nucleotide and aa sequences", "TEST", 98, 129]]], ["The majority of the aa differences (34) between the two clusters were observed at the amino-proximal end of the protein (19\u2013130) (Fig. 3).", [["amino", "CHEMICAL", 86, 91], ["amino-proximal end", "PROTEIN", 86, 104], ["the protein", "TEST", 108, 119], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["The central portion of the proteins (aa 131\u2013278) was well conserved, containing only five aa changes, while the remaining changes (five) were found in the last 16 aa of the protein.", [["aa 131\u2013278", "PROTEIN", 37, 47], ["central", "ANATOMY_MODIFIER", 4, 11]]], ["The majority (65.9%) of the aa substitutions were non-conservative.", [["the aa substitutions", "PROBLEM", 24, 44]]], ["Six aa changes were found between NDL00-1 and CAN99-81 (S/G-31, L/P-64, I/T-78, A/T-201, T/A-202, I/T280).", [["NDL00-1", "GENE_OR_GENE_PRODUCT", 34, 41], ["CAN99-81", "SIMPLE_CHEMICAL", 46, 54], ["Six aa changes", "TEST", 0, 14], ["NDL00", "TEST", 34, 39], ["CAN99", "TEST", 46, 51], ["S/G", "TEST", 56, 59], ["L/P", "TEST", 64, 67], ["I/T", "TEST", 72, 75], ["A/T", "TEST", 80, 83], ["T/A", "TEST", 89, 92]]], ["None of these aa changes were unique to the NDL00-1 sequence.", [["NDL00-1", "GENE_OR_GENE_PRODUCT", 44, 51], ["NDL00-1 sequence", "DNA", 44, 60]]], ["The 201 and 280 threonine residues present in the NDL00-1 sequence were also found in other cluster 1 and 2 Canadian hMPV isolates and the four remainder aa substitutions were identical to cluster 2 sequences.Sequence of the P gene ::: ResultsThe P protein of hMPV showed a significant level of divergence with those of other members of the pneumoviruses (Barr et al., 1994, Buchholz et al., 1999, Dar et al., 2001, Karron et al., 1997, Ling et al., 1995, Satake et al., 1984) (Table 4).", [["threonine", "CHEMICAL", 16, 25], ["threonine", "CHEMICAL", 16, 25], ["threonine", "AMINO_ACID", 16, 25], ["NDL00-1", "GENE_OR_GENE_PRODUCT", 50, 57], ["hMPV", "ORGANISM", 117, 121], ["hMPV", "ORGANISM", 260, 264], ["NDL00-1 sequence", "DNA", 50, 66], ["cluster 2 sequences", "DNA", 189, 208], ["P gene", "DNA", 225, 231], ["P protein", "PROTEIN", 247, 256], ["Canadian hMPV", "SPECIES", 108, 121], ["threonine residues", "TEST", 16, 34], ["The P protein", "TEST", 243, 256], ["hMPV", "PROBLEM", 260, 264]]], ["The highest levels of identity were observed with the P protein of APVs (50\u201368%), with the greatest identity shared with APV-C (Dar et al., 2001, Ling et al., 1995).", [["APV", "CHEMICAL", 121, 124], ["APV-C", "CHEMICAL", 121, 126], ["APVs", "GENE_OR_GENE_PRODUCT", 67, 71], ["APV-C", "SIMPLE_CHEMICAL", 121, 126], ["P protein", "PROTEIN", 54, 63], ["APVs", "PROTEIN", 67, 71], ["the P protein", "TEST", 50, 63], ["APVs", "TEST", 67, 71]]], ["The identity level was only 23\u201328% with mammalian pneumoviruses (Barr et al., 1994, Buchholz et al., 1999, Karron et al., 1997, Satake et al., 1984).", [["The identity level", "TEST", 0, 18]]], ["The aa region encompassing residues 171\u2013226 represents a highly conserved domain in pneumovirus P proteins (Ling et al., 1995) (Fig. 3).", [["171\u2013226", "CHEMICAL", 36, 43], ["171\u2013226", "AMINO_ACID", 36, 43], ["pneumovirus P proteins", "PROTEIN", 84, 106], ["a highly conserved domain in pneumovirus P proteins", "PROBLEM", 55, 106]]], ["The amino-terminal portion of this region has a heptad repeat sequence that is frequently implicated in the formation of \u03b1-helices and coiled coils (Ling et al., 1995, McLachlan and Karn, 1983).", [["amino-terminal", "CHEMICAL", 4, 18], ["amino", "CHEMICAL", 4, 9], ["\u03b1-helices", "SIMPLE_CHEMICAL", 121, 130], ["amino-terminal portion", "PROTEIN", 4, 26], ["heptad repeat sequence", "PROTEIN", 48, 70], ["\u03b1-helices", "PROTEIN", 121, 130], ["a heptad repeat sequence", "TEST", 46, 70], ["\u03b1-helices and coiled coils", "TREATMENT", 121, 147]]], ["This region of the hMPV P proteins had greater aa identity with both avian and mammalian pneumovirus 80.0\u201387.5% and 62.5\u201367.9%, respectively (Fig. 4).", [["hMPV", "ORGANISM", 19, 23], ["mammalian pneumovirus", "ORGANISM", 79, 100], ["hMPV P proteins", "PROTEIN", 19, 34], ["the hMPV P proteins", "TEST", 15, 34], ["mammalian pneumovirus", "TEST", 79, 100], ["hMPV", "OBSERVATION", 19, 23]]], ["Similar to the P proteins of other pneumovirus, the majority (82\u201385%) of proline residues present in the hMPV P protein were found in the N-terminal half of the protein (Dar et al., 2001, Ling et al., 1995).", [["proline", "CHEMICAL", 73, 80], ["proline", "CHEMICAL", 73, 80], ["N", "CHEMICAL", 138, 139], ["proline", "AMINO_ACID", 73, 80], ["hMPV", "ORGANISM", 105, 109], ["P proteins", "PROTEIN", 15, 25], ["hMPV P protein", "PROTEIN", 105, 119], ["N-terminal half", "PROTEIN", 138, 153], ["other pneumovirus", "PROBLEM", 29, 46], ["proline residues", "PROBLEM", 73, 89], ["the hMPV P protein", "TEST", 101, 119]]], ["The large number of charged residues found at the C-terminal portion of hMPV P is another common feature shared in all pneumovirus.", [["C", "CHEMICAL", 50, 51], ["hMPV", "ORGANISM", 72, 76], ["pneumovirus", "CANCER", 119, 130], ["C-terminal portion", "PROTEIN", 50, 68], ["hMPV P", "PROTEIN", 72, 78], ["charged residues", "PROBLEM", 20, 36], ["hMPV", "PROBLEM", 72, 76], ["large", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["charged residues", "OBSERVATION", 20, 36], ["terminal", "ANATOMY_MODIFIER", 52, 60], ["hMPV", "OBSERVATION", 72, 76], ["pneumovirus", "OBSERVATION", 119, 130]]], ["As observed for APV-C, HRSV and BRSV, the P protein of hMPV did not contain any cysteine residues.", [["APV", "CHEMICAL", 16, 19], ["cysteine", "CHEMICAL", 80, 88], ["APV-C", "GENE_OR_GENE_PRODUCT", 16, 21], ["HRSV", "ORGANISM", 23, 27], ["BRSV", "ORGANISM", 32, 36], ["hMPV", "ORGANISM", 55, 59], ["P protein", "PROTEIN", 42, 51], ["BRSV", "SPECIES", 32, 36], ["HRSV", "SPECIES", 23, 27], ["BRSV", "SPECIES", 32, 36], ["hMPV", "SPECIES", 55, 59], ["APV", "TEST", 16, 19], ["HRSV", "PROBLEM", 23, 27], ["BRSV", "PROBLEM", 32, 36], ["the P protein", "TEST", 38, 51], ["hMPV", "PROBLEM", 55, 59], ["any cysteine residues", "PROBLEM", 76, 97], ["cysteine residues", "OBSERVATION", 80, 97]]], ["In contrast, the P proteins of APV-A and B have two cysteine residues, and five cysteine residues are found in the PVM protein (Barr et al., 1994, Ling et al., 1995).Sequence of the M gene ::: ResultsSequence alignment analysis showed that the M gene of hMPV was 765 nucleotides in length, encoding a predicted protein of 254 aa residues with a predicted molecular mass of 27.6 kDa (Fig. 4).", [["APV", "CHEMICAL", 31, 34], ["APV-A and B", "CHEMICAL", 31, 42], ["cysteine", "CHEMICAL", 52, 60], ["cysteine", "CHEMICAL", 80, 88], ["nucleotides", "CHEMICAL", 267, 278], ["APV-A", "GENE_OR_GENE_PRODUCT", 31, 36], ["B", "GENE_OR_GENE_PRODUCT", 41, 42], ["cysteine", "AMINO_ACID", 52, 60], ["cysteine", "AMINO_ACID", 80, 88], ["hMPV", "ORGANISM", 254, 258], ["P proteins", "PROTEIN", 17, 27], ["B", "PROTEIN", 41, 42], ["PVM protein", "PROTEIN", 115, 126], ["M gene", "DNA", 182, 188], ["M gene", "DNA", 244, 250], ["hMPV", "SPECIES", 254, 258], ["the P proteins", "TEST", 13, 27], ["APV", "TEST", 31, 34], ["two cysteine residues", "TREATMENT", 48, 69], ["five cysteine residues", "PROBLEM", 75, 97], ["ResultsSequence alignment analysis", "TEST", 193, 227], ["hMPV", "PROBLEM", 254, 258], ["a predicted protein", "TEST", 299, 318], ["a predicted molecular mass", "PROBLEM", 343, 369], ["cysteine residues", "OBSERVATION", 52, 69], ["cysteine residues", "OBSERVATION", 80, 97], ["PVM protein", "ANATOMY", 115, 126], ["mass", "OBSERVATION", 365, 369], ["27.6 kDa", "OBSERVATION_MODIFIER", 373, 381]]], ["The M genes of hMPV isolates were highly conserved both within (94.1\u2013100% identity) and between (83.5\u201385.6% identity) clusters (Table 3).", [["hMPV", "ORGANISM", 15, 19], ["M genes", "DNA", 4, 11], ["hMPV", "SPECIES", 15, 19], ["hMPV isolates", "PROBLEM", 15, 28], ["hMPV isolates", "OBSERVATION", 15, 28]]], ["These differences were reflected at the aa level with identity of 96.9\u201397.6% for members of different clusters and 98.8\u2013100% for isolates belonging to the same cluster.", [["identity", "TEST", 54, 62], ["different clusters", "TEST", 92, 110], ["isolates", "PROBLEM", 129, 137]]], ["The aa sequences of the M protein of NDL00-1 was identical to the one of CAN99-81 and showed similar levels of aa identity with the two hMPV clusters.", [["NDL00-1", "GENE_OR_GENE_PRODUCT", 37, 44], ["CAN99-81", "CELL", 73, 81], ["hMPV", "ORGANISM", 136, 140], ["M protein", "PROTEIN", 24, 33], ["NDL00", "PROTEIN", 37, 42], ["CAN99-81", "DNA", 73, 81], ["The aa sequences", "TEST", 0, 16], ["the M protein", "TEST", 20, 33], ["NDL00", "TEST", 37, 42], ["CAN99", "TEST", 73, 78], ["hMPV clusters", "OBSERVATION", 136, 149]]], ["The majority of aa substitutions between the two clusters were conservative and distributed throughout the entire protein (Fig. 4).", [["aa substitutions", "PROBLEM", 16, 32], ["aa substitutions", "OBSERVATION", 16, 32], ["conservative", "OBSERVATION", 63, 75]]], ["The M protein of hMPV was most closely related to the M proteins of APVs with aa identity ranging from 76\u201388%, compared to the reduced aa identity 37\u201340% observed with the remaining pneumoviruses (Table 4) (Buchholz et al., 1999, Easton and Chambers, 1997, Karron et al., 1997, Randhawa et al., 1996, Satake et al., 1984, Seal, 1998, Yu et al., 1992).", [["hMPV", "ORGANISM", 17, 21], ["APVs", "GENE_OR_GENE_PRODUCT", 68, 72], ["M protein", "PROTEIN", 4, 13], ["M proteins", "PROTEIN", 54, 64], ["APVs", "PROTEIN", 68, 72], ["hMPV", "SPECIES", 17, 21], ["The M protein", "TEST", 0, 13], ["hMPV", "PROBLEM", 17, 21], ["aa identity", "TEST", 78, 89], ["aa identity", "TEST", 135, 146], ["hMPV", "OBSERVATION", 17, 21]]], ["A short region located at the N-terminal end of the protein (aa 14\u201319) was conserved for all pneumovirus M proteins, although the biological significance of this region is unknown.Sequence of the F gene ::: ResultsThe F gene was 1620 bases in length, encoding a protein of 539 aa residues with a predicted molecular mass of 58.4 kDa (Fig. 5).", [["N", "CHEMICAL", 30, 31], ["pneumovirus M proteins", "GENE_OR_GENE_PRODUCT", 93, 115], ["F", "GENE_OR_GENE_PRODUCT", 218, 219], ["N-terminal end", "DNA", 30, 44], ["aa 14\u201319", "PROTEIN", 61, 69], ["pneumovirus M proteins", "PROTEIN", 93, 115], ["F gene", "DNA", 196, 202], ["F gene", "DNA", 218, 224], ["A short region", "PROBLEM", 0, 14], ["all pneumovirus M proteins", "PROBLEM", 89, 115], ["a protein", "TEST", 260, 269], ["a predicted molecular mass", "PROBLEM", 294, 320], ["short", "OBSERVATION_MODIFIER", 2, 7], ["terminal", "ANATOMY_MODIFIER", 32, 40], ["mass", "OBSERVATION", 316, 320], ["58.4 kDa", "OBSERVATION_MODIFIER", 324, 332]]], ["The F gene was well conserved within each group with 94.3\u2013100% and 98.3%\u2013100% for the nucleotide and aa sequences identity, respectively (Table 3).", [["F", "GENE_OR_GENE_PRODUCT", 4, 5], ["F gene", "DNA", 4, 10], ["the nucleotide and aa sequences identity", "TEST", 82, 122]]], ["Between the two clusters the identity was 83.0\u201383.6% and 94.1\u201395.4% for the nucleotide and aa sequences, respectively.", [["nucleotide", "CHEMICAL", 76, 86], ["nucleotide", "CHEMICAL", 76, 86], ["the identity", "TEST", 25, 37], ["the nucleotide and aa sequences", "TEST", 72, 103]]], ["The aa sequence of the F protein of NDL00-1 had 100% identity with the one of CAN99-81.", [["NDL00-1", "GENE_OR_GENE_PRODUCT", 36, 43], ["F protein", "PROTEIN", 23, 32], ["NDL00", "PROTEIN", 36, 41], ["The aa sequence", "TEST", 0, 15], ["the F protein", "TEST", 19, 32], ["NDL00", "TEST", 36, 41], ["CAN99", "TEST", 78, 83]]], ["The majority (75.0%) of aa substitutions between the two clusters were conservative.", [["aa substitutions", "TREATMENT", 24, 40], ["conservative", "OBSERVATION", 71, 83]]], ["Sequence comparison with avian pneumoviruses showed identity levels of 67\u201368% with APV subgroup A and B and 81\u201382% with subgroup C (Table 4) (Naylor et al., 1998, Seal et al., 2000).", [["APV", "CHEMICAL", 83, 86], ["avian pneumoviruses", "ORGANISM", 25, 44], ["B", "CANCER", 102, 103], ["avian pneumoviruses", "TEST", 25, 44], ["identity levels", "TEST", 52, 67], ["subgroup C (Table", "TREATMENT", 120, 137]]], ["The F gene of hMPV was less conserved with the mammalian pneumoviruses and showed 30\u201343% aa identity (Buchholz et al., 1999, Chambers et al., 1992, Collins et al., 1984, Karron et al., 1997, Seal, 1998).Sequence of the F gene ::: ResultsThe F proteins of pneumoviruses are synthesized as a precursor F0 that is cleaved by cellular protease into two subunits, F1 and F2.", [["cellular", "ANATOMY", 322, 330], ["F", "GENE_OR_GENE_PRODUCT", 4, 5], ["hMPV", "ORGANISM", 14, 18], ["F proteins", "GENE_OR_GENE_PRODUCT", 241, 251], ["pneumoviruses", "GENE_OR_GENE_PRODUCT", 255, 268], ["cellular", "CELL", 322, 330], ["F gene", "DNA", 4, 10], ["F gene", "DNA", 219, 225], ["F proteins", "PROTEIN", 241, 251], ["pneumoviruses", "PROTEIN", 255, 268], ["F0", "PROTEIN", 300, 302], ["cellular protease", "PROTEIN", 322, 339], ["F1", "PROTEIN", 359, 361], ["F2", "PROTEIN", 366, 368], ["hMPV", "SPECIES", 14, 18], ["hMPV", "PROBLEM", 14, 18], ["the mammalian pneumoviruses", "TEST", 43, 70], ["pneumoviruses", "PROBLEM", 255, 268], ["a precursor F0", "TREATMENT", 288, 302], ["hMPV", "OBSERVATION", 14, 18]]], ["Most pneumoviruses cleavage peptide sequences contain the cleavage motif for the cellular furin protease (R/K-X-R/K-R) (Collins et al., 2001).", [["cellular", "ANATOMY", 81, 89], ["pneumoviruses", "GENE_OR_GENE_PRODUCT", 5, 18], ["cellular", "CELL", 81, 89], ["K-R", "GENE_OR_GENE_PRODUCT", 114, 117], ["cleavage motif", "PROTEIN", 58, 72], ["cellular furin protease", "PROTEIN", 81, 104], ["R", "PROTEIN", 106, 107], ["K", "PROTEIN", 108, 109], ["X", "PROTEIN", 110, 111], ["R", "PROTEIN", 112, 113], ["K", "PROTEIN", 114, 115], ["Most pneumoviruses cleavage peptide sequences", "PROBLEM", 0, 45], ["the cleavage motif", "TREATMENT", 54, 72], ["the cellular furin protease", "TEST", 77, 104], ["K", "TEST", 108, 109]]], ["However, the cleavage peptide sequence of APV-C (RKAR) varies from the consensus sequence (Seal et al., 2000).", [["APV", "CHEMICAL", 42, 45], ["APV-C", "GENE_OR_GENE_PRODUCT", 42, 47], ["RKAR", "GENE_OR_GENE_PRODUCT", 49, 53], ["RKAR", "PROTEIN", 49, 53], ["consensus sequence", "DNA", 71, 89], ["the cleavage peptide sequence", "TEST", 9, 38], ["APV", "TEST", 42, 45], ["the consensus sequence", "TEST", 67, 89]]], ["Similarly, sequence analyses revealed that the cleavage peptide sequence of hMPV F protein (RQSR) differs from that of the furin protease motif (Fig. 5).", [["hMPV F", "GENE_OR_GENE_PRODUCT", 76, 82], ["RQSR", "GENE_OR_GENE_PRODUCT", 92, 96], ["furin", "GENE_OR_GENE_PRODUCT", 123, 128], ["hMPV F protein", "PROTEIN", 76, 90], ["RQSR", "PROTEIN", 92, 96], ["furin protease motif", "PROTEIN", 123, 143], ["sequence analyses", "TEST", 11, 28], ["the cleavage peptide sequence", "PROBLEM", 43, 72], ["hMPV F protein", "TEST", 76, 90], ["the furin protease motif", "TREATMENT", 119, 143]]], ["Cleavage of the F0 precursor releases the hydrophobic fusion peptide at the N-terminus of the F1 subunit.", [["N", "CHEMICAL", 76, 77], ["F0 precursor", "PROTEIN", 16, 28], ["N-terminus", "PROTEIN", 76, 86], ["F1 subunit", "PROTEIN", 94, 104], ["the F0 precursor", "TREATMENT", 12, 28], ["the hydrophobic fusion peptide", "TREATMENT", 38, 68], ["hydrophobic fusion", "OBSERVATION", 42, 60]]], ["The F1 and F2 subunits of the two hMPV lineages showed a similar level of conservation with aa identities of 94% and 97%, respectively.", [["hMPV", "ORGANISM", 34, 38], ["F1 and F2 subunits", "PROTEIN", 4, 22], ["aa identities", "TEST", 92, 105]]], ["These identity levels were similar to those observed within HRSV subtypes (F1, 98% and F2, 95%) (Naylor et al., 1998).", [["These identity levels", "TEST", 0, 21], ["HRSV subtypes", "TEST", 60, 73], ["F2", "TEST", 87, 89]]], ["In contrast, greater divergence (83% identity) was observed between subtypes of HRSV and APV (Naylor et al., 1998).", [["APV", "CHEMICAL", 89, 92], ["HRSV", "ORGANISM", 80, 84], ["HRSV", "SPECIES", 80, 84], ["HRSV", "PROBLEM", 80, 84]]], ["Similar to APVs, the carboxy-terminal transmembrane domain and cytoplasmic tail of the two hMPV clusters diverge significantly (16%) (Naylor et al., 1998, Seal et al., 2000).", [["cytoplasmic tail", "ANATOMY", 63, 79], ["carboxy", "CHEMICAL", 21, 28], ["APVs", "GENE_OR_GENE_PRODUCT", 11, 15], ["cytoplasmic tail", "CELLULAR_COMPONENT", 63, 79], ["hMPV", "ORGANISM", 91, 95], ["APVs", "PROTEIN", 11, 15], ["carboxy-terminal transmembrane domain", "PROTEIN", 21, 58], ["cytoplasmic tail", "PROTEIN", 63, 79], ["APVs", "TEST", 11, 15], ["the carboxy-terminal transmembrane domain", "TEST", 17, 58], ["the two hMPV clusters", "TEST", 83, 104], ["cytoplasmic tail", "OBSERVATION", 63, 79]]], ["However, this region of the hMPV F protein showed greater aa identity between clusters (84%) than the one observed between the different APV subgroups (32%\u201339%) (Naylor et al., 1998, Seal et al., 2000).", [["APV", "CHEMICAL", 137, 140], ["APV", "CHEMICAL", 137, 140], ["hMPV F", "GENE_OR_GENE_PRODUCT", 28, 34], ["hMPV F protein", "PROTEIN", 28, 42], ["the hMPV F protein", "TEST", 24, 42], ["hMPV", "OBSERVATION", 28, 32], ["greater", "OBSERVATION_MODIFIER", 50, 57], ["aa identity", "OBSERVATION", 58, 69], ["clusters", "OBSERVATION_MODIFIER", 78, 86], ["different", "OBSERVATION_MODIFIER", 127, 136], ["APV", "OBSERVATION_MODIFIER", 137, 140]]], ["The remaining portion of the hMPV F1 subunit was more conserved with only 4.2% aa divergence between the two clusters.", [["hMPV", "ORGANISM", 29, 33], ["hMPV F1 subunit", "PROTEIN", 29, 44], ["remaining", "OBSERVATION_MODIFIER", 4, 13], ["portion", "OBSERVATION_MODIFIER", 14, 21], ["hMPV", "OBSERVATION", 29, 33]]], ["The two heptad repeats domains (HRA and HRB) necessary for viral fusion of paramyxoviruses (Chambers et al., 1990, Buckland and Wild, 1989, Lamb, 1993, Russell et al., 2001) are also present in the hMPV F gene.", [["HRB", "GENE_OR_GENE_PRODUCT", 40, 43], ["hMPV F", "GENE_OR_GENE_PRODUCT", 198, 204], ["heptad repeats domains", "PROTEIN", 8, 30], ["HRA", "PROTEIN", 32, 35], ["HRB", "PROTEIN", 40, 43], ["hMPV F gene", "DNA", 198, 209], ["The two heptad repeats domains (HRA and HRB)", "TREATMENT", 0, 44], ["viral fusion of paramyxoviruses", "TREATMENT", 59, 90], ["hMPV", "OBSERVATION", 198, 202]]], ["There were three potential N-glycosylation sites at aa 57, 172 and 353, two of which (57 and 172) were also present among the F proteins of all APV subgroups (Naylor et al., 1998, Seal et al., 2000).", [["APV", "CHEMICAL", 144, 147], ["N", "CHEMICAL", 27, 28], ["APV", "CHEMICAL", 144, 147], ["N-glycosylation sites", "PROTEIN", 27, 48], ["F proteins", "PROTEIN", 126, 136]]], ["The aa residues at position 102 (Arg), 103 (Phe), 106 (Gly) and 111 (Gly) are structurally important to paramyxovirus F proteins (Horvath and Lamb, 1992) and are present in all pneumoviruses.", [["Arg", "CHEMICAL", 33, 36], ["Phe", "CHEMICAL", 44, 47], ["Gly", "CHEMICAL", 55, 58], ["Gly", "CHEMICAL", 69, 72], ["Arg", "AMINO_ACID", 33, 36], ["Phe", "AMINO_ACID", 44, 47], ["Gly", "AMINO_ACID", 69, 72], ["paramyxovirus F proteins", "GENE_OR_GENE_PRODUCT", 104, 128], ["pneumoviruses", "CANCER", 177, 190], ["paramyxovirus F proteins", "PROTEIN", 104, 128], ["The aa residues at position", "TEST", 0, 27], ["Arg", "TEST", 33, 36], ["Phe", "TEST", 44, 47], ["paramyxovirus F proteins", "TEST", 104, 128]]], ["These aa residues were conserved for the two clusters of hMPV F proteins.DiscussionThe phylogenetic analysis of the complete N, P, M and F genes of the Canadian isolates was consistent with previous reports (Peret et al., 2002, van den Hoogen et al., 2001), and showed the presence of two genetic clusters.", [["hMPV F proteins", "GENE_OR_GENE_PRODUCT", 57, 72], ["hMPV F proteins", "PROTEIN", 57, 72], ["N, P, M and F genes", "DNA", 125, 144], ["These aa residues", "PROBLEM", 0, 17], ["hMPV F proteins", "PROBLEM", 57, 72], ["The phylogenetic analysis", "TEST", 83, 108], ["hMPV", "OBSERVATION", 57, 61]]], ["Comparison of these sequences with the ones reported from the Netherlands and Australia showed that all hMPV isolates reported to date cluster within the same two genetic groups, suggesting that a relatively homogeneous population of hMPV is circulating worldwide (Nissen et al., 2002, van den Hoogen et al., 2001).", [["hMPV", "DISEASE", 234, 238], ["hMPV", "ORGANISM", 104, 108], ["hMPV", "ORGANISM", 234, 238], ["hMPV", "SPECIES", 104, 108], ["hMPV", "SPECIES", 234, 238], ["these sequences", "TEST", 14, 29], ["all hMPV isolates", "PROBLEM", 100, 117], ["hMPV", "PROBLEM", 234, 238], ["relatively", "OBSERVATION_MODIFIER", 197, 207], ["homogeneous", "OBSERVATION_MODIFIER", 208, 219], ["hMPV", "OBSERVATION", 234, 238]]], ["In fact, hMPV Canadian cluster 1 isolates showed over 96% amino acid identity with the NDL00-1 Dutch isolates for all the viral protein analyzed (van den Hoogen et al., 2002).", [["amino acid", "CHEMICAL", 58, 68], ["amino acid", "CHEMICAL", 58, 68], ["hMPV", "ORGANISM", 9, 13], ["amino acid", "AMINO_ACID", 58, 68], ["NDL00", "PROTEIN", 87, 92], ["viral protein", "PROTEIN", 122, 135], ["amino acid identity", "TEST", 58, 77]]], ["Our results also show that both hMPV clusters were co-circulating in Canada during 1997, 1999 and 2000.", [["hMPV", "ORGANISM", 32, 36], ["hMPV", "OBSERVATION", 32, 36]]], ["This is comparable to what is observed for the two subgroups of HRSV, which have been co-circulating in most yearly epidemics (Collins et al., 2001).", [["HRSV", "ORGANISM", 64, 68], ["HRSV", "SPECIES", 64, 68], ["HRSV", "PROBLEM", 64, 68], ["HRSV", "OBSERVATION", 64, 68]]], ["Similar to other pneumoviruses, the genetic diversity observed for the hMPV genes may lead to antigenic variability and these two hMPV genetic clusters may also represent two different antigenic groups.", [["hMPV", "ORGANISM", 71, 75], ["hMPV", "ORGANISM", 130, 134], ["hMPV genes", "DNA", 71, 81], ["hMPV", "SPECIES", 71, 75], ["hMPV", "SPECIES", 130, 134], ["other pneumoviruses", "PROBLEM", 11, 30], ["the hMPV genes", "PROBLEM", 67, 81], ["antigenic variability", "PROBLEM", 94, 115], ["these two hMPV genetic clusters", "PROBLEM", 120, 151], ["pneumoviruses", "OBSERVATION", 17, 30], ["hMPV", "OBSERVATION", 71, 75], ["may also represent", "UNCERTAINTY", 152, 170], ["two", "OBSERVATION_MODIFIER", 171, 174], ["different", "OBSERVATION_MODIFIER", 175, 184], ["antigenic groups", "OBSERVATION", 185, 201]]], ["However, distinct lineages of HRSV have been identified within each subgroup, and shown to co-circulate during epidemics and to have broad geographic distribution (Cane and Pringle, 1991, Cane and Pringle, 1995, Coggins et al., 1998, Garcia et al., 1994, Martinez et al., 1999).", [["HRSV", "ORGANISM", 30, 34], ["HRSV", "SPECIES", 30, 34], ["HRSV", "SPECIES", 30, 34], ["HRSV", "PROBLEM", 30, 34], ["epidemics", "PROBLEM", 111, 120], ["distinct", "OBSERVATION_MODIFIER", 9, 17], ["lineages", "OBSERVATION_MODIFIER", 18, 26], ["HRSV", "OBSERVATION", 30, 34], ["broad", "OBSERVATION_MODIFIER", 133, 138], ["geographic", "OBSERVATION_MODIFIER", 139, 149], ["distribution", "OBSERVATION_MODIFIER", 150, 162]]], ["The nucleotide identities observed between the two hMPV clusters for each of the genes analyzed are comparable to the ones obtained between members of the two HRSV subgroups (Naylor et al., 1998).", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["hMPV", "ORGANISM", 51, 55], ["HRSV", "ORGANISM", 159, 163], ["two", "OBSERVATION_MODIFIER", 47, 50], ["hMPV", "OBSERVATION", 51, 55]]], ["However, a greater proportion of silent nucleic acid substitutions are found in the F genes of hMPV clusters leading to an aa identity that is closer to the one observed within HRSV subgroups.", [["nucleic acid", "CHEMICAL", 40, 52], ["hMPV", "ORGANISM", 95, 99], ["HRSV", "ORGANISM", 177, 181], ["F genes", "DNA", 84, 91], ["silent nucleic acid substitutions", "PROBLEM", 33, 66], ["hMPV clusters", "PROBLEM", 95, 108], ["an aa identity", "PROBLEM", 120, 134], ["greater", "OBSERVATION_MODIFIER", 11, 18], ["nucleic acid substitutions", "OBSERVATION", 40, 66], ["hMPV", "ANATOMY", 95, 99]]], ["At this point, it is still unclear if the differences observed between the hMPV isolates are representative of two distinct hMPV antigenic subgroups.", [["hMPV", "ORGANISM", 75, 79], ["hMPV", "ORGANISM", 124, 128], ["hMPV", "SPECIES", 75, 79], ["the hMPV isolates", "PROBLEM", 71, 88], ["two distinct hMPV antigenic subgroups", "PROBLEM", 111, 148], ["hMPV", "OBSERVATION", 75, 79], ["distinct", "OBSERVATION_MODIFIER", 115, 123], ["hMPV", "OBSERVATION", 124, 128], ["antigenic subgroups", "OBSERVATION", 129, 148]]], ["The characterization of the hMPV G genes for which the antigenic diversity is most evident for RSV and APV, as well as serologic studies, are needed to determine the antigenic significance of the genetic diversity observed for hMPV.DiscussionMolecular analysis of the N, P, M and F genes provided further support for the assignment of hMPV to the Metapneumovirus genus of the Paramyxovirinae subfamily.", [["APV", "CHEMICAL", 103, 106], ["hMPV", "DISEASE", 227, 231], ["hMPV", "ORGANISM", 28, 32], ["G", "GENE_OR_GENE_PRODUCT", 33, 34], ["RSV", "ORGANISM", 95, 98], ["hMPV", "ORGANISM", 227, 231], ["hMPV", "ORGANISM", 335, 339], ["Metapneumovirus genus", "ORGANISM", 347, 368], ["Paramyxovirinae", "GENE_OR_GENE_PRODUCT", 376, 391], ["hMPV G genes", "DNA", 28, 40], ["N, P, M and F genes", "DNA", 268, 287], ["Paramyxovirinae subfamily", "PROTEIN", 376, 401], ["hMPV", "SPECIES", 28, 32], ["RSV", "SPECIES", 95, 98], ["hMPV", "SPECIES", 227, 231], ["hMPV", "SPECIES", 335, 339], ["the hMPV G genes", "PROBLEM", 24, 40], ["the antigenic diversity", "PROBLEM", 51, 74], ["RSV", "PROBLEM", 95, 98], ["APV", "TEST", 103, 106], ["serologic studies", "TEST", 119, 136], ["hMPV", "PROBLEM", 227, 231], ["further support", "TREATMENT", 297, 312], ["hMPV", "PROBLEM", 335, 339], ["hMPV", "OBSERVATION", 28, 32], ["most evident", "UNCERTAINTY", 78, 90], ["Metapneumovirus", "OBSERVATION", 347, 362]]], ["Analysis of the genomic organization of hMPV revealed several similar features to APVs, especially to the subgroup C (van den Hoogen et al., 2001).", [["hMPV", "ORGANISM", 40, 44], ["hMPV", "SPECIES", 40, 44], ["hMPV", "PROBLEM", 40, 44], ["hMPV", "OBSERVATION", 40, 44], ["several", "OBSERVATION_MODIFIER", 54, 61], ["similar", "OBSERVATION_MODIFIER", 62, 69]]], ["They share the same putative gene start sequence (GGGACAAGUGAAA), as well as the same gene end sequences for the N gene (AGUAAUUA6).", [["GGGACAAGUGAAA", "GENE_OR_GENE_PRODUCT", 50, 63], ["putative gene start sequence", "DNA", 20, 48], ["N gene", "DNA", 113, 119], ["AGUAAUUA6", "DNA", 121, 130]]], ["Although not identical, the gene end sequences of the other genes also show some similarity to APVs.", [["APVs", "DNA", 95, 99]]], ["The 3\u2032 noncoding region of the M and F genes varies significantly between the two hMPV clusters.", [["M and F", "GENE_OR_GENE_PRODUCT", 31, 38], ["hMPV", "ORGANISM", 82, 86], ["3\u2032 noncoding region", "DNA", 4, 23], ["M and F genes", "DNA", 31, 44], ["region", "ANATOMY_MODIFIER", 17, 23], ["hMPV clusters", "OBSERVATION", 82, 95]]], ["This finding is comparable to the low conservation of some 3\u2032 noncoding sequences of HRSV and APV isolates belonging to different subgroups (Bayon-Auboyer et al., 2000, Seal et al., 2000).DiscussionSequence alignment studies show that the hMPV proteins are more closely related to the subgroup C of APV, with aa identities for the different proteins ranging from 66 to 89% (van den Hoogen et al., 2002).", [["APV", "CHEMICAL", 94, 97], ["APV", "CHEMICAL", 299, 302], ["HRSV", "ORGANISM", 85, 89], ["APV isolates", "ORGANISM", 94, 106], ["hMPV", "ORGANISM", 239, 243], ["APV", "SIMPLE_CHEMICAL", 299, 302], ["3\u2032 noncoding sequences", "DNA", 59, 81], ["hMPV proteins", "PROTEIN", 239, 252], ["HRSV", "SPECIES", 85, 89], ["HRSV", "PROBLEM", 85, 89], ["APV isolates", "TREATMENT", 94, 106], ["Sequence alignment studies", "TEST", 198, 224], ["the hMPV proteins", "PROBLEM", 235, 252], ["the different proteins", "TEST", 327, 349], ["hMPV", "OBSERVATION", 239, 243]]], ["A greater divergence is observed with the non-avian pneumovirus members and the aa identity drops to 23\u201345%.", [["A greater divergence", "PROBLEM", 0, 20], ["the aa identity", "TEST", 76, 91], ["greater", "OBSERVATION_MODIFIER", 2, 9], ["divergence", "OBSERVATION", 10, 20]]], ["The N, M and F genes were the most conserved whereas the P genes show greater divergence.", [["F", "GENE_OR_GENE_PRODUCT", 13, 14], ["N, M and F genes", "DNA", 4, 20], ["P genes", "DNA", 57, 64]]], ["Comparison of the predicted aa sequences revealed that the N, M, P and F proteins share most of the common features characterized for these proteins in other pneumoviruses.", [["pneumoviruses", "CANCER", 158, 171], ["N, M, P and F proteins", "PROTEIN", 59, 81], ["the predicted aa sequences", "TEST", 14, 40], ["the N, M, P and F proteins", "TEST", 55, 81], ["these proteins in other pneumoviruses", "PROBLEM", 134, 171]]], ["However, the cleavage peptide sequence for the hMPV F protein (RQSR) varies from the one described for other pneumoviruses, and differs from the furin protease motif (R/K-X-R/K-R) present in all pneumovirus except for APV-C.", [["APV-C.", "CHEMICAL", 218, 224], ["hMPV F", "GENE_OR_GENE_PRODUCT", 47, 53], ["furin", "GENE_OR_GENE_PRODUCT", 145, 150], ["K-R", "GENE_OR_GENE_PRODUCT", 175, 178], ["hMPV F protein", "PROTEIN", 47, 61], ["RQSR", "PROTEIN", 63, 67], ["pneumoviruses", "PROTEIN", 109, 122], ["furin protease motif", "PROTEIN", 145, 165], ["K", "PROTEIN", 169, 170], ["X", "PROTEIN", 171, 172], ["R", "PROTEIN", 173, 174], ["K", "PROTEIN", 175, 176], ["the cleavage peptide sequence", "PROBLEM", 9, 38], ["the hMPV F protein", "TEST", 43, 61], ["other pneumoviruses", "PROBLEM", 103, 122], ["the furin protease motif", "TEST", 141, 165], ["K", "TEST", 169, 170], ["APV", "TEST", 218, 221]]], ["When compared to hMPV, the cleavage sites of other pneumoviruses contain additional Arg-Lys residues.", [["Arg-Lys", "CHEMICAL", 84, 91], ["Arg", "CHEMICAL", 84, 87], ["Lys", "CHEMICAL", 88, 91], ["hMPV", "ORGANISM", 17, 21], ["pneumoviruses", "GENE_OR_GENE_PRODUCT", 51, 64], ["hMPV", "SPECIES", 17, 21], ["hMPV", "PROBLEM", 17, 21], ["other pneumoviruses", "TREATMENT", 45, 64], ["Lys residues", "OBSERVATION", 88, 100]]], ["The substitution of these basic aa in the hMPV cleavage site may play a role in viral pathogenesis, since it may modify the efficiency of cleavage by the host protease.", [["hMPV", "ORGANISM", 42, 46], ["hMPV cleavage site", "DNA", 42, 60], ["protease", "PROTEIN", 159, 167], ["these basic aa", "TREATMENT", 20, 34], ["the hMPV cleavage site", "PROBLEM", 38, 60], ["viral pathogenesis", "PROBLEM", 80, 98], ["the host protease", "TREATMENT", 150, 167], ["hMPV", "OBSERVATION", 42, 46]]], ["The virulence of Newcastle disease virus (NDV) a member of the Rubulavirus genus of the Paramyxovirinae subfamily has been linked to the number of basic residues present at the F protein cleavage site.", [["Newcastle disease", "DISEASE", 17, 34], ["Newcastle disease virus", "ORGANISM", 17, 40], ["NDV", "ORGANISM", 42, 45], ["Rubulavirus genus", "ORGANISM", 63, 80], ["Paramyxovirinae", "GENE_OR_GENE_PRODUCT", 88, 103], ["Paramyxovirinae subfamily", "PROTEIN", 88, 113], ["F protein cleavage site", "PROTEIN", 177, 200], ["Newcastle disease virus", "SPECIES", 17, 40], ["Newcastle disease virus", "SPECIES", 17, 40], ["NDV", "SPECIES", 42, 45], ["Newcastle disease virus", "PROBLEM", 17, 40], ["basic residues", "PROBLEM", 147, 161], ["Newcastle disease", "OBSERVATION", 17, 34], ["basic residues", "OBSERVATION", 147, 161]]], ["NDV virulent strains have two pairs of basic residues at the cleavage site, whereas avirulent strains have two basic residues (Collins et al., 1993).DiscussionThe close relationship observed between hMPV and APV-C suggests that hMPV originated from birds.", [["APV", "CHEMICAL", 208, 211], ["APV-C", "CHEMICAL", 208, 213], ["NDV", "ORGANISM", 0, 3], ["hMPV", "ORGANISM", 199, 203], ["APV-C", "ORGANISM", 208, 213], ["hMPV", "ORGANISM", 228, 232], ["birds", "ORGANISM", 249, 254], ["NDV", "SPECIES", 0, 3], ["NDV", "SPECIES", 0, 3], ["hMPV", "SPECIES", 228, 232], ["NDV virulent strains", "PROBLEM", 0, 20], ["basic residues at the cleavage site", "PROBLEM", 39, 74], ["avirulent strains", "PROBLEM", 84, 101], ["hMPV", "PROBLEM", 199, 203], ["hMPV", "PROBLEM", 228, 232], ["basic residues", "OBSERVATION", 39, 53], ["two", "OBSERVATION_MODIFIER", 107, 110], ["basic", "OBSERVATION_MODIFIER", 111, 116], ["residues", "OBSERVATION_MODIFIER", 117, 125], ["hMPV", "OBSERVATION", 228, 232]]], ["It is also possible that APV-C could have evolved from human precursor strains of hMPV that infected birds.", [["APV", "CHEMICAL", 25, 28], ["APV-C", "CHEMICAL", 25, 30], ["APV-C", "GENE_OR_GENE_PRODUCT", 25, 30], ["human", "ORGANISM", 55, 60], ["hMPV", "ORGANISM", 82, 86], ["birds", "ORGANISM", 101, 106], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["hMPV", "SPECIES", 82, 86], ["APV-C", "PROBLEM", 25, 30], ["human precursor strains", "PROBLEM", 55, 78], ["hMPV", "PROBLEM", 82, 86], ["also possible", "UNCERTAINTY", 6, 19]]], ["APV-C has only recently been described infecting commercial poultry (mid-1990s) (Dar et al., 2001, Seal, 1998, Seal et al., 2000).", [["APV-C", "CHEMICAL", 0, 5], ["APV-C", "CHEMICAL", 0, 5], ["APV-C", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["It was speculated that hMPV is an avian virus that is also able to infect humans (van den Hoogen et al., 2001).", [["hMPV", "DISEASE", 23, 27], ["hMPV", "ORGANISM", 23, 27], ["humans", "ORGANISM", 74, 80], ["humans", "SPECIES", 74, 80], ["hMPV", "SPECIES", 23, 27], ["humans", "SPECIES", 74, 80], ["hMPV", "PROBLEM", 23, 27], ["an avian virus", "PROBLEM", 31, 45], ["hMPV", "OBSERVATION", 23, 27]]], ["However, data obtained by van den Hoogen et al., indicate that the human virus is unable to infect turkeys and chickens, but can infect monkeys experimentally (van den Hoogen et al., 2001).", [["human", "ORGANISM", 67, 72], ["turkeys", "ORGANISM", 99, 106], ["chickens", "ORGANISM", 111, 119], ["monkeys", "ORGANISM", 136, 143], ["human", "SPECIES", 67, 72], ["turkeys", "SPECIES", 99, 106], ["chickens", "SPECIES", 111, 119], ["monkeys", "SPECIES", 136, 143], ["human virus", "SPECIES", 67, 78], ["turkeys", "SPECIES", 99, 106], ["chickens", "SPECIES", 111, 119], ["the human virus", "PROBLEM", 63, 78]]], ["The relative importance of hMPV on viral respiratory tract illnesses is still not known, but serological studies demonstrated that by the age of five, practically all children in the Netherlands have been in contact with the virus and that it has been present in the population for at least 50 years (van den Hoogen et al., 2001).", [["respiratory tract", "ANATOMY", 41, 58], ["hMPV", "DISEASE", 27, 31], ["viral respiratory tract illnesses", "DISEASE", 35, 68], ["hMPV", "ORGANISM", 27, 31], ["tract", "ORGANISM_SUBDIVISION", 53, 58], ["children", "ORGANISM", 167, 175], ["children", "SPECIES", 167, 175], ["hMPV", "SPECIES", 27, 31], ["hMPV", "PROBLEM", 27, 31], ["viral respiratory tract illnesses", "PROBLEM", 35, 68], ["serological studies", "TEST", 93, 112], ["hMPV", "OBSERVATION", 27, 31]]], ["These initial studies on the prevalence of hMPV and its possible worldwide distribution strengthen the importance for a better understanding of the newly identified pneumovirus.", [["hMPV", "DISEASE", 43, 47], ["hMPV", "ORGANISM", 43, 47], ["pneumovirus", "CANCER", 165, 176], ["hMPV", "SPECIES", 43, 47], ["These initial studies", "TEST", 0, 21], ["hMPV", "PROBLEM", 43, 47], ["the newly identified pneumovirus", "PROBLEM", 144, 176]]]], "851b17fc71b060398f94abaccb3d39557f6f537c": [["Access to Care for Dementia patients suffering from COVID-19Gabriele Cipriani, MD * (1) (2); Mario Di Fiorino, MD (2) (1) Neurology Unit, Versilia Hospital, via Aurelia, 55043, Lido di Camaiore, Lucca (Lu)Access to Care for Dementia patients suffering from COVID-19(2) Psychiatry Unit, Versilia Hospital, via Aurelia, 55043, Lido di Camaiore, Lucca (Lu) All co-authors have contributed significantly confirming their agreement to this submission.Access to Care for Dementia patients suffering from COVID-19No financial support The first known cases of COVID-19 in Italy were observed on January 31 in two Chinese tourists holidaying in Rome.", [["Dementia", "DISEASE", 19, 27], ["COVID", "DISEASE", 52, 57], ["Dementia", "DISEASE", 224, 232], ["Dementia", "DISEASE", 465, 473], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 233, 241], ["patients", "ORGANISM", 474, 482], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 233, 241], ["patients", "SPECIES", 474, 482], ["Dementia", "PROBLEM", 19, 27], ["Lido di Camaiore", "TREATMENT", 177, 193], ["Dementia", "PROBLEM", 224, 232], ["Lido", "TREATMENT", 325, 329], ["Dementia", "PROBLEM", 465, 473], ["COVID", "TREATMENT", 498, 503], ["financial support", "TREATMENT", 509, 526], ["COVID", "TEST", 552, 557]]], ["The mortality rate of coronavirus arrived at 12.2%, higher than that registered in other countries.", [["coronavirus", "DISEASE", 22, 33], ["coronavirus", "ORGANISM", 22, 33], ["The mortality rate", "TEST", 0, 18], ["coronavirus", "PROBLEM", 22, 33]]], ["This fact may be partially explained by the country's relatively high proportion of older people.", [["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96], ["may be partially explained", "UNCERTAINTY", 10, 36]]], ["Mortality rate appeared to be higher for the elderly patient: for people between 80 and 89 years of age, the fatality rate was 31% 2 .", [["patient", "ORGANISM", 53, 60], ["people", "ORGANISM", 66, 72], ["patient", "SPECIES", 53, 60], ["people", "SPECIES", 66, 72], ["Mortality rate", "TEST", 0, 14], ["the fatality rate", "TEST", 105, 122]]], ["Anyway, a silent surge in fatalities in nursing homes, where dozens of patients a day are dying untested for the virus.", [["fatalities", "DISEASE", 26, 36], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["the virus", "PROBLEM", 109, 118]]], ["The deaths occurred despite that, immediately after the virus emerged in northern Italy on February 21, care homes cut off access to visitors to limit the contagion risk to elderly patients most vulnerable to the disease.", [["deaths", "DISEASE", 4, 10], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["The deaths", "PROBLEM", 0, 10], ["the disease", "PROBLEM", 209, 220], ["deaths", "OBSERVATION", 4, 10], ["disease", "OBSERVATION", 213, 220]]], ["At the Pio Albergo Trivulzio, the historic nursing home in Milan, there were about a hundred deaths, 70 in March, to which another 30 have been added since the beginning of April.", [["deaths", "DISEASE", 93, 99]]], ["For the containment and management of emergency from COVID-19, government authorities have introduced draconian measures 3 .", [["COVID", "TEST", 53, 58], ["draconian measures", "TREATMENT", 102, 120]]], ["However, if it is difficult trying to keep the patient's daily routine and the structuring of his day as constant, even more, arduous is to obtain from demented people the respect of simple safeguard measures such as wearing masks and washing hands.", [["patient", "ORGANISM", 47, 54], ["people", "ORGANISM", 161, 167], ["patient", "SPECIES", 47, 54], ["people", "SPECIES", 161, 167], ["simple safeguard measures", "TREATMENT", 183, 208]]], ["On March 20, 2020, the Italian Higher Institute of Health reported data about characteristics of coronavirus patients who died in Italy.", [["coronavirus", "DISEASE", 97, 108], ["coronavirus", "ORGANISM", 97, 108], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117]]], ["Dementia was assessed as one of the most common comorbidities (11.9%) among COVID-19 positive deceased patients.", [["Dementia", "DISEASE", 0, 8], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["Dementia", "PROBLEM", 0, 8], ["COVID", "TEST", 76, 81]]], ["This fact gives rise to a disconcerting problem.", [["a disconcerting problem", "PROBLEM", 24, 47]]], ["On April 9, 2020, the number of coronavirus patients treated in Intensive Care Units (ICU) reached nearly 3.6 thousand.", [["coronavirus", "DISEASE", 32, 43], ["coronavirus", "ORGANISM", 32, 43], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52]]], ["Is a person cognitively impaired admitted to ICU?", [["cognitively impaired", "DISEASE", 12, 32], ["person", "SPECIES", 5, 11]]], ["It is undeniable that people should have an equal chance when there are sufficient resources, but when there are limited means, doctors do take various factors into account resources.", [["people", "ORGANISM", 22, 28], ["people", "SPECIES", 22, 28]]], ["The Italian College of Anesthesia, Analgesia, Resuscitation and Intensive Care, issued guidelines 4 .", [["Anesthesia", "TREATMENT", 23, 33], ["Analgesia", "TREATMENT", 35, 44], ["Resuscitation", "TREATMENT", 46, 59]]], ["Their conclusion is shocking: It may become necessary to establish an age limit for access to intensive care.", [["intensive care", "TREATMENT", 94, 108]]], ["As a result, patients with underlying conditions and elderly patients such as demented persons may not be treated in favor of healthier and/or younger people who have more chances of recovery.", [["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 61, 69], ["persons", "ORGANISM", 87, 94], ["people", "ORGANISM", 151, 157], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 61, 69], ["persons", "SPECIES", 87, 94], ["people", "SPECIES", 151, 157], ["underlying conditions", "PROBLEM", 27, 48]]], ["In our opinion, discrimination based on personal characteristics (such as age or disability) is inadmissible, while we believe it is acceptable to say that patients who have no chance of survival receive purely palliative care.", [["disability", "DISEASE", 81, 91], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["purely palliative care", "TREATMENT", 204, 226]]]], "PMC7135258": [["Infection control in childrenInfection control following a biologic agent attack is complex, with some added considerations for the pediatric population.", [["Infection control", "TREATMENT", 0, 17], ["childrenInfection control", "TREATMENT", 21, 46], ["the pediatric population", "TREATMENT", 128, 152]]], ["First, early attribution of a cluster of febrile, respiratory illnesses to an intentional biologic agent attack in children might be difficult because children experience respiratory symptoms with common colds more often than adults, and they cannot easily report the subtleties of their own symptoms [7].", [["respiratory", "ANATOMY", 171, 182], ["febrile", "DISEASE", 41, 48], ["respiratory illnesses", "DISEASE", 50, 71], ["colds", "DISEASE", 204, 209], ["children", "ORGANISM", 115, 123], ["children", "ORGANISM", 151, 159], ["children", "SPECIES", 115, 123], ["children", "SPECIES", 151, 159], ["febrile", "PROBLEM", 41, 48], ["respiratory illnesses", "PROBLEM", 50, 71], ["respiratory symptoms", "PROBLEM", 171, 191], ["common colds", "PROBLEM", 197, 209], ["cluster", "OBSERVATION_MODIFIER", 30, 37], ["febrile", "OBSERVATION_MODIFIER", 41, 48]]], ["Furthermore, strict isolation is complicated in children.", [["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56]]], ["Young patients might need to be sedated, especially if isolated in negative pressure tents or rooms.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["sedated", "TREATMENT", 32, 39]]], ["Parents might need to remain with their children in isolation, which can expose them to the infectious agents.", [["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48]]], ["In addition, pediatric hospitals need to prepare to care not only for the sick children but also for their parents if separation is to be avoided.", [["children", "ORGANISM", 79, 87], ["children", "SPECIES", 79, 87]]], ["Prolonged isolation can dramatically affect children's and parent's well being and their social relations [8].", [["children", "ORGANISM", 44, 52], ["children", "SPECIES", 44, 52], ["Prolonged isolation", "TREATMENT", 0, 19]]], ["Pediatric infection control after a bioterrorist event is even further complicated by the fact that there is little consistency in design, structure, organization, and implementation of infection control throughout pediatric facilities in the United States [9].", [["infection", "DISEASE", 10, 19], ["infection", "DISEASE", 186, 195], ["Pediatric infection control", "TREATMENT", 0, 27], ["infection control", "TREATMENT", 186, 203], ["infection", "OBSERVATION", 10, 19], ["little", "OBSERVATION_MODIFIER", 109, 115], ["consistency", "OBSERVATION_MODIFIER", 116, 127], ["infection", "OBSERVATION", 186, 195]]], ["Unresolved current controversies in pediatric isolation and infection control include the correct application of standard precautions and best precautions to prevent transmission of disease [10].", [["infection", "DISEASE", 60, 69], ["pediatric isolation", "TREATMENT", 36, 55], ["infection control", "TREATMENT", 60, 77], ["standard precautions", "TREATMENT", 113, 133], ["best precautions", "TREATMENT", 138, 154], ["disease", "PROBLEM", 182, 189], ["infection", "OBSERVATION", 60, 69]]], ["Four general issues of infection control in pediatrics apply regardless of whether bioterrorism is involved:1.Early recognition and identification of agent2.Notification of public health agencies3.Decontamination, infection control safety measures, isolation, and quarantine4.Treatment, prophylaxis, and vaccination", [["infection", "DISEASE", 23, 32], ["infection", "DISEASE", 214, 223], ["quarantine4", "CHEMICAL", 264, 275], ["quarantine4", "CHEMICAL", 264, 275], ["agent2", "DNA", 150, 156], ["infection control", "TREATMENT", 23, 40], ["agent2", "TREATMENT", 150, 156], ["Decontamination", "TREATMENT", 197, 212], ["infection control safety measures", "TREATMENT", 214, 247], ["isolation", "TREATMENT", 249, 258], ["quarantine4", "TREATMENT", 264, 275], ["Treatment", "TREATMENT", 276, 285], ["prophylaxis", "TREATMENT", 287, 298], ["vaccination", "TREATMENT", 304, 315], ["infection", "OBSERVATION", 23, 32], ["infection", "OBSERVATION", 214, 223]]]], "47af8168767ac2a465a3744cffea615594a982fa": [["Concerns over the accidental or deliberate release of novel pathogens has prompted a debate about the conduct or funding of biological research in the name of human health and security.", [["human", "ORGANISM", 159, 164], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 159, 164], ["novel pathogens", "PROBLEM", 54, 69]]], ["Of particular concern is \"gain-of-function\" (GOF) research resulting in the creation of a \"potential pandemic pathogen (PPP)\" (GOF/PPP research) where, inter alia, the host range, virulence, or transmissibility of a pathogen is enhanced.", [["a \"potential pandemic pathogen", "PROBLEM", 88, 118], ["GOF/PPP research", "TEST", 127, 143], ["virulence", "PROBLEM", 180, 189], ["a pathogen", "PROBLEM", 214, 224], ["host range", "OBSERVATION", 168, 178], ["pathogen", "OBSERVATION", 216, 224], ["enhanced", "OBSERVATION_MODIFIER", 228, 236]]], ["For example, in 2011 researchers modified highly pathogenic avian influenza (HPAI) H5N1 to transmit via respiratory droplets in mammals (Herfst et al., 2012; Imai et al., 2012) .", [["respiratory droplets", "ANATOMY", 104, 124], ["avian influenza", "DISEASE", 60, 75], ["HPAI", "DISEASE", 77, 81], ["avian influenza (HPAI) H5N1", "ORGANISM", 60, 87], ["avian influenza", "SPECIES", 60, 75], ["HPAI", "SPECIES", 77, 81], ["HPAI", "SPECIES", 77, 81], ["influenza", "PROBLEM", 66, 75], ["H5N1", "PROBLEM", 83, 87]]]], "PMC7114443": [["IntroductionCoronaviruses (CoVs) are large, enveloped viruses containing linear, positive-sense, single-stranded RNA genomes.", [["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["CoVs", "PROTEIN", 27, 31], ["linear, positive-sense, single-stranded RNA genomes", "DNA", 73, 124], ["IntroductionCoronaviruses (CoVs)", "PROBLEM", 0, 32], ["large", "OBSERVATION_MODIFIER", 37, 42], ["enveloped", "OBSERVATION_MODIFIER", 44, 53], ["viruses", "OBSERVATION", 54, 61], ["linear", "OBSERVATION_MODIFIER", 73, 79], ["positive", "OBSERVATION_MODIFIER", 81, 89], ["RNA genomes", "OBSERVATION", 113, 124]]], ["Their genomes range approximately from 27- to 32-kb in length and contain 7\u201314 open reading frames (ORFs) (Woo et al., 2009a).", [["7\u201314 open reading frames", "DNA", 74, 98], ["ORFs", "DNA", 100, 104], ["range", "OBSERVATION_MODIFIER", 14, 19]]], ["Six major ORFs encoding polymerase complex (ORF1a and ORF1b), spike glycoprotein (S), envelope protein (E), membrane glycoprotein (M), and nucleocapsid protein (N) are present in all CoVs (Poon et al., 2005).", [["ORF1a", "GENE_OR_GENE_PRODUCT", 44, 49], ["ORF1b", "GENE_OR_GENE_PRODUCT", 54, 59], ["spike glycoprotein (S)", "GENE_OR_GENE_PRODUCT", 62, 84], ["envelope protein (E), membrane glycoprotein", "GENE_OR_GENE_PRODUCT", 86, 129], ["nucleocapsid protein (N)", "GENE_OR_GENE_PRODUCT", 139, 163], ["CoVs", "PATHOLOGICAL_FORMATION", 183, 187], ["ORFs", "DNA", 10, 14], ["polymerase complex", "PROTEIN", 24, 42], ["ORF1a", "PROTEIN", 44, 49], ["ORF1b", "PROTEIN", 54, 59], ["spike glycoprotein", "PROTEIN", 62, 80], ["S", "PROTEIN", 82, 83], ["envelope protein", "PROTEIN", 86, 102], ["E", "PROTEIN", 104, 105], ["membrane glycoprotein", "PROTEIN", 108, 129], ["M", "PROTEIN", 131, 132], ["nucleocapsid protein", "PROTEIN", 139, 159], ["N", "PROTEIN", 161, 162], ["Six major ORFs encoding polymerase complex", "PROBLEM", 0, 42], ["ORF1a", "TEST", 44, 49], ["ORF1b", "TEST", 54, 59], ["spike glycoprotein (S", "TEST", 62, 83], ["envelope protein", "TEST", 86, 102]]], ["In addition, up to seven putative accessory ORFs and one ORF encoding hemagglutinin-esterase glycoprotein (HE) are interspersed between the six major ORFs.", [["hemagglutinin-esterase glycoprotein", "GENE_OR_GENE_PRODUCT", 70, 105], ["HE", "GENE_OR_GENE_PRODUCT", 107, 109], ["accessory ORFs", "DNA", 34, 48], ["ORF", "DNA", 57, 60], ["hemagglutinin", "PROTEIN", 70, 83], ["esterase glycoprotein", "PROTEIN", 84, 105], ["HE", "PROTEIN", 107, 109], ["ORFs", "DNA", 150, 154], ["seven putative accessory ORFs", "PROBLEM", 19, 48], ["hemagglutinin-esterase glycoprotein", "TREATMENT", 70, 105]]], ["The numbers and sizes of these accessory ORFs differ markedly among CoVs (Woo et al., 2009a).IntroductionCoVs have been identified from a broad range of birds and mammals including humans in which they can cause respiratory, enteric, hepatic and neurologic diseases of varying severity (Weiss and Navas-Martin, 2005).", [["respiratory", "ANATOMY", 212, 223], ["hepatic", "ANATOMY", 234, 241], ["neurologic", "ANATOMY", 246, 256], ["respiratory, enteric, hepatic and neurologic diseases", "DISEASE", 212, 265], ["birds", "ORGANISM", 153, 158], ["humans", "ORGANISM", 181, 187], ["hepatic", "MULTI-TISSUE_STRUCTURE", 234, 241], ["accessory ORFs", "DNA", 31, 45], ["humans", "SPECIES", 181, 187], ["humans", "SPECIES", 181, 187], ["these accessory ORFs", "PROBLEM", 25, 45], ["IntroductionCoVs", "TREATMENT", 93, 109], ["respiratory, enteric, hepatic and neurologic diseases of varying severity", "PROBLEM", 212, 285], ["numbers", "OBSERVATION_MODIFIER", 4, 11], ["sizes", "OBSERVATION_MODIFIER", 16, 21], ["accessory ORFs", "OBSERVATION", 31, 45], ["enteric", "ANATOMY", 225, 232], ["hepatic", "ANATOMY", 234, 241], ["neurologic diseases", "OBSERVATION", 246, 265]]], ["CoVs in the subfamily Coronavirinae are classified into three genera, Alphacoronavirus, Betacoronavirus, and Gammacoronavirus (former serogroups 1\u20133) (de Groot et al., 2011).", [["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 22, 35], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 88, 103], ["CoVs", "PROTEIN", 0, 4], ["CoVs", "PROBLEM", 0, 4], ["Alphacoronavirus", "TEST", 70, 86], ["Betacoronavirus", "TREATMENT", 88, 103]]], ["Alpha- and beta-coronaviruses have been exclusively isolated from mammals and majority of gamma-coronaviruses from birds.", [["Alpha-", "GENE_OR_GENE_PRODUCT", 0, 6], ["beta", "GENE_OR_GENE_PRODUCT", 11, 15], ["gamma-coronaviruses", "ORGANISM", 90, 109], ["birds", "ORGANISM", 115, 120], ["Alpha- and beta-coronaviruses", "PROTEIN", 0, 29], ["Alpha", "TEST", 0, 5], ["beta-coronaviruses", "PROBLEM", 11, 29], ["gamma-coronaviruses", "PROBLEM", 90, 109], ["gamma-coronaviruses", "OBSERVATION", 90, 109]]], ["CoVs of a distinctive lineage were recently detected from birds and pigs (Chu et al., 2011, Woo et al., 2009b, Woo et al., 2012) and have been proposed to belong to a new genus, provisionally named Deltacoronavirus (de Groot et al., 2011).", [["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["birds", "ORGANISM", 58, 63], ["pigs", "ORGANISM", 68, 72], ["CoVs", "PROTEIN", 0, 4], ["pigs", "SPECIES", 68, 72], ["a distinctive lineage", "PROBLEM", 8, 29], ["distinctive", "OBSERVATION_MODIFIER", 10, 21], ["lineage", "OBSERVATION", 22, 29]]], ["The finding that the outbreak of severe acute respiratory syndrome (SARS) in early 2003 was caused by a novel CoV (SARS-CoV) has boosted interest in the search for novel CoVs in humans and animals.", [["acute respiratory syndrome", "DISEASE", 40, 66], ["SARS", "DISEASE", 68, 72], ["SARS", "DISEASE", 115, 119], ["CoV", "ORGANISM", 110, 113], ["SARS-CoV", "ORGANISM", 115, 123], ["CoVs", "GENE_OR_GENE_PRODUCT", 170, 174], ["humans", "ORGANISM", 178, 184], ["humans", "SPECIES", 178, 184], ["SARS-CoV", "SPECIES", 115, 123], ["humans", "SPECIES", 178, 184], ["severe acute respiratory syndrome", "PROBLEM", 33, 66], ["SARS", "PROBLEM", 68, 72], ["a novel CoV (SARS-CoV", "PROBLEM", 102, 123], ["novel CoVs in humans", "PROBLEM", 164, 184], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["respiratory syndrome", "OBSERVATION", 46, 66]]], ["At least 30 previously unrecognized distinctive CoVs from human and various animal reservoirs were reported during recent years, including SARS-related CoVs and CoVs from all genera in the subfamily Coronavirinae which have significantly expanded our understanding of CoV diversity and complexity (Woo et al., 2009a).", [["SARS", "DISEASE", 139, 143], ["CoVs", "CANCER", 48, 52], ["human", "ORGANISM", 58, 63], ["CoVs", "GENE_OR_GENE_PRODUCT", 152, 156], ["CoVs", "GENE_OR_GENE_PRODUCT", 161, 165], ["CoV", "ORGANISM", 268, 271], ["CoVs", "DNA", 152, 156], ["CoVs", "DNA", 161, 165], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["distinctive CoVs from human and various animal reservoirs", "PROBLEM", 36, 93], ["SARS", "PROBLEM", 139, 143], ["CoVs", "PROBLEM", 152, 156], ["CoVs", "PROBLEM", 161, 165], ["distinctive CoVs", "OBSERVATION", 36, 52]]], ["Based on available data, bats appear to harbor a great diversity of CoVs.", [["bats", "ORGANISM", 25, 29], ["CoVs", "GENE_OR_GENE_PRODUCT", 68, 72], ["CoVs", "DNA", 68, 72], ["great", "OBSERVATION_MODIFIER", 49, 54], ["diversity", "OBSERVATION", 55, 64], ["CoVs", "OBSERVATION", 68, 72]]], ["The frequency and diversity of CoV detection in bats, now in multiple continents, suggest that bats are likely a source for CoV introduction into other species globally and possibly play an important role in the ecology and evolution of CoVs.IntroductionRecently we reported the identification of 41 divergent CoVs in bats from Kenya, based on limited ORF1b sequences (Tong et al., 2009).", [["CoV", "ORGANISM", 31, 34], ["bats", "ORGANISM", 95, 99], ["CoV", "ORGANISM", 124, 127], ["CoVs", "GENE_OR_GENE_PRODUCT", 237, 241], ["CoVs", "GENE_OR_GENE_PRODUCT", 310, 314], ["CoVs", "DNA", 237, 241], ["CoVs", "DNA", 310, 314], ["ORF1b sequences", "DNA", 352, 367], ["CoV detection", "TEST", 31, 44], ["CoV introduction into other species globally", "PROBLEM", 124, 168], ["CoVs", "PROBLEM", 237, 241], ["41 divergent CoVs", "PROBLEM", 297, 314], ["limited ORF1b sequences", "TEST", 344, 367], ["diversity", "OBSERVATION_MODIFIER", 18, 27], ["CoV detection", "OBSERVATION", 31, 44]]], ["These newly discovered bat CoVs were grouped into 8 different phylogenetic clusters.", [["bat", "ORGANISM", 23, 26], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["bat CoVs", "DNA", 23, 31], ["bat CoVs", "PROBLEM", 23, 31], ["bat CoVs", "OBSERVATION", 23, 31], ["8 different", "OBSERVATION_MODIFIER", 50, 61], ["phylogenetic clusters", "OBSERVATION", 62, 83]]], ["Of these, five clusters belonged to previously identified Alphacoronavirus genus, and three clusters belonged to previously identified Betacoronavirus genus, including a SARS-related CoV lineage.", [["SARS", "DISEASE", 170, 174], ["CoV", "ORGANISM", 183, 186], ["Alphacoronavirus genus", "PROBLEM", 58, 80], ["a SARS", "PROBLEM", 168, 174], ["Alphacoronavirus genus", "OBSERVATION", 58, 80], ["CoV lineage", "OBSERVATION", 183, 194]]], ["In the present study, we expand our sequence data for seven CoVs, representing 7 of the 8 distinctive clusters we identified in Kenya bats during 2006 summer (Tong et al., 2009).", [["CoVs", "GENE_OR_GENE_PRODUCT", 60, 64], ["CoVs", "PROTEIN", 60, 64], ["our sequence data", "TEST", 32, 49], ["seven CoVs", "PROBLEM", 54, 64]]], ["The sample representing the eighth cluster of a SARS-related CoV was a weak positive and had limited specimen amount, therefore further sequencing studies were not included in this analysis.", [["sample", "ANATOMY", 4, 10], ["SARS", "DISEASE", 48, 52], ["CoV", "ORGANISM", 61, 64], ["The sample", "TEST", 0, 10], ["a SARS-related CoV", "PROBLEM", 46, 64], ["a weak positive", "PROBLEM", 69, 84], ["further sequencing studies", "TEST", 128, 154], ["this analysis", "TEST", 176, 189]]], ["The purpose of our study was to further characterize the genomes and refine the phylogenetic relationships of these seven CoVs with other CoVs, based on the ORFs 1b, S, E, M, and N.Bat sampling and RNA extraction ::: Materials and methodsKenya was chosen as a major comparative Old World study location in Africa as part of the CDC Global Disease Detection program.", [["CoVs", "GENE_OR_GENE_PRODUCT", 122, 126], ["CoVs", "GENE_OR_GENE_PRODUCT", 138, 142], ["CoVs", "DNA", 122, 126], ["CoVs", "DNA", 138, 142], ["ORFs", "DNA", 157, 161], ["our study", "TEST", 15, 24], ["other CoVs", "PROBLEM", 132, 142], ["the ORFs", "TEST", 153, 161], ["the CDC Global Disease Detection program", "PROBLEM", 324, 364]]], ["The protocols for animal capture and use were approved by the CDC Animal Institutional Care and Use Committee and the Ethics and Animal Care and Use Committee of the Kenya Wildlife Service (Nairobi, Kenya).", [["The protocols", "TREATMENT", 0, 13]]], ["In brief, representative samples at each site were collected from bats of available species, including adult and juvenile of both sexes.", [["samples", "ANATOMY", 25, 32], ["representative samples at each site", "PROBLEM", 10, 45]]], ["After euthanasia, a complete necropsy was performed in compliance with the approved field protocols.", [["euthanasia", "PROBLEM", 6, 16], ["a complete necropsy", "TEST", 18, 37], ["the approved field protocols", "TREATMENT", 71, 99]]], ["Samples included blood, various organs (liver, lung, and kidney), rectal and oral swabs.Bat sampling and RNA extraction ::: Materials and methodsIn this study, seven CoV-positive rectal swabs were selected as representatives of the seven different phylogenetic groups (Tong et al., 2009) for extensive genome sequencing.", [["Samples", "ANATOMY", 0, 7], ["blood", "ANATOMY", 17, 22], ["organs", "ANATOMY", 32, 38], ["liver", "ANATOMY", 40, 45], ["lung", "ANATOMY", 47, 51], ["kidney", "ANATOMY", 57, 63], ["rectal", "ANATOMY", 66, 72], ["oral swabs", "ANATOMY", 77, 87], ["rectal swabs", "ANATOMY", 179, 191], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["organs", "ORGAN", 32, 38], ["liver", "ORGAN", 40, 45], ["lung", "ORGAN", 47, 51], ["kidney", "ORGAN", 57, 63], ["rectal", "ORGANISM_SUBDIVISION", 66, 72], ["oral", "ORGANISM_SUBDIVISION", 77, 81], ["swabs", "ORGANISM_SUBSTANCE", 82, 87], ["CoV", "ORGANISM", 166, 169], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 179, 191], ["Samples", "TEST", 0, 7], ["blood, various organs", "TEST", 17, 38], ["rectal and oral swabs", "TEST", 66, 87], ["this study", "TEST", 148, 158], ["seven CoV", "TEST", 160, 169], ["positive rectal swabs", "PROBLEM", 170, 191], ["extensive genome sequencing", "TREATMENT", 292, 319], ["liver", "ANATOMY", 40, 45], ["lung", "ANATOMY", 47, 51], ["kidney", "ANATOMY", 57, 63], ["rectal", "ANATOMY", 66, 72], ["rectal", "ANATOMY", 179, 185]]], ["These are Rousettus bat coronavirus/Kenya/KY06/2006 (BtKY06), Chaerephon bat coronavirus/Kenya/KY22/2006 (BtKY22), Eidolon bat coronavirus/Kenya/KY24/2006 (BtKY24), Miniopterus bat coronavirus/Kenya/KY27/2006 (BtKY27), Miniopterus bat coronavirus/Kenya/KY33/2006 (BtKY33), Chaerephon bat coronavirus/Kenya/KY41/2006 (BtKY41), and Cardioderma bat coronavirus/Kenya/KY43/2006 (BtKY43).", [["Rousettus bat coronavirus", "ORGANISM", 10, 35], ["Kenya/KY06/2006", "ORGANISM", 36, 51], ["BtKY06", "ORGANISM", 53, 59], ["Chaerephon bat coronavirus", "ORGANISM", 62, 88], ["Kenya/KY22/2006", "ORGANISM", 89, 104], ["BtKY22", "ORGANISM", 106, 112], ["Eidolon bat coronavirus", "ORGANISM", 115, 138], ["Kenya/KY24/2006", "ORGANISM", 139, 154], ["BtKY24", "ORGANISM", 156, 162], ["Miniopterus bat coronavirus", "ORGANISM", 165, 192], ["BtKY27", "ORGANISM", 210, 216], ["Miniopterus bat coronavirus", "ORGANISM", 219, 246], ["BtKY33", "ORGANISM", 264, 270], ["Chaerephon bat coronavirus", "ORGANISM", 273, 299], ["Kenya", "ORGANISM", 300, 305], ["BtKY41", "ORGANISM", 317, 323], ["Cardioderma bat coronavirus", "ORGANISM", 330, 357], ["Kenya", "ORGANISM", 358, 363], ["BtKY43", "CANCER", 375, 381], ["bat coronavirus", "SPECIES", 20, 35], ["Chaerephon bat coronavirus", "SPECIES", 62, 88], ["Eidolon bat coronavirus", "SPECIES", 115, 138], ["Miniopterus bat coronavirus", "SPECIES", 165, 192], ["Miniopterus bat coronavirus", "SPECIES", 219, 246], ["Chaerephon bat coronavirus", "SPECIES", 273, 299], ["Cardioderma bat coronavirus", "SPECIES", 330, 357], ["Rousettus bat coronavirus/Kenya/KY06/2006 (BtKY06)", "SPECIES", 10, 60], ["Chaerephon bat coronavirus/Kenya/KY22/2006 (BtKY22)", "SPECIES", 62, 113], ["Eidolon bat coronavirus/Kenya/KY24/2006 (BtKY24)", "SPECIES", 115, 163], ["Miniopterus bat coronavirus/Kenya/KY27/2006 (BtKY27)", "SPECIES", 165, 217], ["Miniopterus bat coronavirus/Kenya/KY33/2006 (BtKY33)", "SPECIES", 219, 271], ["Chaerephon bat coronavirus/Kenya/KY41/2006 (BtKY41)", "SPECIES", 273, 324], ["Cardioderma bat coronavirus/Kenya/KY43/2006", "SPECIES", 330, 373], ["Eidolon bat coronavirus", "TREATMENT", 115, 138], ["Miniopterus", "TREATMENT", 165, 176]]], ["BtKY43 was not described previously, but represents a group of 4 Kenya bat CoVs (BtKY03, BtKY12, BtKY13, and BtKY29) (Tong et al., 2009).", [["BtKY43", "GENE_OR_GENE_PRODUCT", 0, 6], ["bat", "ORGANISM", 71, 74], ["CoVs", "GENE_OR_GENE_PRODUCT", 75, 79], ["BtKY03", "GENE_OR_GENE_PRODUCT", 81, 87], ["BtKY12", "GENE_OR_GENE_PRODUCT", 89, 95], ["BtKY13", "GENE_OR_GENE_PRODUCT", 97, 103], ["BtKY29", "GENE_OR_GENE_PRODUCT", 109, 115], ["BtKY43", "PROTEIN", 0, 6]]], ["Total nucleic acids (TNA) were extracted by using the QIAamp MinElute Virus Spin Kit (Qiagen, Santa Clarita, CA) according to the manufacturer's instructions from 200 \u03bcl of phosphate buffered saline suspension of the rectal swab and homogenized organ tissues (liver, lung, and/or kidney) of each bat except for bats BtKY33 and BtKY43 whose organ tissues were not available.", [["rectal swab", "ANATOMY", 217, 228], ["organ tissues", "ANATOMY", 245, 258], ["liver", "ANATOMY", 260, 265], ["lung", "ANATOMY", 267, 271], ["kidney", "ANATOMY", 280, 286], ["organ tissues", "ANATOMY", 340, 353], ["nucleic acids", "CHEMICAL", 6, 19], ["phosphate", "CHEMICAL", 173, 182], ["phosphate", "CHEMICAL", 173, 182], ["Total nucleic acids", "SIMPLE_CHEMICAL", 0, 19], ["TNA", "SIMPLE_CHEMICAL", 21, 24], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 173, 198], ["rectal swab", "ORGANISM_SUBSTANCE", 217, 228], ["organ tissues", "TISSUE", 245, 258], ["liver", "ORGAN", 260, 265], ["lung", "ORGAN", 267, 271], ["kidney", "ORGAN", 280, 286], ["BtKY33", "GENE_OR_GENE_PRODUCT", 316, 322], ["BtKY43", "CELL", 327, 333], ["organ tissues", "TISSUE", 340, 353], ["Total nucleic acids (TNA", "TREATMENT", 0, 24], ["the QIAamp MinElute Virus Spin Kit (Qiagen, Santa Clarita, CA)", "TREATMENT", 50, 112], ["phosphate buffered saline suspension", "TREATMENT", 173, 209], ["the rectal swab", "TEST", 213, 228], ["rectal", "ANATOMY", 217, 223], ["organ tissues", "ANATOMY", 245, 258], ["liver", "ANATOMY", 260, 265], ["lung", "ANATOMY", 267, 271], ["kidney", "ANATOMY", 280, 286]]], ["The TNA was eluted in 80 \u03bcl DEPC-treated water and then stored at \u221280 \u00b0C.Reverse transcription-PCR (RT-PCR) ::: Materials and methodsEach CoV-positive result on the rectal swab included in this study was repeated from different TNA aliquots.", [["rectal swab", "ANATOMY", 165, 176], ["DEPC", "CHEMICAL", 28, 32], ["DEPC", "CHEMICAL", 28, 32], ["TNA", "GENE_OR_GENE_PRODUCT", 4, 7], ["DEPC", "SIMPLE_CHEMICAL", 28, 32], ["CoV", "ORGANISM", 138, 141], ["rectal swab", "MULTI-TISSUE_STRUCTURE", 165, 176], ["TNA", "PROTEIN", 4, 7], ["The TNA", "TEST", 0, 7], ["Reverse transcription", "TEST", 73, 94], ["PCR", "TEST", 95, 98], ["methodsEach CoV", "TEST", 126, 141], ["the rectal swab", "TEST", 161, 176], ["this study", "TEST", 189, 199], ["different TNA aliquots", "TREATMENT", 218, 240], ["rectal", "ANATOMY", 165, 171]]], ["The presence of CoV RNA in organ tissues of these bats was determined using the pan CoV RT-PCR assays as described previously (Tong et al., 2009) and the sequence specific and/or group specific CoV RT-PCR assays (Table S1).", [["organ tissues", "ANATOMY", 27, 40], ["CoV", "GENE_OR_GENE_PRODUCT", 16, 19], ["organ tissues", "TISSUE", 27, 40], ["bats", "ORGANISM", 50, 54], ["CoV RNA", "RNA", 16, 23], ["CoV RNA in organ tissues", "PROBLEM", 16, 40], ["the pan CoV RT-PCR assays", "TEST", 76, 101], ["the sequence specific", "TEST", 150, 171], ["CoV RT-PCR assays", "TEST", 194, 211], ["CoV RNA", "OBSERVATION", 16, 23]]], ["The RT-PCR were performed as described previously (Tong et al., 2009).", [["The RT-PCR", "TEST", 0, 10]]], ["Standard precautions were taken to avoid cross-contamination of samples before and after RNA extraction and amplification.", [["samples", "ANATOMY", 64, 71], ["Standard precautions", "TREATMENT", 0, 20], ["RNA extraction", "TREATMENT", 89, 103]]], ["Purified DNA amplicons were sequenced with the RT-PCR primers on an ABI Prism 3130 automated capillary sequencer using a BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Carlsbad, CA).Partial genome sequencing ::: Materials and methodsHigh throughput 454 pyrosequencing on CoV RNA-positive bat samples was initially attempted, but failed to acquire any CoV-associated reads due to lower sensitivity.", [["capillary", "ANATOMY", 93, 102], ["samples", "ANATOMY", 310, 317], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["capillary", "TISSUE", 93, 102], ["CoV", "ORGANISM", 289, 292], ["bat", "ORGANISM", 306, 309], ["CoV", "ORGANISM", 369, 372], ["Purified DNA amplicons", "DNA", 0, 22], ["RT-PCR primers", "DNA", 47, 61], ["CoV RNA", "RNA", 289, 296], ["Purified DNA amplicons", "PROBLEM", 0, 22], ["the RT", "TEST", 43, 49], ["PCR primers", "TEST", 50, 61], ["an ABI Prism", "TEST", 65, 77], ["capillary sequencer", "TEST", 93, 112], ["a BigDye Terminator", "TREATMENT", 119, 138], ["methods", "TEST", 244, 251], ["CoV RNA", "TEST", 289, 296], ["positive bat samples", "PROBLEM", 297, 317], ["any CoV", "TEST", 365, 372], ["lower sensitivity", "PROBLEM", 397, 414]]], ["Therefore the RT-PCR-amplicon sequencing by Sanger chain-termination method was chosen in this study.", [["the RT-PCR", "TEST", 10, 20], ["amplicon sequencing", "TREATMENT", 21, 40], ["Sanger chain", "TEST", 44, 56], ["this study", "TEST", 90, 100]]], ["Each of the seven contiguous sequences was obtained by using 4\u20136 pairs of semi-nested or nested consensus degenerate group specific primers and 4\u20137 pairs of semi-nested or nested sequence-specific bridging primers which generated a series of 8\u201313 overlapping fragments covering 15\u201316kb genomic sequences at the 3\u2032 end (Table S1).", [["fragments", "ANATOMY", 259, 268], ["4\u20136 pairs", "DNA", 61, 70], ["semi-nested or nested consensus degenerate group specific primers", "DNA", 74, 139], ["8\u201313 overlapping fragments", "DNA", 242, 268], ["15\u201316kb genomic sequences", "DNA", 278, 303], ["3\u2032 end", "DNA", 311, 317], ["semi-nested or nested consensus degenerate group specific primers", "PROBLEM", 74, 139], ["semi-nested or nested sequence", "PROBLEM", 157, 187], ["specific bridging primers", "PROBLEM", 188, 213], ["a series of 8\u201313 overlapping fragments", "TREATMENT", 230, 268], ["kb genomic sequences", "TEST", 283, 303], ["fragments", "OBSERVATION_MODIFIER", 259, 268]]], ["The other half genome sequence containing the ORF1a, was not recovered in this analysis due to the limited amount of rectal swab samples.", [["rectal swab samples", "ANATOMY", 117, 136], ["ORF1a", "GENE_OR_GENE_PRODUCT", 46, 51], ["rectal swab samples", "CANCER", 117, 136], ["half genome sequence", "DNA", 10, 30], ["ORF1a", "DNA", 46, 51], ["this analysis", "TEST", 74, 87], ["rectal swab samples", "TEST", 117, 136], ["rectal", "ANATOMY", 117, 123]]], ["The 3\u2032 end of genome sequence was determined using the 3\u2032 RACE kit (Roche, Indianapolis, IN) according to the manufacturer's instructions.", [["3\u2032 end", "DNA", 4, 10], ["genome sequence", "DNA", 14, 29]]], ["Semi-nested or nested primers were used to improve the PCR sensitivity.", [["Semi-nested or nested primers", "TREATMENT", 0, 29], ["the PCR sensitivity", "TEST", 51, 70]]], ["When nested primers were not available, the PCR product was re-amplified using the same RT-PCR primers.", [["RT-PCR primers", "DNA", 88, 102], ["the PCR product", "TEST", 40, 55], ["the same RT-PCR primers", "TREATMENT", 79, 102]]], ["The RT-PCR reactions were performed with SuperScript III one-step RT-PCR High Fidelity kit (Invitrogen, San Diego, CA) according to the manufacturer's instructions, and the second round RCR reactions were performed with AccuPrime Taq DNA polymerase High Fidelity kit (Invitrogen, San Diego, CA).", [["DNA", "CELLULAR_COMPONENT", 234, 237], ["AccuPrime Taq DNA polymerase", "PROTEIN", 220, 248], ["The RT-PCR reactions", "TEST", 0, 20], ["SuperScript III", "TREATMENT", 41, 56], ["the second round RCR reactions", "PROBLEM", 169, 199], ["AccuPrime Taq DNA polymerase", "TEST", 220, 248]]], ["The RT-PCR products were visualized on 1% agarose gels containing 0.5 \u03bcg/mL of ethidium bromide, and purified by QIAquick PCR purification kit (QIAGEN, Santa Clarita, CA).", [["ethidium bromide", "CHEMICAL", 79, 95], ["ethidium bromide", "CHEMICAL", 79, 95], ["agarose", "SIMPLE_CHEMICAL", 42, 49], ["ethidium bromide", "SIMPLE_CHEMICAL", 79, 95], ["The RT-PCR products", "TREATMENT", 0, 19], ["1% agarose gels", "TREATMENT", 39, 54], ["ethidium bromide", "TREATMENT", 79, 95]]], ["The RT-PCR amplicons for each sample were first sequenced with the consensus degenerate RT-PCR primers in both directions, and then the remaining internal gaps and 3\u2032 end genome were sequenced with sequence-specific bridging primers in both directions as described previously.", [["sample", "ANATOMY", 30, 36], ["RT-PCR amplicons", "DNA", 4, 20], ["consensus degenerate RT-PCR primers", "DNA", 67, 102], ["3\u2032 end genome", "DNA", 164, 177], ["The RT-PCR amplicons", "TREATMENT", 0, 20], ["each sample", "TEST", 25, 36], ["PCR primers", "TEST", 91, 102], ["sequence", "TEST", 198, 206], ["internal", "ANATOMY_MODIFIER", 146, 154], ["bridging primers", "OBSERVATION", 216, 232], ["both", "ANATOMY_MODIFIER", 236, 240]]], ["The genomic sequences (ORF1b, S, ORF3, E, M, and N) of BtKY22, BtKY33, BtKY27, BtKY41, BtKY43, BtKY06, and BtKY24 were deposited in NCBI GenBank (HQ728480\u2013HQ728486).Sequence analysis ::: Materials and methodsSequences were assembled in Sequencher (Genecodes, Ann Arbor, MI).", [["ORF1b", "GENE_OR_GENE_PRODUCT", 23, 28], ["ORF3", "GENE_OR_GENE_PRODUCT", 33, 37], ["E", "GENE_OR_GENE_PRODUCT", 39, 40], ["BtKY22", "GENE_OR_GENE_PRODUCT", 55, 61], ["BtKY33", "GENE_OR_GENE_PRODUCT", 63, 69], ["BtKY27", "GENE_OR_GENE_PRODUCT", 71, 77], ["BtKY41", "GENE_OR_GENE_PRODUCT", 79, 85], ["BtKY43", "GENE_OR_GENE_PRODUCT", 87, 93], ["BtKY06", "GENE_OR_GENE_PRODUCT", 95, 101], ["BtKY24", "GENE_OR_GENE_PRODUCT", 107, 113], ["genomic sequences", "DNA", 4, 21], ["ORF1b", "DNA", 23, 28], ["S", "DNA", 30, 31], ["ORF3", "DNA", 33, 37], ["E", "DNA", 39, 40], ["BtKY22", "DNA", 55, 61], ["BtKY33", "DNA", 63, 69], ["BtKY27", "DNA", 71, 77], ["BtKY41", "DNA", 79, 85], ["BtKY43", "DNA", 87, 93], ["BtKY06", "DNA", 95, 101], ["BtKY24", "DNA", 107, 113], ["NCBI GenBank", "DNA", 132, 144], ["The genomic sequences", "TEST", 0, 21], ["ORF1b", "TEST", 23, 28], ["ORF3", "TEST", 33, 37], ["BtKY22", "TEST", 55, 61], ["BtKY33", "TEST", 63, 69], ["BtKY41", "TEST", 79, 85], ["Sequence analysis", "TEST", 165, 182], ["methodsSequences", "TEST", 201, 217]]], ["Each putative ORF was predicted using the NCBI ORF finder (http://www.ncbi.nlm.nih.gov/gorf/gorf.html).", [["ORF", "DNA", 14, 17], ["NCBI ORF finder", "DNA", 42, 57], ["Each putative ORF", "PROBLEM", 0, 17]]], ["N-glycosylation sites were predicted using NetNGlyc 1.0 Server (http://www.cbs.dtu.dk/services/NetNGlyc/).", [["N", "CHEMICAL", 0, 1], ["N-glycosylation sites", "DNA", 0, 21], ["glycosylation sites", "TREATMENT", 2, 21]]], ["BLAST analyses were performed against NCBI non-redundant protein database (Altschul et al., 1990) and against the Conserved Domain Database for protein classification (CDD) (Marchler-Bauer et al., 2005) to characterize the putative ORFs.Sequence analysis ::: Materials and methodsAlignments of the seven Kenya bat CoV gene sequences with a representative set of 43 other CoV sequences, available in the public domain, were performed using the MUSCLE v3.6 (Edgar, 2004).", [["bat", "ORGANISM", 310, 313], ["CoV", "ORGANISM", 314, 317], ["CoV", "ORGANISM", 371, 374], ["putative ORFs", "DNA", 223, 236], ["Kenya bat CoV gene sequences", "DNA", 304, 332], ["CoV sequences", "DNA", 371, 384], ["Kenya bat CoV", "SPECIES", 304, 317], ["BLAST analyses", "TEST", 0, 14], ["protein classification", "TEST", 144, 166], ["the putative ORFs", "PROBLEM", 219, 236], ["Sequence analysis", "TEST", 237, 254], ["other CoV sequences", "TEST", 365, 384], ["putative ORFs", "OBSERVATION", 223, 236], ["MUSCLE", "ANATOMY", 443, 449]]], ["We constructed maximum likelihood trees for each gene alignment (ORF1b, S, E, M, and N) in MEGA software package v5.0 (Tamura et al., 2011) with 1000 bootstrap replications.", [["ORF1b", "DNA", 65, 70], ["each gene alignment", "TEST", 44, 63], ["ORF1b", "TEST", 65, 70]]], ["We used General-Time-Reversible nucleotide (nt) substitution model with 4 categories of gamma distributed rate heterogeneity and a proportion of invariant sites (GTR + \u03b34 + I).", [["nucleotide", "CHEMICAL", 32, 42], ["nucleotide", "CHEMICAL", 32, 42], ["Reversible nucleotide (nt) substitution model", "TREATMENT", 21, 66], ["gamma distributed rate heterogeneity", "PROBLEM", 88, 124], ["invariant sites", "PROBLEM", 145, 160], ["GTR", "TEST", 162, 165], ["invariant sites", "OBSERVATION", 145, 160]]], ["To identify potential recombination events of the seven Kenya bat CoVs, three methods implemented in recombination detection program RDP version 2 (Martin et al., 2005) were used, including MaxChi (Smith, 1992), Chimaera (Posada et al., 2002), and Geneconv (Padidam et al., 1999).", [["Kenya bat CoVs", "SPECIES", 56, 70], ["potential recombination events", "PROBLEM", 12, 42]]], ["Events detected by all three methods with default parameters were considered as potential recombination events.Detection of CoV RNA in bat tissues ::: Results and discussionThe aliquots of bat rectal samples for BtKY27, BtKY33, BtKY22, BtKY41, BtKY43, BtKY24, and BtKY06 were confirmed positive by the pan CoV RT-PCR assay, while among tissues (liver, lung, and/or kidney) that were available from bats BtKY27, BtKY22, BtKY41, BtKY24, and BtKY06, only the liver from bat BtKY22 (Chaerephon sp.) and the kidney from bat BtKY24 (Eidolon helvum) tested positive by RT-PCR.", [["bat tissues", "ANATOMY", 135, 146], ["rectal samples", "ANATOMY", 193, 207], ["tissues", "ANATOMY", 336, 343], ["liver", "ANATOMY", 345, 350], ["lung", "ANATOMY", 352, 356], ["kidney", "ANATOMY", 365, 371], ["liver", "ANATOMY", 456, 461], ["kidney", "ANATOMY", 503, 509], ["CoV", "GENE_OR_GENE_PRODUCT", 124, 127], ["bat tissues", "TISSUE", 135, 146], ["bat", "ORGANISM", 189, 192], ["rectal samples", "CANCER", 193, 207], ["BtKY27", "GENE_OR_GENE_PRODUCT", 212, 218], ["BtKY33", "GENE_OR_GENE_PRODUCT", 220, 226], ["BtKY22", "GENE_OR_GENE_PRODUCT", 228, 234], ["BtKY41", "GENE_OR_GENE_PRODUCT", 236, 242], ["BtKY43", "GENE_OR_GENE_PRODUCT", 244, 250], ["BtKY24", "GENE_OR_GENE_PRODUCT", 252, 258], ["BtKY06", "GENE_OR_GENE_PRODUCT", 264, 270], ["tissues", "TISSUE", 336, 343], ["liver", "ORGAN", 345, 350], ["lung", "ORGAN", 352, 356], ["kidney", "ORGAN", 365, 371], ["BtKY27", "GENE_OR_GENE_PRODUCT", 403, 409], ["BtKY22", "GENE_OR_GENE_PRODUCT", 411, 417], ["BtKY41", "GENE_OR_GENE_PRODUCT", 419, 425], ["BtKY24", "GENE_OR_GENE_PRODUCT", 427, 433], ["BtKY06", "GENE_OR_GENE_PRODUCT", 439, 445], ["liver", "ORGAN", 456, 461], ["bat BtKY22", "ORGANISM", 467, 477], ["Chaerephon sp.", "ORGANISM", 479, 493], ["kidney", "ORGAN", 503, 509], ["bat BtKY24", "ORGANISM", 515, 525], ["Eidolon helvum", "ORGANISM", 527, 541], ["CoV RNA", "RNA", 124, 131], ["BtKY27", "PROTEIN", 212, 218], ["BtKY33", "PROTEIN", 220, 226], ["BtKY22", "PROTEIN", 228, 234], ["BtKY41", "PROTEIN", 236, 242], ["BtKY43", "PROTEIN", 244, 250], ["BtKY24", "PROTEIN", 252, 258], ["BtKY06", "PROTEIN", 264, 270], ["BtKY22", "DNA", 411, 417], ["BtKY41", "DNA", 419, 425], ["BtKY24", "DNA", 427, 433], ["BtKY06", "DNA", 439, 445], ["Chaerephon sp.", "SPECIES", 479, 493], ["Eidolon helvum", "SPECIES", 527, 541], ["pan CoV", "SPECIES", 302, 309], ["Eidolon helvum", "SPECIES", 527, 541], ["default parameters", "TEST", 42, 60], ["CoV RNA in bat tissues", "PROBLEM", 124, 146], ["bat rectal samples", "TEST", 189, 207], ["BtKY27", "TEST", 212, 218], ["BtKY22", "TEST", 228, 234], ["BtKY06", "TEST", 264, 270], ["the pan CoV RT-PCR assay", "TEST", 298, 322], ["the kidney", "TEST", 499, 509], ["bat BtKY24", "TEST", 515, 525], ["Eidolon helvum", "TEST", 527, 541], ["PCR", "TEST", 565, 568], ["CoV RNA", "OBSERVATION", 124, 131], ["liver", "ANATOMY", 345, 350], ["lung", "ANATOMY", 352, 356], ["kidney", "ANATOMY", 365, 371], ["liver", "ANATOMY", 456, 461], ["kidney", "ANATOMY", 503, 509]]], ["These data support an infection process rather than transit of ingested infected material through the digestive tract as the source of viral RNA in rectal swabs, particularly because these bat species do not feed on vertebrates.", [["digestive tract", "ANATOMY", 102, 117], ["rectal swabs", "ANATOMY", 148, 160], ["infection", "DISEASE", 22, 31], ["digestive tract", "ORGANISM_SUBDIVISION", 102, 117], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 148, 160], ["viral RNA", "RNA", 135, 144], ["an infection process", "PROBLEM", 19, 39], ["ingested infected material through the digestive tract", "PROBLEM", 63, 117], ["viral RNA in rectal swabs", "PROBLEM", 135, 160], ["these bat species", "PROBLEM", 183, 200], ["infection", "OBSERVATION", 22, 31], ["infected", "OBSERVATION", 72, 80], ["digestive tract", "ANATOMY", 102, 117], ["viral RNA", "OBSERVATION", 135, 144], ["rectal swabs", "ANATOMY", 148, 160]]], ["Negative results for other tissues may be explained by specific pathobiology and a limited tropism to the available tissues.Partial genome sequence and organization ::: Results and discussionEach acquired CoV genome sequence covers the complete ORF1b, S protein, ORF3, E protein, M protein, N protein, other putative ORFs after N and the 3\u2032 end untranslated region with a poly A tail.", [["tissues", "ANATOMY", 27, 34], ["tissues", "ANATOMY", 116, 123], ["tissues", "TISSUE", 27, 34], ["tissues", "TISSUE", 116, 123], ["CoV", "ORGANISM", 205, 208], ["ORF1b", "GENE_OR_GENE_PRODUCT", 245, 250], ["S protein", "GENE_OR_GENE_PRODUCT", 252, 261], ["ORF3", "GENE_OR_GENE_PRODUCT", 263, 267], ["E protein", "GENE_OR_GENE_PRODUCT", 269, 278], ["M protein", "GENE_OR_GENE_PRODUCT", 280, 289], ["CoV genome sequence", "DNA", 205, 224], ["ORF1b", "PROTEIN", 245, 250], ["S protein", "PROTEIN", 252, 261], ["ORF3", "PROTEIN", 263, 267], ["E protein", "PROTEIN", 269, 278], ["M protein", "PROTEIN", 280, 289], ["N protein", "PROTEIN", 291, 300], ["ORFs", "DNA", 317, 321], ["N and the 3\u2032 end untranslated region", "DNA", 328, 364], ["poly A tail", "PROTEIN", 372, 383], ["other tissues", "PROBLEM", 21, 34], ["CoV genome sequence", "TEST", 205, 224], ["the complete ORF1b", "TEST", 232, 250], ["S protein", "TEST", 252, 261], ["ORF3", "TEST", 263, 267], ["E protein", "TEST", 269, 278], ["M protein", "TEST", 280, 289], ["N protein", "TEST", 291, 300], ["other putative ORFs", "PROBLEM", 302, 321], ["N and the 3\u2032 end untranslated region", "TREATMENT", 328, 364], ["tail", "OBSERVATION_MODIFIER", 379, 383]]], ["The genome organization and size for each of the ORFs are shown in Fig. 1and Table 1, respectively.", [["ORFs", "DNA", 49, 53], ["the ORFs", "TEST", 45, 53], ["genome organization", "OBSERVATION", 4, 23], ["size", "OBSERVATION_MODIFIER", 28, 32]]], ["They are similar to other known CoV genome organization in the order of 5\u2032-ORF1b, S, ORF3, E, M, and N-3\u2032, but have a variable number of putative ORFs downstream of the N gene.", [["CoV", "ORGANISM", 32, 35], ["5\u2032-ORF1b", "GENE_OR_GENE_PRODUCT", 72, 80], ["ORF3", "GENE_OR_GENE_PRODUCT", 85, 89], ["E", "GENE_OR_GENE_PRODUCT", 91, 92], ["N-3", "GENE_OR_GENE_PRODUCT", 101, 104], ["CoV genome", "DNA", 32, 42], ["5\u2032", "DNA", 72, 74], ["ORF1b", "DNA", 75, 80], ["S", "DNA", 82, 83], ["ORF3", "DNA", 85, 89], ["E", "DNA", 91, 92], ["N", "DNA", 101, 102], ["ORFs", "DNA", 146, 150], ["N gene", "DNA", 169, 175], ["other known CoV genome organization", "PROBLEM", 20, 55], ["ORF3", "TEST", 85, 89], ["CoV genome", "OBSERVATION", 32, 42]]], ["The sizes of these seven genomic sequences from ORF1b to the 3\u2032 end are between \u223c15k and \u223c16k and their G + C contents are between 37.6% and 42.6%.", [["ORF1b", "GENE_OR_GENE_PRODUCT", 48, 53], ["G + C", "GENE_OR_GENE_PRODUCT", 104, 109], ["genomic sequences", "DNA", 25, 42], ["ORF1b", "DNA", 48, 53], ["3\u2032 end", "DNA", 61, 67], ["k", "TEST", 83, 84], ["their G + C contents", "TEST", 98, 118], ["sizes", "OBSERVATION_MODIFIER", 4, 9]]], ["BtKY27 has no evidence of a putative ORF downstream of the N gene, but possesses a short untranslated region and poly-A tail similar to Bat-CoV 1A (Chu et al., 2008).", [["BtKY27", "CHEMICAL", 0, 6], ["BtKY27", "GENE_OR_GENE_PRODUCT", 0, 6], ["Bat-CoV 1A", "GENE_OR_GENE_PRODUCT", 136, 146], ["BtKY27", "DNA", 0, 6], ["ORF", "DNA", 37, 40], ["N gene", "DNA", 59, 65], ["short untranslated region", "DNA", 83, 108], ["poly-A tail", "DNA", 113, 124], ["Bat-CoV 1A", "DNA", 136, 146], ["Bat-CoV", "SPECIES", 136, 143], ["a putative ORF downstream", "PROBLEM", 26, 51], ["a short untranslated region", "PROBLEM", 81, 108], ["no evidence of", "UNCERTAINTY", 11, 25], ["short", "OBSERVATION_MODIFIER", 83, 88], ["tail", "ANATOMY_MODIFIER", 120, 124]]], ["BtKY22, BtKY33 and BtKY43 have one small putative ORF (76\u2013161 amino acids (aa)) downstream of the N with no significant homology to previously described CoV ORFs.", [["amino acids", "CHEMICAL", 62, 73], ["BtKY22", "GENE_OR_GENE_PRODUCT", 0, 6], ["BtKY33", "GENE_OR_GENE_PRODUCT", 8, 14], ["BtKY43", "GENE_OR_GENE_PRODUCT", 19, 25], ["amino acids", "AMINO_ACID", 62, 73], ["BtKY22", "PROTEIN", 0, 6], ["BtKY33", "DNA", 8, 14], ["BtKY43", "DNA", 19, 25], ["ORF", "DNA", 50, 53], ["CoV ORFs", "DNA", 153, 161], ["one small putative ORF", "PROBLEM", 31, 53], ["amino acids", "TEST", 62, 73], ["significant homology to previously described CoV ORFs", "PROBLEM", 108, 161], ["small", "OBSERVATION_MODIFIER", 35, 40], ["CoV ORFs", "OBSERVATION", 153, 161]]], ["BtKY06 and BtKY24 have two small putative ORFs downstream of the N with sequence similarity to NS7a and NS7b in Bat-CoV HKU9, respectively (Woo et al., 2007).", [["BtKY06", "GENE_OR_GENE_PRODUCT", 0, 6], ["BtKY24", "GENE_OR_GENE_PRODUCT", 11, 17], ["NS7a", "GENE_OR_GENE_PRODUCT", 95, 99], ["NS7b", "GENE_OR_GENE_PRODUCT", 104, 108], ["Bat-CoV", "GENE_OR_GENE_PRODUCT", 112, 119], ["BtKY06", "DNA", 0, 6], ["BtKY24", "DNA", 11, 17], ["ORFs", "DNA", 42, 46], ["N", "DNA", 65, 66], ["NS7a", "DNA", 95, 99], ["NS7b", "DNA", 104, 108], ["Bat-CoV HKU9", "DNA", 112, 124], ["Bat-CoV", "SPECIES", 112, 119], ["two small putative ORFs", "PROBLEM", 23, 46], ["sequence similarity", "TEST", 72, 91], ["NS7a", "TEST", 95, 99], ["small", "OBSERVATION_MODIFIER", 27, 32], ["putative ORFs", "OBSERVATION", 33, 46], ["downstream", "OBSERVATION_MODIFIER", 47, 57]]], ["BtKY41 has two small putative ORFs downstream of the N, which are overlapped and have no significant sequence homology to the previously described ORFs.Partial genome sequence and organization ::: Results and discussionLike most alphacoronaviruses, the BtKY27, BtKY33, BtKY22, BtKY41, and BtKY43 viruses share a core sequence 5\u2032-CUAAAC-3\u2032 or similar putative transcription regulatory sequence (TRS) upstream of ORFs S, M, N, and ORFx and ORFy (Table 1) (Chu et al., 2008, Woo et al., 2005).", [["BtKY41", "CHEMICAL", 0, 6], ["BtKY41", "GENE_OR_GENE_PRODUCT", 0, 6], ["BtKY27", "GENE_OR_GENE_PRODUCT", 253, 259], ["BtKY33", "GENE_OR_GENE_PRODUCT", 261, 267], ["BtKY22", "GENE_OR_GENE_PRODUCT", 269, 275], ["BtKY41", "GENE_OR_GENE_PRODUCT", 277, 283], ["BtKY43", "GENE_OR_GENE_PRODUCT", 289, 295], ["5\u2032-CUAAAC-3", "GENE_OR_GENE_PRODUCT", 326, 337], ["BtKY41", "DNA", 0, 6], ["ORFs", "DNA", 30, 34], ["N", "DNA", 53, 54], ["ORFs", "DNA", 147, 151], ["BtKY27, BtKY33, BtKY22, BtKY41, and BtKY43 viruses", "DNA", 253, 303], ["transcription regulatory sequence", "DNA", 359, 392], ["TRS", "DNA", 394, 397], ["ORFs", "DNA", 411, 415], ["ORFx", "DNA", 429, 433], ["ORFy", "DNA", 438, 442], ["significant sequence homology", "PROBLEM", 89, 118], ["a core sequence", "TEST", 310, 325], ["CUAAAC", "TEST", 329, 335], ["ORFs S", "TEST", 411, 417], ["ORFx", "TEST", 429, 433], ["two", "OBSERVATION_MODIFIER", 11, 14], ["small", "OBSERVATION_MODIFIER", 15, 20], ["putative ORFs", "OBSERVATION", 21, 34], ["downstream", "OBSERVATION_MODIFIER", 35, 45]]], ["ORF3 and E have putative core TRSs that sometimes varied from that for the other ORFs.", [["ORF3", "GENE_OR_GENE_PRODUCT", 0, 4], ["E", "GENE_OR_GENE_PRODUCT", 9, 10], ["TRSs", "GENE_OR_GENE_PRODUCT", 30, 34], ["ORF3", "DNA", 0, 4], ["E", "DNA", 9, 10], ["putative core TRSs", "DNA", 16, 34], ["ORFs", "DNA", 81, 85]]], ["The BtKY06 and BtKY24 have a core sequence TRS 5\u2032-ACGAAC-3\u2032 in the upstream of each ORF except E which has a core sequence TRS 5\u2032-UCGAAC-3\u2032 (Table 1).Partial genome sequence and organization ::: Results and discussionSpike proteins are the type I glycosylated membrane proteins, with a putative signal peptide at the N terminal.", [["membrane", "ANATOMY", 260, 268], ["N", "CHEMICAL", 317, 318], ["BtKY06", "GENE_OR_GENE_PRODUCT", 4, 10], ["BtKY24", "GENE_OR_GENE_PRODUCT", 15, 21], ["membrane", "CELLULAR_COMPONENT", 260, 268], ["BtKY06", "DNA", 4, 10], ["BtKY24", "DNA", 15, 21], ["core sequence TRS 5\u2032-ACGAAC-3\u2032", "DNA", 29, 59], ["ORF", "DNA", 84, 87], ["E", "DNA", 95, 96], ["core sequence TRS 5\u2032-UCGAAC-3\u2032", "DNA", 109, 139], ["Spike proteins", "PROTEIN", 217, 231], ["type I glycosylated membrane proteins", "PROTEIN", 240, 277], ["N terminal", "PROTEIN", 317, 327], ["a core sequence TRS", "TEST", 27, 46], ["ACGAAC", "TEST", 50, 56], ["a core sequence TRS", "TEST", 107, 126], ["UCGAAC", "TEST", 130, 136], ["Spike proteins", "TEST", 217, 231], ["the type I glycosylated membrane proteins", "PROBLEM", 236, 277], ["a putative signal peptide", "PROBLEM", 284, 309]]], ["There are 31, 27, 28, 25, 31, 20, and 19 potential N-glycosylation sites in BtKY22, BtKY27, BtKY33, BtKY41, BtKY43, BtKY24, and BtKY06, respectively.", [["N", "CHEMICAL", 51, 52], ["BtKY22", "GENE_OR_GENE_PRODUCT", 76, 82], ["BtKY27", "GENE_OR_GENE_PRODUCT", 84, 90], ["BtKY33", "GENE_OR_GENE_PRODUCT", 92, 98], ["BtKY41", "GENE_OR_GENE_PRODUCT", 100, 106], ["BtKY43", "GENE_OR_GENE_PRODUCT", 108, 114], ["BtKY24", "GENE_OR_GENE_PRODUCT", 116, 122], ["BtKY06", "GENE_OR_GENE_PRODUCT", 128, 134], ["N-glycosylation sites", "PROTEIN", 51, 72], ["BtKY22, BtKY27, BtKY33, BtKY41, BtKY43, BtKY24, and BtKY06", "DNA", 76, 134]]], ["As shown in Fig. 2, spike proteins of the seven bat CoVs lack furin protease recognition site, such as RRADR-S in Murine Hepatitis Virus (MHV), RRSRG-A in human CoV OC43 (HCoV OC43), RRSRR-A in bovine CoV (BCoV) (Follis et al., 2006), and cathepsin L cleavage site (VAYT-M) as in SARS-CoV (Bosch et al., 2008).", [["Murine Hepatitis Virus", "DISEASE", 114, 136], ["bat", "ORGANISM", 48, 51], ["CoVs", "GENE_OR_GENE_PRODUCT", 52, 56], ["furin", "GENE_OR_GENE_PRODUCT", 62, 67], ["RRADR-S", "GENE_OR_GENE_PRODUCT", 103, 110], ["Murine Hepatitis Virus", "ORGANISM", 114, 136], ["MHV", "ORGANISM", 138, 141], ["RRSRG-A", "GENE_OR_GENE_PRODUCT", 144, 151], ["human", "ORGANISM", 155, 160], ["CoV OC43", "ORGANISM", 161, 169], ["HCoV OC43", "CELL", 171, 180], ["RRSRR-A", "GENE_OR_GENE_PRODUCT", 183, 190], ["bovine", "ORGANISM", 194, 200], ["CoV", "ORGANISM", 201, 204], ["BCoV", "ORGANISM", 206, 210], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 239, 250], ["SARS-CoV", "ORGANISM", 280, 288], ["spike proteins", "PROTEIN", 20, 34], ["CoVs", "PROTEIN", 52, 56], ["furin protease recognition site", "PROTEIN", 62, 93], ["RRADR", "PROTEIN", 103, 108], ["cathepsin L cleavage site", "DNA", 239, 264], ["Murine Hepatitis Virus", "SPECIES", 114, 136], ["human", "SPECIES", 155, 160], ["bovine", "SPECIES", 194, 200], ["Murine Hepatitis Virus", "SPECIES", 114, 136], ["MHV", "SPECIES", 138, 141], ["human CoV", "SPECIES", 155, 164], ["HCoV", "SPECIES", 171, 175], ["bovine CoV", "SPECIES", 194, 204], ["BCoV", "SPECIES", 206, 210], ["SARS-CoV", "SPECIES", 280, 288], ["spike proteins", "PROBLEM", 20, 34], ["the seven bat CoVs lack furin protease recognition site", "PROBLEM", 38, 93], ["RRADR", "TEST", 103, 108], ["Murine Hepatitis Virus", "PROBLEM", 114, 136], ["RRSRG", "TEST", 144, 149], ["OC43", "TEST", 176, 180], ["RRSRR", "TEST", 183, 188], ["cathepsin L cleavage site", "TREATMENT", 239, 264]]], ["In spite of lacking conserved cleavage sites, they all consist of two domains, S1 and S2, showing the conserved GxCx motif in S1 around the cleavage site and the conserved nonamer motif IPTNFSISI or similar motif in S2.", [["S1", "GENE_OR_GENE_PRODUCT", 79, 81], ["S2", "GENE_OR_GENE_PRODUCT", 86, 88], ["S1", "PROTEIN", 79, 81], ["S2", "PROTEIN", 86, 88], ["GxCx motif", "PROTEIN", 112, 122], ["S1", "PROTEIN", 126, 128], ["cleavage site", "PROTEIN", 140, 153], ["conserved nonamer motif", "PROTEIN", 162, 185], ["IPTNFSISI", "PROTEIN", 186, 195], ["S2", "PROTEIN", 216, 218], ["lacking conserved cleavage sites", "PROBLEM", 12, 44], ["the conserved GxCx motif", "PROBLEM", 98, 122], ["the cleavage site", "PROBLEM", 136, 153], ["similar motif in S2", "PROBLEM", 199, 218], ["cleavage sites", "OBSERVATION", 30, 44], ["S1", "ANATOMY", 79, 81], ["S2", "ANATOMY", 86, 88], ["S1", "ANATOMY", 126, 128]]], ["These motifs have been observed in other known CoVs (Follis et al., 2006).", [["CoVs", "PATHOLOGICAL_FORMATION", 47, 51]]], ["The S1 is responsible for virus binding to the receptor on the target cells and may contain receptor binding domains (RBDs) that directly bind to host cellular receptors.", [["cells", "ANATOMY", 70, 75], ["cellular", "ANATOMY", 151, 159], ["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["cells", "CELL", 70, 75], ["receptor binding domains", "GENE_OR_GENE_PRODUCT", 92, 116], ["RBDs", "GENE_OR_GENE_PRODUCT", 118, 122], ["cellular", "CELL", 151, 159], ["S1", "PROTEIN", 4, 6], ["target cells", "CELL_TYPE", 63, 75], ["receptor binding domains", "PROTEIN", 92, 116], ["RBDs", "PROTEIN", 118, 122], ["host cellular receptors", "PROTEIN", 146, 169], ["virus binding", "PROBLEM", 26, 39], ["receptor binding domains", "PROBLEM", 92, 116], ["S1", "ANATOMY", 4, 6], ["responsible for", "UNCERTAINTY", 10, 25], ["virus", "OBSERVATION", 26, 31]]], ["For example, the RBDs of HCoV 229E, TGEV, and HCoV NL63 in Alphacoronavirus are mapped at the C terminus of their S1 domain (Bonavia et al., 2003, Godet et al., 1994, Lin et al., 2008).", [["RBDs", "GENE_OR_GENE_PRODUCT", 17, 21], ["HCoV 229E", "GENE_OR_GENE_PRODUCT", 25, 34], ["TGEV", "ORGANISM", 36, 40], ["HCoV NL63", "GENE_OR_GENE_PRODUCT", 46, 55], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 59, 75], ["RBDs", "DNA", 17, 21], ["HCoV 229E, TGEV, and HCoV NL63", "DNA", 25, 55], ["C terminus", "PROTEIN", 94, 104], ["S1 domain", "PROTEIN", 114, 123], ["HCoV", "SPECIES", 25, 29], ["TGEV", "SPECIES", 36, 40], ["HCoV", "SPECIES", 46, 50], ["the RBDs", "TEST", 13, 21], ["HCoV", "TEST", 25, 29], ["TGEV", "TEST", 36, 40], ["HCoV", "TEST", 46, 50], ["S1", "ANATOMY", 114, 116]]], ["The RBDs of MHV and SARS-CoV in Betacoronavirus are mapped at N terminus and central region of S1 domain, respectively (Li et al., 2005, Lin et al., 2008).", [["SARS", "DISEASE", 20, 24], ["MHV", "ORGANISM", 12, 15], ["SARS-CoV", "ORGANISM", 20, 28], ["Betacoronavirus", "CANCER", 32, 47], ["RBDs", "PROTEIN", 4, 8], ["N terminus", "PROTEIN", 62, 72], ["S1 domain", "PROTEIN", 95, 104], ["MHV", "SPECIES", 12, 15], ["SARS-CoV", "SPECIES", 20, 28], ["The RBDs", "TEST", 0, 8], ["MHV", "PROBLEM", 12, 15], ["SARS", "PROBLEM", 20, 24], ["CoV in Betacoronavirus", "TREATMENT", 25, 47], ["MHV", "OBSERVATION", 12, 15], ["CoV", "OBSERVATION_MODIFIER", 25, 28], ["terminus", "ANATOMY_MODIFIER", 64, 72], ["central", "ANATOMY_MODIFIER", 77, 84], ["region", "ANATOMY_MODIFIER", 85, 91], ["S1 domain", "ANATOMY", 95, 104]]], ["Alignment of aa sequences of S1 regions from BtKY22, BtKY27, BtKY33, BtKY41, and BtKY43 of Alphacoronavirus with the corresponding known RBD S1 regions of HCoV 229E, TGEV, and HCoV NL 63 showed 33\u201341% identity in S1 RBD domains to HCoV 229E and 24\u201329% identity to TGEV and HCoV NL63 (Fig. S1A\u2013C).", [["BtKY22", "GENE_OR_GENE_PRODUCT", 45, 51], ["BtKY27", "GENE_OR_GENE_PRODUCT", 53, 59], ["BtKY33", "GENE_OR_GENE_PRODUCT", 61, 67], ["BtKY41", "GENE_OR_GENE_PRODUCT", 69, 75], ["BtKY43", "GENE_OR_GENE_PRODUCT", 81, 87], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 91, 107], ["RBD S1", "GENE_OR_GENE_PRODUCT", 137, 143], ["HCoV 229E", "GENE_OR_GENE_PRODUCT", 155, 164], ["TGEV", "ORGANISM", 166, 170], ["HCoV NL 63", "ORGANISM", 176, 186], ["TGEV", "ORGANISM", 264, 268], ["S1 regions", "DNA", 29, 39], ["BtKY22", "DNA", 45, 51], ["BtKY27", "DNA", 53, 59], ["BtKY33", "DNA", 61, 67], ["BtKY41", "PROTEIN", 69, 75], ["BtKY43", "DNA", 81, 87], ["RBD S1 regions", "DNA", 137, 151], ["HCoV 229E", "DNA", 155, 164], ["S1 RBD domains", "DNA", 213, 227], ["HCoV 229E", "DNA", 231, 240], ["S1A\u2013C", "PROTEIN", 289, 294], ["TGEV", "SPECIES", 264, 268], ["HCoV", "SPECIES", 155, 159], ["TGEV", "SPECIES", 166, 170], ["HCoV", "SPECIES", 176, 180], ["TGEV", "SPECIES", 264, 268], ["HCoV", "SPECIES", 273, 277], ["Alignment of aa sequences of S1 regions", "TEST", 0, 39], ["BtKY22", "TEST", 45, 51], ["BtKY27", "TEST", 53, 59], ["BtKY33", "TEST", 61, 67], ["BtKY41", "TEST", 69, 75], ["Alphacoronavirus", "TEST", 91, 107], ["HCoV", "TEST", 155, 159], ["TGEV", "TEST", 166, 170], ["HCoV", "TEST", 176, 180], ["HCoV", "TEST", 231, 235], ["TGEV", "TEST", 264, 268], ["HCoV", "TEST", 273, 277], ["S1", "ANATOMY", 29, 31], ["regions", "ANATOMY_MODIFIER", 32, 39], ["RBD S1", "ANATOMY", 137, 143]]], ["BtKY24 and BtKY06 from Betacoronavirus are quite different in the corresponding RBD S1 regions from SARS-CoV and MHV (17\u201319% identity) (Fig. S1D\u2013E).", [["SARS", "DISEASE", 100, 104], ["BtKY24", "GENE_OR_GENE_PRODUCT", 0, 6], ["BtKY06", "GENE_OR_GENE_PRODUCT", 11, 17], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 23, 38], ["SARS-CoV", "ORGANISM", 100, 108], ["MHV", "ORGANISM", 113, 116], ["BtKY24", "PROTEIN", 0, 6], ["BtKY06", "DNA", 11, 17], ["RBD S1 regions", "DNA", 80, 94], ["SARS-CoV", "SPECIES", 100, 108], ["MHV", "SPECIES", 113, 116], ["SARS", "TEST", 100, 104], ["CoV", "TEST", 105, 108], ["MHV", "TEST", 113, 116], ["different", "OBSERVATION_MODIFIER", 49, 58], ["RBD S1", "ANATOMY", 80, 86], ["regions", "ANATOMY_MODIFIER", 87, 94], ["SARS", "OBSERVATION", 100, 104], ["CoV", "OBSERVATION_MODIFIER", 105, 108], ["MHV", "OBSERVATION_MODIFIER", 113, 116]]], ["The dissimilarity of S1 regions of these bat CoVs to other CoVs may suggest their different host specificity.Phylogeny ::: Results and discussionWe constructed phylogenetic trees using maximum likelihood method based on nt sequences of ORF1b, S, E, M and N genes with representative viruses whose corresponding sequences of their genomes were available (Fig. 3).", [["S1", "GENE_OR_GENE_PRODUCT", 21, 23], ["bat", "ORGANISM", 41, 44], ["CoVs", "GENE_OR_GENE_PRODUCT", 45, 49], ["CoVs", "GENE_OR_GENE_PRODUCT", 59, 63], ["ORF1b", "GENE_OR_GENE_PRODUCT", 236, 241], ["E", "GENE_OR_GENE_PRODUCT", 246, 247], ["S1 regions", "DNA", 21, 31], ["bat CoVs", "PROTEIN", 41, 49], ["CoVs", "DNA", 59, 63], ["nt sequences", "DNA", 220, 232], ["ORF1b, S, E, M and N genes", "DNA", 236, 262], ["maximum likelihood method", "TEST", 185, 210], ["nt sequences", "TEST", 220, 232], ["ORF1b", "TEST", 236, 241], ["representative viruses", "PROBLEM", 268, 290], ["S1", "ANATOMY_MODIFIER", 21, 23], ["regions", "ANATOMY_MODIFIER", 24, 31], ["bat CoVs", "OBSERVATION", 41, 49], ["CoVs", "OBSERVATION", 59, 63]]], ["The phylogeny of E gene is not shown due to the short length and limited value for inferring species phylogenies.", [["E", "GENE_OR_GENE_PRODUCT", 17, 18], ["E gene", "DNA", 17, 23], ["the short length", "PROBLEM", 44, 60], ["inferring species phylogenies", "PROBLEM", 83, 112]]], ["Similar topologies were observed in the phylogenetic trees based on each of 5 ORFs (Fig. 3).", [["ORFs", "DNA", 78, 82], ["Similar topologies", "PROBLEM", 0, 18], ["topologies", "OBSERVATION", 8, 18]]], ["The analysis revealed that among the seven bat CoVs, five belonged to Alphacoronavirus while the other two belonged to Betacoronavirus (Fig. 3).", [["CoVs", "GENE_OR_GENE_PRODUCT", 47, 51], ["The analysis", "TEST", 0, 12], ["the seven bat CoVs", "PROBLEM", 33, 51], ["Alphacoronavirus", "TREATMENT", 70, 86]]], ["Phylogenetic clusterings within Alphacoronavirus varied slightly when different genes were analyzed.", [["Alphacoronavirus", "CANCER", 32, 48], ["Phylogenetic clusterings within Alphacoronavirus", "PROBLEM", 0, 48]]], ["For example, BtKY22 and BtKY43 grouped into one monophyletic clade in ORF1b tree while they were grouped differently in the S and N gene trees with generally insignificant bootstrap values (Fig. 3).", [["BtKY22", "GENE_OR_GENE_PRODUCT", 13, 19], ["BtKY43", "GENE_OR_GENE_PRODUCT", 24, 30], ["ORF1b tree", "MULTI-TISSUE_STRUCTURE", 70, 80], ["BtKY22", "DNA", 13, 19], ["BtKY43", "DNA", 24, 30], ["ORF1b tree", "DNA", 70, 80], ["BtKY22", "TEST", 13, 19], ["monophyletic clade", "OBSERVATION", 48, 66], ["tree", "ANATOMY_MODIFIER", 76, 80]]], ["Although recombination was suspected, we found no evidence of recombination in the seven analyzed viruses using MaxChi (Smith, 1992), Chimaera (Posada et al., 2002), and Geneconv (Padidam et al., 1999).", [["recombination", "PROBLEM", 62, 75], ["no evidence of", "UNCERTAINTY", 47, 61], ["recombination", "OBSERVATION", 62, 75]]], ["Since the analyses were based on representatives from each CoV species, the results suggest a lack of inter-species recombination in these viruses.", [["CoV", "ORGANISM", 59, 62], ["the analyses", "TEST", 6, 18], ["each CoV species", "PROBLEM", 54, 70]]], ["One explanation is that the recombination frequency decreases significantly when the sequence divergence is high (Kleiboeker et al., 2005, van Vugt et al., 2001).", [["the sequence divergence", "TEST", 81, 104]]], ["Alternatively, the lack of inter-specie recombination is due to rare co-infections as the viruses adapted to different bats species.", [["inter-specie recombination", "PROBLEM", 27, 53], ["rare co-infections", "PROBLEM", 64, 82], ["the viruses", "PROBLEM", 86, 97], ["different bats species", "PROBLEM", 109, 131], ["co-infections", "OBSERVATION", 69, 82]]], ["Therefore, the phylogenetic incongruence observed in the gene trees is probably due to low phylogenetic signals, which may be improved by sampling more CoVs that are related to BtKY22 and BtKY43.Phylogeny ::: Results and discussionThe pairwise nt comparisons among these seven bat CoV gene sequences revealed 67\u201376% overall nt identity.", [["CoVs", "GENE_OR_GENE_PRODUCT", 152, 156], ["BtKY22", "GENE_OR_GENE_PRODUCT", 177, 183], ["BtKY43", "GENE_OR_GENE_PRODUCT", 188, 194], ["CoV", "GENE_OR_GENE_PRODUCT", 281, 284], ["CoVs", "PROTEIN", 152, 156], ["BtKY22", "DNA", 177, 183], ["BtKY43", "DNA", 188, 194], ["bat CoV gene sequences", "DNA", 277, 299], ["bat CoV", "SPECIES", 277, 284], ["the phylogenetic incongruence", "PROBLEM", 11, 40], ["low phylogenetic signals", "PROBLEM", 87, 111], ["sampling more CoVs", "PROBLEM", 138, 156], ["these seven bat CoV gene sequences", "TEST", 265, 299], ["phylogenetic incongruence", "OBSERVATION", 15, 40], ["gene trees", "OBSERVATION", 57, 67], ["probably due to", "UNCERTAINTY", 71, 86], ["low", "OBSERVATION_MODIFIER", 87, 90], ["phylogenetic signals", "OBSERVATION", 91, 111], ["may be", "UNCERTAINTY", 119, 125], ["improved", "OBSERVATION_MODIFIER", 126, 134]]], ["Among the five alphacoronaviruses, three (BtKY22, BtKY41 and BtKY43) were distantly related to other known alphacoronaviruses with only 69\u201371% overall nt identity and with <90% aa identity in all five conserved domains (nsps 12\u201316) of ORF1b (Table 2).", [["BtKY22", "GENE_OR_GENE_PRODUCT", 42, 48], ["BtKY41", "GENE_OR_GENE_PRODUCT", 50, 56], ["BtKY43", "GENE_OR_GENE_PRODUCT", 61, 67], ["alphacoronaviruses", "CANCER", 107, 125], ["ORF1b", "GENE_OR_GENE_PRODUCT", 235, 240], ["alphacoronaviruses", "PROTEIN", 15, 33], ["BtKY22", "PROTEIN", 42, 48], ["BtKY41", "PROTEIN", 50, 56], ["BtKY43", "PROTEIN", 61, 67], ["nsps 12\u201316", "PROTEIN", 220, 230], ["ORF1b", "PROTEIN", 235, 240], ["other known alphacoronaviruses", "PROBLEM", 95, 125], ["nsps", "TEST", 220, 224]]], ["The aa distances in the 816 bp fragment of the RdRp gene from the Kenya bat CoVs described in this study were compared to the aa sequences from their close reference viruses (Table S2).Phylogeny ::: Results and discussionBtKY22, BtKY41, and BtKY43 had >4.8% aa distance in the RdRp fragment (Table S2).", [["discussionBtKY22", "GENE_OR_GENE_PRODUCT", 211, 227], ["BtKY41", "GENE_OR_GENE_PRODUCT", 229, 235], ["BtKY43", "GENE_OR_GENE_PRODUCT", 241, 247], ["816 bp fragment", "DNA", 24, 39], ["RdRp gene", "DNA", 47, 56], ["Kenya bat CoVs", "DNA", 66, 80], ["aa sequences", "DNA", 126, 138], ["discussionBtKY22", "PROTEIN", 211, 227], ["RdRp fragment", "DNA", 277, 290], ["Kenya bat", "SPECIES", 66, 75], ["The aa distances", "PROBLEM", 0, 16], ["the Kenya bat CoVs", "PROBLEM", 62, 80], ["this study", "TEST", 94, 104], ["the aa sequences", "TEST", 122, 138], ["discussionBtKY22", "TEST", 211, 227], ["BtKY41", "TEST", 229, 235], ["BtKY43", "TEST", 241, 247], ["the RdRp fragment", "PROBLEM", 273, 290], ["aa", "OBSERVATION_MODIFIER", 4, 6], ["distances", "OBSERVATION_MODIFIER", 7, 16], ["fragment", "OBSERVATION_MODIFIER", 31, 39], ["RdRp gene", "OBSERVATION", 47, 56], ["Kenya", "OBSERVATION", 66, 71], ["bat CoVs", "OBSERVATION", 72, 80], ["RdRp fragment", "OBSERVATION", 277, 290]]], ["This suggests that they are most likely three distinctive alphacoronvirus species.", [["alphacoronvirus species", "CELL", 58, 81], ["three distinctive alphacoronvirus species", "PROBLEM", 40, 81], ["most likely", "UNCERTAINTY", 28, 39], ["distinctive", "OBSERVATION_MODIFIER", 46, 57], ["alphacoronvirus species", "OBSERVATION", 58, 81]]], ["BtKY27 and BtKY33 identified in Miniopterus bats were closely related to Bat-CoV 1A, which was identified from bent-winged Miniopterus bat in Hong Kong (Chu et al., 2006) with 85% and 75% overall nt identity and with >90% aa identity in 5/5 and 4/5 conserved domains (nsps 12\u201316) in ORF1b, respectively (Table 2).", [["BtKY27", "GENE_OR_GENE_PRODUCT", 0, 6], ["BtKY33", "GENE_OR_GENE_PRODUCT", 11, 17], ["Miniopterus bats", "ORGANISM", 32, 48], ["Bat-CoV 1A", "ORGANISM", 73, 83], ["Miniopterus bat", "ORGANISM", 123, 138], ["ORF1b", "GENE_OR_GENE_PRODUCT", 283, 288], ["BtKY27", "DNA", 0, 6], ["BtKY33", "DNA", 11, 17], ["Bat-CoV 1A", "DNA", 73, 83], ["5/5 and 4/5 conserved domains", "DNA", 237, 266], ["nsps 12\u201316", "PROTEIN", 268, 278], ["ORF1b", "PROTEIN", 283, 288], ["Miniopterus bat", "SPECIES", 123, 138], ["Miniopterus bats", "SPECIES", 32, 48], ["Bat-CoV", "SPECIES", 73, 80], ["Miniopterus bat", "SPECIES", 123, 138], ["aa identity", "TEST", 222, 233], ["nsps", "TEST", 268, 272]]], ["BtKY27 and BtKY33 had <4.8% aa distance in the 816 bp RdRp to their close reference viruses indicating that they are members of the established bat CoV species in Alphacoronavirus.Phylogeny ::: Results and discussionAs for the two members of Betacoronavirus genus identified, one (BtKY06 identified in Rousettus aegyptiacus bat) was likely a member of Bat-CoV HKU9 species identified from Rousettus leschenaulti bat in China (Woo et al., 2007), sharing 90% overall nt identity and 99% aa identity in 4/5 conserved domains (nsps12-16) in ORF1b (Table 2).", [["BtKY27", "GENE_OR_GENE_PRODUCT", 0, 6], ["BtKY33", "GENE_OR_GENE_PRODUCT", 11, 17], ["bat CoV species", "ORGANISM", 144, 159], ["Alphacoronavirus", "CANCER", 163, 179], ["Betacoronavirus genus", "ORGANISM", 242, 263], ["Rousettus aegyptiacus bat", "ORGANISM", 302, 327], ["Bat-CoV HKU9", "ORGANISM", 352, 364], ["Rousettus leschenaulti bat", "ORGANISM", 389, 415], ["BtKY27", "PROTEIN", 0, 6], ["816 bp RdRp", "DNA", 47, 58], ["Bat-CoV HKU9 species", "PROTEIN", 352, 372], ["4/5 conserved domains", "PROTEIN", 500, 521], ["nsps12", "PROTEIN", 523, 529], ["ORF1b", "PROTEIN", 537, 542], ["Rousettus aegyptiacus bat", "SPECIES", 302, 327], ["Bat-CoV", "SPECIES", 352, 359], ["Rousettus leschenaulti bat", "SPECIES", 389, 415], ["bat CoV", "SPECIES", 144, 151], ["Rousettus aegyptiacus bat", "SPECIES", 302, 327], ["Bat-CoV", "SPECIES", 352, 359], ["Rousettus leschenaulti bat", "SPECIES", 389, 415], ["BtKY33", "TEST", 11, 17], ["bp RdRp", "TEST", 51, 58], ["the established bat CoV species in Alphacoronavirus", "PROBLEM", 128, 179], ["Betacoronavirus genus", "PROBLEM", 242, 263], ["aa identity", "TEST", 485, 496], ["nsps12", "TEST", 523, 529]]], ["The other (BtKY24) was distantly related to other known betacoronaviruses with \u226470% overall nt identity and <90% aa identity in all 5 conserved domains (nsps 12\u201316) from ORF1b (Table 2).", [["BtKY24", "GENE_OR_GENE_PRODUCT", 11, 17], ["betacoronaviruses", "CANCER", 56, 73], ["ORF1b", "GENE_OR_GENE_PRODUCT", 170, 175], ["nsps 12\u201316", "PROTEIN", 153, 163], ["ORF1b", "PROTEIN", 170, 175], ["other known betacoronaviruses", "PROBLEM", 44, 73], ["overall nt identity", "PROBLEM", 84, 103], ["aa identity", "TEST", 113, 124], ["nsps", "TEST", 153, 157]]], ["Additionally, based on the RGU criteria, BtKY24 had >6.3% aa distance in the 816 bp RdRp fragment compared to its closest reference virus indicating that it is most likely a distinctive betacoronavirus.Phylogeny ::: Results and discussionIn conclusion, sequence data for the structural and non-structural ORFs in the 3\u2032-end of the genome of seven Kenya bat CoVs confirmed the high diversity and their phylogenetical placement into Alphacoronavirus and Betacoronavirus genera.", [["betacoronavirus", "CANCER", 186, 201], ["CoVs", "GENE_OR_GENE_PRODUCT", 357, 361], ["816 bp RdRp fragment", "DNA", 77, 97], ["non-structural ORFs", "DNA", 290, 309], ["3\u2032-end", "DNA", 317, 323], ["Kenya bat", "SPECIES", 347, 356], ["the RGU criteria", "TEST", 23, 39], ["BtKY24", "TEST", 41, 47], ["the 816 bp RdRp fragment", "PROBLEM", 73, 97], ["a distinctive betacoronavirus", "PROBLEM", 172, 201], ["sequence data", "TEST", 253, 266], ["the structural and non-structural ORFs", "PROBLEM", 271, 309], ["the high diversity", "PROBLEM", 372, 390], ["their phylogenetical placement into Alphacoronavirus", "TREATMENT", 395, 447], ["Betacoronavirus genera", "TREATMENT", 452, 474], ["RdRp fragment", "OBSERVATION", 84, 97], ["most likely", "UNCERTAINTY", 160, 171], ["distinctive", "OBSERVATION_MODIFIER", 174, 185], ["betacoronavirus", "OBSERVATION", 186, 201], ["non-structural ORFs", "OBSERVATION", 290, 309], ["high diversity", "OBSERVATION", 376, 390]]], ["The four clusters of Kenya bat CoVs represented by BtKY22, BtKY41, BtKY43, and BtKY24 respectively, most likely belonged to novel CoV species, the two clusters represented by BtKY27 and BtKY33 were likely members of Bat-CoV 1A, and the cluster represented by BtKY06 was likely a member of Bat-CoV HKU9 species.", [["bat", "ORGANISM", 27, 30], ["CoVs", "GENE_OR_GENE_PRODUCT", 31, 35], ["BtKY22", "GENE_OR_GENE_PRODUCT", 51, 57], ["BtKY41", "GENE_OR_GENE_PRODUCT", 59, 65], ["BtKY43", "GENE_OR_GENE_PRODUCT", 67, 73], ["BtKY24", "GENE_OR_GENE_PRODUCT", 79, 85], ["CoV", "ORGANISM", 130, 133], ["BtKY27", "GENE_OR_GENE_PRODUCT", 175, 181], ["BtKY33", "GENE_OR_GENE_PRODUCT", 186, 192], ["Bat-CoV 1A", "GENE_OR_GENE_PRODUCT", 216, 226], ["BtKY06", "GENE_OR_GENE_PRODUCT", 259, 265], ["Bat-CoV HKU9 species", "ORGANISM", 289, 309], ["BtKY22", "PROTEIN", 51, 57], ["BtKY41", "PROTEIN", 59, 65], ["BtKY43", "PROTEIN", 67, 73], ["BtKY24", "PROTEIN", 79, 85], ["BtKY27", "DNA", 175, 181], ["BtKY33", "DNA", 186, 192], ["Bat-CoV 1A", "PROTEIN", 216, 226], ["BtKY06", "DNA", 259, 265], ["Bat-CoV HKU9 species", "PROTEIN", 289, 309], ["Kenya bat CoVs", "SPECIES", 21, 35], ["Bat-CoV", "SPECIES", 216, 223], ["Bat-CoV", "SPECIES", 289, 296], ["Kenya bat CoVs", "TEST", 21, 35], ["novel CoV species", "PROBLEM", 124, 141], ["Bat-CoV 1A", "PROBLEM", 216, 226], ["CoV HKU9 species", "PROBLEM", 293, 309], ["four", "OBSERVATION_MODIFIER", 4, 8], ["clusters", "OBSERVATION_MODIFIER", 9, 17], ["most likely", "UNCERTAINTY", 100, 111], ["CoV species", "OBSERVATION", 130, 141]]], ["As noted with other novel CoVs, the genome organization is similar but differences were found in the number of putative ORFs downstream from the ORF N. The present results are in line with previous findings of extensive diversity of CoVs detected in bats and confirm that bat CoVs mainly belong to the Alphacoronavirus and Betacoronavirus genera (Lau et al., 2005, Lau et al., 2007, Tang et al., 2006, Woo et al., 2007, Woo et al., 2009b).", [["CoVs", "GENE_OR_GENE_PRODUCT", 26, 30], ["CoVs", "GENE_OR_GENE_PRODUCT", 233, 237], ["bat", "ORGANISM", 272, 275], ["CoVs", "GENE_OR_GENE_PRODUCT", 276, 280], ["CoVs", "DNA", 26, 30], ["ORFs", "DNA", 120, 124], ["ORF", "DNA", 145, 148], ["CoVs", "DNA", 233, 237], ["bat CoVs", "PROTEIN", 272, 280], ["other novel CoVs", "PROBLEM", 14, 30], ["CoVs", "PROBLEM", 233, 237], ["bat CoVs", "PROBLEM", 272, 280], ["extensive", "OBSERVATION_MODIFIER", 210, 219], ["diversity", "OBSERVATION", 220, 229], ["CoVs", "OBSERVATION", 233, 237]]], ["Consistent with other reports, none of the bat CoVs characterized in the present study was sufficiently similar to the human SARS-CoV and other human CoVs to be suggested their direct progenitors.", [["progenitors", "ANATOMY", 184, 195], ["SARS", "DISEASE", 125, 129], ["bat", "ORGANISM", 43, 46], ["CoVs", "GENE_OR_GENE_PRODUCT", 47, 51], ["human", "ORGANISM", 119, 124], ["SARS-CoV", "ORGANISM", 125, 133], ["human", "ORGANISM", 144, 149], ["CoVs", "GENE_OR_GENE_PRODUCT", 150, 154], ["progenitors", "CELL", 184, 195], ["bat CoVs", "PROTEIN", 43, 51], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 144, 149], ["human SARS-CoV", "SPECIES", 119, 133], ["human", "SPECIES", 144, 149], ["the bat CoVs", "PROBLEM", 39, 51], ["the present study", "TEST", 69, 86]]], ["The examples of host switching among CoVs after relatively minor sequence changes in S1 domain of spike protein (Haijema et al., 2003, Kuo et al., 2000, Qu et al., 2005) suggest the potential risks for introduction into humans as occurred with SARS-CoV.", [["SARS", "DISEASE", 244, 248], ["CoVs", "GENE_OR_GENE_PRODUCT", 37, 41], ["humans", "ORGANISM", 220, 226], ["SARS-CoV", "ORGANISM", 244, 252], ["CoVs", "PROTEIN", 37, 41], ["S1 domain", "PROTEIN", 85, 94], ["spike protein", "PROTEIN", 98, 111], ["humans", "SPECIES", 220, 226], ["humans", "SPECIES", 220, 226], ["SARS-CoV", "SPECIES", 244, 252], ["relatively minor sequence changes", "PROBLEM", 48, 81], ["spike protein", "PROBLEM", 98, 111], ["introduction into humans", "TREATMENT", 202, 226]]], ["Therefore characterization of novel CoVs and understanding species diversity in animals should help understand and respond to emerging zoonotic infections.", [["zoonotic infections", "DISEASE", 135, 154], ["CoVs", "GENE_OR_GENE_PRODUCT", 36, 40], ["novel CoVs", "PROBLEM", 30, 40], ["emerging zoonotic infections", "PROBLEM", 126, 154]]]], "5105971a345abc7240ae41207d785375a298a50d": [["IntroductionBovine torovirus (BToV), a member of the Coronaviridae family, was first detected in the USA during an outbreak of diarrhea in cattle in 1982 (Woode et al., 1982) .", [["diarrhea", "DISEASE", 127, 135], ["IntroductionBovine torovirus", "ORGANISM", 0, 28], ["BToV", "GENE_OR_GENE_PRODUCT", 30, 34], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 53, 66], ["cattle", "SPECIES", 139, 145], ["BToV", "SPECIES", 30, 34], ["cattle", "SPECIES", 139, 145], ["diarrhea", "PROBLEM", 127, 135]]], ["Since then, epidemiological studies of BToV have shown that it is widespread throughout the world (Duckmanton et al., 1998a; Koopmans et al., 1991; Haschek et al., 2006; Hoet et al., 2002 Hoet et al., , 2003 Liebler et al., 1992 ).", [["BToV", "CANCER", 39, 43], ["epidemiological studies", "TEST", 12, 35], ["widespread", "OBSERVATION_MODIFIER", 66, 76]]], ["An artificial inoculation trial also demonstrated the pathogenesis of BToV in cattle (Pohlenz et al., 1984; Woode et al., 1982) .", [["BToV", "DISEASE", 70, 74], ["cattle", "ORGANISM", 78, 84], ["cattle", "SPECIES", 78, 84], ["BToV", "SPECIES", 70, 74], ["cattle", "SPECIES", 78, 84], ["An artificial inoculation trial", "TREATMENT", 0, 31], ["artificial inoculation", "OBSERVATION", 3, 25]]], ["These data strongly suggest that BToV has relevance to diarrhea in cattle.", [["BToV", "CHEMICAL", 33, 37], ["diarrhea", "DISEASE", 55, 63], ["BToV", "GENE_OR_GENE_PRODUCT", 33, 37], ["cattle", "ORGANISM", 67, 73], ["cattle", "SPECIES", 67, 73], ["cattle", "SPECIES", 67, 73], ["diarrhea", "PROBLEM", 55, 63]]], ["However, no epidemiological research has been reported from Japan.", [["no", "UNCERTAINTY", 9, 11]]], ["To detect BToV, electron microscopy (EM), enzyme-linked immunosorbent assay (ELISA), and polymerase chain reaction (PCR) are performed because this virus cannot be grown in cell culture (Koopmans et al., 1991; Liebler et al., 1992; Scott et al., 1996) .", [["cell", "ANATOMY", 173, 177], ["cell culture", "CELL", 173, 185], ["BToV", "PROTEIN", 10, 14], ["electron microscopy", "TEST", 16, 35], ["enzyme", "TEST", 42, 48], ["immunosorbent assay", "TEST", 56, 75], ["ELISA", "TEST", 77, 82], ["polymerase chain reaction", "PROBLEM", 89, 114], ["PCR", "TEST", 116, 119], ["this virus", "PROBLEM", 143, 153], ["cell culture", "TEST", 173, 185]]], ["PCR is more sensitive than ELISA, and its detectability is nearly identical to EM (Duckmanton et al., 1998a; Hoet et al., 2002) .", [["PCR", "TEST", 0, 3], ["ELISA", "TEST", 27, 32], ["more sensitive", "OBSERVATION_MODIFIER", 7, 21]]], ["Consequently, the accumulation of a genetic database has progressed by analyzing gene products from different BToV isolates (Duckmanton et al., 1998b; Smits et al., 2003) .", [["a genetic database", "PROBLEM", 34, 52]]], ["The BToV genome consists of RNA polymerase, spike (S), membrane (M), hemagglutinin-estrase (HE), and nucleocapsid (N) genes (Draker et al., 2006) .", [["spike (S)", "GENE_OR_GENE_PRODUCT", 44, 53], ["membrane", "CELLULAR_COMPONENT", 55, 63], ["hemagglutinin-estrase", "GENE_OR_GENE_PRODUCT", 69, 90], ["HE", "GENE_OR_GENE_PRODUCT", 92, 94], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 101, 117], ["BToV genome", "DNA", 4, 15], ["RNA polymerase", "PROTEIN", 28, 42], ["spike (S)", "PROTEIN", 44, 53], ["hemagglutinin", "PROTEIN", 69, 82], ["estrase", "PROTEIN", 83, 90], ["HE", "PROTEIN", 92, 94], ["nucleocapsid (N) genes", "DNA", 101, 123], ["RNA polymerase", "TEST", 28, 42], ["spike (S), membrane (M", "PROBLEM", 44, 66], ["hemagglutinin", "TEST", 69, 82], ["RNA polymerase", "OBSERVATION", 28, 42]]], ["In particular, the N and M coding regions show high homology among the published BToV isolates, but can distinguish them from coronavirus and other toroviruses (equine isolate Berne virus, porcine torovirus, human torovirus; Koopmans and Horzinek, 1994) .", [["coronavirus", "DISEASE", 126, 137], ["BToV", "GENE_OR_GENE_PRODUCT", 81, 85], ["coronavirus", "ORGANISM", 126, 137], ["equine isolate", "ORGANISM", 161, 175], ["Berne virus", "ORGANISM", 176, 187], ["porcine torovirus", "ORGANISM", 189, 206], ["human", "ORGANISM", 208, 213], ["N and M coding regions", "DNA", 19, 41], ["coronavirus", "SPECIES", 126, 137], ["equine", "SPECIES", 161, 167], ["Berne virus", "SPECIES", 176, 187], ["porcine", "SPECIES", 189, 196], ["human", "SPECIES", 208, 213], ["Berne virus", "SPECIES", 176, 187], ["human", "SPECIES", 208, 213], ["coronavirus", "PROBLEM", 126, 137], ["other toroviruses", "PROBLEM", 142, 159], ["equine isolate Berne virus", "PROBLEM", 161, 187], ["porcine torovirus", "TREATMENT", 189, 206]]], ["Therefore, detecting BToV N and M genes is thought be the most sensitive and specific method for detecting BToV in fecal samples.", [["fecal samples", "ANATOMY", 115, 128], ["BToV N", "GENE_OR_GENE_PRODUCT", 21, 27], ["BToV", "SIMPLE_CHEMICAL", 107, 111], ["fecal samples", "ORGANISM_SUBSTANCE", 115, 128], ["BToV N and M genes", "DNA", 21, 39], ["BToV", "PROTEIN", 107, 111], ["BToV", "SPECIES", 107, 111], ["BToV N and M genes", "PROBLEM", 21, 39], ["fecal", "ANATOMY", 115, 120]]], ["The S gene is known to affect antigenicity in other coronaviruses (Gallagher and Buchmeier, 2001) .", [["coronaviruses", "ORGANISM", 52, 65], ["S gene", "DNA", 4, 10]]], ["Therefore, analysis of the S gene in BToV positive samples is important in determining its antigenicity.IntroductionIn this study, we analyzed 231 fecal samples from Japanese cattle for BToV.", [["samples", "ANATOMY", 51, 58], ["fecal samples", "ANATOMY", 147, 160], ["fecal samples", "ORGANISM_SUBSTANCE", 147, 160], ["cattle", "ORGANISM", 175, 181], ["S gene", "DNA", 27, 33], ["cattle", "SPECIES", 175, 181], ["cattle", "SPECIES", 175, 181], ["BToV", "SPECIES", 186, 190], ["analysis", "TEST", 11, 19], ["the S gene in BToV positive samples", "TEST", 23, 58], ["this study", "TEST", 119, 129], ["fecal samples", "TEST", 147, 160]]], ["We used nested reverse transcription (RT) PCR with primers designed for BToV-specific N, M, and S genes.", [["BToV-specific N, M, and S genes", "DNA", 72, 103], ["nested reverse transcription (RT) PCR", "TREATMENT", 8, 45], ["BToV", "TEST", 72, 76]]], ["We also compared the nucleotide sequences to investigate genetic diversity among the samples.SpecimensA total of 231 individual fecal samples (167 from diarrheic cattle and 64 control samples from asymptomatic cattle) were collected from 32 farms in 12 prefectures in Japan ( Fig. 1) between April 2004 and March 2005.", [["samples", "ANATOMY", 85, 92], ["fecal samples", "ANATOMY", 128, 141], ["samples", "ANATOMY", 184, 191], ["nucleotide", "CHEMICAL", 21, 31], ["fecal samples", "CANCER", 128, 141], ["cattle", "ORGANISM", 210, 216], ["nucleotide sequences", "DNA", 21, 41], ["cattle", "SPECIES", 162, 168], ["cattle", "SPECIES", 210, 216], ["cattle", "SPECIES", 162, 168], ["cattle", "SPECIES", 210, 216], ["the nucleotide sequences", "TEST", 17, 41], ["the samples", "TEST", 81, 92], ["SpecimensA", "TEST", 93, 103], ["individual fecal samples", "TEST", 117, 141], ["diarrheic cattle", "TEST", 152, 168], ["asymptomatic cattle", "TREATMENT", 197, 216]]], ["All 231 fecal samples were used for BToV, bovine coronavirus (BCV), and rotavirus detection.", [["fecal samples", "ANATOMY", 8, 21], ["fecal samples", "CANCER", 8, 21], ["bovine", "ORGANISM", 42, 48], ["coronavirus", "ORGANISM", 49, 60], ["BCV", "ORGANISM", 62, 65], ["rotavirus", "ORGANISM", 72, 81], ["bovine", "SPECIES", 42, 48], ["BToV", "SPECIES", 36, 40], ["bovine coronavirus", "SPECIES", 42, 60], ["BCV", "SPECIES", 62, 65], ["rotavirus", "SPECIES", 72, 81], ["fecal samples", "TEST", 8, 21], ["BToV", "TEST", 36, 40], ["bovine coronavirus", "PROBLEM", 42, 60], ["rotavirus detection", "PROBLEM", 72, 91]]], ["The majority of cattle were between 1 week and 6 years old at the time of sample collection.RNA extractionThe fecal samples were diluted in 10\u00d7 volume of phosphatebuffered saline (PBS, pH 7.5) and centrifuged at 1000 \u00d7 g for 1 min at room temperature.", [["sample", "ANATOMY", 74, 80], ["fecal samples", "ANATOMY", 110, 123], ["cattle", "ORGANISM", 16, 22], ["fecal samples", "ORGANISM_SUBSTANCE", 110, 123], ["saline", "SIMPLE_CHEMICAL", 172, 178], ["cattle", "SPECIES", 16, 22], ["cattle", "SPECIES", 16, 22], ["sample collection", "PROBLEM", 74, 91], ["RNA extraction", "TREATMENT", 92, 106], ["The fecal samples", "TEST", 106, 123], ["phosphatebuffered saline (PBS", "TREATMENT", 154, 183], ["pH", "TEST", 185, 187], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["collection", "OBSERVATION", 81, 91], ["fecal", "ANATOMY", 110, 115]]], ["The supernatant was transferred to a new tube and centrifuged again at 8000 \u00d7 g for 5 min at room temperature.", [["supernatant", "ANATOMY", 4, 15], ["tube", "ANATOMY", 41, 45], ["tube", "TISSUE", 41, 45], ["a new tube", "TREATMENT", 35, 45], ["tube", "OBSERVATION", 41, 45]]], ["RNA was extracted from the supernatant using an RNeasy Kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer's instructions.", [["supernatant", "ANATOMY", 27, 38], ["RNA", "RNA", 0, 3]]], ["For each extraction period, ddH 2 O was used as a negative control.Detection of BoTV and BCVWe used nested RT-PCR for BToV and RT-PCR for BCV detection.", [["ddH 2 O", "CHEMICAL", 28, 35], ["ddH 2 O", "CHEMICAL", 28, 35], ["ddH 2 O", "SIMPLE_CHEMICAL", 28, 35], ["BCV", "ORGANISM", 138, 141], ["BoTV", "DNA", 80, 84], ["BCVWe", "DNA", 89, 94], ["BoTV", "SPECIES", 80, 84], ["BToV", "SPECIES", 118, 122], ["BCV", "SPECIES", 138, 141], ["ddH", "PROBLEM", 28, 31], ["BToV", "TEST", 118, 122], ["RT-PCR", "TEST", 127, 133], ["BCV detection", "TEST", 138, 151]]], ["Primers targeting BToV N, M, and S genes were designed based on reported BToV sequences (Duckmanton et al., 1998b; Smits et al., 2003) .", [["BToV N", "GENE_OR_GENE_PRODUCT", 18, 24], ["BToV N, M, and S genes", "DNA", 18, 40], ["BToV sequences", "DNA", 73, 87]]], ["The primers, reference sequences, and the expected sizes of the fragments obtained in the first and nested round of amplification are shown in Table 1 primers targeting the BCV N gene were as follows: forward: 5 -TGC CAG GAT GAT GGC GCG TG-3 and reverse: 5 -AGA AGC ACA TCA GGG GAT TC-3 .", [["BCV N", "GENE_OR_GENE_PRODUCT", 173, 178], ["BCV N gene", "DNA", 173, 183], ["TGC CAG GAT GAT GGC GCG TG-3 and reverse: 5 -AGA AGC ACA TCA GGG GAT TC-3", "DNA", 213, 286], ["reference sequences", "TEST", 13, 32], ["the fragments", "PROBLEM", 60, 73], ["GGC", "TEST", 229, 232], ["GCG", "TEST", 233, 236], ["TG", "TEST", 237, 239], ["GGG GAT TC", "TEST", 274, 284], ["sizes", "OBSERVATION_MODIFIER", 51, 56], ["fragments", "OBSERVATION", 64, 73]]], ["Superscript II (Invitrogen Corp., Carlsbad, CA, USA) was used for reverse transcription using the reverse primer of each first round PCR primer.", [["Superscript II", "PROTEIN", 0, 14], ["reverse primer", "DNA", 98, 112], ["PCR primer", "DNA", 133, 143], ["reverse transcription", "TREATMENT", 66, 87], ["the reverse primer", "TREATMENT", 94, 112]]], ["PCR was performed using TaKaRa Taq (TaKaRa, Tokyo, Japan).", [["TaKaRa Taq", "PROTEIN", 24, 34], ["PCR", "TEST", 0, 3], ["TaKaRa Taq", "TREATMENT", 24, 34]]], ["The mixture of reaction reagents was treated according to the manufacturer's instructions.", [["reaction reagents", "TREATMENT", 15, 32]]], ["The conditions of PCR were as follows: 30 cycles of denaturing at 94 \u2022 C for 1 min, annealing at 53 \u2022 C for 1 min, and extension at 72 \u2022 C for 1 min, followed by a final cycle of extension at 72 \u2022 C for 5 min.", [["PCR", "TEST", 18, 21], ["denaturing", "TEST", 52, 62], ["extension", "TEST", 119, 128]]], ["For each reaction, ddH 2 O was used as a negative control.", [["ddH 2 O", "CHEMICAL", 19, 26], ["ddH 2 O", "CHEMICAL", 19, 26], ["ddH 2 O", "SIMPLE_CHEMICAL", 19, 26], ["each reaction", "PROBLEM", 4, 17], ["ddH", "PROBLEM", 19, 22]]], ["PCR products were detected by electrophoresis on a 2.0% agarose gel.Detection of rotavirusWe followed the methods of Okada and Matsumoto (2002) for detection of rotavirus using the fecal supernatant, as in the samples for RNA extraction.Genetic analysis of BToV PCR productsThe nested RT-PCR products corresponding to the BToV N, M, and S open reading frames (ORFs) were directly sequenced by Dragon GenomicsCtr (TaKaRa Bio Inc., Mie, Japan) with the ABI Prism BigDye Terminator version 3.1 cycle sequencing kit and an Applied Biosystems 3730 \u00d7 l DNA analyzer (Applied Biosystems Inc., CA, USA).", [["fecal supernatant", "ANATOMY", 181, 198], ["samples", "ANATOMY", 210, 217], ["agarose", "SIMPLE_CHEMICAL", 56, 63], ["rotavirus", "ORGANISM", 161, 170], ["DNA", "CELLULAR_COMPONENT", 547, 550], ["BToV PCR products", "PROTEIN", 257, 274], ["nested RT-PCR products", "DNA", 278, 300], ["BToV N, M, and S open reading frames", "DNA", 322, 358], ["ORFs", "DNA", 360, 364], ["rotavirus", "SPECIES", 161, 170], ["PCR products", "TREATMENT", 0, 12], ["a 2.0% agarose gel", "TREATMENT", 49, 67], ["rotavirusWe", "TREATMENT", 81, 92], ["rotavirus", "PROBLEM", 161, 170], ["the fecal supernatant", "PROBLEM", 177, 198], ["RNA extraction", "TREATMENT", 222, 236], ["Genetic analysis", "TEST", 237, 253], ["BToV PCR products", "TREATMENT", 257, 274], ["The nested RT-PCR products", "TREATMENT", 274, 300], ["the ABI Prism BigDye Terminator version", "TREATMENT", 447, 486], ["sequencing kit", "TEST", 497, 511], ["an Applied Biosystems", "TREATMENT", 516, 537], ["l DNA analyzer", "TREATMENT", 545, 559], ["fecal", "ANATOMY", 181, 186]]], ["For the analysis of sequence relationships, BRV-1, BRV-2, and B145 BToV isolates, which have been detected in cattle from other countries, were used as reference.", [["BRV-1", "GENE_OR_GENE_PRODUCT", 44, 49], ["BRV-2", "CELL", 51, 56], ["B145 BToV isolates", "ORGANISM", 62, 80], ["cattle", "SPECIES", 110, 116], ["BRV-1", "SPECIES", 44, 49], ["cattle", "SPECIES", 110, 116], ["the analysis", "TEST", 4, 16], ["sequence relationships", "TEST", 20, 42], ["BRV", "TEST", 44, 47], ["BRV", "TEST", 51, 54], ["B145 BToV isolates", "TEST", 62, 80]]], ["The accession numbers (National Center for Biotechnology Information) of the reference sequences are given in Tables 3-5 .", [["the reference sequences", "TEST", 73, 96]]], ["RT-PCR products were purified using a DNA purification kit (QIAGEN) and digested by several restriction enzymes (TOYOBO, Tokyo, Japan) according to the manufacturer's instructions.", [["DNA", "CELLULAR_COMPONENT", 38, 41], ["restriction enzymes", "PROTEIN", 92, 111], ["TOYOBO", "PROTEIN", 113, 119], ["RT-PCR products", "TREATMENT", 0, 15], ["a DNA purification kit", "TREATMENT", 36, 58]]], ["The size of the DNA fragments was estimated using a 1-kb plus DNA ladder (Invitrogen).Phylogenetic analysis of the BToV S genePhylogenetic analysis of the deduced amino acid sequence of the BToV S gene was preformed using the neighbor-joining method (Saitou and Nei, 1987) .Condition of BToV-positive samplesBToV gene products corresponding to the N, M, and S ORFs were detected in 2.1% (5/231), 3.5% (8/231), and 0% (0/231) of the samples, respectively, by first round PCR and were detected in 6.5% (15/231), 6.1% (14/231), and 5.6% (13/231) of samples by subsequent nested PCR (Table 2) .", [["fragments", "ANATOMY", 20, 29], ["samples", "ANATOMY", 432, 439], ["samples", "ANATOMY", 546, 553], ["amino acid", "CHEMICAL", 163, 173], ["amino acid", "CHEMICAL", 163, 173], ["DNA", "CELLULAR_COMPONENT", 16, 19], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["amino acid", "AMINO_ACID", 163, 173], ["BToV S", "GENE_OR_GENE_PRODUCT", 190, 196], ["BToV", "GENE_OR_GENE_PRODUCT", 287, 291], ["samplesBToV", "GENE_OR_GENE_PRODUCT", 301, 312], ["samples", "CANCER", 546, 553], ["DNA fragments", "DNA", 16, 29], ["1-kb plus DNA ladder", "DNA", 52, 72], ["BToV S gene", "DNA", 190, 201], ["BToV-positive samplesBToV gene products", "DNA", 287, 326], ["N, M, and S ORFs", "DNA", 348, 364], ["the DNA fragments", "PROBLEM", 12, 29], ["a 1-kb plus DNA ladder", "TREATMENT", 50, 72], ["Phylogenetic analysis", "TEST", 86, 107], ["the BToV S genePhylogenetic analysis", "TEST", 111, 147], ["the deduced amino acid sequence", "TEST", 151, 182], ["BToV", "TEST", 287, 291], ["positive samplesBToV gene products", "PROBLEM", 292, 326], ["samples", "TEST", 546, 553], ["subsequent nested PCR", "TEST", 557, 578], ["size", "OBSERVATION_MODIFIER", 4, 8], ["DNA fragments", "OBSERVATION", 16, 29]]], ["Among the 15 samples that were positive for the BToV N gene, 14 were derived from diarrheic samples (8.4%) and 1 was derived from an asymptomatic sample (1.6%).", [["samples", "ANATOMY", 13, 20], ["samples", "ANATOMY", 92, 99], ["sample", "ANATOMY", 146, 152], ["samples", "CANCER", 13, 20], ["BToV N", "GENE_OR_GENE_PRODUCT", 48, 54], ["diarrheic samples", "CANCER", 82, 99], ["BToV N gene", "DNA", 48, 59], ["the 15 samples", "TEST", 6, 20], ["diarrheic samples", "TEST", 82, 99], ["an asymptomatic sample", "TEST", 130, 152]]], ["The positive samples were collected in 4 of 12 prefectures in Japan (Fig. 1 ).", [["samples", "ANATOMY", 13, 20], ["The positive samples", "TEST", 0, 20], ["positive", "OBSERVATION_MODIFIER", 4, 12]]], ["Of these 14 positive diarrheic samples, 7 were also positive for BCV, but all were negative for rotavirus (Table 2) .", [["samples", "ANATOMY", 31, 38], ["rotavirus", "DISEASE", 96, 105], ["diarrheic samples", "CANCER", 21, 38], ["BCV", "ORGANISM", 65, 68], ["BCV", "SPECIES", 65, 68], ["rotavirus", "SPECIES", 96, 105], ["these 14 positive diarrheic samples", "PROBLEM", 3, 38], ["BCV", "PROBLEM", 65, 68], ["rotavirus", "PROBLEM", 96, 105]]], ["BCV was detected in 47 samples (20.3%) and rotavirus was detected in 15 samples (6.5%).", [["samples", "ANATOMY", 23, 30], ["samples", "ANATOMY", 72, 79], ["BCV", "ORGANISM", 0, 3], ["samples", "CANCER", 23, 30], ["rotavirus", "ORGANISM", 43, 52], ["BCV", "SPECIES", 0, 3], ["rotavirus", "SPECIES", 43, 52], ["BCV", "TEST", 0, 3], ["rotavirus", "PROBLEM", 43, 52]]], ["These tests were performed two or three times to confirm the initial results.Genetic diversity of PCR productsThe nucleotide sequences of N and M selected gene fragments showed more than 97% identity among the BToV isolates, except for the N genes of BRV-1 and BRV-2 (Tables 3 and 4 ).", [["nucleotide", "CHEMICAL", 114, 124], ["BRV-1", "GENE_OR_GENE_PRODUCT", 251, 256], ["BRV-2", "CELL", 261, 266], ["PCR products", "PROTEIN", 98, 110], ["N and M selected gene fragments", "DNA", 138, 169], ["N genes", "DNA", 240, 247], ["BRV", "DNA", 251, 254], ["BRV", "DNA", 261, 264], ["BRV-1", "SPECIES", 251, 256], ["These tests", "TEST", 0, 11], ["PCR products", "TREATMENT", 98, 110], ["The nucleotide sequences", "TEST", 110, 134], ["the BToV isolates", "TEST", 206, 223], ["BRV", "TEST", 251, 254], ["BRV", "TEST", 261, 264], ["PCR products", "OBSERVATION", 98, 110]]], ["Group I includes samples K-567, K-683, and K-684; Group II includes K-629 and K-637 through K645; and Group III includes K-674 and K-676.", [["samples", "ANATOMY", 17, 24], ["K-567", "CHEMICAL", 25, 30], ["K-683", "CHEMICAL", 32, 37], ["K-684", "CHEMICAL", 43, 48], ["K-629", "CHEMICAL", 68, 73], ["K-637", "CHEMICAL", 78, 83], ["K-674", "CHEMICAL", 121, 126], ["K-676", "CHEMICAL", 131, 136], ["K-567", "CHEMICAL", 25, 30], ["K-683", "CHEMICAL", 32, 37], ["K-684", "CHEMICAL", 43, 48], ["K-629", "CHEMICAL", 68, 73], ["K-637", "CHEMICAL", 78, 83], ["K-674", "CHEMICAL", 121, 126], ["K-676", "CHEMICAL", 131, 136], ["K-567", "SIMPLE_CHEMICAL", 25, 30], ["K-683", "SIMPLE_CHEMICAL", 32, 37], ["K-684", "SIMPLE_CHEMICAL", 43, 48], ["K-629", "SIMPLE_CHEMICAL", 68, 73], ["K-637", "SIMPLE_CHEMICAL", 78, 83], ["K645", "SIMPLE_CHEMICAL", 92, 96], ["K-674", "SIMPLE_CHEMICAL", 121, 126], ["K-676", "SIMPLE_CHEMICAL", 131, 136], ["K-684", "SPECIES", 43, 48], ["samples K", "TEST", 17, 26], ["K", "TEST", 32, 33], ["K", "TEST", 43, 44], ["Group II", "TEST", 50, 58], ["K", "TEST", 68, 69], ["K", "TEST", 78, 79], ["K645", "TEST", 92, 96], ["Group III", "TEST", 102, 111], ["K", "TEST", 121, 122], ["K", "TEST", 131, 132]]], ["The reference BToVs used for sequence comparison and accession numbers are as follows: B145 (AJ575388), BRV-1 (AY427798), and BRV-2 (AF076621).", [["BRV-1", "GENE_OR_GENE_PRODUCT", 104, 109], ["BRV-2", "GENE_OR_GENE_PRODUCT", 126, 131], ["BToVs", "DNA", 14, 19], ["BRV-1", "SPECIES", 104, 109], ["sequence comparison", "TEST", 29, 48], ["accession numbers", "TEST", 53, 70], ["BRV", "TEST", 104, 107], ["BRV", "TEST", 126, 129]]], ["Amino acid identity (%)Genetic diversity of PCR productsGroup I includes samples K-637 through K644; Group II includes K-683 and K-684.", [["samples", "ANATOMY", 73, 80], ["Amino acid", "CHEMICAL", 0, 10], ["K-637", "CHEMICAL", 81, 86], ["K-683", "CHEMICAL", 119, 124], ["K-684", "CHEMICAL", 129, 134], ["Amino acid", "CHEMICAL", 0, 10], ["K-683", "CHEMICAL", 119, 124], ["K-684", "CHEMICAL", 129, 134], ["Amino acid", "AMINO_ACID", 0, 10], ["K-637", "SIMPLE_CHEMICAL", 81, 86], ["K-683", "SIMPLE_CHEMICAL", 119, 124], ["K-684", "SIMPLE_CHEMICAL", 129, 134], ["PCR products", "PROTEIN", 44, 56], ["Amino acid identity", "TEST", 0, 19], ["PCR products", "TREATMENT", 44, 56], ["samples K", "TEST", 73, 82], ["Group II", "TEST", 101, 109], ["K", "TEST", 119, 120], ["K", "TEST", 129, 130]]], ["The reference BToVs used for sequence comparison and accession numbers are as follows: B145 (AJ575375), BRV-1 (AY427798), and BRV-2 (AF076621).Genetic diversity of PCR productsThe nucleotide sequences of the BToV S gene fragment showed lower identity than those of N and M, even among the domestic samples (Table 5) We performed further analysis of the BToV S gene to characterize these samples.", [["samples", "ANATOMY", 387, 394], ["nucleotide", "CHEMICAL", 180, 190], ["nucleotide", "CHEMICAL", 180, 190], ["BRV-1", "GENE_OR_GENE_PRODUCT", 104, 109], ["BRV-2", "GENE_OR_GENE_PRODUCT", 126, 131], ["BToV S", "GENE_OR_GENE_PRODUCT", 208, 214], ["BToV S", "GENE_OR_GENE_PRODUCT", 353, 359], ["BToVs", "DNA", 14, 19], ["PCR products", "PROTEIN", 164, 176], ["BToV S gene fragment", "DNA", 208, 228], ["BToV S gene", "DNA", 353, 364], ["BRV-1", "SPECIES", 104, 109], ["sequence comparison", "TEST", 29, 48], ["accession numbers", "TEST", 53, 70], ["BRV", "TEST", 104, 107], ["BRV", "TEST", 126, 129], ["PCR products", "TREATMENT", 164, 176], ["The nucleotide sequences", "TEST", 176, 200], ["further analysis", "TEST", 329, 345], ["these samples", "TEST", 381, 394], ["PCR products", "OBSERVATION", 164, 176], ["lower", "OBSERVATION_MODIFIER", 236, 241]]], ["We generated a phylogenetic tree with the deduced amino acid sequences of the BToV S gene fragments, Amino acid identity (%)Genetic diversity of PCR productsGroup I includes samples K-637, K-638, K-640 through K642, K-644, and K-645, which possess identical sequences.", [["samples", "ANATOMY", 174, 181], ["amino acid", "CHEMICAL", 50, 60], ["Amino acid", "CHEMICAL", 101, 111], ["K-637", "CHEMICAL", 182, 187], ["K-638", "CHEMICAL", 189, 194], ["K-640", "CHEMICAL", 196, 201], ["K-644", "CHEMICAL", 216, 221], ["K-645", "CHEMICAL", 227, 232], ["amino acid", "CHEMICAL", 50, 60], ["Amino acid", "CHEMICAL", 101, 111], ["K-645", "CHEMICAL", 227, 232], ["amino acid", "AMINO_ACID", 50, 60], ["BToV S", "GENE_OR_GENE_PRODUCT", 78, 84], ["Amino acid", "SIMPLE_CHEMICAL", 101, 111], ["K-638", "SIMPLE_CHEMICAL", 189, 194], ["K-640", "GENE_OR_GENE_PRODUCT", 196, 201], ["K-644", "GENE_OR_GENE_PRODUCT", 216, 221], ["K-645", "GENE_OR_GENE_PRODUCT", 227, 232], ["BToV S gene fragments", "DNA", 78, 99], ["PCR products", "PROTEIN", 145, 157], ["the deduced amino acid sequences", "TEST", 38, 70], ["the BToV S gene fragments", "TREATMENT", 74, 99], ["Amino acid identity", "TEST", 101, 120], ["PCR products", "TREATMENT", 145, 157], ["samples K", "TEST", 174, 183], ["K", "TEST", 189, 190], ["K", "TEST", 196, 197], ["K642", "TEST", 210, 214], ["K", "TEST", 216, 217], ["K", "TEST", 227, 228]]], ["The reference BToVs used for sequence comparison and accession numbers are as follows: B145 (AJ575373), BRV-1 (AY427798), and BRV-2 (AF076621).", [["BRV-1", "GENE_OR_GENE_PRODUCT", 104, 109], ["BRV-2", "GENE_OR_GENE_PRODUCT", 126, 131], ["BToVs", "DNA", 14, 19], ["BRV-1", "SPECIES", 104, 109], ["sequence comparison", "TEST", 29, 48], ["accession numbers", "TEST", 53, 70], ["BRV", "TEST", 104, 107], ["BRV", "TEST", 126, 129]]], ["Neighbor-joining phylogenetic tree showing the relationships among the deduced S amino acid sequences of BToV from Japan and from the reference strains described in Table 5 .", [["amino acid", "CHEMICAL", 81, 91], ["amino acid", "CHEMICAL", 81, 91], ["amino acid", "AMINO_ACID", 81, 91], ["S amino acid sequences", "PROTEIN", 79, 101], ["the deduced S amino acid sequences", "PROBLEM", 67, 101]]], ["The numbers represent the distance to the nearest node.Genetic diversity of PCR productsincluding previously reported BToV sequences, to investigate the phylogenetic relationship among these viruses.", [["node", "ANATOMY", 50, 54], ["node", "MULTI-TISSUE_STRUCTURE", 50, 54], ["BToV sequences", "DNA", 118, 132], ["PCR", "TEST", 76, 79], ["BToV sequences", "TEST", 118, 132], ["node", "OBSERVATION", 50, 54], ["viruses", "OBSERVATION", 191, 198]]], ["The BToV S gene found in Japanese isolates was divided into three clusters (Fig. 2) : Cluster 1 (samples K-567, K-637 through K-642, K-644, and K-645), Cluster 2 (samples K-674 and K-676), and Cluster 3 (samples K-683 and K-684).RFLP analysis of BToV-positive samplesWe established a method to rapidly confirm the phylogenetic cluster to which a sample belonged.", [["samples", "ANATOMY", 260, 267], ["K-684", "CHEMICAL", 222, 227], ["BToV S", "GENE_OR_GENE_PRODUCT", 4, 10], ["K-644", "GENE_OR_GENE_PRODUCT", 133, 138], ["K-645", "GENE_OR_GENE_PRODUCT", 144, 149], ["BToV", "GENE_OR_GENE_PRODUCT", 246, 250], ["BToV S gene", "DNA", 4, 15], ["RFLP", "DNA", 229, 233], ["The BToV S gene", "TEST", 0, 15], ["Japanese isolates", "PROBLEM", 25, 42], ["K", "TEST", 105, 106], ["K", "TEST", 112, 113], ["K", "TEST", 126, 127], ["K", "TEST", 133, 134], ["K", "TEST", 144, 145], ["Cluster", "TEST", 152, 159], ["K", "TEST", 171, 172], ["K", "TEST", 181, 182], ["Cluster", "TEST", 193, 200], ["samples K", "TEST", 204, 213], ["K", "TEST", 222, 223], ["RFLP analysis", "TEST", 229, 242], ["BToV", "TEST", 246, 250], ["positive samples", "PROBLEM", 251, 267], ["a method", "TREATMENT", 282, 290]]], ["Based on the nucleotide sequences, we screened restriction enzymes and performed RFLP analysis of the BToV S fragment.", [["nucleotide", "CHEMICAL", 13, 23], ["nucleotide sequences", "DNA", 13, 33], ["restriction enzymes", "PROTEIN", 47, 66], ["RFLP", "DNA", 81, 85], ["BToV S fragment", "DNA", 102, 117], ["the nucleotide sequences", "TEST", 9, 33], ["restriction enzymes", "TEST", 47, 66], ["RFLP analysis", "TEST", 81, 94], ["the BToV S fragment", "PROBLEM", 98, 117], ["fragment", "OBSERVATION_MODIFIER", 109, 117]]], ["The three clusters could be differentiated using HaeIII or AccI.", [["HaeIII", "GENE_OR_GENE_PRODUCT", 49, 55], ["AccI", "GENE_OR_GENE_PRODUCT", 59, 63], ["HaeIII", "DNA", 49, 55], ["AccI", "PROTEIN", 59, 63], ["AccI", "TREATMENT", 59, 63]]], ["Within cluster-1, K-567 could be differentiated from K-637 through K-642, K-644, and K-645 by detection of a distinctive 142-bp fragment using AccI (Fig. 3) .DiscussionWe performed an epidemiological analysis of BToV in Japan by looking for BToV-specific genes in 231 fecal samples collected in 2004 and 2005.", [["fecal samples", "ANATOMY", 268, 281], ["K-567", "CHEMICAL", 18, 23], ["K-637", "CHEMICAL", 53, 58], ["K-642", "CHEMICAL", 67, 72], ["K-644", "CHEMICAL", 74, 79], ["K-645", "CHEMICAL", 85, 90], ["K-644", "CHEMICAL", 74, 79], ["K-645", "CHEMICAL", 85, 90], ["K-567", "SIMPLE_CHEMICAL", 18, 23], ["K-637", "GENE_OR_GENE_PRODUCT", 53, 58], ["K-642", "GENE_OR_GENE_PRODUCT", 67, 72], ["K-644", "GENE_OR_GENE_PRODUCT", 74, 79], ["K-645", "GENE_OR_GENE_PRODUCT", 85, 90], ["BToV", "GENE_OR_GENE_PRODUCT", 241, 245], ["fecal samples", "CANCER", 268, 281], ["142-bp fragment", "DNA", 121, 136], ["AccI", "PROTEIN", 143, 147], ["BToV-specific genes", "DNA", 241, 260], ["K", "TEST", 18, 19], ["K", "TEST", 53, 54], ["K", "TEST", 67, 68], ["K", "TEST", 74, 75], ["K", "TEST", 85, 86], ["a distinctive 142-bp fragment", "PROBLEM", 107, 136], ["AccI", "TEST", 143, 147], ["an epidemiological analysis", "TEST", 181, 208], ["BToV", "TEST", 241, 245], ["fecal samples", "TEST", 268, 281]]], ["We performed nested RT-PCR to improve the detectability of BToV by using primers located in the consensus sequence of the reported BToVs.", [["BToV", "CANCER", 59, 63], ["BToVs", "GENE_OR_GENE_PRODUCT", 131, 136], ["BToV", "DNA", 59, 63], ["consensus sequence", "DNA", 96, 114], ["BToVs", "DNA", 131, 136], ["BToV", "SPECIES", 59, 63], ["nested RT-PCR", "TREATMENT", 13, 26], ["primers", "TREATMENT", 73, 80]]], ["Consequently, we obtained 15 BToV-positive samples.", [["samples", "ANATOMY", 43, 50], ["BToV", "GENE_OR_GENE_PRODUCT", 29, 33], ["BToV", "PROTEIN", 29, 33]]], ["Improvements in the detectability of BToV N, M, and S PCR products were observed in all samples by nested PCR as compared to first round PCR, suggesting the usefulness of this method in detecting BToV.", [["samples", "ANATOMY", 88, 95], ["BToV", "SPECIES", 196, 200], ["BToV N, M, and S PCR products", "TEST", 37, 66], ["nested PCR", "TEST", 99, 109], ["first round PCR", "TEST", 125, 140], ["this method", "TEST", 171, 182], ["detectability", "OBSERVATION_MODIFIER", 20, 33]]], ["The M gene could not be amplified from sample K-629, and this sample and sample K-643 were both negative for the S gene.", [["sample", "ANATOMY", 62, 68], ["K-629", "CHEMICAL", 46, 51], ["K", "CHEMICAL", 80, 81], ["K-643", "GENE_OR_GENE_PRODUCT", 80, 85], ["M gene", "DNA", 4, 10], ["S gene", "DNA", 113, 119], ["sample K", "TEST", 39, 47], ["this sample", "TEST", 57, 68], ["sample K", "TEST", 73, 81]]], ["However, since the N gene could be amplified from both samples, it is likely that nucleotide differences may exist in the primer annealing region used for M and S amplification and the corresponding sequences of these isolates.DiscussionOf the 14 BToV-positive diarrheic samples, 7 were negative for BCV and rotavirus, well known diarrheic agents of cattle.", [["samples", "ANATOMY", 55, 62], ["samples", "ANATOMY", 271, 278], ["nucleotide", "CHEMICAL", 82, 92], ["nucleotide", "CHEMICAL", 82, 92], ["BToV", "GENE_OR_GENE_PRODUCT", 247, 251], ["BCV", "ORGANISM", 300, 303], ["cattle", "ORGANISM", 350, 356], ["N gene", "DNA", 19, 25], ["primer annealing region", "DNA", 122, 145], ["cattle", "SPECIES", 350, 356], ["BCV", "SPECIES", 300, 303], ["rotavirus", "SPECIES", 308, 317], ["cattle", "SPECIES", 350, 356], ["nucleotide differences", "PROBLEM", 82, 104], ["the primer annealing region", "PROBLEM", 118, 145], ["M and S amplification", "TREATMENT", 155, 176], ["positive diarrheic samples", "PROBLEM", 252, 278], ["BCV", "PROBLEM", 300, 303], ["rotavirus", "PROBLEM", 308, 317]]], ["However, since infections with BCV, rotavirus, or other enteropathogens could have occurred before the samples were taken, it is impossible to determine whether BToV was the primary cause of diarrhea in these samples.", [["samples", "ANATOMY", 103, 110], ["samples", "ANATOMY", 209, 216], ["infections", "DISEASE", 15, 25], ["rotavirus", "DISEASE", 36, 45], ["diarrhea", "DISEASE", 191, 199], ["BCV", "ORGANISM", 31, 34], ["rotavirus", "ORGANISM", 36, 45], ["samples", "CANCER", 209, 216], ["BCV", "SPECIES", 31, 34], ["rotavirus", "SPECIES", 36, 45], ["BToV", "SPECIES", 161, 165], ["infections", "PROBLEM", 15, 25], ["BCV", "PROBLEM", 31, 34], ["rotavirus", "PROBLEM", 36, 45], ["other enteropathogens", "PROBLEM", 50, 71], ["the samples", "TEST", 99, 110], ["diarrhea in these samples", "PROBLEM", 191, 216], ["diarrhea", "OBSERVATION", 191, 199]]], ["However, there have been several reports indicating the relationship of BToV and diarrhea in cattle.", [["BToV", "DISEASE", 72, 76], ["diarrhea", "DISEASE", 81, 89], ["BToV", "GENE_OR_GENE_PRODUCT", 72, 76], ["cattle", "ORGANISM", 93, 99], ["cattle", "SPECIES", 93, 99], ["cattle", "SPECIES", 93, 99], ["diarrhea", "PROBLEM", 81, 89]]], ["Further, we detected BToV at a significantly higher rate in diarrheic samples than in asymptomatic samples.", [["samples", "ANATOMY", 70, 77], ["samples", "ANATOMY", 99, 106], ["BToV", "GENE_OR_GENE_PRODUCT", 21, 25], ["diarrheic samples", "CANCER", 60, 77], ["BToV", "PROTEIN", 21, 25], ["diarrheic samples", "PROBLEM", 60, 77]]], ["These results suggest that BToV may act as a risk factor for diarrhea in Japanese cattle.DiscussionThe nucleotide sequences of the BToV S fragments had lower identity compared to the sequence identity of N and M fragments.", [["BToV", "CHEMICAL", 27, 31], ["diarrhea", "DISEASE", 61, 69], ["nucleotide", "CHEMICAL", 103, 113], ["nucleotide", "CHEMICAL", 103, 113], ["BToV", "SIMPLE_CHEMICAL", 27, 31], ["BToV S fragments", "DNA", 131, 147], ["N and M fragments", "DNA", 204, 221], ["cattle", "SPECIES", 82, 88], ["cattle", "SPECIES", 82, 88], ["diarrhea", "PROBLEM", 61, 69], ["The nucleotide sequences", "TEST", 99, 123], ["the BToV S fragments", "PROBLEM", 127, 147], ["lower identity", "PROBLEM", 152, 166], ["fragments", "OBSERVATION", 212, 221]]], ["In coronaviruses, which possess a similar structure to torovirus, a hypervariable region exists in the S gene (Wang et al., 1992) .", [["coronaviruses", "ORGANISM", 3, 16], ["torovirus", "GENE_OR_GENE_PRODUCT", 55, 64], ["torovirus", "DNA", 55, 64], ["S gene", "DNA", 103, 109], ["coronaviruses", "PROBLEM", 3, 16], ["a similar structure to torovirus", "PROBLEM", 32, 64], ["a hypervariable region", "PROBLEM", 66, 88], ["coronaviruses", "OBSERVATION", 3, 16], ["similar", "OBSERVATION_MODIFIER", 34, 41], ["structure", "OBSERVATION", 42, 51], ["hypervariable", "OBSERVATION_MODIFIER", 68, 81]]], ["One amino acid substitution causes a change in virus neutralization activity in BCV (Yoo and Deregt, 2001) .", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["BCV", "ORGANISM", 80, 83], ["BCV", "SPECIES", 80, 83], ["One amino acid substitution", "TREATMENT", 0, 27], ["a change in virus neutralization activity", "PROBLEM", 35, 76], ["amino", "OBSERVATION", 4, 9], ["acid substitution", "OBSERVATION", 10, 27], ["change", "OBSERVATION_MODIFIER", 37, 43], ["virus", "OBSERVATION_MODIFIER", 47, 52], ["neutralization activity", "OBSERVATION", 53, 76]]], ["Thus, the S gene has been used to genetically characterize each strain of coronaviruses (Jackwood et al., 2005; Phillips et al., 2001; Yoo and Deregt, 2001) .", [["coronaviruses", "ORGANISM", 74, 87], ["S gene", "DNA", 10, 16]]], ["The BToV S molecule is thought to be located on the surface of the virus membrane and to have a similar function to the coronavirus spike (Horzinek et al., 1987) .DiscussionTwo BToV serotypes exist (BRV-1 and BRV-2; Duckmanton et al., 1998b) , but further research on their antigenic properties is required to characterize them.", [["surface", "ANATOMY", 52, 59], ["membrane", "ANATOMY", 73, 81], ["BToV S molecule", "GENE_OR_GENE_PRODUCT", 4, 19], ["surface", "CELLULAR_COMPONENT", 52, 59], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["coronavirus", "ORGANISM", 120, 131], ["BRV-2", "CELL", 209, 214], ["BToV S molecule", "PROTEIN", 4, 19], ["The BToV S molecule", "PROBLEM", 0, 19], ["the coronavirus spike", "PROBLEM", 116, 137], ["BToV serotypes", "TEST", 177, 191], ["BRV", "TEST", 199, 202], ["BRV", "TEST", 209, 212], ["molecule", "OBSERVATION", 11, 19], ["thought to be", "UNCERTAINTY", 23, 36], ["virus membrane", "OBSERVATION", 67, 81], ["coronavirus spike", "OBSERVATION", 120, 137]]], ["There are few reports studying BToV, probably due to the fact that BToV cannot be yet propagated in cell culture.", [["cell culture", "ANATOMY", 100, 112], ["BToV", "CANCER", 31, 35], ["BToV", "SIMPLE_CHEMICAL", 67, 71], ["cell culture", "CELL", 100, 112], ["BToV", "PROTEIN", 67, 71], ["cell culture", "CELL_LINE", 100, 112], ["cell culture", "TEST", 100, 112], ["few", "OBSERVATION_MODIFIER", 10, 13], ["probably due to", "UNCERTAINTY", 37, 52]]], ["For the same reason, there are few reports characterizing BToV.", [["BToV", "CANCER", 58, 62]]], ["In this study, we genetically characterized BToV samples by phylogenetic analysis of the deduced amino acid sequence of the BToV S gene, including the previously reported BRV-1, BRV-2, and B145 sequences.", [["BToV samples", "ANATOMY", 44, 56], ["amino acid", "CHEMICAL", 97, 107], ["amino acid", "CHEMICAL", 97, 107], ["BToV samples", "CANCER", 44, 56], ["amino acid", "AMINO_ACID", 97, 107], ["BToV S", "GENE_OR_GENE_PRODUCT", 124, 130], ["BRV-1", "GENE_OR_GENE_PRODUCT", 171, 176], ["BRV-2", "GENE_OR_GENE_PRODUCT", 178, 183], ["B145", "GENE_OR_GENE_PRODUCT", 189, 193], ["BToV S gene", "DNA", 124, 135], ["BRV-1, BRV-2, and B145 sequences", "DNA", 171, 203], ["this study", "TEST", 3, 13], ["phylogenetic analysis", "TEST", 60, 81], ["the deduced amino acid sequence", "TEST", 85, 116], ["BRV", "TEST", 171, 174], ["BRV", "TEST", 178, 181]]], ["The detected BToVs were separated into three clusters.", [["BToVs", "GENE_OR_GENE_PRODUCT", 13, 18], ["BToVs", "DNA", 13, 18]]], ["Cluster 2, which included samples K-674 and K-676, was located relatively closer to BRV-1.", [["K-674", "CHEMICAL", 34, 39], ["K-676", "CHEMICAL", 44, 49], ["K-676", "GENE_OR_GENE_PRODUCT", 44, 49], ["BRV-1", "GENE_OR_GENE_PRODUCT", 84, 89], ["BRV-1", "DNA", 84, 89], ["samples K", "TEST", 26, 35], ["K", "TEST", 44, 45], ["BRV", "TEST", 84, 87]]], ["Cluster 1, the most frequently detected BToV cluster, was located distal to BRV-1, BRV-2, and B145.", [["Cluster 1", "GENE_OR_GENE_PRODUCT", 0, 9], ["BToV", "CANCER", 40, 44], ["BRV-1", "GENE_OR_GENE_PRODUCT", 76, 81], ["BRV-2", "GENE_OR_GENE_PRODUCT", 83, 88], ["B145", "GENE_OR_GENE_PRODUCT", 94, 98], ["BToV cluster", "DNA", 40, 52], ["BRV-1", "DNA", 76, 81], ["BRV-2", "DNA", 83, 88], ["B145", "DNA", 94, 98], ["BRV", "TEST", 76, 79], ["BRV", "TEST", 83, 86], ["distal", "ANATOMY_MODIFIER", 66, 72]]], ["Cluster 3, which included samples K-683 and K-684, also seems to be separeted from these reference strains but relatively closer to cluster 1.", [["K-683", "CHEMICAL", 34, 39], ["K-684", "CHEMICAL", 44, 49], ["K-684", "GENE_OR_GENE_PRODUCT", 44, 49], ["samples K", "TEST", 26, 35], ["K", "TEST", 44, 45], ["these reference strains", "PROBLEM", 83, 106]]], ["In addition, high divergence was observed in the N sequence between the domestic samples and BRV-1 and BRV-2.", [["samples", "ANATOMY", 81, 88], ["BRV-1", "GENE_OR_GENE_PRODUCT", 93, 98], ["BRV-2", "CELL", 103, 108], ["N sequence", "DNA", 49, 59], ["BRV-1", "SPECIES", 93, 98], ["high divergence", "PROBLEM", 13, 28], ["the N sequence", "TEST", 45, 59], ["the domestic samples", "TEST", 68, 88], ["BRV", "TEST", 93, 96], ["BRV", "TEST", 103, 106], ["high divergence", "OBSERVATION", 13, 28]]], ["These results raise the possibility that the predominant BToV in Japan are closer to the European strain B145 than to BRV-1 and BRV-2 regarding N gene properties.", [["BToV", "CANCER", 57, 61], ["BRV-1", "CELL", 118, 123], ["BRV-2", "CELL", 128, 133], ["BRV-1 and BRV-2", "DNA", 118, 133], ["N gene", "DNA", 144, 150], ["BRV-1", "SPECIES", 118, 123], ["BRV", "TEST", 118, 121], ["raise the possibility", "UNCERTAINTY", 14, 35]]], ["Therefore, it is important to identify the antigenic properties and to clarify their correlation with genetic properties.DiscussionThe phylogenetic clusters were correlated with the geographic sources of the samples.", [["samples", "ANATOMY", 208, 215], ["the samples", "TEST", 204, 215]]], ["The BToV-positive areas did not adjoin each other but were spread throughout Japan, spanning the BToV-negative areas.", [["BToV", "GENE_OR_GENE_PRODUCT", 4, 8], ["The BToV", "TEST", 0, 8], ["positive", "OBSERVATION", 9, 17], ["spread", "OBSERVATION", 59, 65], ["negative", "OBSERVATION", 102, 110], ["areas", "OBSERVATION_MODIFIER", 111, 116]]], ["These results suggest that BToV is geographically differentiated in Japan.DiscussionAdditionally, intertypic recombination occurs in torovirus (Smits et al., 2003) .", [["geographically", "OBSERVATION_MODIFIER", 35, 49], ["differentiated", "OBSERVATION_MODIFIER", 50, 64]]], ["Therefore, it is important to continue the investigation of the genetic divergence of BToV.", [["BToV", "CANCER", 86, 90]]], ["To support this, we developed an RFLP method to distinguish the clusters indicated by the phylogenetic classification.", [["an RFLP method", "TEST", 30, 44]]], ["Although both HaeIII and AccI discriminate among the clusters, the cutting patterns differ.", [["HaeIII", "GENE_OR_GENE_PRODUCT", 14, 20], ["AccI", "GENE_OR_GENE_PRODUCT", 25, 29], ["HaeIII", "DNA", 14, 20], ["AccI", "DNA", 25, 29]]], ["From the predicted cutting pattern, it is also possible to distinguish among BRV-1, BRV-2, and B145.", [["BRV-1", "CELL", 77, 82], ["BRV-2", "CELL", 84, 89], ["B145", "CELL", 95, 99], ["B145", "DNA", 95, 99], ["BRV-1", "SPECIES", 77, 82], ["BRV", "TEST", 77, 80], ["BRV", "TEST", 84, 87]]], ["The combination of these two enzymes will further help to determine the polymorphism of novel BToV isolates in the future.DiscussionIn addition to the analysis of the S gene performed in this study, analysis of the HE gene would further aid to establish the phylogenetic and evolutionary relationship among all known BToV isolates.", [["BToV", "GENE_OR_GENE_PRODUCT", 94, 98], ["HE", "GENE_OR_GENE_PRODUCT", 215, 217], ["S gene", "DNA", 167, 173], ["HE gene", "DNA", 215, 222], ["these two enzymes", "TEST", 19, 36], ["novel BToV isolates", "TREATMENT", 88, 107], ["the analysis", "TEST", 147, 159], ["this study", "TEST", 187, 197]]], ["And it is also important to identify the retention of the BToV antibody to predict the prevalence and epidemiplogy of BToV in Japan.", [["BToV antibody", "GENE_OR_GENE_PRODUCT", 58, 71], ["BToV antibody", "PROTEIN", 58, 71], ["BToV", "SPECIES", 118, 122], ["the BToV antibody", "TREATMENT", 54, 71]]]]}